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In Chapter 1, a summary of transition-metal catalysed C–C bond cleavage of small ring systems that 
are pertinent to this thesis is presented. In Chapters 2 and 3, a modular Rh(I)-catalysed entry to various 
7- and 8-membered N-heterocycles is outlined. Under an atmosphere of CO, aminocyclopropanes 
equipped with pendant nucleophiles undergo directed C–C bond activation to provide versatile 
rhodacyclopentanone intermediates. Subsequent intramolecular nucleophilic addition of an aryl or N-
based nucleophile to the rhodacyclopentanone intermediate is followed by C–C or C–N bond formation 
to provide a range of sp3-rich N-heterocycles. These studies demonstrate how the combination of 
cyclopropane strain release and the templating effect of catalytically generated metallacycles can be 
utilised to achieve challenging medium-sized ring closures.  
Chapter 4 details a conceptual blueprint that enables direct and atom economical access to a 
selection of complex polyheterocycles. These processes capitalise upon the amphiphilic reactivity of 
rhodacyclopentanones for the construction of two new ring systems, the first of which is enabled by the 
intrinsic electrophilicity of rhodacyclopentanones, and the second by their latent nucleophilicity. 
Importantly, this reactivity mode is only unveiled by carbonylative C–C bond activation of a stable 
aminocyclopropane precursor. By using this approach, a diverse array of polycyclisations are achieved, 
including systems that involve powerful dearomatisations and medium ring formations.  
In Chapter 5, studies are directed towards the total synthesis of (rac)-conolidine and related 
indole alkaloids. The newly developed 7-step synthetic route to (rac)-conolidine features a 
Rh(I)-catalysed carbonylative ring expansion of a cyclopropylamide to establish the 8-membered 
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Chapter 1 – Introduction 
1.1 Tackling the declining rate of drug discovery 
The modern pharmaceutical industry is unquestionably a success story in terms of its positive impact 
on improving health and driving medical innovation, but for small-molecule drug discovery 
programmes, high attrition rates remain a formidable challenge.1,2 To help address this issue, the 
pharmaceutical sector has invested considerably in high throughput screening (HTS) methods to rapidly 
evaluate large libraries of drug candidates.3 The shift to HTS practices has led to the identification of 
promising leads and the discovery of new drugs; however, efforts are often wasted pursuing structures 
that exhibit poor physiochemical properties.4 In part, this is due to the reliance of medicinal chemists 
on adopting certain bond forming strategies,5,6 and, within this context, palladium-catalysed 
cross-couplings7 (e.g. the Suzuki-Miyaura reaction8,9) have evolved to become mainstay reactions in 
modern medicinal chemistry (Scheme 1A).10 However, the widespread use of this type of strategy 
frequently leads to larger and more lipophilic compounds with high aromatic character, properties that 
are generally not conducive within drug discovery platforms.11,12 Indeed, a recent study by Lovering 
and co-workers demonstrated that drug candidates possessing high fractional sp3-character (Fsp3),  
where Fsp3 is defined as the fraction of sp3 hybridised carbon atoms vs. the total number of carbon 
atoms, have a greater chance of transitioning through the drug discovery process and ultimately make 
it to the clinic.13 Additionally, compounds with high Fsp3 values often display improved binding 
affinities to their intended biological target and reduced off-target toxicity effects.14 
Whilst the discovery of new drugs is an interdisciplinary challenge, synthetic chemistry can be 
the rate-determining step in the identification of new molecules that possess the necessary properties to 
become safe and efficacious drugs. Therefore, on the account of the above, there is a pressing need to 
escape from the sp2-rich, planar structures generated from Pd(0)-catalysed cross-coupling reactions and, 
instead, a strategic desire to investigate sp3-rich molecules in drug discovery campaigns. Stimulated by 
this challenge, synthetic chemists have embarked on several strategies; for example, C–C bond 
activation has emerged as a powerful tool for synthesising medicinally relevant scaffolds from relatively 
simple precursors. In particular, methodologies that exploit C–C oxidative addition of strained rings 
(e.g. cyclopropane or cyclobutane derivatives) have recently garnered significant attention from 
synthetic chemists as a means to generate sp3-rich organometallics catalytically, which can then undergo 
further manipulations (e.g. migratory insertion of π-unsaturates followed by reductive elimination) to 
deliver sp3-rich products (Scheme 1B).    






Scheme 1: Comparison of a Pd(II)-intermediate with strained-ring derived organometallic.  
In the Bower group, an extensive research programme has been undertaken to investigate the 
capacity of sp3-metallacylic intermediates, with a strong focus on the generation and reactivity modes 
of rhodacyclopentanones.15-24 Under Rh(I)-catalysed conditions, rhodacyclopentanones are generated 
by carbonylative C–C bond activation of cyclopropane precursors bearing a suitable directing group 
(Scheme 2). These versatile intermediates can be trapped by π-unsaturates or N- or C-based 
nucleophiles to deliver a diverse array of sp3-rich, heterocyclic structures, many of which are found in 
medicinally important natural products and pharmaceutical reagents. Before presenting an overview of 
this strategy, a discussion on start-of-the-art examples of strain-driven C–C bond activation processes 
will be given.   
  
Scheme 2: Formation of rhodacyclopentanones and target reactions with π-unsaturates.  
1.2 Oxidative addition of transition metals into strained C–C bonds 
Cyclopropane and cyclobutane derivatives play an important role in C–C bond activations as the release 
of ring strain facilitates metal insertion and provides a thermodynamic and kinetic driving force. 
Additionally, the HOMO and LUMO orbitals of cyclopropanes (and to a lesser extent cyclobutanes) 
have significant p-orbital character (due to the narrow bond angles within the cyclopropane ring) which 
makes them well-suited to bonding interactions with transition metal orbitals.25 As such, the oxidative 
addition of transition metals into strained C–C bonds of 3- and 4-membered ring systems is a 
well-established process.26-28 The first example of C–C oxidative addition into a cyclopropane was 





reported by Tipper in 1955, which involved insertion of PtCl2 into cyclopropane to deliver a 
platinacyclobutane.29 Since this report, multiple classes of cyclopropane and cyclobutane derivatives 
have found wide utility in the development of metal-catalysed C–C bond activation methodologies 
(Figure 1).  
 
Figure 1: Categories of cyclopropanes and cyclobutanes employed in C–C oxidative addition processes. 
In the following sections, examples of catalytic cycloadditions proceeding via oxidative 
addition to strained C–C bonds will be presented. The first part will cover cycloaddition processes 
involving cyclopropenes and alkylidenecyclopropane systems. The discussion will then focus on 
processes involving less-activated cyclopropanes, including aminocyclopropanes and cyclopropyl 
ketones, followed by selected methodologies based on C–C bond cleavage of cyclobutanones and 
benzocyclobutenones. Finally, in Section 1.3, an overview of processes developed previously in the 
Bower group will be presented. Whilst other classes of cyclopropane- and cyclobutane-based ring 
systems (e.g. vinylcyclopropanes,28,30-33 and biphenylenes28) participate in cycloaddition processes, 
these will not be discussed as they fall outside the scope of the work contained in this thesis. 
1.2.1 Multicomponent cycloaddition processes of cyclopropane-based systems  
1.2.1.1 Cyclopropene-based systems  
The internal unsaturation of cyclopropene rings renders them highly susceptible to C–C oxidative 
addition by transition metals. However, despite this propensity, few examples involving cyclopropenes 
exist in the literature, possibly due to the lack of flexible synthetic approaches targeting cyclopropene 
substrates. Notwithstanding this limitation, in 2010, Wang and co-workers published a Rh(I)-catalysed 
carbonylative (3+1+2) cycloaddition of cyclopropenes bearing pendant alkynes or alkenes to afford 5,6-
bicyclic heterocycles (e.g. 3a and 3b) (Scheme 3).34 It was proposed that the Rh(I)-catalyst inserts 
preferentially into the C–C single bond of 1, and following migratory insertion of CO, provides 
rhodacyclopentenone 2. From here, insertion of the tethered π-unsaturate, followed by C–C reductive 
elimination delivers the desired product. For processes involving alkenes (e.g. the formation of adduct 
3b), the transformation proceeded with high diastereoselectivity for the trans-ring junction.      






Scheme 3: Rh(I)-catalysed carbonylative (3+1+2) cycloadditions of cyclopropenes with alkynes and alkenes.  
1.2.1.2 Alkylidenecyclopropane-based processes 
Alkylidenecyclopropanes (ACPs) are another class of highly strained cyclopropane-based system 
which are reactive to C–C oxidative addition by transition metals (approximate strain energy of 39 vs. 
55 kcal mol-1 for cyclopropenes).35 For this substrate class, the metal can insert into either the proximal 
(bond a) or distal (bond b) C–C bond of alkylidenecyclopropane 4, which leads to regioisomeric 
metallacycles 5a and 5b (Scheme 4). These metallacyclobutanes can be used directly or, in the case of 
5b, rearrangement can occur prior to engagement with a π-unsaturated component to give metallacycle 
5b’. In light of these scenarios, alkylidenecyclopropanes have emerged as highly versatile initiating 
motifs for cycloaddition reactions and interestingly, the mechanistic outcome of such reactions can be 
influenced by the choice of metal catalyst. In the following section, examples of processes involving 
selective metal insertion into either bond a or bond b of alkylidenecyclopropanes will be outlined.  
 
Scheme 4: Transition metal C–C bond insertion into alkylidenecyclopropanes.  
In 2003, Mascareñas and co-workers developed a protocol for the Pd(0)-catalysed (3+2) 
cycloaddition of ACPs 6 with tethered alkynes to furnish bicyclic products (e.g. 9a and 9b) (Scheme 
5).36 Computational studies revealed that the most favourable reaction pathway involves initial insertion 
of the Pd(0)-catalyst into the distal bond of alkylidenecyclopropane 6, from which subsequent  
isomerisation leads to complex 7.37 Next, alkyne carbometallation to 6-membered palladacycle 8a, and 
C–C reductive elimination delivers the desired products 9a–b. The Mascareñas group further expanded 
the methodology to include alkylidenecyclopropane substrates bearing other π-unsaturated 
functionalities, such as alkenes,38 allenes39 and 1,3-dienes,40 which, in turn, allows flexible access to a 
range of ring systems. 






Scheme 5: Pd(0)-catalysed (3+2) cycloaddition of ACPs with tethered alkynes.  
Notably, the same group reported that 6-membered palladacycle 8b (cf. 8a) could undergo a 
second carbometallation sequence prior to reductive elimination. For example, alkylidenecyclopropane 
10, containing an internal alkyne and a terminal alkene component, underwent (3+2+2) cyclisation to 
provide 5,7,5-tricycles (e.g. 12a and 12b) (Scheme 6).41 In this transformation, palladacycle 8b 
undergoes carbometallation of the pendant alkene (instead of reductive elimination) to form 
8-membered palladacycle 11 and subsequent reductive elimination delivers the observed products 
12a–b. The authors noted that with the Pd(0)-catalyst, the system was prone to formation of (3+2) 
side-products (via reductive elimination from 8b). To address this issue, a later study identified an 
upgraded Rh(I)-catalyst system, which, in turn, enabled chemoselective formation of the (3+2+2) 
cycloaddition adducts 12 in enhanced yields.42 Computational studies were performed in order to 
account for the differences in reactivity for the Pd(0)- and Rh(I)-catalyst systems. It was found that, in 
the case of the Rh(I)-based system, the barrier for reductive elimination from the (3+2) intermediate (cf. 
palladacycle 8b) is substantially higher in energy than that from the (3+2+2) intermediate (cf. 
palladacycle 11).42,43 This is in agreement with the experimental absence of the (3+2) cycloadducts 12. 
In contrast, for the Pd(0)-based system, reductive elimination from palladacycle 8b and 
carbopalladation of 8b to 11 are competitive processes.  
 
Scheme 6: Pd(0)-catalysed (3+2+2) cycloaddition of alkylidenecyclopropanes.   





In 2008, Evans and Ingleby outlined a Rh(I)-catalysed intermolecular (3+2+2) cycloaddition of 
alkylidenecyclopropane 13 with exogenous electron-deficient alkynes 14 for the construction of cis-
fused 5,7-bicycles (e.g. 19a and 19b) with high regiocontrol (5:1–12:1 r.r.) (Scheme 7A).44 The authors 
postulated that bicycles 19a–b are formed by an initial sequence involving oxidative addition of the 
Rh(I)-catalyst into the distal C–C bond of 13, followed by rearrangement of 15 to rhodacyclobutane 16. 
From this central intermediate, the mechanism diverges depending on the order of insertion of the 
π-unsaturated components. In pathway A, insertion of the tethered alkene to 17 is followed by insertion 
of the alkyne component and reductive elimination to afford products 19a–b. Alternatively, in pathway 
B, alkyne insertion into 16 affords rhodacyclohexene 18. Subsequent insertion of the alkene unit and 
reductive elimination delivers products 19a–b. Moreover, this method provides concise access to 
structural motifs that are found in several natural products. To demonstrate its utility, Evans and Ingleby 
successfully applied this methodology to the three-step total synthesis of the sesquiterpene, 
pyrovellerolactone.45 However, despite this application, a potential drawback of this methodology is 
that it is limited to electron-poor alkynes (i.e. the E substituent of 14 = CO2Me or C(O)Me). To address 
this shortcoming, a subsequent report disclosed that the introduction of a triethoxysilyl group on the 
alkene unit of alkylidenecyclopropane 20 improves the scope of the (3+2+2) cycloaddition to include 
non-activated alkynes (Scheme 7B).46  
 
Scheme 7: Rh(I)-catalysed (3+2+2) cycloaddition of alkylidenecyclopropanes with alkynes and alkenes.    





 In a later report, Evans and co-workers detailed an intermolecular Rh(I)-catalysed (3+2+2) 
cycloaddition of alkylidenecyclopropanes 21 and exogenous substituted allenes to provide 5,7-bicyclics 
bearing tri- and tetrasubstituted exocyclic olefins (e.g. 22a and 22b) (Scheme 8).47 By inserting an 
additional methylene spacer in the alkyne tether, the scope was extended to include 6,7-heterocycles 
(not depicted). The authors proposed that the geometry of the substituted exocyclic alkene unit is 
controlled by preferential syn-carbometallation of the less hindered face of the terminal allene π-bond.  
 
Scheme 8: Rh(I)-catalysed (3+2+2) cyclisation of alkylidenecyclopropanes with external allenes.  
In 2012, Evans and co-workers disclosed Rh(I)-catalysed (3+1+2) cycloadditions of 
alkylidenecyclopropanes 23 with carbon monoxide to form cis-fused bicyclohexenones (e.g. 27a and 
27b) in excellent yield and high diastereocontrol (Scheme 9A).48 Computational studies support a 
mechanistic pathway proceeding via insertion of the Rh-CO complex into the distal bond of 23 to give 
rhodacycle 24, followed by isomerisation to complex 25. From here, alkene insertion to η3-allyl species 
26 is followed by a sequence comprising of migratory insertion of CO, C–C reductive elimination and 
alkene isomerisation to afford products 27a–b. Preliminary studies using [Rh(cod)2]OTf in combination 
with a chiral P,N-ligand L1 gave rise to good levels of enantioselectivity (e.g. 89% e.e. for 27a) 
(Scheme 9B). Later in 2014, Kim and Chung reported a related protocol in which Rh(I)-catalysed 
carbonylative (3+1+2) cycloaddition of ACPs with tethered alkynes generated bicyclic phenol 
derivatives.49  






Scheme 9: Rh(I)-catalysed carbonylative (3+1+2) cycloadditions of alkylidenecyclopropanes and 
computationally supported mechanism.  
More recently, interest in the development of complementary processes that utilise 
Ni(0)-catalysts has grown rapidly, particularly as Ni(0)-catalysts behave differently to Pd(0)- and 
Rh(I)-catalysts. Indeed, as early as the 1970s it was shown that Ni(0)-catalysts generally insert into the 
proximal C–C bond of alkylidenecyclopropanes (i.e. bond a of 4, Scheme 4), instead of into the distal 
bond (i.e. bond b of 4, Scheme 4).50,51 This preference is in contrast to the Pd(0)- and Rh(I)-catalysed 
processes discussed so far and, as a result, presents the opportunity for identical alkylidenecyclopropane 
precursors to be transformed into different ring systems depending on the choice of catalyst employed. 
Mascareñas first exploited this effect to promote the formation of 6,7-fused bicycles (e.g. 31a and 31b) 
by a Ni(0)-catalysed (3+2+2) cycloaddition of alkylidenecyclopropane 28 with external alkenes 
(Scheme 10A).52 Computational studies indicate the Ni(0)-catalyst is directed into the proximal bond 
of alkylidenecyclopropane 28 by the tethered alkyne unit. The resulting nickelacycle 29 undergoes 
consecutive alkyne and alkene carbometallation to give intermediate 30, which upon reductive 
elimination affords the 6,7-bicyclic products. Subsequent reports have highlighted the versatility of 
nickelacycles related to 28; for example, in 2014, the Mascareñas group reported a Ni(0)-catalysed 
intramolecular (3+2+2) cycloaddition of ACPs with tethered alkenes and alkynes to provide tricyclic 
ring systems (cf. Scheme 6).53 Additionally, Zhang and co-workers detailed the synthesis of aryl-fused 
products 33 via cleavage of the proximal bond of ACPs 32 under Ni(0)-catalysis (Scheme 10B).54  






Scheme 10: Ni(0)-catalysed cycloadditions of ACPs.  
1.2.1.3 Cyclopropyl ketone/imine-based processes 
The examples discussed so far highlight notable progress in processes involving C–C cleavage of 
cyclopropanes possessing fused or adjacent C-based π-unsaturation. In addition to these achievements, 
significant interest has also been directed towards processes involving C–C bond activation of 
cyclopropanes bearing electron-withdrawing π-unsaturation, such as cyclopropyl ketones,55-57 
cyclopropyl imines58-60 and cyclopropylamides.61 From a synthetic viewpoint, these substrates are 
appealing because substituted analogues are, in most cases, easily accessible and often in 
enantioenriched form. In 2006, Liu and Montgomery,55 and Ogoshi and co-workers57 independently 
reported the Ni(0)-catalysed cycloaddition of cyclopropyl ketones (e.g. 34) and alkenes to give 
substituted cyclopentanes (e.g. 36) (Scheme 11A). In these examples, 6-membered oxanickelacycle 35 
was identified as a key intermediate, which following intermolecular conjugate addition to the enone 
species and reductive elimination, affords cyclopentane 36.  






Scheme 11: Ni(0)-catalysed (3+2) cycloadditions of cyclopropylketones 
 In 2011, Ogoshi and co-workers extended the methodology to include alkynes, and in this case, 
the inclusion of a Lewis-acidic organoaluminium co-catalyst was necessary to facilitate the formation 
of cyclopentene products 40 (Scheme 11B).62 The authors proposed that Me2AlCl activates the ketone 
which, in turn, facilitates coordination of an alkyne-ligated Ni(0)-complex and enables C–C oxidative 
addition to give nickelacyclobutane 37. Key intermediate 37 is stabilised by a Ni–Cl interaction that 
prevents isomerisation to a 6-membered nickelacycle (cf. 35). Migratory insertion of the external alkyne 
into 37 is followed by reductive elimination to deliver cyclopentene 38.     
 Alongside these advancements, additional studies have shown that other metals, including Rh 
and Pd,63 insert into cyclopropyl ketones. In 2009, Zhang and co-workers disclosed the Rh(I)-catalysed 
carbonylative cyclisation of propargylic cyclopropyl ketones 39 to form furan-fused cyclopentanones 
(e.g. 42a and 42b) (Scheme 12).64 The proposed mechanism proceeds via regioselective C–C oxidative 
addition of the Rh(I)-catalyst into the proximal C–C bond of 39 to give rhodacyclobutane 40. 
Rearrangement of 40 to rhodacycle 41, followed by insertion of CO and reductive elimination affords 
the observed products 42a–b.  






Scheme 12: Carbonylative rearrangement of alkynyl cyclopropyl ketones.  
1.2.1.4 Directed metal-addition to non-activated cyclopropanes 
In contrast to the processes discussed above, examples of metal-catalysed cycloadditions of 
non-activated cyclopropanes have been slow to emerge.26,65 For such systems, an extra layer of 
complexity arises due to issues regarding regioselectivity of C–C oxidative addition and 
metallacyclobutane stability (Scheme 13).   
 
Scheme 13: Metal-catalysed C–C bond activation of non-activated cyclopropanes.  
The issue of stability outlined in Scheme 13 can be eased by fast capture of the 
metallacyclobutane with carbon monoxide to provide a relativity stable metallacyclopentanone. This 
carbonylative strategy was first detailed by Wilkinson and co-workers in 1968, in which exposure of 
cyclopropane to [Rh(CO)2Cl]2 resulted in ring expansion to deliver a monomeric phosphine-bound 
rhodacyclopentanone.66 Building upon this discovery, Koga and Narasaka disclosed that the 
Rh(I)-catalysed (3+1+2) cycloaddition of cyclopropane 43 with a tethered alkyne and carbon monoxide 
generated bicyclic cyclohexanone 45 in good yield and high selectivity (63% yield, 20:1, 45:45’) 
(Scheme 14).67 The reaction was proposed to proceed via rhodacyclopentanone 44, which derives from 
insertion of the Rh(I)-catalyst into the more hindered C–C bond of 43. Additionally, in this process, the 
authors proposed that the regioselectivity is controlled by coordination of the Rh(I)-catalyst to the 
tethered alkyne component. From rhodacyclopentanone 44, migratory insertion of the alkyne unit and 
reductive elimination affords product 45. Shortcomings of this approach include the requirement for a 
high pressure of carbon monoxide and high reaction temperatures; therefore, protocols that can 
overcome these limitations and enable efficient and selective access to related metallacyclic 
intermediates are highly sought after.  






Scheme 14: Rh(I)-catalysed carbonylative (3+1+2) cycloaddition of cyclopropane with a tethered alkyne.  
 With these issues in mind, in 2013 the Bower group demonstrated the regioselective generation 
of amino-rhodacyclopentanones from aminocyclopropanes by employing an N-directing group strategy 
(Scheme 15).15 The strategy utilises a carbonyl-based directing group to promote regioselective 
oxidative addition of a Rh(I)-catalyst into the proximal bond a of aminocyclopropane 46. From here, 
migratory insertion of carbon monoxide into the resulting rhodacyclobutane 47 delivers 
rhodacyclopentanone 48. Importantly, it has been shown that the steps leading up to 
rhodacyclopentanone 47 are reversible. The ability to access rhodacyclopentanones both selectively and 
efficiently has provided a general platform from which a range of downstream catalytic transformations 
have been developed. A detailed overview of this carbonylative ring expansion strategy is presented in 
Section 1.3.  
 
Scheme 15: Rh(I)-catalysed carbonylative ring expansion of aminocyclopropanes.  
1.2.2 Multicomponent cycloadditions of cyclobutane-based systems 
Significant efforts have also been devoted to the development of metal-catalysed strain-driven C–C 
bond activations of cyclobutane-based substrates and, within this field, cyclobutanone and 
benzocyclobutenones have emerged as privileged substrates.68 In 1994, pioneering work by Ito and 
Murakami demonstrated that Rh(I)-catalysts insert into the less hindered acyl–C(sp3) bond of 
cyclobutanone derivatives, a strategy which offers an alternative entry to rhodacyclopentanones 
(Scheme 16).69 Since this seminal publication, rhodacyclopentanones generated from cyclobutanones 
and benzocyclobutenones have been exploited by a number of research groups to access diverse hetero- 
and carbocycles and, in certain cases, this has been achieved enantioselectively.27,70 In general, oxidative 
addition of Rh(I)-catalysts into cyclobutanones occurs at the weaker acyl–C(sp2) bond over the 
comparatively stronger C(sp3)–C(sp3) bond. In the following section, significant advances of 





cyclobutanone- and benzocyclobutenone-derived rhodacyclopenta(e)nones (and related 
metallacyclopentanones) will be outlined.  
 
Scheme 16: Alternative entry to rhodacyclopentanones from cyclobutanones.  
1.2.2.1 Cyclobutanone-based processes 
In 2014, Cramer and co-workers disclosed the enantioselective synthesis of benzofused bicyclic ketones 
(e.g. 50a and 50b) from cyclobutanones 49 using a [Rh(cod)Cl]2/(R)-DTBM-SEGPHOS catalyst 
system (Scheme 17A).71,72 In this transformation, oxidative addition of the Rh(I)-catalyst into the 
acyl–C(sp3) bond of cyclobutanone 49 is the enantiodetermining step. Migratory insertion of the 
tethered alkene into the resulting rhodacyclopentanone, followed by reductive elimination provides 
ketones 50a and 50b. In a subsequent report, Cramer extended the cycloaddition strategy to 
cyclobutanones bearing tethered carbonyls to afford bridged lactones (e.g. 52a and 52b) in high yield 
and enantioselectivity (e.g. 83% yield and 99% e.e. for 52a) (Scheme 17B).73 The same fundamental 
mechanistic steps for this substrate class were invoked as for the cyclobutanone 49. Of note, this 
protocol is significant for its complete selectivity for C–C bond activation over insertion of the 
Rh(I)-catalyst into the aldehydic C–H bond (i.e. aldehydic C–H bond of cyclobutanone 51, R2 = H).  
 
Scheme 17: Enantioselective C–C bond activation of cyclobutanones.  
For certain catalytic processes, competing decarbonylation from the key rhodacyclopentanone 
intermediate can be a major side-reaction that leads to undesired ring contractions or fragmentation 
pathways.74 To side-step this deleterious pathway, the Dong group utilised a temporary directing group 
strategy in the Rh(I)-catalysed (4+2) cycloaddition of cyclobutanones 53 to provide N-heterobicyclic 





ketones (e.g. 58a and 58b) (Scheme 18).75 Inspired by previous reports by Jun and co-workers,76,77 
treatment of cyclobutanone 53 with 2-amino-3-methylpyridine 54 results in the in situ formation of 
imine 55, which then directs insertion of the Rh(I)-catalyst into the α-bond of cyclobutanone 55 by 
forming a chelation complex with the metal. Subsequent migratory insertion of the alkene unit into 56, 
followed by reductive elimination installs the bridged scaffold to give intermediate 57. Finally, 
hydrolysis of imine 57 affords the [3.3.1]-bridged ketone products 58a/b. Note that rhodacycle 56 
cannot undergo decarbonylation. Recently, in 2020 the Dong group reported a notable extension of this 
(4+2) cycloaddition by replacing the alkene component of 53 with an alkyne unit, which, in turn, 
enabled access to chiral [3.3.1]-bridged bicyclic products.78 The authors reported that high 
enantioselectivities can be achieved by employing cationic [Rh(cod)2]NTf2 and (R)-DTBM-SEGPHOS, 
and more significantly, for this new transformation, the imine-protecting group was no longer required.  
 
Scheme 18: Imine-directing group strategy to avoid decarbonylation of cyclobutanones.  
In a related publication, Dong and co-workers reported the combination of [Rh(CH2H4)Cl]2 and 
chiral TADDOL-derived phosphoramidite ligand (L2) effects the enantioselective (4+1) cyclisation of 
cyclobutanone 59 bearing a pendant allene to provide [4.2.1]-bicyclic ketones (e.g. 63a and 63b) in 
good yields and enantioselectivities (e.g. 99% e.e. for 63a) (Scheme 19).79 In this transformation, 
generation of rhodacyclopentanone 60 is followed by migratory insertion of the allene unit to give 
π-allyl intermediate 61. From here, β-hydride elimination to enone 62 is followed by hydrometallation 
and reductive elimination to give the observed product 63. The proposed mechanism was supported by 
deuterium-labelling studies. Interestingly, the [3.3.1]-bicyclic product 64 (formed via reductive 
elimination from intermediate 60) was observed only in small quantities.  






Scheme 19: Rh(I)-catalysed allene insertion into cyclobutanones.  
Further exemplary work by Dong described the Rh(I)-catalysed (4+2) cycloaddition of 
unsymmetrical cyclobutanones 65 with tethered alkynes to generate fused-cyclohexanones (e.g. 69a 
and 69b) (Scheme 20).80 The regioselectivity of the initial metal addition step was investigated by 
13C-labelling studies, which revealed a preference for the Rh(I)-catalyst to insert into the less-hindered 
distal C(acyl)–C(sp3) bond of 65. The resulting rhodacyclopentanone 66 isomerises via decarbonylation 
to give rhodacyclobutane 67, which then undergoes CO reinsertion at the less hindered alkyl position 
to provide rhodacyclopentanone 68. From here, alkyne carbometallation and reductive elimination 
affords the observed products 69a–b.  
 
 Scheme 20: Rh(I)-catalysed alkyne insertion into cyclobutanones via a decarbonylation/carbonylation sequence. 
In contrast to the preceding examples, recent contributions by Murakami and co-workers have 
shown that conversion of cyclobutanone 70 to acyl silane 73 is possible by employing a Pd(0)-catalyst 
system (Scheme 21).81 Mechanistic studies indicated that the transformation is initiated by 
Pd(0)-addition to the Si–Si bond of cyclobutanone 70 to give Pd(II)-intermediate 71. This key 
intermediate then triggers C–C bond activation of the cyclobutanone moiety, which generates Pd(IV)-
complex 72. From here, consecutive C–Si/acyl–Si reductive eliminations deliver acyl silane 73.   






Scheme 21: Pd-catalysed cyclobutanone C–C bond activation by initial insertion into a Si-Si bond.  
1.2.2.2 Benzocyclobutenone-based processes 
The processes discussed so far in this section are all triggered by insertion of a metal catalyst into the 
C(acyl)–C(sp3) of a cyclobutanone derivative. Alongside these advancements, it has also been shown 
that rhodacycloindanones can be derived from benzocyclobutenone precursors. Seminal work by 
Liebeskind demonstrated that Wilkinson’s catalyst can insert into the C(sp3)–acyl bond of 
benzocyclobutenone 74 to provide rhodacycloindanone 75a, which isomerises to the more stable 
regioisomer 75b upon heating (Scheme 22A).82 Later in 2015, computational studies revealed that 
isomerisation likely occurs by a retrocarbonylation/carbonylation sequence, rather than by reversible 
oxidative addition.83  
 
Scheme 22: Formation of rhodacycloindanones and related catalytic processes.  
In recent years, the Dong group has capitalised upon the formation of 
benzocyclobutenone-derived rhodacyclopentenones for the development of several Rh(I)-catalysed 





intramolecular cyclisations. Early studies demonstrated that exposure of benzocyclobutenones 76 to 
phosphine-ligated Rh(I)-systems resulted in isomerisation to benzocyclopentenones (e.g. 78a and 78b) 
(Scheme 22B).84 Mechanistic experiments and computational studies support a pathway involving 
Rh(I)-insertion into the less-substituted acyl–C(sp3) bond of 76, followed by β-hydride elimination and 
hydrometallation to rhodacycle 77, from which reductive elimination delivers the observed products.85 
Later in 2012, Dong and co-workers reported the regio- and enantioselective Rh(I)-catalysed cyclisation 
of benzocyclobutenones 79 bearing tethered alkenes to generate complex tricyclics (e.g. 80a and 80b) 
in moderate yield and high enantioselectivity (e.g. 63% yield and 98% e.e. for 80a) (Scheme 23A).86,87 
Interestingly, the resulting product 80a/b can be reduced to the corresponding saturated tricycle under 
Rh(I)-catalysed hydrogenative conditions. The utility of this process was showcased in the asymmetric 
total synthesis of (–)-cycloclavine and (–)-5-epi-cycloclavine (Scheme 23B).88 In this approach, 
allylaniline 81 (prepared in three steps) underwent Rh(I)-catalysed cyclisation to secure the 
fused-tricyclic core of key intermediate 82 in 95% yield and 98% e.e. This intermediate was then 
elaborated to the target molecule in a further 6 steps. Additionally, related processes involving the 
insertion of alternative π-unsaturated units, including alkynes,89 acrylamides,90 ketones91 and oximes,92 
into benzocyclobutenone-derived rhodacyclopentenones have been reported.   
 
Scheme 23: Synthesis of tricyclic heterocycles via Rh(I)-catalysed cycloadditions of benzocyclobutenones.  
 Contrary to these aforementioned processes, in 2017 Murakami outlined a Pd(0)-catalysed 
intermolecular cross metathesis of benzocyclobutenone 83 with silacyclobutane to form benzofused 
8-membered silacycles (e.g. 86a and 86b) (Scheme 24).93 Of note, optimisation studies identified t-octyl 
isocyanide as a crucial additive; this led to the isolation of palladacyclopentenone 84, which was shown 
to be catalytically active in the transformation. Computational studies support a mechanism involving 
two sequential oxidative additions and two subsequent reductive eliminations. The initial oxidative 
addition cleaves the C(aryl)–C(acyl) bond of benzocyclobutenone 83 to generate 





palladacyclopentenone 84. The second oxidative addition with silacyclobutane leads to Pd(IV)-complex 
85. This intermediate then undergoes consecutive C–Si and C(acyl)–C reductive eliminations to 
produce the observed products 86a/b.94  
 
Scheme 24: Pd(0)-catalysed intermolecular coupling of benzocyclobutanones and silacyclobutanes. 
The processes outlined in this introduction not only highlight notable achievements in 
metal-catalysed C–C bond activation of cyclopropane and cyclobutane derivatives, but also illustrates 
the diverse range of sp3-rich structures that can be accessed by adopting this approach. The varied 
reactivity modes of these sp3-rich metallacycles towards π-systems, combined with the ability to create 
a chiral environment, enables previously inconceivable molecular disconnections, which, in turn, 
facilitates the rapid synthesis of natural products and pharmaceutically relevant scaffolds. In particular, 
recent years have witnessed steady advances in applying this strain-release approach towards the 
synthesis of medium-sized ring systems. With this primary objective in mind, the research contained in 
this thesis concerns the synthesis of various 7- and 8-membered (poly)heterocycles via Rh(I)-catalysed 
carbonylative ring expansion of aminocyclopropane precursors. As an introduction to the research 
contained in the following chapters, key aspects of prior cycloaddition processes developed in the 
Bower group that are based upon Rh(I)-addition to aminocyclopropanes will now be presented.   
1.3 A directing group strategy for the generation of rhodacyclopentones 
In 2013, the Bower group initiated a research programme into the carbonylative C–C bond activation 
of aminocyclopropanes. As stated previously, critical to the success of this strategy was the 
regioselective generation of the requisite rhodacyclopentanone intermediate (see Scheme 15). 
Preliminary insertion studies revealed that exposure of carbamate-protected aminocyclopropane 87 to 
a cationic Rh(I)-source, under an atmosphere of argon, afforded linear alkene 88 as the sole product 
(Scheme 25A).15 Presumably formation of alkene 88 arises via directed Rh(I)-addition to the proximal 
bond a of 88 (i.e. generation of rhodacyclobutane I), followed by β-hydride elimination and C–H 
reductive elimination. Conversely, treatment of aminocyclopropane 87 with a neutral Rh(I)-catalyst 
proceeded to form branched alkene 89 in 9% yield, via Rh(I)-addition to the distal bond b of 87 (Scheme 





25A). It was postulated that the neutral Rh(I)-catalyst is not sufficiently Lewis acidic to be directed 
under non-carbonylative conditions. In the absence of the directing group, both cationic and neutral 
Rh(I)-sources inserted into the less hindered C–C bond (bond b) of cyclopropane 90 to provide branched 
alkenes 91/92 (Scheme 25B). Taken together, these results confirm that carbamate-directed oxidative 
addition is possible if the Rh(I)-catalyst is sufficiently Lewis acidic.  
 
Scheme 25: Preliminary insertion experiments and evaluation of potential directing groups.  
Next, to probe the relative properties of different carbamate-protecting groups, exposure of 
aminocyclopropanes 94a–c to stoichiometric amounts of [Rh(CO)2Cl]2 resulted in the formation of 
dimeric rhodacyclopentanones 95a–c (Scheme 25C).15,18 The structures of rhodacyclopentanones 95a–c 
were confirmed by X-ray diffraction. These experiments confirmed that rhodacyclopentanone 
formation results from directed Rh(I)-addition to the proximal cyclopropyl C–C bond and that the  
Rh–carbonyl directing group interaction remains ligated. Furthermore, the stretching frequency of the 
CO ligand trans to the directing group was used to quantify the donor strength of each directing group 
(Scheme 25C). From these experiments, the CO stretching frequencies indicate that directing group 
strength is proportional to the Lewis basicity of the carbonyl, and the following rank was determined: 
urea > carbamate > amide. The data acquired from these investigations was used to guide and inform 
subsequent methodology development.  





1.3.1 Rh(I)-catalysed (3+1+2) cyclisation of cyclopropane derivatives 
Having successfully demonstrated the selective generation of rhodacyclopentanones, subsequent 
studies investigated how this directing group strategy could be incorporated into a prototypical 
cycloaddition reaction. Initial studies focused on the development of a (3+1+2) cycloaddition between 
aminocyclopropanes, CO and tethered alkynes (Scheme 26). For such a transformation, the choice of 
N-directing group was critical as it must be sufficiently Lewis basic to outcompete the alkyne for 
coordination of the Rh(I)-catalyst prior to oxidative addition, but be labile enough to dissociate to allow 
alkyne coordination to the metal centre. It was discovered that strongly Lewis basic ureas fulfilled these 
criteria and offered enhanced efficiencies compared to carbamates and amides (cf. Scheme 25C).15 
Under optimised conditions, the process tolerated a range of substituents on the alkyne component, 
including alkyl- and aryl- substituted variants 96a–b, which afforded the desired cycloadducts 97a–b 
in 64% and 66% yield respectively. Additionally, for substrates possessing substituents on the tether 
(e.g 96c and 96d) good yields were obtained (e.g. 71% yield for 97c and 61% for 97d) with moderate 
levels of diastereoselectivity.      
 
Scheme 26: Development of a prototype Rh(I)-catalysed carbonylative cyclisation of aminocyclopropanes.  
 In 2015, the Bower group published a second (3+1+2) cycloaddition involving Cbz-substituted 
aminocyclopropanes 98a–d, CO and a tethered alkene unit to afford bicyclic ketones 99a–d in moderate 
to excellent yield, and with high selectivity for a trans-ring junction (Scheme 27).17 In this example, it 
was found that a less Lewis basic and more synthetically flexible carbamate could be used as the 
directing group. Notably, the high diastereoselectivities observed for R1/R2 substituted adducts (e.g. 





99b–d) likely arise via reversible formation of diastereomeric rhodacyclopetnaones I and I’ under 
cationic conditions (Scheme 27B). In this way, diastereoselectivity is controlled by the relative ease of 
alkene insertion into either diastereomeric rhodacyclopentanones I and II’. This hypothesis was 
supported by exchange studies involving stoichiometrically generated rhodacyclopentanones. 
Additionally, optimisation studies revealed that the reaction rate and yield were greatly enhanced by 
the inclusion of (E)-(CHCOOMe)2 and iso-butyramide additives. Whilst, the precise role of these 
additives was unclear, it was proposed that (E)-(CHCOOMe)2 might act as an electron-deficient 
ligand.95  
 
Scheme 27: Rh(I)-catalysed (3+1+2) cycloadditions of alkene-tethered cyclopropylcarbamates. 
The processes described so far employed non-substituted aminocyclopropane units; however, 
further studies in the Bower group have demonstrated that more highly substituted systems are also 
effective. For such systems, an additional layer of complexity arises regarding the regioselectivity of 
C–C oxidative addition. Accordingly, to gain insight into the preferred regiochemical outcome of 
processes involving trans- and cis-1,2-disubstitued cyclopropanes, a series of model 
rhodacyclopentanones were prepared (Scheme 28A). It was discovered that exposure of trans-1,2-
disubsubstitued aminocyclopropane trans-100 to stoichiometric amounts of [Rh(CO)2Cl]2 led to 





exclusive formation of dimeric species 101. Rhodacyclopentanone 101 derives from regioselective 
cleavage of the less hindered proximal C–C bond (bond a) of cyclopropane trans-100. On the other 
hand, cis-1,2-disubstituted aminocyclopropane cis-102 underwent C–C bond activation at the more 
hindered proximal C–C bond (bond b) to deliver species 103. It was reasoned that for cis-1,2-
disubstituted aminocyclopropanes, activation of the more electron-rich proximal bond (and therefore 
more strongly coordinating) is preferred as the steric constraints of the system are somewhat alleviated. 
The observations made in these studies correlated with the regioselectivities observed in (3+1+2) 
cycloaddition processes (Scheme 28B). For example, under optimised conditions, trans-104 reacted via 
Rh(I)-addition to the less-hindered bond a to afford cycloadduct 105 in 67% yield with high levels of 
regiocontrol (15:1 r.r.). Conversely, cis-104 reacted via Rh(I)-addition to the more-hindered bond b to 
provide cycloadduct 106 in 42% yield (15:1 r.r.). Therefore, the relative stereochemistry of the 
cyclopropane unit controls the regioselectivity of C–C bond activation; however, as shall be highlighted 
in subsequent studies, product regioselectivities do not always reflect the preferred regioselectivity of 
rhodacyclopentanone formation.   
   
Scheme 28: Regioselectivity observed in the Rh(I)-catalysed cyclisation of 1,2-disubstituted cyclopropanes. 





1.3.2 Nucleophilic addition to rhodacyclopentanones 
1.3.2.1 Intermolecular nucleophilic addition to rhodacyclopentanones 
During investigations into the (3+1+2) cycloaddition of cyclopropylcarbamate 107, former PhD student 
Dr. N. McCreanor observed the formation of carbonylation product 109 when iso-butyramide was used 
as a stoichiometric additive (instead of the desired cycloaddition product 110), (Scheme 29A).96 
Althought the exact mechanism for the formation of imide 109 is unclear, it most likely involves initial 
formation of rhodacyclopentanone 108, which is then intercepted by iso-butyramide by one of three 
mechanisms: (i) nucleophilic addition to the rhodacyclopentanone carbonyl; ii) nucleophilic addition to 
the Rh(III)-centre followed by C–N reductive elimination; or iii) σ-bond metathesis (Scheme 29B). In 
2000, Murakami and co-workers demonstrated that rhodacyclopentanones can be trapped by 
intramolecular phenolic oxygen nucleophiles.97 In contrast to these processes, this result represents the 
first example of intermolecular nucleophilic addition to rhodacyclopentanones, and thus presented the 
opportunity to explore new modes of reactivity of rhodacyclopentanone-based catalysis.  
 
Scheme 29: Formation of iso-butyramide adduct 109 and the possible modes of nucleophilic trapping of 
rhodacyclopentanone 108.  
Intrigued by the unexpected formation of 109, subsequent studies examined the nucleophilic 
addition of O-nucleophiles to cyclopropylcarbamate 111 (Scheme 30). Under partially optimised 
cationic conditions, phenol and benzyl alcohol were identified as effective nucleophiles, which afforded 
γ-amino-acid ester derivatives 112a and 112b in 47% and 50% yield, respectively. These investigations 





were subsequently abandoned in favour of a more synthetically valuable intramolecular variant (see 
Section 1.3.2.2). 
 
Scheme 30: Synthesis of γ-amino acid derivatives by intermolecular nucleophilic addition to 
rhodacyclopentanones.  
Recently, Wang and co-workers reported a related protocol involving intermolecular 
nucleophilic addition of α-hydroxy ketones to rhodacyclopentanones to generate α-amino acid esters 
(e.g. 116a−c, Scheme 31).98 This transformation presumably proceeds in an analogous manner (cf. 
Schemes 29 and 30) and involves initial formation of rhodacyclopentanone 114. Next, a chelating 
nucleophile coordinates to rhodacyclopentanone 114, generating metallacycle 115, from which 
subsequent reductive elimination and protodemetallation affords the observed products 116a–c.  
 
Scheme 31: Wang’s intermolecular nucleophilic addition of α-hydroxyketones to rhodacyclopentanones.  





1.3.2.2 Intramolecular nucleophilic addition to rhodacyclopentanones 
The discovery that rhodacyclopentanones could be trapped with intermolecular nucleophiles raised 
perhaps an even more interesting question: could rhodacyclopentanones be trapped with intramolecular 
nucleophiles to target valuable medium-sized heterocycles? It is well known that the synthesis of 
medium rings (8–11 membered) is challenging.99-101 For example, classical cyclisation of linear chains 
to deliver medium rings is kinetically and thermodynamically unfavourable due to entropic and 
enthalpic effects (vs. 5–7 membered rings) (Scheme 32). Entropic effects concern the frequency of 
encounters between reactive groups at the chain ends of linear precursors. On the other hand, enthalpic 
effects are associated with the cyclised product and arise due to unfavourable interactions between 
atoms across the ring. As a result, the efficiency of end-to-end cyclisation-based approaches tends to be 
highly variable and substrate dependent. With regards to the synthesis of medium-sized rings via 
intramolecular nucleophilic addition to rhodacyclopentanones, it was hypothesised that the barrier to 
cyclisation could be alleviated by two means (Scheme 32). Firstly, the kinetic barrier to cyclisation 
would be reduced through the initial formation of a “normal-sized” and kinetically accessible bicyclic 
intermediate 117. And secondly, the thermodynamic cost of forming a medium-sized ring product 
would be compensated by the release of cyclopropane ring strain. 
 
Scheme 32: Design strategy for the synthesis of medium-sized rings via kinetically accessible intermediate 117.   
1.3.2.3 (6+1) carbonylative cyclisation of cyclopropylureas 
In order to examine the strategy proposed in Scheme 32, N. McCreanor and former PhD student Dr. S. 
Stanton synthesised a diverse library of aminocyclopropanes bearing carbonyl directing groups with 
tethered O- or N-nucleophiles and subjected them to carbonylative conditions (more details are provided 
in Chapter 3).96,102 From these investigations, a prototype reaction was identified and developed in 
which cyclopropylurea substrates 118 underwent Rh(I)-catalysed carbonylative (6+1) cyclisation to 
form 7-membered diazepanes 119 and 120 (Scheme 33). In this transformation, rhodacyclopentanone 
121 derived from cyclopropylurea 118 is “captured” by the pendent NH unit to form metallabicycle 122 





(Scheme 33B). At this stage, C–N reductive elimination (“collapse”) affords Rh(I)-intermediate 123, 
which then undergoes protodemetallation to diazepane 119, or β-hydride elimination to diazepane 120. 
β-Hydride elimination from intermediate 123 forms a Rh(I)-hydride species and it is speculated that the 
active Rh(I)-catalyst is regenerated by oxidative protonation and reductive elimination of 
dihydrogen.97,103 
  
Scheme 33: “Capture-collapse” carbonylative heterocyclisation of cyclopropylureas to deliver 7-membered 
diazepanes. 
Interestingly, it was discovered that the oxidation level at the C4/C5 position in the product can 
be controlled by the choice of R1 substituent on the urea substrate, thereby allowing selective formation 
of either C4/C5 unsaturated or saturated products. More specifically, if R1 is large (i.e. R1 = alkyl or 
aryl), irreversible β-hydride elimination favours the unsaturated product 120. Conversely, if R1 is small 
(i.e. R1 = H) reversible β-hydride elimination is operational, allowing for eventual protodemetallation 
to saturated product 119. Under optimised carbonylative reaction conditions ([Rh(cod)2]BARF, PPh3, 





C6H5CO2H, 1,2-DCB, 100 °C), a range of N,N’-disubstituted cyclopropylureas 118a–c and 
trisubstituted cyclopropylureas 118d–f underwent cyclisation to the corresponding diazepane products 
in 54–85% yield (Scheme 33C). The substrates for this process are easily accessible by reacting the 
corresponding aminocyclopropanes with the desired N-aryl or N-alkyl isocyanate which, in turn, allows 
the two-step synthesis of a variety of interesting and challenging heterocyclic ring systems. 
Processes involving trans- and cis-1,2-disubstituted cyclopropane systems led to unexpected 
regiochemical outcomes and provided important insights into the mechanism (Schemes 34 and 35). For 
example, carbonylative cyclisation of trans-1,2-disubstituted cyclopropylurea trans-124 afforded 
C3-substituted diazepane 126 as the major product, where C–C bond activation has occurred via the 
more hindered bond b (Scheme 34). The selectivity observed is the inverse to that discussed previously 
in Section 1.3.1 (cf. Scheme 28). This unanticipated reactivity was rationalised by invoking C–N 
reductive elimination as the first irreversible step of the process (Scheme 34B). While C–C bond 
activation of bond a is more sterically accessible, subsequent C–N reductive elimination of 127 to 
metallacycle 128 is likely to be slow due to the developing steric clash between the bulky Rh(III)-centre 
and the R3-substituent. Consequently, under equilibrating conditions, re-protonation of the nitrogen, 
retrocarbonylation and C–C reductive elimination regenerates cyclopropylurea trans-124’. From here, 
reversible metallacycle formation enables access to the less favourable rhodacyclopentanone 129 (via 
Rh(I)-addition to the more hindered bond b of trans-124’), which then undergoes more facile C–N 
reductive elimination to metallacycle 130 (cf. 128, 1,2- vs. 1,3-relationship) and after β-hydride 
elimination, product 126’ is obtained.   






Scheme 34: Regioselectivity of the (6+1) carbonylative cyclisation of trans-1,2-disubstituted cyclopropylureas. 
On the other hand, carbonylative cyclisation of cis-1,2-disubstituted cyclopropylurea cis-131 
delivered C4-substituted diazepane 132 as the major product (Scheme 35A), whereby C–C bond 
activation occurred via the less hindered bond a. The selectivity observed is the inverse to that discussed 
previously in Section 1.3.1 (cf. Scheme 28). The observed switch in regiochemical outcome was 
justified by a similar selectivity model (Scheme 35B). In this instance, rhodacyclopentanone formation 
via bond b is favoured leading to metallacycle 134; however, subsequent C–N reductive elimination 
(134 to 135) is proposed to be slow due to developing steric clashes between the N-R2 group and the 
R3-substituent. As a result, reversible rhodacyclopentanone formation allows access to alternative 
metallacycle 136, from which C–N reductive elimination is more facile and this effect leads to selective 
formation of C4-substituted diazepane 132’. Taken together, the results for trans- and cis-1,2-
disubstituted cyclopropane systems indicated that regioselectivity is determined by the ease of C–N 
reductive elimination and not by the ease of C–C activation.  






Scheme 35: Regioselectivity of the (6+1) carbonylative cyclisation of cis-1,2-disubstituted cyclopropylureas.  
1.3.2.4 (6+1) carbonylative cyclisation of N-aryl and N-vinyl aminocyclopropanes 
Building upon the above successes, the Bower group further explored the power of “capture-collapse” 
heterocyclisations and, in 2018, disclosed the first example that involved C-based nucleophiles.21 Under 
an atmosphere of CO, Rh(I)-catalysed cyclisation of N-aryl aminocyclopropanes 138 generated 
7-membered benzazepines 142 (Scheme 36).104 Here, the mechanistic pathway was proposed to proceed 
via carbonyl directed C–C bond activation of aminocyclopropane 138 to rhodacyclopentanone 139, 
followed by C–H metallation (“capture”) to give 5,5-metallabicyclic intermediate 140. Subsequent 
C(sp2)–C(sp2) reductive elimination (“collapse”) to 141 and protodemetallation affords the target 
azepines 142. This study demonstrated for the first time the compatibility of combining C(sp2)–H 
metallation step from rhodacyclopentanones with C–C bond forming reductive elimination to form 
azepines. Under optimised conditions ([Rh(cod)2]OTf (7.5 mol%), P(4-CF3C6H4)3 (15 mol%), 
2-NO2C6H4CO2H (100 mol%) in PhCN) benzazepine 142a was generated in 82% yield. Notably, in the 
absence of 2-NO2C6H4CO2H, the yield of 142a was less than 30%, thus suggesting that the acid additive 
aids the final protodemetallation step (141 to 142). The reaction proved tolerant of a range of electron-
withdrawing and electron-donating substituents on the aryl ring. For systems with meta-substituents, 
the process was highly regioselective, as demonstrated by the formation of benzazepine 142b where 





C–C bond formation has occurred at the more sterically accessible ortho-position. Importantly, the 
scope was further elaborated to include N-vinyl substrates, which allowed direct access to 
non-benzofused azepine products 143a–b in 41–61% yield. A series of mechanistic studies on an N-aryl 
system suggest that C–C reductive elimination is the first irreversible step of the catalytic cycle. 
 
Scheme 36: Synthesis of (benz)azepines from N-aryl or N-vinyl cyclopropanes by sequential C–C and C–H bond 
activation. [a] 2-NO2C6H4CO2H was omitted. [b] 3-NCC6H4CO2H was used instead of 2-NO2C6H4CO2H. 
Extension of the protocol to trans-1,2-disubstituted aminocyclopropanes proved challenging 
and required further optimisation. Using the same conditions as shown in Scheme 36, 
trans-1,2-disubstituted aminocyclopropane trans-144 underwent Rh(I)-catalysed cyclisation to form 
approximately equal ratios of C3- and C4-methylated regioisomers 145 and 146 (Scheme 37). By a 
similar hypothesis to that presented in Section 1.3.2.3, the former product arises from the kinetically 
favoured rhodacyclopentanone 147, but subsequent C–C reductive elimination is presumed to be slow 
due to the developing steric clash between the Rh(III)-centre and the C3 substituent (Scheme 37B). 
Accordingly, reversible metallacycle formation provides kinetically disfavoured regioisomer 149, 
which can undergo C–C reductive elimination more readily to give C4-substituted product 146. To 
circumvent this issue, a more electron-deficient phosphine ligand was selected as this might promote 
faster C–C reductive of 147 to 148.105 Indeed, replacement of P(4-CF3C6H4)3 with P(C6F5)3 enabled 
selective formation of the C3-regioisomer 145 in 68% yield. Substituted cyclopropanes are easily 





accessed in enantioenriched form and pleasingly, these new conditions enabled stereospecific 
introduction of substituents at the C3 position.   
 
Scheme 37: Rh(I)-catalysed carbonylative cyclisation of trans-1,2-disubstituted cyclopropanes. [a] The yield was 
determined by 1H NMR spectroscopy using 1,4-dinitrobenzene as an internal standard. [b] Isolated yield. 
  





1.4 Project Aims 
As outlined in the previous section, the Bower group has a long-standing interest in the C–C bond 
activation of aminocyclopropanes to access sp3-rich heterobicyclic molecules via reactive 
rhodacyclopentanone intermediates. One significant advancement of this work led to the discovery that 
rhodacyclopentanones could be trapped with pendant nucleophiles to form 7-membered N-heterocycles 
via the “capture-collapse” heterocyclisation strategy. Outside of these pioneering examples and 
π-insertion processes, the reactivity of rhodacyclopentanones remains relatively unexplored. However, 
intramolecular nucleophilic addition to rhodacyclopentanones is, in principal, well-suited for the 
synthesis of valuable medium-sized rings. Therefore, the primary goal of this project is to evaluate 
further the generality of the “capture-collapse” heterocyclisation protocol to form 7- and 8-membered 
heterocyclic products (Chapters 2 and 3). Subsequent investigations will examine the ambiphilic 
reactivity of rhodacyclopentanones in the synthesis of polyheterocycles (Chapter 4). Finally, application 
of the “capture-collapse” heterocyclisation methodology will be examined in the total synthesis of 
(rac)-conolidine (Chapter 5). Herein, the successful (and unsuccessful) realisation of these goals is 
discussed. 
 
Scheme 38: Project Aims.





Chapter 2 – Modular access to 8-membered N-heterocycles by directed C–C 
bond activation of aminocyclopropanes 
Parts of the work detailed in this chapter have been adapted from a publication by Boyd et al. 
(Angew. Chem. Int. Ed. 2019, 58, 18844) 
2.1 Reaction design and discovery 
Following the successful development of a metallacycle-based blueprint to access 7-membered 
heterocycles, the question was raised as to whether related “capture-collapse” heterocyclisations could 
be employed to generate ≥8-membered heterocycles. With this definitive goal in mind, substrates of 
type I were designed and trialled under carbonylative cyclisation conditions. (Scheme 39). It was 
anticipated that nucleophilic “capture” of rhodacyclopentanone II (II to III) and subsequent C–C 
reductive elimination (“collapse”) would furnish 8-membered N-heterocycles with the general structure 
IV. As stated previously, this approach is appealing because the release of cyclopropane ring strain and 
the intermediacy of kinetically accessible bicycles (i.e. II and III) avoid the usual enthalpic and entropic 
barriers associated with medium-sized ring closure. Additionally, it was reasoned that incorporation of 
the carbonyl directing group into the new ring system would impart a conformational bias (restricted 
rotation of the amide unit) and consequently enhance access to key intermediate III. However, the 
success of such a strategy is dependent on (1) equilibrium access to the 6,5-metallabicycle III and (2) 
the barrier for C-Nu reductive elimination (i.e. III to IV).  
 
Scheme 39: Generalised reaction design for the synthesis of 8-membered N-heterocycles by “capture-collapse” 
heterocyclisation.   
In order to validate the above hypothesis, aminocyclopropylamide 151a was readily synthesised 
in two steps (vide infra) and exposed to carbonylative conditions using a cationic Rh(I)/PhCN catalyst 
system (Scheme 40). Under these conditions, amide 151a underwent cyclisation to afford equal 
amounts of C7/8 saturated heterocycle 152a and C7/8 unsaturated heterocycle 153a. As shown in 
Scheme 40, the proposed mechanism proceeds via initial carbonyl directed formation of 
rhodacyclopentanone I. Next, directing group dissociation enables metallation of the indole unit by the 
Rh(III)-centre to form 6,5-metallabicyclic II. Subsequent C(sp2)–C(sp2) reductive elimination secures 





the new C–C bond and generates Rh(I)-alkyl intermediate III. From here, either protodemetallation or 
competing β-hydride elimination pathways deliver heterocycles 152a/153a respectively. Interestingly, 
heterocycle 152a exhibited a broadened 1H NMR spectrum at room temperature; variable temperature 
NMR studies suggest that this is due to slow conformational interconversion of the strained 8-membered 
ring (more details are provided in Section 7.3.1). Additionally, no competing C–N bond formation via 
the NH unit of 151a was observed. Motivated by the novel structures of heterocycles 152a/153a and 
given the therapeutic importance of medium ring heterocycles, indole 151a was selected as a model 
substrate for further optimisation studies.  
 
Scheme 40: Carbonylative ring expansion of aminocyclopropane 151a delivered 8-membered N-heterocycles 
152a and 153a. [a] The yield was determined by 1H NMR spectroscopy using 1,4-dinitrobenzene as an internal 
standard. 
2.2 Biological importance of medium rings 
Cyclic molecular scaffolds constitute a vital component of a myriad of biologically active natural 
products and medicinally important synthetic molecules.106,107 For example, medium ring heterocycles 
have been incorporated into the design of antimalarial, anticancer, anticoagulant small molecules, as 
well as protein kinase D, protein-tyrosine phosphatase 1B and Rho kinase inhibitors (for selected 
examples see Figure 2).108-113 Compared to normal ring sizes and macrocycles (12+ membered rings), 
the conformational constraints and diverse 3D spatial properties of medium-sized frameworks are often 





associated with favourable pharmacological properties, such as; (i) increased binding affinity to a 
receptor,114,115 (ii) improved bioavailability115 and, in some cases, (iii) enhanced cell permeability.116,117 
However, despite these attractive features, medium rings are noticeably underrepresented in marketed 
drugs and drug discovery libraries. Arguably, the main obstacle preventing further application is the 
lack of broadly applicable methodologies available for accessing medium ring targets.106,118-120 Indeed, 
cyclisation-based approaches and cycloaddition reactions to generate 5- and 6- membered rings are 
common, but similar strategies to form medium-sized rings are often inhibited by entropic factors and 
transannular interactions (see Scheme 32).  
 
Figure 2: Bioactive medium-sized heterocycles.  
2.3 Synthetic approaches to 8-membered N-heterocycles 
To address this issue, recent developments in metal-catalysed cycloadditions have significantly 
increased the number of approaches to 8-membered carbocycles.121 Notable reports include 
metal-mediated (2+2+2+2),122,123 (4+2+2),124-126 (4+4)127,128 and (6+2)129-131 cycloadditions. 
Notwithstanding these advances, catalytic approaches that deliver N-heterocycles have been slow to 
emerge. The first documented Rh(I)-catalysed (4+2+2) cycloaddition for the enantioselective synthesis 
of N-heterocycles was reported by Rovis and co-workers in 2009 (Scheme 41A).132 In this example, 
exposure of dienyl isocyanates 154 and terminal alkynes 155 to a neutral Rh(I)-catalyst, in combination 
with a chiral phosphoramidite ligand L3, afforded bicyclic azocines 156 in good yields and with 
excellent enantioselectivity. Following this publication, Louie and co-workers reported the synthesis of 
azocanes 159 through a Ni(0)-catalysed cycloaddition of diynes 157 and azetidionine 158 under mild 
conditions (Scheme 41B).133  






Scheme 41: Transition metal-catalysed cycloadditions delivering 8-membered N-heterocycles. 
As shown above in Figure 2, benzannulated and heteroaromatic-annulated heterocycles form 
the structural core of numerous therapeutically important natural and synthetic molecules. To date, 
common synthetic routes to medium-sized benzannulated heterocycles include 
lactonisation/lactamisation,120 transition metal-catalysed cross-couplings134,135 and ring-closing 
metathesis.136,137 Of particular relevance to this work, Cossy and co-workers reported the synthesis of 
benzoxocines (e.g. 161a and 161b) possessing a [6.1.0] bicyclic framework via Rh(II)-catalysed 
cycloisomerisation of cyclopropenes 160 (Scheme 42).138 Under optimised conditions, benzoxocine 
161a was obtained in excellent yield and diastereoselectivity. The same strategy could be combined 
with a N-protecting group cleavage step to access benzazocane 161b, albeit with reduced efficiency.  
 
Scheme 42: Rh(II)-catalysed cycloisomerisation of cyclopropenes to generate benzoannulated 8-membered 
N-heterocycles. 
In 2015, Ma and co-workers developed a Rh(III)-catalysed (4+2+2) cyclisation between 
N-pivaloyloxy benzamides 162 and 1,6-allene-enes 163 to construct 8-membered lactams (Scheme 





43).139 These reactions proceeded at room temperature to afford the target benzannulated products 164 
in moderate to good yield (23–68% yield).      
 
Scheme 43: Rh(III)-catalysed (4+2+2) cycloadditions of benzamides and 1,6-allene-enes.  
Although progress has been made to access benzannulated carbo- and heterocycles,120 
complementary methods that provide heteroarene-fused medium-sized rings remain scarce. In this 
regard, there are only limited examples using Au, Ag or Ir catalysis to afford indole-fused 8-membered 
heterocycles.140-146 More recently, elegant examples by Zhao and co-workers have demonstrated the 
enantioselective synthesis of indole- or benzofuran-fused 9- and 10-membered heterocycles 167/169 by 
Pd(0)-catalysed (5+4)147,148 or (6+4)149 intermolecular cycloaddition reactions of azadienes (165a or 
165b) with vinylethylene carbonates 166 or vinyl oxetanes 168 (Scheme 44).  
 
Scheme 44: Pd-catalysed cycloadditions delivering indole- or benzofuran-fused 9- and 10-membered 
heterocycles. 
Whilst this section has shown that methodologies that access to indole- or benzofuran-fused 
medium-sized heterocycles are gradually emerging, examples that include other heteroarenes (e.g. 
pyrrole-annulated medium rings) are rare and, in many instances, are limited to the formation of 7-
membered ring analogues.150-154 It is conspicuous that little progress has been made to broaden the range 
of heteroaromatic units that can be fused to medium rings, which, in turn, would enable increased entry 
to pharmaceutically relevant chemical space. Hence, new methods are urgently required and ideally 





these would proceed in a direct, atom economical, diversity-orientated and stereocontrolled manner. 
With these factors in mind, studies into the newly discovered formation of heterocycles 152a/153a 
began (Scheme 40). The project was conducted in collaboration with Dr G.-W. Wang and his 
contributions are clearly indicated in the text and by footnotes under relevant Tables and Schemes.  
2.4 Preliminary Optimisation and Reaction Scope 
At the outset of this project, the initial objective was to optimise reaction conditions for the formation 
of sp3-rich saturated heterocycle 152a. As the factors governing the terminating step (i.e. 
protodemetallation or β-hydride elimination) remained unclear, a significant challenge would be 
controlling the oxidation level of the product (i.e. 152a vs. 153a). In an ideal scenario, it was hoped that 
complementary conditions would be achievable in order to selectively access either C7/8 saturated 
heterocycle 152a or C7/8 unsaturated heterocycle 153a. Key screening results from these optimisation 
studies are reported in Tables 1 and 2. The choice of solvent was found to be critical; changing from a 
coordinating solvent (e.g. PhCN) to non-coordinating solvent (e.g. 1,2-DCB) effectively inhibited 
formation of 152a (Table 1, entries 1 vs. 2), suggesting that the solvent plays an important role in 
stabilising the Rh-centre. Other coordinating solvents were assessed (e.g. DMSO and valeronitrile) but 
none of these resulted in improved yield, presumably because they coordinated too strongly to the metal 
centre and thus prevented coordination of the directing group. Using PhCN as the solvent, various 
electron-deficient phosphine ligands were tested in the reaction, with P(4-FC6H4)3 proving to be optimal 
(Table 1, entry 3). Increasing the loading of 2-NO2C6H5CO2H from 30 mol% to 100 mol% led to a 
further increase in yield of saturated heterocycle 152a to 60% (Table 1, entry 7). In accordance with 
previous studies,21 it was proposed that the acid additive serves as a proton source to facilitate the final 
protodemetallation step (i.e. III to 152a, Scheme 40). Alternative cationic Rh(I)-catalysts, including 
[Rh(cod)2]BARF and [Rh(cod)2]BF4, resulted in reduced yield of saturated 152a (Table 1, entries 8−9). 
Increasing or decreasing the reaction temperature (e.g. 130 ℃ vs. 140 ℃ vs. 150 ℃) was also 
detrimental to the yield of heterocycle 152a.  






Table 1: Selected optimisation results from the in the Rh(I)-catalysed carbonylative cyclisation of 
cyclopropylamide 151a. [a] The yield was determined by 1H NMR spectroscopy using 1,4-dinitrobenzene as an 
internal standard. [b] Isolated yields.  
In all the conditions evaluated so far, C7/8 saturated product 152a was observed as the major 
product. Subsequently, it was hypothesised that further refinement of the acid and ligand loadings might 
improve the yield and selectively for 152a. Notably, in the absence of the acid additive, only trace 
amounts of 152a were formed (Table 2, entry 1). Additionally, when the phosphine ligand was omitted, 
the yield and selectivity of 152a also decreased (24% yield, 152a:153a = 1.0:1, Table 2, entry 2). These 
control experiments verified that both the acid additive and phosphine ligand are necessary for reactivity. 
Systematic examination of the acid loading (Table 2, entries 3−8) revealed that 150 mol% of 
2-NO2C6H5CO2H increased the yield of 152a, delivering the target molecule in 72% isolated yield and 
with moderate selectivity over 153a (Table 2, entry 7, 152a:153a = 5.0:1). The selectivity for saturated 
product 152a was improved further by adjusting the ligand:catalyst ratio (1:1 vs. 2:1 vs. 3:1; Table 2, 
entries 7−9) with a 3:1 ratio providing product 152a with excellent yield and selectivity. The optimised 
reaction conditions, as outlined in Table 2, entry 10, delivered heterocycle 152a in 72% isolated yield 
and with 10:1 selectivity over unsaturated adduct 153a.  






Table 2: Evaluation of acid and ligand loadings in the Rh(I)-catalysed carbonylative cyclisation of 
cyclopropylamide 151a. [a] The yields were determined by 1H NMR spectroscopy using 1,4-dinitrobenzene as an 
internal standard. [b] Isolated yields. The ratio of 152a:153a was determined by 1H NMR analysis of crude 
material.   
2.4.1 Synthesis and scope of indole C2-cyclopropylamides  
Having optimised the carbonylative cyclisation of indole 151a, the scope of the reaction with respect to 
substituents on the indole unit was examined. To enable these studies, cyclopropylamide substrates 
151b–h were readily synthesised in a two-step process as shown in Scheme 45. Reductive amination of 
cyclopropylamine with either benzaldehyde or butyraldehyde delivered amines 170a and 170b in 67–97% 
yield. Subsequent EDCI-coupling of 170a/170b with the corresponding carboxylic acid afforded 
151a–d and 151f–j in moderate to good yield (57−79% yield, Scheme 45). In the case of phenyl 
derivative 151e, the target molecule was obtained by Suzuki cross-coupling of bromo-151g with phenyl 
boronic acid which proceeded in 71% yield.    






Scheme 45: Synthesis of indole C2-cyclopropylamides. Reagents and conditions i) corresponding aldehyde, 
NaHCO3, MeOH, reflux, 18 h then NaBH4, 0 °C to r.t., 18 h; ii) corresponding carboxylic acid, EDCI, DMAP, 
CH2Cl2, r.t. 8–18 h; iii) phenylboronic acid, Pd(PPh3)4, K2CO3, 1,4-dioxane/H2O (3:1), 105 ℃, 4 h, 71%.  
With a selection of cyclopropylamides in hand, the generality of the new protocol was 
scrutinised (Table 3). Heterocyclisations of indole derivatives with electron-donating substituents (e.g. 
R2 = methoxy, methyl, phenyl) proceeded efficiently, affording saturated heterocycles 152c, 152d, 152e 
and 152f in 48%−60% yield, and with consistently good selectivity over the C7-8 unsaturated variants 
153c−f (7:1 to 12:1). In all cases, the saturated products 152c−f could be easily separated from minor 
unsaturated products 153c−f by column chromatography. Even C5-bromo derivative 152g reacted, 
albeit in lower conversion, to afford 152g in 25% yield, with the remaining mass balance consisting of 
a mixture of unreacted 151g and protodebrominated 151g (i.e. 151a). Nevertheless, it is encouraging 
that the potentially labile C−Br bond of 151g remained intact to facilitate post-cyclisation 
functionalisation. However, this method is not without its limitations; in particular, fluorinated 
analogues 151h and 151i showed no reactivity, indicating that electron-withdrawing substituents on the 
indole unit are not compatible. The same outcome was observed for C4-substituted substrates, such as 
methoxy bearing 151j. The lack of reactivity of 151j could be explained by unfavourable steric 
interactions between the C4-substituent and the requisite rhodacycle (cf. II and III, Scheme 40), which 
consequently inhibits formation of 152j.  






Table 3: Rh(I)-catalysed carbonylative cyclisation via the C-3 position of indole cyclopropylamides. Isolated 
yields of the major product are given. The ratio of 152a–j:153a–j was determined by 1H NMR analysis of crude 
material and is given in parentheses.  
All of the carbonylative heterocyclisations described in this section have employed tertiary 
cyclopropylamide substrates. Therefore, to determine if secondary cyclopropylamides are compatible 
substrates, N−H cyclopropylamide 171a was subjected to the new protocol. In the event, expected 
8-membered heterocycles 172a/173b were not observed; instead γ-lactam 174a was isolated as the sole 
product in 50% yield (Scheme 46). Although the exact mechanism for the formation of γ-lactam 174a 
remains unclear, one possible mechanism is outlined in Scheme 46, and involves initial formation of 
rhodacyclopentanone 175. However, unlike in the previous examples (cf. rhodacyclopentanone II, 
Scheme 40), it was speculated that rhodacyclopentanone 175 can undergo β-hydride elimination via the 
N-H unit to deliver enamide 176 with a tethered Rh(III)-hydride moiety. From here, hydrometallation 
leads to 6-membered rhodacycle 177 and then C−N reductive elimination delivers the observed 
γ-lactam product 174a. Presumably this reaction pathway is favoured because complex 175 is stable; 
therefore, rotation around the amide unit is less likely as it would bring the rhodacyclopentanone into 
close proximity with the indole unit. The change in reaction outcome reinforces the original design 
hypothesis that restricted conformational freedom of the endocyclic amide unit is required to access the 
necessary metallabicycle (i.e. II to III, Scheme 40). The synthesis of γ-lactams by Rh(I)-catalysed 
carbonylative ring-expansion of aminocyclopropanes has previously been reported in the literature.155 





A comparison with this method and subsequent investigations into the synthesis of related γ-lactams 
will be addressed in Section 3.3.  
 
Scheme 46: Proposed mechanistic pathway for the formation of γ-lactam 174a by the Rh(I)-catalsyed 
carbonylative cyclisation of secondary cyclopropylamide 171a.  
2.4.2 Evaluation of alternative heteroaromatic C2-cyclopropylamides 
Encouraged by the successful cyclisation of indole derivatives 151a–g, the protocol was extended to 
other classes of heteroarenes. C2-cyclopropylamides 151k–n were synthesised following the equivalent 
two-step procedure described for indole derivatives 151 (cf. Scheme 45, see Section 7.3.1 for further 
details). Pyrrole (151k), furan (151l) and thiophene (151m) systems participated in the transformation 
to provide C7/8 saturated heterocycles 152k–m in moderate to good yield (24–48%, Table 4) and with 
moderate levels of selectivity over unsaturated heterocycles 153k–m (4:1 to 6:1). Of note, the yield of 
these systems corresponds with the nucleophilicity of heteroaromatic unit 
(pyrrole>furan>thiophene),156 suggesting that perhaps the C(sp2)−H metallation step proceeds via 
electrophilic aromatic substitution (i.e. from II to III, Scheme 40) and not a concerted metallation 
deprotonation (CMD) type pathway. On the other hand, while the conversion of N-methyl pyrrole 151n 
to heterocycles 152n and 153n was high, selectivity was low (combined yield of 72%, 152n:153n = 
2:1). This result suggests that a more electron rich heteroarene promotes β-hydride elimination over 
C8-protodemetallation. However, the exact reason for the different product ratios obtained by simply 
methylating the starting material cannot be easily explained (N−H pyrrole 152k:153k, 6:1 vs. N-methyl 
pyrrole 152n:153n, 2:1). It was postulated that an electron-rich heteroarene may facilitate β-hydride 
elimination by enhancing the developing cross-conjugation between the arene and C7−C8 double bond. 
This interpretation must be treated with caution and alternative mechanistic pathways for the formation 





of 153n cannot be discounted (see Section 2.6 for further discussion). Regardless, the reduced 
selectivity for the formation of N-methyl pyrrole 152n was not considered a major restriction (owing to 
the ease of installation the methyl group from NH-pyrrole 152k) and without doubt, NH-pyrrole 152k 
is a more synthetically flexible target.   
 
Table 4: Evaluation of alternative heteroaromatic C2-cyclopropylamides. Isolated yields of the major product are 
given. The ratio of 152k–n:153k–n was determined by 1H NMR analysis of crude material and is given in 
parentheses. [a] P(3,4,5-(F)3C6H2)3 (22.5 mol%) was used.  
2.4.3 Evaluation of heteroaromatic C3-cyclopropylamides  
The studies outlined so far form 8-membered ring heterocycles via the C3 position of the heteroarene 
unit. Five-membered heteroaromatics are nucleophilic via C2 and C3; consequently, it was proposed 
that complementary processes might be achieved by attaching the cyclopropylamide unit to the C3 
position, which, in turn, would allow for cyclisation via the C2 position of the heteroarene. To test this 
hypothesis, indole 178a was readily prepared (see Section 7.3.1) and under the established 
Rh(I)-catalysed carbonylation protocol, C7/8 saturated heterocycle 179a was formed in 42% yield with 
moderate selectivity over alkene 180a (Table 5, 179a:180a = 4:1). Pleasingly, the process extended to 
other heteroaromatics, as demonstrated by the cyclisation of 178b–e, which generated 179b–e in 
synthetically useful yields (24−67% yield). Significantly for products 179c–e competing cyclisation via 
C4 was not observed and the structure of 179e was confirmed by single crystal X-ray diffraction. The 
processes in Table 5 offer distinct regioselectivity from those in Tables 3 and 4, such that depending on 
the substrate used, the position of the N-centre can easily be programmed into the 8-membered ring 
system.  






Table 5: Rh(I)-catalysed carbonylative cyclisation via the C-2 position of heteroaromatic cyclopropylamides. 
Isolated yields of the major product are given. The ratio of 179a–e:180a–e was determined by 1H NMR analysis 
of crude material and is given in parentheses. [a] The yield was determined by 1H NMR spectroscopy using 
1,4-dinitrobenzene as an internal standard.  
Taken on balance, the results obtained from this scope exploration did not reach our threshold 
for a robust and general protocol. In other words, even though the protocol could be applied to a wide 
range of heteroaromatic substrates, additional efforts were needed to fine-tune the yield and selectivity 
for the desired saturated products. It was therefore decided that that the reaction should be redeveloped 
from first principles. Thus, indole 178a was selected for further optimisation studies and investigations 
to identify second generation conditions began.  
2.5 Second Generation Optimisation Studies  
First, a simple survey of reaction solvents (DMF, DMSO, valeronitrile) was undertaken, but no desired 
product was observed in these reactions, and indole 178a either degraded or did not react. Interestingly, 
substitution of PhCN for 1,2-DCB (a non-coordinating solvent) afforded 7-membered heterocycle 181 
in 5% in situ yield (Scheme 47). It is unclear exactly how heterocycle 181 forms, but one possibility 
might involve extrusion of CO via insertion of the Rh(I)-catalyst into the acyl–C(sp2) bond of 179a 
(Scheme 47A).69 Alternatively, a rhodacyclobutane-based pathway might be operational (Scheme 47B). 
In this scenario, directed formation of rhodacycle 182 is followed by extrusion of CO to give 
intermediate 183. From here, C(sp2)–Csp3) reductive elimination and protodemetallation affords 
7-membered heterocycle 181. Investigations into the feasibility of these mechanistic proposals are 
discussed in more detail in Section 2.7.2. 






Scheme 47: Rh(I)-catalysed carbonylative heterocyclisation of indole 178a in 1,2-DCB delivered 7-membered 
heterocycle 181. [a] The yield was determined by 1H NMR spectroscopy using 1,4-dinitrobenzene as an internal 
standard.  
Returning to the primary task of improving the yield and selectivity of 179a, a number of 
electron-deficient ligands were evaluated in PhCN with [Rh(cod)2]OTf, but none of these improved the 
yield of heterocycle 179a (Table 6, entries 1–4). Different cationic Rh(I)-sources, including 
[Rh(cod)2]BARF and [Rh(cod)2]BF4, also failed to increase the yield (Table 6, entries 5–6). 
Subsequently, a range of neutral Rh(I)-catalysts, (e.g. [Rh(cod)OMe]2, [Rh(cod)OH]2 and [Rh(cod)Cl]2, 
Table 6, entries 7–9) were trialled. It was found that switching to [Rh(cod)OMe]2 provided a 
breakthrough, with the target heterocycle 179a isolated in 58% yield and with improved selectivity over 
180a (179a:180a = 6.5:1, Table 6, entry 9). Presumably the methoxide ligand can exchange more 
effectively with the acid additive to form an active Rh(I)-carboxylate catalyst.157 In line with these 
thoughts, a wide array of acid additives (e.g. AdCO2H, fumaric acid, diphenyl acetic acid, hexanoic 
acid and electronically distinct benzoic acid derivatives) was screened. In general, good efficiency was 
maintained with these acid additives (typically 45–72 % in situ yield of 179a) but none offered 
significant advantages over 2-NO2C6H5CO2H with respect to selectivity for C7/8 saturated 179a 
(typically 179a:180a = 2:1). Additionally, these studies revealed no trends with respect to the steric 
environment, acidity or the coordinating ability of the acid additive; therefore, as 2-NO2C6H5CO2H 
offered the highest levels of selectivity, optimisation studies continued with this acid.  






Table 6: Selected optimisation results from the Rh(I)-catalysed carbonylative cyclisation of cyclopropylamide 
179a. The ratio of 179a:180a was determined by 1H NMR analysis of crude material. [a] 3.75 mol% was used for 
dimeric Rh(I)-catalysts and 7.5 mol% was used for monomeric Rh(I)-catalysts. [a] The yield was determined by 
1H NMR spectroscopy using 1,4-dinitrobenzene as an internal standard. [c] Isolated yields. [d] 20 mol% silver 
benzoate used as an additive. [e] The reaction temperature was 130 ℃.  
A key reaction parameter that had not been investigated so far was the reaction concentration. 
Interestingly, increasing the concentration (0.1 M vs. 0.2 M vs 0.3 M) had a beneficial effect on the ratio 
of 179a:180a (Table 6, entries 9 and 11–12). When the reaction was carried out 0.3 M, saturated product 
179a was obtained in slightly diminished yield of 56%, but improved levels of selectivity were achieved 
(179a:180a = 9.5:1, Table 6, entry 12). Increasing the concentration from 0.3 M to 0.4 M was 
detrimental to the yield of 179a (Table 6, entry 13). Whereas, lowering the reaction temperature to 130 ℃ 
at 0.3 M afforded the target saturated heterocycle in 58% yield and with 10:1 selectivity over the 
unsaturated product 180a (Table 6, entry 14). No further improvement in yield was achieved through 
variation of these or other reaction components. Compared to the first generation conditions (see Table 
2), the second generation conditions (as outlined in Table 6, entry 14) afforded the target saturated 





heterocycle 179a in a superior yield (58% vs. 44%) and more critically with enhanced selectivity over 
the unsaturated adduct 180a (4:1 vs. 10:1). These improvements were achieved by replacing 
[Rh(cod)2]OTf with [Rh(cod)OMe]2 and increasing the concentration of the reaction mixture.  
2.6 Evaluation of second generation conditions 
Having established an upgraded protocol, the second generation conditions were used to reinvestigate 
the scope of the (7+1) carbonylation cyclisation (Table 7). For comparative purposes, the yields and 
product ratios obtained under the cationic Rh(I)-catalysed conditions developed in Section 2.4 are 
quoted in square brackets.  
 






Table 7: Evaluation of second generation catalysis conditions. Isolated yields of the major product are given. The 
ratio of 152a–o:153a–o and 179a–f:180a–f was determined by 1H NMR analysis of crude material and is given 





in parentheses. The yield of 152a–n/179a–e and ratio 152a–n:153a–n/179a–e:180a–e using first generation 
conditions is reported in square brackets. [a] P(3,4,5-(F)3C6H2)3 (22.5 mol%) was used. [b] The yield was 
determined by 1H NMR spectroscopy using 1,4-dinitrobenzene as an internal standard. [c] The reaction 
temperature was 140 ℃.  
Under the new conditions, cyclisation via the C3 position of electronically distinct indoles 
provided adducts 152a–f and 152h in moderate to excellent yield (44–77%), and with good selectivity 
(8:1 to >15:1) over the corresponding C7/8 unsaturated variants 153 (Table 7A). Of note is the dramatic 
improvement in yield of fluorinated product 152h (65% yield), which was previously not observed 
using the [Rh(cod)2]OTf catalyst system. Other classes of heteroarene also participated with greater 
efficiency. For example, heterocyclisation of thiophene 151m proceeded smoothly to give 152m in 50% 
isolated yield, compared to 24% under the first generation conditions. Likewise, cyclisation via the C2 
position of heteroarenes 178c–f afforded saturated adducts 179c–f in good to excellent yield (51–72%) 
and with good selectivity over 180c–f (Table 7B). However, limitations in the scope include benzofuran 
152o, aryl bromide 152g and benzothiophene 179b, which were generated in 17%, 18% and 23% yield 
respectively. In addition, attempted carbonylative cyclisation of C4-substituted indole substrates, such 
as difluoro analogue 151i and methoxy analogue 151j, delivered no product and unreacted starting 
material was recovered completely. Overall, despite these minor limitations, the new second generation 
conditions significantly increased the yield of the target heterocycles 152/179, and considering the 
challenges associated with medium-sized closure, these results proved more than satisfactory.  
To expand the synthetic versatility further, we next examined the carbonylative 
heterocyclisation of pyrrole 186a, where the C2 position is blocked by a methyl group (Scheme 48). 
Exposure of pyrrole 186a, prepared in two steps from pyrrole 184 and amine 170a (Scheme 48A), to 
the [Rh(cod)OMe]2/P-(4-FC6H4)3/2-NO2C6H4CO2H catalyst system provided C7/8 saturated 
heterocycle 187a in 25% yield and unsaturated heterocycle 188a in 12% isolated yield (Scheme 48B). 
The majority of the remaining mass balance consisted of unreacted pyrrole 186a (32%).   






Scheme 48: Preparation and Rh(I)-catalysed carbonylative cyclisation of pyrrole 186a. A) Reagents and 
conditions; (i) LiOH.H2O, 1,4-dioxane/H2O, reflux, 4 hours, 95%; (ii) EDCI, DMAP (10 mol%), CH2Cl2, r.t., 16 
h, 40%. [a] The yield was determined by 1H NMR spectroscopy using 1,4-dinitrobenzene as an internal standard. 
Attempts to improve the yield of C7/8 saturated heterocycle 187a by evaluating the Rh(I)-pre- 
catalyst (e.g. [Rh(cod)2]OTf, [Rh(cod)2]BARF or [Rh(cod)OH]2), the phosphine ligand (electron-rich 
vs. electron-poor) and the reaction temperature (120 ℃ vs. 130 ℃ vs. 140 ℃) provided no improvement. 
However, the replacement of 2-NO2C6H4CO2H with AdCO2H gave a marked improvement in the 
reaction yield. Using 150 mol% of AdCO2H, the total cyclisation yield was 58% with approximately 
equal amounts of heterocycles 187a and 188a (Table 8, entry 3). To address the selectivity issue, it was 
anticipated that altering the loading of AdCO2H would favour formation of saturated 187a. However, 
whilst decreasing or increasing the loading of AdCO2H afforded 187a with comparable yields, the 
selectivity over 188a remained unchanged (i.e. 187a:188a = 1:1, Table 8, entries 3–5).  
 
Table 8: Selected optimisation results from the Rh(I)-catalysed carbonylative cyclisation of cyclopropylamide 
186a. [a] The yield was determined by 1H NMR spectroscopy using 1,4-dinitrobenzene as an internal standard. 
[b] Isolated yields. [c] The reaction concentration was 0.1 M. 





It was proposed that the poor selectivity for 187a might have resulted from the steric bulk of 
the amide benzyl group preventing protodemetallation in the desired terminating step. Accordingly, 
replacement of the benzyl group of 186a with a smaller methyl group was investigated. Against 
expectation, the heterocyclisation of N-methyl cyclopropylamide 186b under [Rh(cod)OMe]2/AdCO2H 
conditions proceeded with similar efficiency and selectivity (Scheme 49). Heterocycles 187b and 188b 
were not isolated but assigned based on comparison with the benzyl variants 187a/188a. 
 
Scheme 49:Rh(I)-catalysed carbonylative cyclisation of pyrrole 186b. [a] The yield was determined by 1H NMR 
spectroscopy using 1,4-dinitrobenzene as an internal standard. 
As efforts to hone selectivity for the saturated product 187a by virtue of the catalytic system 
and by design of the substrate proved ineffective, an alternative strategy was sought. To this end, 
following exposure of pyrrole 186a to [Rh(cod)OMe]2/AdCO2H carbonylative conditions, the crude 
mixture was subjected to Rh(I)-catalysed hydrogenation conditions.158,159 This procedural modification 
enabled smooth reduction of the enamide of 188a and, in doing so, pyrrole 187a was isolated in 58% 
yield for the two-step process (Scheme 50). Alternatively, reduction of the enamide of 188a could be 
achieved using milder conditions. For example, hydrogenation of 188a using Pd/C/H2 (1 atm), afforded 
saturated heterocycle 187a in 89% yield (more details are provided in Section 7.3.1).    
 
Scheme 50: Two-step reaction sequence for the formation of pyrrole 187a. 
The heterocyclisations discussed so far all rely on electron-rich heteroarenes as the nucleophilic 
component. Therefore, to test the limits of the arene unit, phenyl-based systems 189 and 190 were 
explored; however, both substrates were unreactive under the standard catalytic conditions (Scheme 
51). These results confirm that an electron-rich arene is essential for reactivity. Additionally, imidazole 
191 was also found to be incompatible, presumably because the basic nitrogen atom coordinates to the 
Rh(I)-catalyst and deactivates it (Scheme 51).  






Scheme 51: Evaluation of alternative (hetero)arene substrates.  
2.6 Mechanistic studies 
At this stage, a series of experiments was undertaken to probe the mechanism of the reaction (Schemes 
52 and 53). More specifically, we wanted to (i) elucidate the role of the acid additive and (ii) establish 
the first irreversible step of the transformation. To enable these studies, indole 178a was selected 
because the signal corresponding to the C2-proton could be distinguished by 1H NMR spectroscopy in 
d3-acetonitrile. When the heterocyclisation of indole 178a was run using 2-NO2C6H4CO2D (prepared 
by dissolving 2-NO2C6H4CO2H in d4-methanol and concentrating in vacuo three times) deuterium 
incorporation was observed at C-6 (30% D) and C-8 (16% D) (deuterio-179aa, Equation 1). At partial 
conversion, significantly lower levels of deuterium incorporation were observed at C-6 (10% D) and 
C-8 (10% D) (deuterio-179ab, Equation 2). More importantly, 1H and 2D NMR analysis of recovered 
staring material from this experiment, revealed low levels of deuteration in deuterio-178aa at C-2 
(4% D). Taken together, these observations are consistent with deuterium incorporation at C-8 
occurring at the proposed protodemetallation step (i.e. III to 152a, Scheme 40) and deuteration at the 
C-6 position occurring via enolisation of the product. To confirm the latter proposition, re-subjection 
of cyclised product 179a to identical catalysis conditions led to 28% deuterium incorporation at C-6 
(deuterio-179ac, Equation 3).  






Scheme 52: Mechanistic experiments.  
The question remained as to how deuterium incorporation at C-2 of deuterio-178aa arises. To 
probe this, indole 192, which lacks a cyclopropyl unit, was exposed to the Rh(I)-catalyst system in the 
presence of 2-NO2C6H4CO2D (Equation 4). No deuterium incorporation was observed at the C2–H 
position, which seemingly rules out an exchange pathway involving carbonyl directed C-H activation 
of 178a. Guided by this evidence and by previous reports,21 we suggest that reversible carbonylative 
C–C bond activation to the rhodacyclopentanone (i.e. rhodacyclopentanone I, Scheme 40) precedes 
reversible C2–H metallation.  
 
Scheme 53: Mechanistic experiments.  
Further insight into the reaction mechanism was gained by stopping the reaction at specific time 
intervals with 178a or deuterio-178ab and determining the conversion to product 179a/deuterio-179ad. 





These studies revealed a relatively small kinetic isotope effect (kH/kD = 1.14, Equation 5),160 suggesting 
that C–H metallation is not turnover limiting. Additionally, these observations are consistent with C–C 
reductive elimination being the first irreversible step, which might be due to the challenging ring size 
being formed. With this rationale in mind, more nucleophilic arenes may promote C–C reductive 
elimination by enhancing equilibrium access to the required metallacycle (cf. metallacycle III, Scheme 
39). This notion is supported by (1) the efficiency trends observed for substrates 151k–m (Table 4) and 
(2) the failure of phenyl-based systems to participate in the reaction (Scheme 51). The minor amounts 
of C7/C8 unsaturated products (153a–o and 180a–f) observed throughout these studies could result 
from β-hydride elimination after the C–C reductive elimination step. In this instance, turnover might be 
achieved by protonation of the Rh(I)-hydride and reductive elimination of dihydrogen (see Schemes 33 
and 40).20,103 
Finally, the importance of an endocyclic amide directing group was confirmed by exposing 
exo-variant 193a to the optimised conditions (Scheme 54). In this example, decomposition of starting 
material 193a occurred and azocane 194a was not observed. Overall, the mechanistic experiments 
outlined in this section are consistent with the proposed carbonylative cyclisation mechanism (Scheme 
40) and corroborate previous observations by the Bower group.21  
 
Scheme 54: Evaluation of exo-variant 193a in the Rh(I)-catalysed carbonylation protocol.  
2.7 Synthesis and scope of substituted aminocyclopropanes 
Having gained a clearer understanding of the reaction mechanism, attention turned to evaluating 
1,2-disubstituted cyclopropylamides under the new protocol.  Key requirements for 1,2-disubstituted 
cyclopropane-based processes include: (1) regioselective generation of the rhodacyclopentanone 
intermediate and (2) transfer of this regiochemistry to the product. As discussed previously, directed 
rhodacyclopentanone formation from trans-1,2-disubstituted cyclopropanes occurs with high 
selectivity via the less hindered proximal C–C bond (see Section 1.3.1). Accordingly, it was envisaged 
that similar regioselectivity would be operative in the new heterocyclisation protocol and therefore, 
selective access to C-7 substituted products would be achievable. Additionally, substituted 
cyclopropanes are easily accessed in enantioenriched form, and so it was anticipated that stereospecific 
introduction of substituents on the 8-membered ring would be accomplishable. 





2.7.1 Synthesis of cyclopropylamides containing 1,2-disubstituted cyclopropanes 
A representative range of 1,2-disubstituted cyclopropylamide substrates was prepared by a previously 
developed route (Scheme 55).16 First, epoxidation of allylbenzene 195 afforded benzyloxirane 196c in 
good yield. Epoxides 196b–c (196b was commercially available) then underwent a modified 
trans-selective Wadsworth-Emmons cyclopropanation with triethylphosphonoacetate to afford 
cycloproylesters 197b–c in excellent yield.161,162 Next, hydrolysis of cyclopropylesters 197b–c provided 
the corresponding carboxylic acids 198b–c. Subsequent Curtius rearrangement of carboxylic acids 
198a–c (198a was commercially available) with diphenylphosphoryl azide in t-BuOH delivered 
Boc-protected aminocyclopropanes 199a–c in 55–79% yield.163 TFA mediated Boc-deprotection of 
199a–c, followed by reductive amination with benzaldehyde gave N-benzyl amines trans-200a–c and 
cis–200a. At this point, trans-200a and cis-200a were separated by column chromatography, thus 
allowing easy access to either diastereomer. EDCI coupling of N-benzyl cyclopropylamines 
trans-200a–c/cis-200a with indole-1H-2-carboxylic acid afforded the 1,2-disubstuted 
cyclopropylamides trans-201a–c, cis-201a in 60–80%. Of note, enantioenriched trans-benzyl 
cyclopropylcarboxylic acid (S,S)-198c was formed from commercially available (R)-propylene oxide 
by a reported procedure.164,165 Advancement to indole (S,S)-201c was achieved in a manner analogous 
to (trans)-201c. 
 
Scheme 55: Synthesis of 1,2-disubstituted aminocyclopropanes. Reagents and conditions: i) m-CPBA, CH2Cl2, 
0 ℃ to r.t., 18 h; ii) triethylphosphonoacetate, n-BuLi, 1,2-dimethoxyethane, 130 ℃, 18 h; iii) 4 M aq. NaOH, 
MeOH, r.t., 18 h; iv) diphenylphosphoryl azide, Et3N, t-BuOH, 80 ℃, 18 h; v) TFA, CH2Cl2, r.t., 2 h then 
benzaldehyde, NaHCO3, MeOH, reflux, 3 h then NaBH4, 0 ℃ to r.t., 18 h; vi) indole-1H-2-carboxylic acid, EDCI,  
DMAP, CH2Cl2, r.t. [a] Commercially available. [b] Commercially available as a 4:1 (trans:cis) diastereomeric 





mixture. [c] The trans- and cis-diastereomers were separated by flash column chromatography. [d] Synthesised 
by G.-W. Wang.  
2.7.2 Evaluation of trans-1,2-disubstituted cyclopropylamides 
With the required trans-1,2-disubstituted cyclopropylamides in hand, they were subjected to the second 
generation [Rh(cod)2OMe] catalyst conditions (Scheme 56). Disappointingly, trans-201a–c all failed 
to undergo the desired heterocyclisation and in each case, substantial amounts of unreacted starting 
material was recovered. It was reasoned that the lack of reactivity exhibited by trans-201a–c stemmed 
from one overarching predicament: the increased steric demands of the systems impeded C–C bond 
activation. Using trans-201b as a model substrate, several key reaction parameters were re-evaluated 
such as catalyst ([Rh(cod)OMe]2 vs. [Rh(cod)2]OTf), phosphine ligand (electron-rich vs. electron-poor), 
acid additive (alternative benzoic acids and aliphatic acids) and temperature (130 ℃ vs. 140 ℃ vs. 
150 ℃). Unfortunately, trans-201b proved extremely resistant to C–C bond activation and no product 
arising from insertion into either the less hindered bond (bond a) or the more hindered bond (bond b) 
of trans-201b was detected under any of the conditions tried.   
 
Scheme 56: Attempted Rh(I)-catalysed carbonylative cyclisation of trans-1,2-disubstituted cycloproproylamides 
trans-201a–c.  
It was hypothesised that the endocyclic amide directing group of trans-201a–c might be 
facilitating insertion of the Rh(I)-catalyst into the N–H bond of the indole unit, and thereby rendering 
that catalyst inactive. Therefore, to circumvent this pathway and to gauge the impact of an N-substituent 
on promoting cyclisation, N-methyl trans-202b, N-benzyl trans-203 and N-tosyl trans-204 were 
prepared and evaluated in the heterocyclisation protocol using [Rh(cod)2]OTf  (Table 9).  






Table 9: Effect of N-indole substituents on the Rh(I)-catalysed carbonylative cyclisation of 
trans-1,2-disubstituted cyclopropylamides. [a] The yield was determined by 1H NMR spectroscopy using 
1,4-dinitrobenzene as an internal standard.  
Remarkably, N-methyl trans-202b cyclised via oxidative addition into the less hindered C–C 
bond (bond a of N-methyl trans-202b) in 14% yield to deliver unsaturated C7-substituted adduct 205b 
as a single regioisomer. Increasing the steric bulk of the N-indole substituent had a detrimental effect 
on the yield (14% for N-methyl 202b vs. 9% for N-benzyl 206). No product was observed when N-tosyl 
trans-204 was employed, confirming an earlier hypothesis that an electron-rich heteroarene is necessary 
(see Scheme 51). Additionally, in all cases, a low mass recovery of starting material was obtained, 
suggesting that the required rhodacyclic intermediates were potentially forming but decomposing prior 
to cyclisation. From a regioselectivity viewpoint, the sole formation C7-substituted heterocycles 
205b/206 indicates that steric preferences of the system overrides the electronic preferences of C–C 
bond activation (i.e. the Rh(I)-catalyst inserts preferentially into bond a of trans-202b/trans-203). 
Nevertheless, based on the studies described so far and from a mechanistic viewpoint, the exclusive 
formation of C7/8 unsaturated heterocycles 205b and 206 was unexpected. To aid the understanding 
of this reaction outcome, the mechanistic pathways to C7-substituted heterocycles 205’/208’ and 
C6-substituted heterocycles 213’/214’ are examined in Scheme 57. 






Scheme 57: Proposed mechanistic pathway for the Rh(I)-catalysed carbonylative heterocyclisation of trans-202’.  
As depicted in Scheme 57, formation of C-7 regioisomer 208’ proceeds via initial oxidative 
addition of the Rh(I)-catalyst into the less hindered C–C bond (bond a) of trans-202’, which, after C–H 
metallation forms metallacycle 209. Subsequent C–C reductive elimination from intermediate 209 is 
most likely to be slow due to the ensuing steric clash between the Rh-centre and the C-7 substituent. 
From intermediate 210, only protodemetallation is permissible to give saturated heterocycle 208’. 
Alternatively, the formation of C-6 regioisomers 213’ and 214’ might occur and in this scenario, 
Rh(I)-addition to the more hindered C–C bond (bond b) of trans-202’ affords the kinetically 
disfavoured metallacycle 211. From intermediate 211, C–C reductive elimination to the C-6 
regioisomer 212 is most likely to be faster (cf. 210, 1,2- vs. 1,3-relationship) and terminating 
protodemetallation or β-hydride elimination gives heterocycles 213’ or 214’. However, neither of these 
mechanistic pathways can account for the formation of C7/8 unsaturated heterocycles 205b/206 as there 
is no syn-β-hydride available at the stage of metallacycle 210. Consequently, it was speculated that the 
formation of these products might be rationalised by invoking the nitrogen lone pair of the amide unit 
(Scheme 57B). In this scenario, following formation of intermediate 210, oxidative protonation of the 





Rh-centre triggers the nitrogen lone pair to eliminate a Rh(I)-hydride species to give iminium ion 217. 
This elimination might be promoted by the relief of unfavourable steric interactions between the R3 
substituent and Rh-centre, and also facilitated by a relatively electron-poor cationic Rh(III)-hydride 
leaving group. Tautomerisation of 217 would then provide unsaturated heterocycle 205’. 
However, despite this rationale, the exclusive formation of C7/8 unsaturated variants 205b and 
206 is still unexpected. Indeed, as shown previously in Table 7, the C7/8 unsaturated analogues 153/180 
were formed as the minor product during the evaluation of simple cyclopropylamides. As such, the 
question was raised as to how to account for the absence of the C7/8 saturated heterocycles 208’ (or 
213’) when 1,2-disubstituted cyclopropylamides were subjected to the catalytic protocol. The 
mechanistic studies discussed in Section 2.4 support the formation of C7/8 saturated heterocycles 
occurring via protodemetallation of an alkyl-Rh(I) intermediate However, it is conceivable that 
generation of these products might arise via  hydrometallation of the C7/8 unsaturated adducts (i.e. 205’) 
with a Rh(III)-hydride species. With this in mind, it was speculated that following Rh(I)-addition to 
trans-202’ and CO insertion (cf. rhodacyclopentanone II, Scheme 40), decomposition to an N-vinyl 
amide via β-hydride elimination might occur more readily than the desired C–H metallation (i.e. 210 to 
208’). Assuming Rh(III)-H is released reversibly, then competition arises between the speculative N-
vinyl amide and the unsaturated product 205’ with regards to subsequent hydrometallation.  
In addition to these factors, the mechanistic insights outlined in Section 2.4, support the notion 
that the C–C reductive elimination step (i.e. III to 152a, Scheme 40) is the first irreversible step. In the 
case of 1,2-disubstituted cyclopropylamides, an extra layer of complexity is added to this step due to 
the unfavourable steric interactions between the Rh-centre and the R3 substituent, thus making it even 
more challenging. To combat this issue, third generation reaction conditions were sought to (1) promote 
C–C reductive elimination and (2) promote protodemetallation in the terminating step.  
2.7.3 Third generation optimisation studies of challenging substrate trans-202a  
Following this unanticipated result, trans-1,2-disubstituted cyclopropylamide trans-202a was selected 
as a pilot substrate for further optimisation studies. In collaboration with G.-W. Wang, over 200 reaction 
conditions were evaluated and the most significant findings are presented in Tables 10 and 11. First, 
neutral Rh(I)-sources, including [Rh(cod)OMe]2 and [Rh(cod)Cl]2, were evaluated, with both catalysts 
improving the yield of C7/8 unsaturated product 205a compared to cationic [Rh(cod)2]OTf (24% for 
[Rh(cod)OMe]2 and 17% for [Rh(cod)Cl]2 vs. 7% for [Rh(cod)2OTf]2, Table 10, entries 1–3). Next, it 
was envisaged that the inclusion of a sterically demanding phosphine ligand might promote faster C–C 
reduction elimination and/or suppress β-hydride elimination and hence promote formation of saturated 
heterocycle 208a. Strikingly, replacement of P(4-FC6H5)3 with (rac)-BINAP afforded a mixture of C7/8 
saturated heterocycle 208a as the major product in 20% yield and C7/8 unsaturated heterocycle 205a 
as the minor product in 13% yield (Table 10, entry 4). Following this promising result, over 20 





commercially available bidentate phosphine ligands were screened, but no increase in yield or 
selectivity for product 208a was achieved. Even more intriguingly, in the absence of (rac)-BINAP 
products 208a and 205a were obtained with similar levels of efficiency (20% and 11% yield 
respectively, Table 10, entry 5). In comparison, when 2-NO2C6H4CO2H was omitted, the saturated 
product 208a was not observed (Table 10, entry 6). These control experiments underpin the synergistic 
role of the acid additive as (1) a proton source to aid protodemetallation as the terminating catalytic step 
(i.e. the conversion of 210 to 208’, Scheme 57A) and (2) as a ligand to stabilise off-cycle Rh-species.   
  
Table 10: Selected results from the optimisation of challenging substrate cyclopropylamide trans-202a. [a] 3.75 
mol% was used for dimeric Rh(I)-catalysts and 7.5 mol% was used for monomeric Rh(I)-catalysts. [b] 7.5 mol% 
rac-BINAP or 15.0 mol% P(4-(F)C6H4)3 was employed. [c] Yields were determined by 1H NMR spectroscopy 
using 1,4-dinitrobenzene as an internal standard. [d] Isolated yield. [e] Results obtained by G.-W. Wang. [f] 
2-NO2C6H4CO2H was omitted. 
Optimisation studies next focussed on screening alternative acid additions. Replacement of 
2-NO2C6H4CO2H with benzoic acid or acetic acid A2 proceeded to generate 208a in improved yields 
of 35% and 29% yield (Table 11, entries 1–2). Other benzoic and aliphatic acids were trialled (e.g. 
4-NMe2C6H4CO2H, AdCO2H, pivalic acid, hexanoic acid) but none offered a further improvement. As 
discussed in Section 1.3.1, (E)-(CHCOOMe)2 was found to be a beneficial additive in the (3+1+2) 
cycloaddition of aminocyclopropanes with tethered alkenes.17 Consequently, it was reasoned that an 
electron-deficient ligand and/or acid additive could be advantageous in both (1) accelerating C–C 
reductive elimination and (2) inhibiting β-hydride elimination and hence improve the yield of 208a.166 
With this hypothesis in mind, (E)-(CHCOOMe)2 was assessed but was found to be completely 
ineffective (Table 11, entry 3). Gratifyingly however, the use of (E)-(CHCOOH)2 delivered the target 
molecule 208a in 44% isolated yield and with good selectivity over unsaturated variant 205a (Table 10, 
entry 4, 208a:205a = 9.0:1). When (E)-(CHCOOMe)2 and (E)-(CHCOOH)2 were used in combination, 





the yield of product 208a was not improved (Table 10, entry 5). Conversely, an increase in the loading 
of [Rh(cod)OMe]2 and (E)-(CHCOOH)2 resulted in an increase in yield of 208a to 50% (Table 11, entry 
6). Finally, running the reaction at 1.0 M afforded the target saturated molecule 208a in 61% yield and 
with excellent selectivity over unsaturated 205a (Table 11, entry 7, 208a:205a = 15.0:1). Further 
variation of reaction parameters did not improve the yield of 208a, therefore optimisation studies of this 
challenging substrate were concluded. Overall, the key changes vs. second generation conditions were 
the omission of P(4-FC6H4)3 and the replacement of 2-NO2C6H4CO2H with (E)-(CHCOOH)2 .  
 
Table 11: Evaluation of different additives in the Rh(I)-catalysed carbonylative cyclisation of challenging 
substrate cyclopropylamide trans-202a.d The ratio of 208a:205a was determined by 1H NMR analysis of crude 
material. [a] Yields were determined by 1H NMR spectroscopy using 1,4-dinitrobenzene as an internal standard. 
[b] Isolated yield. [c] 100 mol% of (E)-(CHCOOMe)2 and (E)-(CHCOOH)2 were used. [d] Results obtained by 
G.-W. Wang. 
2.7.4 Evaluation of third generation reaction conditions 
With the [Rh(cod)OMe]2/(E)-(CHCOOH)2 catalytic system providing efficient access to the C7/8 
saturated heterocycle, the scope with respect to substitution on the cyclopropane ring was examined 
(Table 12A). Pleasingly, these new conditions extended to more sterically demanding systems, such as 
cyclopropylamide trans-202b, which cyclised to provide heterocycle 208b in 50% yield. Importantly, 
heterocyclisation of enantiopure trans-cyclopropylamide (S,S)-202c proceeded with retention of the 
R3-substituted stereocentre to form heterocycle 208c in 50% yield and with good e.r. (98.5:1.5 e.r.). The 





new conditions also extended to substrates with different aromatic nucleophiles, as demonstrated by the 
formation of pyrrole 208d in 48% yield. Likewise, a regiochemically distinct cyclisation via the C2 
position of the heteroarene afforded pyrrole 208e in 31% yield. However, at the present level of 
development, cyclisation of cis-1,2-disubstituted cyclopropylamide cis-202a delivered no product and 
unreacted starting material was recovered.  
 
Table 12: Scope of trans- and cis-1,2-disubstituted cyclopropylamides. The ratio of 208a-e:205a-e was 
determined by 1H NMR analysis and is given in parentheses. The isolated yields for 208b, 208d, 208e include 
205b, 205d, 205e  [a] The reaction time was 120 h. [b] (E)-(CHOOH)2 (150 mol%) was used in PhCN (0.67 M). 
[c] trans-202d, cis-202a, 208d and 208e were synthesised by G.-W. Wang. [d] From (S,S)-202c (98.5:1.5 e.r.). 
[e] The reaction temperature was 150 ℃.  
2.7.5 Fused cyclopropylamides 
Having successfully demonstrated the compatibility of trans-1,2-disubstituted aminocyclopropanes, 
attention turned to evaluate trisubstituted aminocyclopropanes. Of particular interest was fused 
cyclopropane trans-219 because, if compatible in the protocol, it would provide access to 
polyheterocyclic architectures (Scheme 58). Also note that the proximal C–C bonds of trans-219 (bond 
a in trans-219) are chemically identical, which consequently eliminates the issue of regioselectivity in 
the C–C bond activation step. The synthesis of fused cyclopropane trans-219 commenced with 
Rh(II)-catalysed cycloaddition between ethyl diazoacetate and cyclopentene to give cyclopropane 





trans-217 in 70% yield and 3:1 d.r. Cyclopropane trans-217 was then advanced to substrate trans-219 
using the same synthetic sequence utilised for aminocyclopropanes trans-202a–e. (cf. Scheme 55). 
With trans-219 in hand, it was subjected to the third generation [Rh(cod)OMe]2/(E)-(CHCOOH)2 
catalyst system. Disappointingly, trans-219 failed to deliver the target heterocycles 220/221 and 
non-specific degradation of trans-219 occurred. Similarly, the first and second generation conditions 
(as outlined in Table 2 entry 12 and Table 6, entry 14) were also ineffective. It was reasoned that the 
failure of trans-219 to cyclise was due to the developing steric clash between the Rh-centre and the 
fused-cyclopentane ring during the C–C reductive elimination step. No further investigations into the 
carbonylative cyclisation of this challenging substrate were conducted. 
 
Scheme 58: Attempted Rh(I)-catalysed heterocyclisation of fused cyclopropylamide trans-219. A) Reagnets and 
conditions: i) ethyl diazoacetate, cat. Rh2(OAc)4, CH2Cl2, r.t., 16 h; ii) 4 M aq. NaOH, MeOH, r.t., 18 h; iii) 
diphenylphosphoryl azide, Et3N, t-BuOH, 80 ℃, 18 h; iv) TFA, CH2Cl2, r.t., 2 h then benzaldehyde, NaHCO3, 
MeOH, reflux, 3 h then NaBH4, 0 ℃ to r.t., 18 h; v) indole-1H-2-carboxylic acid, EDCI, DMAP (10 mol%), 
CH2Cl2, r.t. 6 h; vi) MeI, NaH (60% dispersion in oil), DMF, r.t., 2 h. [a] Synthesised by G.-W. Wang.  [b] The 
trans- and cis-diastereomers were separated by flash column chromatography. 
2.7.6 Product Derivatisation 
In the above investigations, it has been demonstrated that carbonylative heterocyclisations involving 
trans-1,2-disubstituted cyclopropylamides proceed with high selectivity for C-7 substituted 
heterocycles 208a–e. It was therefore thought that substituents at the C-6 position (i.e. 213’) could be 
introduced using enolate chemistry. To investigate the feasibility of this strategy, heterocycle 208a was 
subjected to derivatisation. Surprisingly, treatment of 208a with LiHMDS, followed by the addition of 
allyl bromide delivered 5-membered heterocycle 223 instead of the desired α-functionalised ketone 222 
(Scheme 59). Presumably formation of 223 occurs via intramolecular attack of enolate 224 onto the 
lactam unit to give intermediate 225, which is then N-alkylated to afford 223. This undesired reaction 
outcome reinforces the propensity of the highly stained 8-membered ring to undergo ring contraction. 





No attempt was made to avoid this deleterious reaction pathway by either an in situ quench or 
employment of an alternative base. 
 
Scheme 59: Derivatisation of indole 208a. Product 223 was synthesised by G.-W. Wang. 
Alternatively, utilising a soft enolisation approach, ketone 208a was readily converted to silyl 
enol ether 226, which was then treated with m-CPBA to furnish α-functionalised product 227 as a single 
diastereomer in 62% yield (Scheme 60). The relative trans diastereorelationship of the C-7 methyl 
substituent to the C-6 OTBS group was confirmed by nOe experiments. 
 
Scheme 60: Derivatisation of indole 208a.  
2.7 Future Directions 
The studies discussed in this chapter have provided efficient access to heteroarene-annulated 
8-membered N-heterocycles. In principal, the fundamental mechanistic steps involved (see Scheme 40) 
and the metallabicyclic templating effect could be exploited to form medium rings of other sizes (i.e. 
9–11 membered rings). Furthermore, the discovery that non-carbonylative 7-membered heterocycle 181 
was formed when 1,2-DCB was used as the reaction solvent presented an opportunity to develop 
non-carbonylative ring expansions of aminocyclopropanes. In the following section, preliminary 
investigations towards both these goals are outlined.   
2.7.1 The search for larger ring systems 
Initially, efforts were directed towards synthesising more challenging 9- and 10-membered indole-fused 
N-heterocycles. To this end, substrates 228 and 232, possessing methylene spacers between the indole 





C-3 position and the cyclopropylamide unit, were subjected to the carbonylative cyclisation protocol 
(Scheme 61A). However, target products 231/233 were not detected and the majority of the mass 
balance consisted of unreacted 228/232. Other conditions were tested (e.g. alternative Rh(I) 
pre-catalysts, phosphine ligands, range of acid additives), but in all cases no desired product was 
obtained. It was proposed that the lack of reactivity exhibited by indoles 228 and 232 was due to two 
factors. Firstly, in accordance with previous studies (see Section 2.6), rhodacyclopentanone formation 
(i.e. 229 or 229’) and subsequent C(sp2)–H metallation are reversible; consequently, on the basis of ring 
size, equilibrium favours the 5,5-membered chelate 229/229’ over the 7,5-Rh(III)-chelate 230 or 
8,5-Rh(III)-chelate 230’. This preference thereby hinders access to key metallabicycles 230/230’ and 
hence prevents the C–C reductive elimination step from occurring. Secondly, substrates 228 and 232 
possess a high degree of conformation flexibility which likely imposes an additional kinetic barrier to 
cyclisation. To circumvent these issues, substrate 234 was designed which possesses a conformationally 
rigid phenyl linker; however, indole 234 was not compatible under a variety of Rh(I)-catalysis 
conditions and non-specific degradation of 234 was observed in each case (Scheme 61B).  
 
Scheme 61: Attempted Rh(I)-catalysed carbonylative cyclisation of cyclopropylamides to form 9- and 
10-membered N-heterocycles. [a] Substrate 228 was synthesised by G.-W. Wang. 
As discussed in Section 2.6, pyrrole 186a could be induced to cyclise via C-4 by pre-installing 
a methyl blocking group at the C-2 position (see Scheme 50). Encouraged by the effectiveness of this 
strategy, we questioned whether a similar tactic could be utilised to promote cyclisation via the 





benzenoid ring of a tailored indole substrate. Methodologies that enable site-selective functionalisation 
of the benzenoid ring of indole remain a formidable challenge due to the inherent reactivity of the C-2 
and C-3 positions.167-169 However, recent advances in transition-metal catalysis have emerged to achieve 
C-4 functionalisation of indole scaffolds and, in the majority of cases, site-selectivity is achieved by 
using a C-3 directing group.169-171 To test the viability of this strategy, C-4 carbamoyl indole 237, 
possessing a C-2 methyl group, was synthesised in a two-step sequence (Scheme 62A). Following a 
known procedure, acylation of aminocyclopropane 170a with 1,1′-carbonyldiimidazole afforded 236 in 
96% yield, which was then converted to indole 237 by AlMe3 mediated Friedel-Crafts carbamoylation 
of 2-methylindole.172 Exposure of indole 237 to [Rh(cod)OMe]2/AdCO2H carbonylative catalysis 
conditions led to a <5% yield of C3-4 annulated product 238. Unfortunately, purification of 238 was 
difficult due to the formation and co-elution of side-product 239. Side-product 239 presumably forms 
via hydrolysis of the corresponding enamide, which is generated by degradation of the 
rhodacyclopentanone intermediate 240. Note that structural assignment of indole 238 is tentative, but 
is supported by characteristic 1H NMR signals and mass spectrometry data. For the same 
aforementioned reasons, it was proposed that access to the critical 5,7-Rh(III)-chelate 241 is 
disfavoured and C–C reductive elimination from 241 is highly challenging due to the innate strain of 
the 9-membered ring being formed. Alternative reaction conditions were evaluated, but no improvement 
could be made and hence investigations into this transformation were stopped.   
 
Scheme 62: Reagents and conditions: i) 1,1′-carbonyldiimidazole, THF, reflux, 16 h, 96%; ii) 2-methylindole, 
AlMe3 (2.0 M in PhMe), PhMe, 0 ℃, 45 minutes then 105 ℃, 4 hours, 70%.  





Following a similar line of thought, C-4 carbamoyl indole 242 was prepared and subjected to 
the [Rh(cod)OMe]2/P(4-FC6H4)3/2-NO2C6H4CO2H catalyst system. It was envisaged that indole 242 
would either undergo cyclisation via the C-3 position to afford the 9-membered heterocycle 243 or via 
the C-5 position to afford the 8-membered heterocycle 244 (Scheme 63). On the basis of intrinsic 
nucleophilicity of the indole core, the former pathway was deemed more likely. However, indole 242 
was extremely resilient to C–C bond activation, even at an elevated temperature of 150 ℃, and neither 
heterocycles 243/244 were observed.  
 
Scheme 63: Attempted Rh(I)-catalysed carbonylation of C-4 carbamoyl indole 242. 
At this point, all investigations to generate 9- and 10-membered heterocyclic products were 
halted. It was concluded that for such ambitious targets, the kinetic barrier to cyclisation becomes 
prohibitively high (due to the increased size of the requisite 5,7-Rh(III)-bicyclic intermediate) and the 
entropic price for achieving an organised Rh(III)-chelate cannot be repaid by the release of 
cyclopropane ring strain. Consequently, the overall reaction pathway is not sufficiently exergonic to 
compensate for the ring strain of the final heterocyclic product. 
2.7.2 The search for a protocol involving non-carbonylative C–C bond activation of 
aminocyclopropanes 
The development of a protocol enabling the non-carbonylative ring expansions of aminocyclopropanes 
is an attractive extension of this work and, more importantly, has not been demonstrated previously. As 
shown in Scheme 47, it was hypothesised that mechanistically heterocycle 181 was formed either via 
decarbonylation of 8-membered heterocycle 179a or via a rhodacyclobutane-based pathway. To test the 
possibility of the former pathway, a sample of pure heterocycle 179a was subjected to identical catalytic 
conditions in 1,2-DCB (either with or without an atmosphere of CO, Scheme 64A). However, from 





these experiments, the 7-membered ring product 181 was not observed and the starting material was 
recovered entirely. This would seemingly rule out a pathway involving decarbonylation of the 
8-membered product 179a.69 To test the likelihood of the latter proposal, indole 178a was exposed to 
the [Rh(cod)OMe]2/1,2-DCB system in the absence of CO (Scheme 64A). However, 181 was not 
detected, thus indicating that CO is required for its generation. Nevertheless, this pathway cannot be 
discounted as the role of CO could simply be to act as a π-acceptor ligand. It is worth noting that 
replacement of [Rh(cod)OMe]2 with [Rh(CO)2Cl]2 was also ineffective. Due to other successful research 
avenues, no further investigations into the formation of 7-membered heterocycle 181 was pursued at 
this time. It is conceivable that non-carbonylative ring expansion of aminocyclopropanes might be 
better suited for the synthesis of 6-membered rings compared to 7-membered adducts. Thus, future 
studies will target the design of a 6-membered variant and an obvious starting point would be to examine 
the non-carbonylative ring expansion of aminocyclopropane 138 (Scheme 64B).  
 
Scheme 64: Preliminary studies to identify a protocol involving non-carbonylative C–C bond activation of 
aminocyclopropanes   
2.8 Summary and Conclusion from the studies in Chapter 2 
In summary, the first Rh(I)-catalysed “capture-collapse” heterocyclisation that provides heteroarene 
annulated 8-membered rings has been developed. The central paradigm of this approach relies upon the 
tandem exploitation of cyclopropane strain relief and metallabicycle templating to overcome the usual 
entropic barriers associated with medium-sized ring closures. The protocol is highly flexible with 
regards to both the nature and position of the heteroaromatic unit, and affords ring systems that are 
difficult to construct using conventional methods. Extensive and thorough optimisation of reaction 





conditions was required to facilitate the formation of saturated, sp3-rich, heterocycles 152/179/208 as 
the major product. Evidence gained through deuterium labelling experiments support reversible 
rhodacyclopentanone formation via carbonylative C–C bond activation and C–H metallation (see 
Schemes 52 and 53). Further studies are needed to extend the methodology to systems with electron-
neutral/poor aromatic units and systems that generate other challenging medium ring sizes (i.e.  ≥8-
membered). 





Chapter 3 – Further investigations into the nucleophilic trapping of 
rhodacyclopentanones 
3.1 Introduction  
In Chapter 2 it was demonstrated that Rh(I)-catalysed “capture-collapse” heterocyclisations could be 
extended to 8-membered N-heterocycles via the trapping of rhodacyclopentanones with tethered 
C-based heteroarene nucleophiles. Given the intrinsic electrophilicity of rhodacyclopentanones, it was 
envisaged that variation of the directing group and the nucleophilic component might provide entry to 
related N-heterocyclic structures (Scheme 65). With this goal in mind, investigations were undertaken 
to evaluate and identify a second intramolecular protocol.  
 
Scheme 65: Mechanistic blueprint for the identification of related “capture-collapse” processes.  
3.1.1 Previous studies conducted in the Bower group  
Before discussing efforts to extend the “capture-collapse” methodology, it is pertinent to highlight 
previous research undertaken in the Bower group in related Rh(I)-catalysed heterocyclisations (Scheme 
66). Former PhD students N. McCreanor and S. Stanton investigated several systems to target 7- and 
8-membered N-heterocycles via the intramolecular trapping of rhodacyclopentanones with tethered N-, 
C- and O-based nucleophiles (e.g. amines, amides, enolates and alcohols)96,102 Efforts involving 
aminocyclopropane substrates with a pendant alcohol, amine or enolate nucleophilic component were 
unsuccessful (Scheme 66A-B); however, S. Stanton discovered that cyclopropylmethylamides 245a–b 
underwent Rh(I)-catalysed carbonylative cyclisation to form azepanes 246a–b in high yield, but with 
poor control over the oxidation level of the C4/C5 position (e.g. 246a was formed in 95% yield with 
5.3:1 selectivity over 247a) (Scheme 66C).102 Preliminary optimisation studies revealed that pyridine 
and Ag(I)-salts were beneficial additives; however, their precise role remained unclear.  






Scheme 66: Previous Rh(I)-catalysed “capture-collapse” heterocyclisations investigated in the Bower group. [a] 
The ratio of 246a–b:247a–b was determined by 1H NMR analysis of crude material and is given in parentheses. 
Several common side-products were observed during these investigations, which provided 
important information on competing side-reactions (Scheme 67). For example, several of the substrates 
depicted in Scheme 66 formed a mixture of linear alkenes 251, cycloadducts 252 or 
protodecyclopropanated starting material 253 when exposed to Rh(I)-catalysed carbonylative 
conditions. Linear alkenes 251 are formed by Rh(I)-addition to the more hindered (bond a) cyclopropyl 
C–C bond of 248 (248 to 249), followed by β-hydride elimination and C–H reductive elimination. 
Cycloadducts 252 likely arise via reaction of the nucleophilic unit with the  enamide of 251. Conversely, 
protodecyclopropanated products 253 are formed by Rh(I)-addition to either bond a or bond b of 248, 
followed by β-hydride elimination, C–H reductive elimination and hydrolysis of the resulting enamide. 
The formation of alkenes 251 (and/or adducts 252) is considered indirect proof that the desired 
rhodacyclopentanone 250 has formed. It is assumed that inefficient trapping of this species allows 
reversal to rhodacyclobutane 249, which ultimately results in undesired side-reactions. The problematic 
steps of these processes could be either directing-group dissociation, nucleophile association, 
nucleophilic deprotonation or C–Nuc reductive elimination. In contrast, the formation of 





protodecyclopropanated side-products 253 are not considered proof of directed Rh(I)-addition as they 
can arise via oxidative addition of either bond a or bond b of cyclopropane 248.  
 
Scheme 67: Common side-products identified from failed Rh(I)-catalysed carbonylative heterocyclisations.  
3.2 The search for a second intramolecular protocol 
To illustrate further the synthetic utility of the Rh(I)-catalysed “capture-collapse” heterocyclisations, 
several cyclopropane-based substrates were designed and evaluated. As the catalytic requirements for 
each substrate class were unknown, each substrate was evaluated under representative carbonylative 
conditions, which included a cationic or neutral Rh(I)-source, phosphine ligand, benzoic acid additive 
and either PhCN or 1,2-DCB as the reaction solvent.  
3.2.1 Studies towards the synthesis of 7-membered N-heterocycles 
Note the work carried out in this section was conducted prior to the studies outlined in Chapter 2 
3.2.1.1 Design and evaluation of cyclopropyl sulfamides 
As discussed previously in Chapter 2, heterocyclic 7- and 8-membered rings are ubiquitous structural 
features in many natural products and pharmaceutical agents (see Section 2.2). Among these scaffolds, 
7-membered cyclic sulfamides have emerged as attractive peptidomimetics in the design of HIV-I 
protease inhibitors (Scheme 86A).173-177 To date, the majority of transformations that generate 
7-membered cyclosulfamide scaffolds can be divided into two reaction classifications: (i) 
intramolecular cyclisation of linear sulfamides via N-alkylation178,179 or ring-closing metathesis180,181 
and (ii) direct incorporation of the sulfamoyl moiety by reacting sulfamide (H2NSO2NH2) with diamines 
at elevated temperatures.174,175 Given the relevance of these heterocycles, the development of a 
streamlined catalytic method for their construction would be of interest. With this in mind, it was 
envisaged that sulfamide I might direct insertion of a suitable Rh(I)-catalyst and carbon monoxide into 
the proximal cyclopropyl C–C bond to give rhodacyclopentanone II (Scheme 86B). From here, ligand 





exchange with the nucleophile and concomitant deprotonation generates rhodacycle III, from which C–
N reductive elimination to Rh(I)-alkyl intermediate IV secures the 7-membered ring. Finally, 
protodemetallation or β-hydride elimination would afford either saturated or unsaturated cyclic 
sulfamides 254/254’ respectively.  
 
Scheme 68: Proposed Rh(I)-catalysed carbonylative heterocyclisation of cyclopropyl sulfamides to generate 
7-membered cyclic sulfamides.  
To reduce this idea to practice, trisubstituted cyclopropyl sulfamide 257a was selected as an 
initial pilot substrate and, following a known procedure, was readily prepared in a 2-step sequence 
(Scheme 69A).182,183 Sequential treatment of chlorosulfonyl isocyanate 255 with 2-chloroethanol and 
benzylamine provided N-sulfamoyloxazolidinone 256 in 65% yield. Subsequent displacement of the 
oxozolidinone ring of 256 by amine 170a afforded sulfamide 257a in 84% yield.  
 
Scheme 69: Preparation and evaluation of sulfamide 257a. Reagents and Conditions: i) 2-chloroethanol, CH2Cl2, 
0 ℃ to r.t. then Et3N and benzylamine, CH2Cl2, 0 °C to r.t. 65%; ii) amine 170a, Et3N, MeCN, reflux, 84%.  
 





With substrate 257a in hand, it was exposed to representative carbonylative conditions using a 
range of Rh(I)-sources in combination with mono-/bidentate phosphine ligands in 1,2-DCB. 
Disappointingly, all attempts to effect carbonylative cyclisation of sulfamide 257a failed, and instead, 
nonspecific degradation of 257a was observed in every case by 1H NMR analysis of the crude reaction 
mixtures (Scheme 69B).  
Undeterred by this set-back, it was reasoned that modulation of the R2 substituent of sulfamide 
I might influence the acidity of the N–H bond and make it more amenable to nucleophilic addition to 
rhodacyclopentanone III, which, in turn, might aid cyclisation. To test this hypothesis, cyclopropyl 
sulfamides 257b–d bearing different R2 substituents were prepared (Scheme 70A). N-Boc derivative 
257b was accessed by successive treatment of chlorosulfonyl isocyanate 255 with tert-butyl alcohol 
and benzylcyclopropyl amine 170a in 83% yield. TFA-mediated Boc-deprotection of 257b delivered 
N-N’-disubstituted cyclopropylsulfamide 257c in 96% yield, and N-acetyl substrate 257c was formed 
in 68% yield by coupling of 257c with acetyl chloride. Cyclopropyl sulfamides 257b–d were then 
exposed to a range of carbonylative conditions; unfortunately, formation of cyclic sulfamides 259/259’ 
were not observed in any case and sulfamides 257b–d either decomposed or remained unreacted  
(Scheme 70B). In light of these difficulties, investigations into the cyclisation of sulfamides were halted 
in favour of alternative systems. In order to assess the viability of a sulfamide directing group, it would 
be insightful to conduct oxidation insertion studies with sulfamides 257a–d (cf. Scheme 25); however, 
these experiments were not investigated at this stage.  
 
Scheme 70: Preparation and evaluation of sulfamides 257b-d. Reagents and Conditions: i) t-BuOH, CH2Cl2, 0 ℃ 
to r.t., then Et3N and amine 170a, CH2Cl2, 0 °C to r.t. 83%; ii) TFA, CH2Cl2, 0 °C; iv) acetyl chloride, pyridine, 
CH2Cl2, r.t..  
3.2.1.2 Design and evaluation of cyclopropyl guanidines 
In subsequent studies, cyclopropyl guanidines I were evaluated as candidate substrates for 
Rh(I)-catalysed “capture-collapse” heterocyclisations (Scheme 71A). It was proposed that N-directed 





C–C bond activation of I to rhodacyclopentanone II, followed by deprotonation and nucleophilic 
addition would provide rhodacycle III. From here, C–N reduction elimination and subsequent proto-
demetallation or β-hydride elimination would deliver cyclic guanidines 260/260’ (Scheme 71A). As the 
requirements of the R1, R2 and R3 substituents of guanidine I were unclear, trisubstituted guanidine 263 
was selected as a trial substrate. Guanidine 263 was readily synthesised from isocyanate 261 following 
a simple 2-step protocol (Scheme 71B).184 Treatment of isocyanate 261 with benzylamine afforded 
thiourea 262 in 98% yield. Next, EDCI-mediated coupling of 262 with amine 170a, provided the desired 
cyclopropyl guanidine 263 in 81% yield.  
 
Scheme 71: B) Reagents and conditions: i) CH2Cl2, 0 °C to r.t., 98%; ii) EDCI, Et3N, CH2Cl2, r.t., 81%. [a] The 
yield was determined by 1H NMR spectroscopy using 1,4-dinitrobenzene as an internal standard. 
Exposure of guanidine 263 to [Rh(cod)OH]2/1,2-DCB catalyst system led to a 7% yield of 
C5/C6 unsaturated 7-membered guanidine 264’ (Scheme 71C). Of note, the saturated analogue 264 was 
not observed by 1H NMR analysis of the crude mixture. Unfortunately, the purification of 264’ was 
problematic due to the formation and co-elution of side-product 265. As discussed above, 
protodecyclopropanated adducts akin to 265 can arise from degradation of the required 
rhodacyclopentanone intermediate (see Scheme 67). Note that the structural assignment of cyclic 
guanidine 264 is tentative, but is supported by characteristic 1H NMR signals, mass spectrometry data 
and comparison to analogous products (cf. diazepane 120). No further improvements could be made to 





the yield of cyclic guanidine 264’, and consequently, no further work was undertaken on this class of 
substrate. 
3.2.1.3 Design and evaluation of cyclopropyl pyridones 
Bicyclic pyridones are important building blocks that are found in a wide range of natural products and 
pharmacologically active molecules. Among this class of compounds, 6,7-bicyclic pyridones (e.g. 266, 
Scheme 72A) are present in several bioactive compounds, and this scaffold, or closely related variants, 
has been incorporated into the design of several analgesics and anti-inflammatory agents.185 Generally, 
the 7-membered ring is assembled via intramolecular nucleophilic substitution or intramolecular 
condensation of 2,6-dihydropyridines.185,186 To complement these approaches, it was proposed that 
N-directed C–C bond activation of cyclopropylpyridone I to rhodacyclopentanone II, followed by C–N 
reductive elimination to alkyl-Rh(I) intermediate III, and either protodemetallation or β-hydride 
elimination would form bicyclic pyridone 266 (Scheme 72A). In order to evaluate this hypothesis, 
cyclopropyl pyridone 269 was prepared as a test substrate (Scheme 72B). Buchwald-Hartwig cross-
coupling between aryl bromide 267 and amine 170a delivered pyridine intermediate 268 in 50% yield. 
Subsequent deprotection of the methoxy group with TMSCl/NaI afforded cyclopropyl pyridone 269 in 
76% yield.  
   
Scheme 72: B) Reagents and conditions: i) Pd(OAc)2 (5 mol%), dppp (10 mol%), NaOt-Bu, PhMe, 80 °C, 14 h, 
50%; ii) NaI, TMSCl, MeCN, 80 °C, 2 h then MeOH, r.t. 2 h, 76%.  
Initially, to demonstrate the feasibility of N-directed oxidative addition, an insertion experiment 
was conducted on cyclopropyl pyridine 268 (Scheme 73A). It was found that, in the absence of CO, 
cyclopropyl pyridine 268 underwent directed Rh(I)-addition via insertion into the more hindered C–C 
bond (bond a) to form linear alkene 270 in 13% yield. This result confirms that N-directed 
Rh(I)-addition is possible from a pyridine-based substrate and the observed regioselectivity is in 
agreement with previous reports (see Scheme 25). Encouraged by this result, it was anticipated that 
under carbonylative conditions, cyclopropyl pyridone 269 might behave in a similar manner and 





tautomerize to its corresponding hydroxypyridine or, alternatively, undergo NH metallation prior to 
N-directed C–C bond activation. Either of these scenarios would enable access to the key 
5,5-rhodacycle intermediate (cf. intermediate II, Scheme 72). With this hypothesis in mind, substrate 
269 was subjected to carbonylative conditions using various Rh(I)-sources and mono-/bidentate 
phosphine ligands in either 1,2-DCB or PhCN. Unfortunately, 269 proved extremely resistant to C–C 
bond activation, and typically 80% recovered starting material was obtained. Increasing the reaction 
temperature to 150 °C led to the formation of protodecyclopropanated side-product 272 in 12% yield, 
but the desired product 271 was not observed (Scheme 73B). The formation of 272 indicates that C–C 
bond activation does occur, and as discussed above, this might indicate that pyridone 269 tautomerizes 
to its corresponding hydroxypyridine prior to C–C bond activation. In an attempt to facilitate 
deprotonation of the pyridone NH, several inorganic bases (e.g. K2CO3 and NaOt-Bu) were included; 
however, the inclusion of bases did not afford bicyclic heterocycle 271 and complete starting material 
recovery was observed. Consequently, after these initial studies, no further work was undertaken on 
this class of substrate. 
 
Scheme 73: [a] The yield was determined by 1H NMR spectroscopy using 1,4-dinitrobenzene as an internal 
standard.  
 3.2.2 Studies towards the synthesis of 8-membered N-heterocycles via a Rh(I)-catalysed  
carbonylative transmetallation-heterocyclisation strategy 
As outlined in Chapter 2, the Rh(I)-catalysed carbonylative cyclisation of cyclopropylamides to target 
8-membered N-heterocycles was successfully realised. However, despite the robustness of this 
approach, the process was restricted to systems with electron-rich heteroaromatic units, which limits 
wider application of the methodology. In particular, phenyl-based system 189 was incompatible under 
the optimised conditions identified for indole-based system 178a, and failed to deliver the target 
heterocycle (see Scheme 51 and Section 2.6). It was therefore hypothesised that pre-functionalisation 





of the phenyl ring of 189 with a boronic acid/ester might promote trapping of the key 
rhodacyclopentanone intermediate via transmetallation (instead of via C–H metallation as detailed in 
Chapter 2) (Scheme 74). In this scenario, it was envisaged that carbonyl-directed rhodacyclopentanone 
formation to I, followed by transmetallation to 6,5-rhodacycle II and C–C reductive elimination would 
deliver alkyl Rh(I)-intermediate III. Finally, protodemetallation or β-hydride elimination would deliver 
benzofused azocine 273. Alternatively, it is conceivable that transmetallation could occur first to give 
an aryl-Rh(I) intermediate,187 from which subsequent C–C oxidative addition and CO insertion would 
allow alternative entry to 6,5-rhodacycle II. Whilst the use of pre-functionalised starting materials 
requires extra synthetic manipulations and reduces the atom economy of the process, the opportunity to 
access medicinally relevant benzoannulated 8-membered N-heterocycles is highly appealing. As 
discussed in Section 2.2, such molecular architectures are highly sought after in the pharmaceutical 
sector.120 Additionally, in recent years, steady advances have been made to install boronic esters 
catalytically from simple arene precursors,188-191 which could potentially allow straight-forward entry 
to the desired pre-functionalised aminocyclopropane substrate.  
 
Scheme 74: Proposed extension to target 8-membered N-heterocycles via a Rh(I)-catalysed carbonylative 
transmetallation-heterocyclisation of a pre-functionalised cyclopropyl organoboron substrate.  
To explore the viability of the process proposed in Scheme 74B, cyclopropyl benzamide 275 
bearing a pinacol boronic ester component was prepared using a 2-step sequence (Scheme 75). 
Conversion of boronic acid 274 to its corresponding pinacol boronic ester derivative (structure not 
shown), followed by HBTU-mediated amide coupling with amine 170a afforded the target substrate 
275 in 55% yield. Substrate 275 was then subjected to Rh(I)-catalysed carbonylative conditions; 
unfortunately, none of the desired benzofused heterocycle 273 formed after 72 h, and typically >70% 





starting material 273 was recovered. Interestingly, the organoborane handle of 275 remained intact at 
130 ℃, and perhaps under more forcing conditions this challenging transformation might be achieved.  
 
Scheme 75: Synthesis and attempted Rh(I)-catalysed carbonylative cyclisation of cyclopropylamide 275. 
Reagents and conditions: i) pinacol, MgSO4, THF, r.t., 20 h, 95%; ii) amine 170a, HBTU, DIPEA, CH2Cl2, r.t., 
16 h, 58%.  
In concurrent studies, aminocyclopropane 278 bearing an exo-directing group was prepared and 
subjected to Rh(I)-catalysed carbonylative conditions (Scheme 76). Entry to aminocyclopropane 278 
was enabled by reductive amination of 2-bromobenzaldehyde 276 with cyclopropylamine, followed by 
Cbz protection to afford 277 in 34% yield over the two steps. Next, Miyaura borylation of 277 under 
Pd(0)-catalysed conditions with B2pin2 furnished boronic ester 278 in 67% yield, alongside benzazepine 
279 in 26% yield. Whilst the formation of benzazepine 279 is an interesting side-reaction, conceptually 
related studies have been disclosed in the literature.192-194 A plausible mechanism for the formation of 
side-product 279 is presented in Scheme 76B. Following oxidative addition, ligand exchange and 
base-mediated concerted-metallation-deprotonation (CMD) of the cyclopropane C–H bond gives 
palladacycle I. Subsequent acid promoted ring opening of the cyclopropane gives 8-membered 
palladacycle II, from which deprotonation and C–C reductive elimination generates benzazepine 
279.193-195  
 
Scheme 76: B) Reagents and conditions: i) amine 170a, NaHCO3, MeOH, reflux, 24 h then NaBH4, 0 °C to r.t., 
5 h, 45%; ii) Cbz-Cl, K2CO3, PhMe, 80 ℃, 24 h, 76%; iii) Pd(dppf)Cl2·CH2Cl2, B2pin2, K2CO3, 1,4-dioxane, 
70 ℃, 16 h.  





Exposure of cyclopropylamide 278 to [Rh(cod)OH]2/1,2-DCB conditions resulted in the sole 
formation of side-product 281 in 44% yield (Scheme 77A). The formation of 281 presumably occurs 
via protodeborylation and protodecyclopropanation of starting material 278, but it is unclear as to the 
order of these side-reactions. To circumvent protodeborylation, the reaction was performed in the 
absence of 2-NO2C6H4CO2H, but this modification also failed to provide the desired heterocycle 280. 
In order to promote the proposed transmetallation step, boronic ester 278 was converted to the less 
hindered boronic acid 282 (Scheme 77B). However, carbonylative cycloaddition of substrate 282 was 
not successful, and heterocycle 283 was not observed. Additionally, the inclusion of water as an additive 
to promote the transmetallation step was not successful.   
 
Scheme 77: B) Reagents and conditions: i) NaIO4, THF:H2O (5:1), r.t., 3 h.  
So far, exploratory efforts to incorporate transmetallation into the “capture-collapse” 
heterocyclisations have been unsuccessful, and the reasons behind this remain unclear. Due to time 
constraints, boronic esters 275/278 and boronic acid 282 were evaluated under a limited number of 
conditions (total of 20 different sets of conditions across all substrates); therefore, additional 
investigations are required to ascertain the feasibility of this strategy. This research avenue will be 
investigated by the Bower group in due course.  
3.3 Preliminary investigations into the synthesis of γ-lactams 
During the studies outlined in Chapter 2, it was discovered that secondary cyclopropylamide 171a 
underwent Rh(I)-catalysed carbonylation to deliver γ-lactam 174a, instead of 8-membered 
N-heterocycles 172a/173a (Scheme 78). Whilst the mechanism for this transformation remains unclear, 
it was proposed that it might involve a putative 6-membered rhodacycle 177, which following C–N 
reductive elimination affords the observed product 174a (see Scheme 46 for proposed mechanism). 





Although this result was unexpected, the formation of similar products under carbonylative conditions 
has previously been reported in the literature. Specifically, in 1971 Iqbal and co-workers reported that 
exposure of unsubstituted cyclopropylamine 284 to a neutral Rh(I)-catalyst and a high pressure of CO 
(150 bar) delivered a mixture of N-substituted γ-lactam products in 40% yield (Scheme 78B).155 To date, 
no mechanistic work has been reported for this transformation; however, it is not unreasonable to 
assume it involves the intermediacy of a rhodacyclopentanone or an azarhodacyclohexanone.  
 
Scheme 78: The formation of N-substituted γ-lactams by carbonylative ring expansion of aminocyclopropanes.   
Compared to Iqbal’s conditions, the formation of γ-lactam 174a in 50% yield under an 
atmospheric pressure of CO is a significant improvement. Driven by this fact, a simplified phenyl 
derivative 171b was selected as a test substrate for further optimisation studies and key preliminary 
findings are presented in Table 13. 





Table 13: Preliminary optimisation results from the Rh(I)-catalysed carbonylative cyclisation of 
cyclopropylamide 171b.d [a] The yield was determined by 1H NMR spectroscopy using 1,4-dinitrobenzene as an 
internal standard. [b] The reaction temperature was 140 ℃. [c] Isolated yield. [d] Phenyl derivative 171b was 
synthesised by M. Shaw for an unrelated project.  
Subjection of phenyl substrate 171b to [Rh(cod)2]OTf, P(4-FC6H4)3 and 2-NO2C6H5CO2H in 
PhCN under an atmosphere of CO delivered the desired γ-lactam adduct 174b in 30% yield (Table 13, 
entry 1). It was found that decreasing the loading of 2-NO2C6H5CO2H afforded product 174b in a 
slightly reduced yield of 26% (Table 13, entry 2). Changing the acid additive to 4-NMe2C6H4CO2H 
and/or the phosphine ligand to P(C6F5)3 also failed to increase the yield of 174 (Table 13, entries 3–5). 
When the phosphine ligand was omitted, γ-lactam 174b was obtained in a comparable yield of 26% 
(Table 13, entry 3 vs. 6). Conversely, when the reaction was performed in the absence of the acid 
additive or in the absence of both the acid additive and the phosphine ligand, the yield of γ-lactam 174b 
decreased (Table 13, entries 7 and 8). Interestingly, these control experiments indicate that inclusion of 
a phosphine ligand is not essential for the formation of γ-lactam 174b. However, due to poor mass 
balance and limited improvements in yield, no further work was undertaken on this transformation. 
3.4 Conclusion and summary from the studies in Chapter 3 
The research outlined in this chapter has described investigations towards the generality of the “capture-
collapse” heterocyclisation strategy, in addition to preliminary studies towards a Rh(I)-catalysed  
formation of γ-lactams from cyclopropylamides. With regards to the former, efforts to extend the scope 
of the nucleophilic component beyond the N- and C-based nucleophiles that are described in initial 
reports,20,21 have met with limited success. Indeed, cyclopropyl sulfamides 257a–d and cyclopropyl 
pyridone 269 were completely ineffective in the “capture-collapse” heterocyclisation strategy (see 
Sections 3.2.1.1 and 3.2.1.3), thus making immediate extension of the protocol to other substrate types 





challenging. On the other hand, exposure of cyclopropyl guanidine 263 to Rh(I)-catalysed          
carbonylative conditions led to a 7% in situ yield of 7-membered guanidine 264’ (Scheme 71). However, 
due to rhodacyclopentanone stability and deleterious side-reactions, this yield could not be improved 
upon. In related studies, preliminary investigations into a Rh(I)-catalysed carbonylative 
transmetallation-heterocyclisation strategy  to access benzofused azocines were also unsuccessful. As 
stated in Section 3.2.2, the development of such a process is in its infancy, and further investigations 
are required in order to determine the feasibility of this strategy.  
 Following the work detailed in this chapter, subsequent research carried out in the Bower group 
has identified a related Rh(I)-catalysed “capture-collapse” heterocyclisation protocol. In particular, Dr. 
A. D. J. Calow and co-workers discovered that rhodacyclopentanone 286 generated from 
cyclopropylamides bearing a tethered aniline unit, underwent C–N reductive elimination to form C7/8 
unsaturated 1,4-diazocanes 287a–c in 17–46% yield (Scheme 79).23 Of note, the corresponding C7/8 
saturated products (structures not depicted) were not observed. The lowest efficiency obtained was for 
4-CF3 system 287c, which indicates the importance of using a relatively nucleophilic aniline. 
Additionally, the processes are oxidative, and GCMS analysis revealed that turnover is achieved by 
reduction of (E)-(CHCOOMe)2 to dimethyl succinate.  
 
Scheme 79: 1,4-Diazocanes via C–N reductive elimination.  
Finally, the initial experiments depicted in Scheme 78 and Table 13 provide proof-of principle 
for the formation of γ-lactam products by carbonylative ring expansion of secondary cyclopropylamides. 
Future studies should focus on improving the yield of lactam 174b and also on gaining a better 
understanding of the reaction mechanism. Progress towards either of these goals should benefit the 
development and expansion of related processes. With this in mind, the ultimate goal for this process 
would be to evaluate enantiopure 1,2-disubstituted cyclopropylamide substrates (e.g. (R,R)-288) as a 
means to access γ-lactam products bearing stereodefined substituents (e.g. 289 or 290) (Scheme 80). 
Additionally, these preliminary studies provide a compelling model upon which to design future 
reactions based on the intermediacy of a Rh(III)-hexacycle. In particular, it would stand to reason that 





rhodacycle 291 might undergo carbometallation with tethered π-unsaturated units prior to reductive 
elimination, which, in turn, might provide 5,7-fused heterocycles (Scheme 80B). Not only would this 
broaden the scope of Rh(I)-catalysed cycloadditions, but also provide evidence of a catalytically 
generated 6-membered rhodacycle 177/291. This research avenue will be investigated by the Bower 
group in due course. 
 
Scheme 80: Proposed extension to access substituted γ-lactam derivatives and 5,7-fused heterocycles.  
 





Chapter 4: Rhodacyclopentanones as linchpins for the synthesis of 
polyheterocycles  
The work detailed in this chapter was conducted in collaboration with Dr. Gang-Wei Wang and Mr 
Tom Young. In order to give a complete overview of the work conducted, selected results obtained by 
G.-W. Wang and T. Young are provided. Results obtained by G.-W. Wang and T. Young are clearly 
indicated in the text and by footnotes under relevant Tables and Schemes. Aspects of this chapter have 
been adapted from a publication by G.-W. Wang et al. 
(J. Am. Chem. Soc. 2020, 142, 1740-1745) 
4.1 Discovery and proposed mechanism of a unique indole dearomatisation protocol 
New strategies that enables the expeditious assembly of complex heterocycles are likely to be of 
significant interest to synthetic and medicinal chemists. In particular, methods that access 
underexplored regions of chemical space, such as sp3-rich systems and polyheterocycles, are in high 
demand from the pharmaceutical sector as they present the opportunity to design novel compound 
libraries.13,106,196 Within this context and as outlined previously (see Section 1.3.2 and Chapter 2), the 
Bower group has devised a strategy where cyclopropane-derived metallacycles engage tethered N- or 
C-based nucleophiles to generate 7- and 8-membered N-heterocycles (e.g. 1,3-diazepanes, 
benzazepanes, azocanes).20,21 This strategy hinges on the tandem exploitation of strain relief and a 
metallabicycle templating effect to overcome the enthalpic and entropic barriers associated with 
medium-sized ring closures. In an effort to extend the applicability of these processes, G.-W. Wang 
examined the suitability of N-carbamoyl aminocyclopropane 292a (Scheme 81). Under an atmosphere 
of CO, it was anticipated that aminocyclopropane 292a would cyclise via putative Rh(I) intermediate 
293 to furnish C2 annulated heterocycle 294a, where C–H bond formation functions as the terminating 
step (293 to 294a). Somewhat surprisingly, it was found that aminocyclopropane 292a was converted 
exclusively to complex polycycle 295a in 10% yield when exposed to the combination of 
[Rh(cod)2]OTf (7.5 mol%), P(3,5-(CF3)2C6H3)3 (15 mol%) and C6H5OCH2CO2H (30 mol%) under an 
atmosphere of CO in 1,2-DCB at 140 ℃.  






Scheme 81: The carbonylative dearomative cyclisation of indole 292a delivered complex polycycle 295a.a [a] 
Result obtained by G.-W. Wang.  
The formation of polycycle 295a posed an intriguing question regarding (i) the mode of C–C 
bond activation and (ii) the order of C–C bond formation. As shown in Scheme 82, two different 
mechanistic pathways were proposed for the formation of polycycle 295a. In both proposals, it was 
postulated that initial formation of 6,5-rhodacycle 296 occurs via carbonyl directed carbonylative C–C 
bond activation of aminocyclopropane 292a and C(sp2)–H metallation; however, the exact order of 
these steps remained unknown. From intermediate 296, it was reasoned that two distinct C–C bond 
forming sequences could access alkyl-Rh(I) intermediate 298. In pathway A, 5-ring C(sp2)–C(sp3) 
reductive elimination to acyl-Rh(I) intermediate 297 is followed by 5-ring carbometallation of the 
indole C2–C3 π-system. Alternatively, in pathway B, 8-ring C(sp2)–C(sp2) reductive elimination to 
alkyl-Rh(I) intermediate 293 is followed by transannular carbometallation of the indole π-system. 
Finally, protodemetallation of alkyl-Rh(I) species 298 affords the observed product 295a. 
 





Scheme 82: Mechanistic rationale for the formation of polycycle 295a.  
In comparison with prior C–C bond activation triggered heterocyclisations,20,21 this 
transformation is particularly noteworthy because it enables the concurrent formation of not one, but 
two new ring systems. Furthermore, this process is a unique example of the use of 
rhodacyclopentanones to effect indole dearomatisation chemistry and is notable for the formation of 
two new C–C bonds at the C-2 position.197-199 Within this context, alternative catalytic methods capable 
of accessing similar molecular scaffolds generally require preinstallation of a substituent at the C-2 
position.200,201 Driven by the uniqueness of this transformation and the mechanistic implications, further 
investigations were warranted. To this end, optimisation and computational studies on the newly 
discovered reaction began in collaboration with G.-W. Wang and T. Young. It was anticipated that such 
analysis would not only provide key mechanistic insights, but also pave the way for expanding the 
reactivity modes of rhodacyclopentanones and thus unlock additional polyheterocyclic bond-forming 
processes.  
4.2 Reaction optimisation and evaluation of scope 
In collaboration with G.-W. Wang, systematic variation of reaction conditions was undertaken to 
improve the yield of polycycle 295a. Over 150 conditions were evaluated and the most pertinent results 
are summarised in Tables 14 and 15. Initial investigations highlighted the importance of a 
non-coordinating solvent as no product was detected when 1,2-DCB was substituted for PhCN (Table 
14, entries 1–2). Next, a representative range of phosphine ligands was assessed, and from this 
evaluation it was found that electron-rich and bidentate ligands were completely ineffective (Table 14, 
entries 3–5). Conversely, electron-deficient ligands performed better, with P(C6F5)3 emerging as the 
most efficient ligand, affording polycycle 295a in 46% yield (Table 14, entry 7). Reducing the reaction 





temperature to 130 ℃ further increased the yield of 295a to 53% (Table 14, entry 8). These results 
indicate that an electron-deficient Rh-complex is required; consequently, it was anticipated that further 
reaction efficiency might be achieved by employing a Rh(I)-catalyst with a more dissociating 
counterion.202 However, switching to a BARF counterion was detrimental to the yield of polycycle 295a 
(Table 14, entries 7 vs. 9). Alternative Rh(I)-sources, including [Rh(cod)2]BF4, [Rh(cod)Cl]2 and 
[Rh(cod)OH]2, were also ineffective (Table 14, entries 10–12). 
 
Table 14: Selected optimisation results for the Rh(I)-catalysed carbonylative polycyclisation of indole 292a.f [a] 
3.75 mol% was used for dimeric Rh(I)-catalysts and 7.5 mol% was used for monomeric Rh(I)-catalysts. [b] The 
yield was determined by 1H NMR spectroscopy using 1,4-dinitrobenzene as an internal standard. [c] 7.5 mol% of 
rac-BINAP was used. [d] Isolated yield. [e] The reaction temperature was 130 ℃. [f] Results obtained by G.-W. 
Wang.  
Subsequently, a broad screen of acid additives encompassing carboxylic (e.g. benzoic acids, 
hexanoic acid, AdCO2H, fumaric acid), sulfonic (e.g. TsOH) and phosphoric (e.g. (C6H5O)2P(O)OH) 
acids was conducted. Although no consistent trends were identified with respect to the steric 
environment, acidity or coordinating ability of the acid additives, 4-NMe2C6H4CO2H emerged as the 
preferred candidate, delivering product 295a in 55% yield (Table 15, entry 1). Possible roles of the acid 
additive are discussed in Section 4.3. A series of control experiments verified the necessity of the acid 
additive but not the phosphine ligand. Specifically, in the absence of 4-NMe2C6H4CO2H, no product 
was formed (Table 15, entry 2); whereas, in the absence of the phosphine ligand, polycycle 295a was 





formed in an enhanced yield of 71% (Table 15, entry 3). Further optimisation studies evaluated the 
loading of 4-NMe2C6H4CO2H and the reaction concentration. Whilst increasing the amount of 
4-NMe2C6H4CO2H from 15 mol% to 30 mol% had a minor effect on the yield of 295a (71% vs. 68%, 
Table 15, entries 3–4), additional increments led to diminished yields (Table 15, entries 5–6). 
Decreasing the concentration to 0.1 M with 30 mol% 4-NMe2C6H4CO2H led to a small improvement in 
the yield of 295a (73% yield, Table 15, entry 7). However, an increase in concentration to 0.3 M was 
detrimental to the yield of 295a (Table 15, entry 8). Finally, it was considered that the reaction might 
be sensitive to adventitious water as Rh(I)-catalysts are known to form hydroxy-bridged dimers in the 
presence of water;203 therefore, drying agents were employed in an attempt to exclude water from the 
system (Table 15, entries 9–10). To this end, the inclusion of 100 mol% of Na2SO4 provided a beneficial 
and reproducible effect, affording the target polyheterocycle 295a in 81% yield Table 15, entry 9. Thus, 
optimal carbonylative conditions involved treatment of 295a with [Rh(cod)2]OTf (7.5 mol%), 
4-NMe2C6H4CO2H (30 mol%), Na2SO4 (100 mol%) in 1,2-DCB (0.1 M) at 130 ℃.  
 
Table 15: Selected optimisation results for the Rh(I)-catalysed carbonylative polycyclisation of indole 292a.c [a] 
The yield was determined by 1H NMR spectroscopy using 1,4-dinitrobenzene as an internal standard. [b] Isolated 
yield. [c] Results obtained by G.-W. Wang.  
4.2.1 Synthesis and evaluation of indole N-carbamoyl aminocyclopropanes  
Having established a viable protocol, attention turned to evaluating the scope and functional group 
tolerance of substituents on the indole unit. To facilitate these studies, G.-W. Wang developed a three-
step sequence to synthesise a variety of N-carbamoyl substrates 292b–o (Scheme 83). The sequence 





began with reductive amination of cyclopropylamine with benzaldehyde or butyraldehyde to afford 
secondary amines 170a–b in excellent yield. From here, treatment of amines 170a–b with triphosgene, 
followed by 1,2-addition of the required indole derivative, delivered N-carbamoyl substrates 292b–o in 
64–98% yield. 
 
Scheme 83: Reagents and conditions: i) corresponding aldehyde, NaHCO3, MeOH, reflux, 18 h then NaBH4, 0 °C 
to r.t., 18 h; ii) triphosgene, pyridine, toluene, 0 °C, 10 mins then 170a or 170b, 0 ℃ to r.t., 2 h; iii) corresponding 
indole, NaH, THF, 0 °C to r.t., 1 h then 299a or 299b. [a] Synthesised by G.-W. Wang.  
With a diverse array of indole derivatives 292a–o in hand, they were assessed in the 
Rh(I)-catalysed carbonylative polycyclisation protocol. In general, both electron-donating and 
electron-withdrawing substituents were accommodated on the indole ring, producing polycyclic targets 
295a–k in good to excellent yield (45–83%) and as single diastereomers (Table 16). The structure of 
295k was confirmed unambiguously by single crystal X-ray diffraction. Notably, potentially labile 
groups remained intact; for example, cyclisation of ester 292f, protected alcohol 292g and aryl bromide 
292h proceeded efficiently to afford polycycles 295f–h in 45–57% yield. The inclusion of 
electron-withdrawing substituents at the C6 position of the indole unit led to reduced efficiencies, such 
that C6-nitro analogue 295m was formed in only 18% yield. This decrease in efficiency is likely due to 
specific electronic requirements of the indole core. Likewise, C7-substituted derivatives 292n and 292o 
also participated with lower efficiency, providing adducts 295n and 295o in 18% and 21% yield 
respectively.  






Table 16: Scope of the indole component in the carbonylative dearomative polycyclisation. [a] Synthesised by 
G.-W. Wang. [b] The reaction temperature was 140 ℃.  
4.2.2 Evaluation of trans-1,2-disubsituted aminocyclopropanes and trisubstituted 
aminocyclopropanes 
Encouraged by these results, further substrate scope involving trans-1,2-disubstituted and trisubstituted 
aminocyclopropanes was investigated by G.-W. Wang (Table 17). A range of trans-1,2-disubstituted 
systems trans-292p–r underwent polycyclisation via selective C–C bond activation of the less hindered 
bond (bond a of trans-292p–r) to deliver products 295p–r in 52–68% yield and with excellent 
diastereocontrol (Table 17A). Of particular note is the enantiospecific conversion of enantioenriched 
trans-292q to polycycle 295q (98.5:1.5 e.r.). The same catalyst system was extended to include 
trisubstituted cyclopropanes trans-292s and trans-292t, with the ensuing carbonylative 
polycyclisations effecting efficient desymmetrisation to afford polycyclic targets 295s and 295t in 55% 
and 40% yields and with complete diastereocontrol (Table 17B). Even more impressively, in the case 
of non-symmetrical trisubstituted cyclopropane trans-292u, the protocol was highly selective for 





activation of the benzylic C–C bond (bond a of trans-292u), which led to the regioselective formation 
of intricate polycycle 295u in 52% yield and with excellent levels of diastereocontrol (Table 17C). The 
structure of 295u was unambiguously determined by X-ray crystallography.  
 
Table 17: Evaluation of trans-1,2-disubstituted cyclopropanes and trisubstituted cyclopropanes.c [a] The reaction 
was run in 1,2-DCB (0.2 M). [b] The reaction temperature was 150 ℃. [c] Results obtained by G.-W. Wang.  
  





4.3 Mechanistic studies 
Having appraised the scope of this unique carbonylative polyheterocyclisation, attention turned to 
investigate its mechanism. To this end, both deuterium exchange experiments and density functional 
theory (DFT) calculations were performed to aid elucidation of key mechanistic steps.    
4.3.1 Deuterium exchange experiments 
Initially, using indole 292a as a model substrate, a series of deuterium exchange experiments were 
performed in collaboration with G.-W. Wang (Schemes 84 and 85). After 24 hours, carbonylative 
polycyclisation of 292a in the presence of D2O (300 mol%) delivered deuterio-295aa and 
deuterio-292aa in 42% and 32% yield (Equation 1). For deuterio-292aa, deuterium incorporation was 
observed at C2–H (17%) and C3–H (43%). Control experiments verified that deuterium incorporation 
at C2–H and C3–H of deuterio-295aa is dependent on the presence of the Rh(I)-catalyst, and not the 
benzoic acid additive or the cyclopropane unit (Equations 4–6). These results support an exchange 
pathway involving reversible C2–H activation of 292a. For deuterio-295a, deuterium incorporation 
was observed at C2–H (27%), C11–Ha (49%) and C11–Hb (20%). When the reaction was run at full 
conversion in the presence of D2O (300 mol%), similar levels of deuterium incorporation were observed 
for deuterio-295ab (compare Equation 1 vs. Equation 2). To confirm that exchange at the C2–H position 
of deuterio-295aa/295ab is due to enolisation of the product, pure cyclised product 295a was 
re-subjected to the standard reaction conditions in the presence of D2O (300 mol%). Analysis of 
recovered deuterio-295ac revealed 13% deuterium incorporation at C2–H, in support of this hypothesis 
(Equation 3). The question remained as to how to account for the deuterium incorporation at C11–Ha 
and C11–Hb of deuterio-295a/295ab. It was proposed that incorporation at the former position most 
likely occurs at the stage of 292a as comparable levels of deuterium incorporation are detected at C3–H 
of deuterio-292aa (49% D for deuterio-295aa and 39% for deuterio-295ab vs. 43% D for deuterio-
292aa). On the other hand, it was reasoned that incorporation at the latter position is consistent with 
syn-stereospecific carbometallation of the C2–C3 π-system prior to protodemetallation (i.e. 293 to 298, 
see Scheme 82). Moreover, nOe analysis of deuterio-295aa showed a strong correlation between C4–H 
and C11–Hb, thus confirming the relative stereochemistry of C11–Ha/C11–Hb and C4–H.  






Scheme 84: Mechanistic experiments.b Standard conditions: [Rh(cod)2]OTf (7.5 mol%), 4-NMe2C6H4CO2H 
(30 mol%), Na2SO4 (100 mol%), CO (1 atm), 1,2-DCB (0.1 M), 130℃. [a] The reaction was run without Na2SO4. 
[b] The results from equations 1–6 were obtained by G.-W. Wang.  
Guided by previous reports,20,21 it was proposed that the proton required for the 
protodemetallation step originates from either the acid additive or C2–H of 292a. Indeed, when the 





carbonylative polyheterocyclisation of 292a was performed using 30 mol% 4-NMe2C6H4CO2D 
(prepared by dissolving 4-NMe2C6H4CO2H in d4-methanol and concentrating in vacuo three times), low 
but detectable levels of deuterium incorporation were observed at C11–Ha and C11–Hb of 
deuterio-295ad (Equation 7). Additional roles of the acid additive, such as acting as a carboxylate 
ligand to facilitate CMD-type cleavage of the C2–H bond cannot be discounted.204 Additionally, when 
deuterio-292ae was exposed to the standard reaction conditions, the deuterium label was predominantly 
transferred to C11–Ha and not C11–Hb (Equation 8). Finally, a small kinetic isotope effect (kH/kD = 1.21) 
was observed by independently exposing equimolar amounts of 292a or deuterio-292af to the standard 
conditions and stopping the reaction at specific time points (Equation 9), thus indicating that cleavage 
of the C–H bond is not turnover-limiting.160  
 
Scheme 85: Mechanistic experiments.a Standard conditions: [Rh(cod)2]OTf (7.5 mol%), 4-NMe2C6H4CO2H (30 
mol%), Na2SO4 (100 mol%), CO (1 atm), 1,2-DCB (0.1 M), 130 ℃. [a] The results from Equations 8 and 9 were 
obtained by G.-W. Wang.  
4.3.2 DFT computational studies 
The experiments depicted in Schemes 84 and 85 are consistent with a mechanistic pathway involving 
stereoretentive protodemetallation of a C11-alkyl-Rh(I) species (i.e. species 298); however, convincing 
evidence for the steps leading up to this intermediate could not be obtained. As such, questions remained 
regarding (i) the mode of C–C bond activation and (ii) the C–C bond forming sequence from the putative 
rhodacycle 296. To address these issues, DFT calculations were conducted by T. Young (Scheme 86). 
For these studies, several points should be noted. Firstly, as the exact ligand environment around the 





rhodium centre cannot be confirmed, these calculations are intended to be comparative and not absolute. 
Secondly, as it difficult to compare the relative stabilities of intermediates with different overall charge 
(neutral vs. cationic), due to large differences in solvation energies,205,206 it is assumed that on the basis 
of experimental evidence, C–H metallation is reversible. Consequently, it is presumed that species A 
and B are not separated by more than a few kcal mol-1 and hence, zero points in energy can be applied 
to these species. 
Initially, we wanted to understand if a reaction pathway involving C–C bond activation 
followed by C–H metallation is favoured or if C–H metallation followed by C–C bond activation is 
preferred (Scheme 86A). It was calculated that carbonyl directed C–C bond activation of A to form E 
is endergonic (ΔG = 7.1 kcal mol-1), with a barrier of 22.5 kcal mol-1. From complex E, migratory 
insertion of CO proceeds through transition state G with a lower energy barrier (12.7 kcal mol-1 vs. 15.4 
kcal mol-1 for E to A) to give rhodacyclopentanone H (ΔG = -22.1 kcal mol-1). In accordance with the 
deuterium labelling studies outlined in Equations 4 and 5, it was considered that the C2–H metallation 
complex akin to B is accessible; but, in this scenario, subsequent C–C bond activation via transition 
state D is prohibitively high (ΔG = 32 kcal mol-1). Therefore, this pathway was deemed unlikely. 
Consequently, the alternate pathway involving carbonyl directed C–C bond activation to generate 
rhodacyclopentanone H is favoured, from which straightforward C–H metallation gives complex I (cf. 
intermediate 296, see Scheme 82). At this stage, two different bond forming sequences were envisaged 
to access the critical alkyl-Rh(I) species P/iso-P (Scheme 86B). In one case, 5-ring C(sp2)–C(sp3) 
reductive elimination to acyl-Rh(I) species M is followed by 5-ring carbometallation of the indole 
C2–C3 π-system via transition state O. It was calculated that the energy required for this transformation 
is high (32.4 kcal mol-1 and 31.9 kcal mol-1 respectively); therefore this pathway is unlikely to be 
operational. On the other hand, complex P can be accessed by C(sp2)–C(sp2) reductive elimination to 
complex L, followed by transannular carbometallation of the indole C2–C3 π -system via transition 
state N. Interestingly, despite the formation of a strained 8-membered ring in complex L,207 both of 
these steps are energetically accessible with barriers of 17.8 kcal mol-1 and 24.5 kcal mol-1. As a result 
of these studies, it was deduced that C–C bond formation via C(sp2)–C(sp2) reductive elimination from 
I is favoured. The nature of the C–C reductive elimination step is in line with previous studies 
concerning the formation of 8-membered N-heterocycles (see Chapter 2), as well as other studies 
regarding the relative ease of C(sp2)–C(sp2) vs. C(sp2)–C(sp3) reductive elimination from 
Rh(III)-intermediates.208 Counter to perceived expectations, it is remarkable that transannular 
carbometallation of complex L to P overrides terminating protodemetallation from complex L (i.e. 
formation of 294a is prohibited, see Scheme 81).207 Additionally, the feasibility of the C(sp2)–C(sp3) 
reductive elimination pathway was further ruled out because experimentally no products originating 
from decarbonylation of intermediates akin to M were detected.209   






Scheme 86: DFT analysis of C–C bond activation and C–C bond forming pathways.a Calculations performed at 
the B3PW91-D3BJ/6-311+G(2d,p),Rh(LANTZ(f))/SMD(DCB)//B3PW91-D3BJ/6¬31G(d),Rh(MWB28) level 





of theory, with thermochemical corrections calculated at T = 403 K and a 1 M standard state. [a] Computational 
analysis was conducted by T. Young.  
4.4 The design and development of Rh(I)-catalysed carbonylative exo-polycyclisation 
cascades 
The studies outlined so far in this chapter have demonstrated that rhodacyclopentanone intermediates 
function as linchpins for the dual construction of two new ring systems of polyheterocycles. In particular, 
the carbonylative cyclisation of aminocyclopropane 292a to polycycle 295a was justified by invoking 
endo-polycyclisation of key alkyl-Rh(I)-intermediate 293 (cf. L/N, see Scheme 86B) onto the C2–C3 
π-system of the indole unit. Building upon this discovery, it was imagined that further classes of 
polycyclisation cascade might be achieved by varying the position and nature of the nucleophilic or 
electrophilic component of suitable aminocyclopropane substrates. By exploring this strategy, a suite 
of innovative endo- or exo-polycyclisation cascades was envisaged (Scheme 87) where the 
electrophilicity of rhodacyclopentanones 303 or 305 facilitates the first annulation, and their latent 
nucleophilicity enables the second (via 304/306). Accordingly, attention shifted to investigate how we 
might steer the reaction to undergo selective endo- or exo-trapping of catalytically generated alkyl-Rh(I) 
species.   
 
Scheme 87: Proposed extension to related Rh(I)-catalysed polycyclisation processes. NuH = nucleophile. E = 
electrophile.    
4.4.1 Development of a prototype Rh(I)-catalysed carbonylative exo-polycyclisation cascade 
To gauge the feasibility of this strategy, G.-W. Wang prepared alkenyl 292v and alkynyl 308a systems 
and exposed them to the optimised carbonylative conditions (Scheme 88). In these exploratory reactions, 
the judicious inclusion of P(4-FC6H4)3 (15 mol%) was necessary to suppress endo-cyclisation via the 





indole π-system of 292v/308a. Under these conditions, alkenyl 292v cyclised to form dearomatised 
polycycle 295v as the sole product in 27% yield, and the product arising from carbometallation of the 
alkene tether (i.e. 8,5-fused polycycle 307) was not observed. In comparison, alkynyl 308a cyclised 
exclusively via exo-selective carbometallation of the alkyne unit to afford 8,5-fused polyheterocycle 
310a in 26% yield. To account for the difference in reactivity, it was reasoned that the strongly 
π-coordinating alkyne unit of 308a promotes selective exo-carbometallation over endo-
carbometallation of the indole π-system. Moreover, polyheterocycle 310a was formed as a single 
geometric isomer, further validating the proposed syn-stereospecific carbometallation step from 
intermediate 309 (cf. intermediate 293, Scheme 82). When the same transformations were performed in 
the absence of the ligand P(4-FC6H4)3 (i.e. under the optimised conditions outlined in Table 15), the 
yield of polycycle 295v increased to 42% yield, whereas 310a was not observed.  
 
Scheme 88: Development of a prototype Rh(I)-catalysed carbonylative C–C bond activation triggered 
exo-polycyclisation.a [a] Results obtained by G.-W. Wang.  
Having demonstrated proof-of-principal for a Rh(I)-catalysed carbonylative 
exo-polycyclisation cascade, subsequent studies focused on improving the yield of polyheterocycle 
310a. Further optimisation studies, carried out by G.-W. Wang, determined that the yield of 8,5-fused 





polycycle 310a could be increased to 55% by replacing P(4-FC6H4)3 with P(3,5-(CH3)3C6H3)3 (Table 
18). Under these optimised conditions, the reaction sequence was extended to related polycyclisation 
processes, delivering indole- and pyrrole-based systems 310b–e in 39–82% yield (Table 18).  
 
Table 18: Rh(I)-catalysed carbonylative C–C bond activation triggered exo-polycyclisations of N-carbamoyl 
indoles and pyrroles. [a] Synthesised by G.-W. Wang.   
To shed more light on the impact of the heteroaromatic core on the preferred mode of 
cyclisation, methyl-substituted indole 292x and pyrrole derivative 314 were prepared and evaluated 
under carbonylative conditions (Scheme 89). Exposure of 292x and 314 to the [Rh(cod)2]OTf/4-
NMe2C6H4CO2H catalyst system resulted in the formation of trace quantities of 8-membered 
N-heterocycles 312a/313a and 312b/313b, as determined by TLC analysis. The corresponding 
indole/pyrrole dearomatised products 295x/316 were not observed. The formation of heterocycles 312a 
and 312b is consistent with the C–C bond forming sequence proposed for polycycle 295a (i.e. C(sp2)–
C(sp2) reductive elimination from intermediate 296 is favoured over C(sp2)–C(sp3) reductive 
elimination, see Scheme 82). Compared with the counterpart indole-based systems 292a–o (cf. Table 
16), the inability of indole 292x and pyrrole 314 to undergo dearomative polycyclisation is not 
surprising. In the case of methyl-substituted indole 292x, presumably the C-3 methyl group inhibits 
carbometallation of the indole C2–C3 π-system; consequently, terminating protodemetallation or β-
hydride elimination from alkyl-Rh(I)-intermediate 311 are favoured. Likewise, given that indole 
adducts undergo dearomatisation more readily than pyrrole variants, due to their stabilising benzenoid 
ring,197-199 the deviation in reaction outcome of pyrrole derivative 314 is not unexpected. Partial 
optimisation of the cyclisation of pyrrole 314 to heterocycle 312b was achieved by performing the 
reaction under phosphine and acid free conditions. Using these modifications, C7/8 saturated 
heterocycle 312b was formed in 49% yield, with 3:1 selectivity over unsaturated adduct 312b 
(conditions B, Scheme 89B). The [Rh(cod)2]OTf/cod catalyst system also improved the yield of C7/8 
saturated heterocycle 312a to 27% (conditions B, Scheme 89A). In contrast to the studies outlined 
previously in this chapter and in Chapter 2, it is remarkable that these transformations proceed in the 





absence of an acid additive (cf. Table 2 and Table 15). Due to other successful research avenues, no 
further optimisation studies into either of these transformations was conducted.   
 
Scheme 89: Evaluation of indole 292x and pyrrole 314 in the Rh(I)-catalysed carbonylative cyclisation protocol. 
[a] The yield was determined by 1H NMR spectroscopy using 1,4-dinitrobenzene as an internal standard. 
4.4.2 Deuterium exchange experiments 
During the development of the exo-polycyclisation cascade, a series of mechanistic experiments were 
conducted to provide evidence for the proposed syn-carbometallation step (Scheme 90).  Specifically, 
when the cyclisation of pyrrole derivative 308d to polycycle 310d was run in the presence of D2O (300 
mol%), deuterium incorporation was detected only at the vinylic C–H position (10% D) of deuterio-
310da (Equation 10). This observation is consistent with the formation of the second ring occurring via 
a syn-carbometallation-protodemetallation sequence from an intermediate related to 309 (cf. 
intermediate 306, Scheme 87). Likewise, when the cyclisation of 308d to 310d was performed in the 
presence of 15 mol% 4-NMe2C6H4CO2D (prepared by dissolving 4-NMe2C6H4CO2H in d4-methanol 
and concentrating in vacuo three times) deuterium incorporation was observed at the vinylic C–H 
position (3% D) of deuterio-310db (Equation 11). Finally, as a control experiment, pure cyclised 
product 310d was re-subjected to carbonylative conditions in the presence of D2O (200 mol%). Analysis 
of recovered deuterio-310dc revealed no exchange at the vinylic position, thereby confirming that 
deuterium exchange occurs during but not after product formation.  






Scheme 90: Mechanistic experiments.a [a] Equation 10 was conducted by G.-W. Wang.  
4.4.3 Extension to further classes of polycyclisation cascade 
With a rationale in hand for the generation of 8,5-fused polyheterocycles 310a–e, it was anticipated that 
additional processes should be achievable by exploring the scope of the nucleophilic component. In 
particular, we were interested in examining the suitability of heteroaromatic C3- and 
C2-cyclopropylamides bearing tethered alkyne units. As discussed previously in Chapter 2, 
heteroarenes were identified as excellent carbon nucleophiles in the Rh(I)-catalysed “capture-collapse” 
heterocyclisations of aminocyclopropanes to target 8-membered N-heterocycles. To validate this idea, 
C3-carbamoyl indole 308f  bearing a pendant alkyne motif was readily synthesised in a four-step 
process (Scheme 91). Following a known procedure, Sonogashira coupling of alkyne 317 with 2-
iodoaniline 318 delivered alcohol 319 in 85% yield.210 Conversion of alcohol 319 to its corresponding 
tosylate and subsequent displacement with cyclopropylamine afforded amine 320. Next, EDCI-
mediated coupling of amine 320 and indole-1H-3-carboxylic acid provided cyclopropylamide 308f in 
84% yield.  
Scheme 91: Synthesis of C3-carbamoyl indole 308f.a Reagents and conditions: i) PdCl2(PPh3)2, CuI, Et3N, 65 ℃, 
12 h, 85%; ii) tosyl chloride, DMAP, Et3N, CH2Cl2, 0℃, 1 h, 85%; iii) cyclopropylamine, CH3CN, 0 ℃ to 90 ℃, 





16 h, 85%; iv) 1H-indole-3-carboxylic acid, EDCI, DMAP, CH2Cl2, r.t., 18 h, 84%. [a] Compounds 320 and 308f 
were synthesised by G.-W. Wang.  
With substrate 308f in hand, attention turned to the critical Rh(I)-catalysed carbonylative 
polycyclisation protocol (Scheme 92). When approaching this transformation, our primary concern was 
if the catalytically generated alkyl-Rh(I)-intermediate 321 could be coaxed into a second C–C bond-
forming process (321 to 310f) or if it would be prone to undergo immediate protodemetallation/β-
hydride elimination to give 8-membered heterocycles 322/322’. Pleasingly, under modified 
carbonylative conditions ([Rh(cod)2]OTf (7.5 mol%), P(4-FC6H4)3 (15 mol%), 2-NO2C6H4CO2H (20 
mol%) in PhCN), 8,5-fused polyheterocycle 310f was generated in 47% yield and 8-membered 
heterocycles 322/322’ were not observed. The preferential formation of polyheterocycle 310f is most 
likely due to the highly coordinating nature of the alkyne tether, which outcompetes 
protodemetallation/β-hydride elimination from alkyl-Rh(I)-intermediate 320, and hence enables the 
second annulation.  
 
Scheme 92: Rh(I)-catalysed carbonylative C–C bond activation triggered exo-polycyclisation of indole 308f. [a] 
The yield was determined by 1H NMR spectroscopy using 1,4-dinitrobenzene as an internal standard.  
The yield of polyheterocycle 310f was improved by increasing the loading of 2-NO2C6H4CO2H 
to 100 mol%; using this modification polyheterocycle 310f was generated in 62% yield (Table 19A). 
Encouraged by the success of this strategy, further substrate scope involving alternative C-3 and C-2 
carbamoyl heteroarenes was evaluated alongside G.-W. Wang (Table 19). Extension to pyrrole 
(308g–h), furan (308i) and thiophene (308j) nucleophiles provided 310g–j with similar levels of 
efficiency (Table 19A). Additionally, complementary exo-polycyclisations involving metallation of the 
C-3 position of heteroarenes were also effective, leading to 8,5-polyheterocycles 310k–n in 43–67% 
yield (Table 19B). By blocking the C-2 position, pyrrole 308o was able to cyclise via the C-4 position, 
affording 310o in 40% yield (Table 19C).  






Table 19: Carbonylative C–C bond activation triggered exo-polycyclisations. [a] The corresponding substrate 308 
and catalysis product 310 were synthesised by G.-W. Wang.  
For completeness and to further illustrate the synthetic utility of the exo-polycyclisation strategy, 
additional results obtained by G.-W. Wang are highlighted in Table 20. Notably, other types of bond 
formation can be incorporated into these cascades; for example, nitrogen nucleophiles can be exploited 
in the formation of the first ring. For instance, cyclopropylurea 308p underwent carbonylative exo-
polycyclisation to deliver 7,5-polycycle 310p in 73% yield (Table 20A). Compared to the processes 
outlined in Tables 18 and 19, this example is unique because the reductive elimination step generates  
a C–N bond rather than a C–C bond and, in addition to this deviation, a 7-membered ring is formed 
instead of an 8-membered ring. Even more impressively, the carbonylative cyclisation of pyrrole 308q 





bearing a 1,3-diene tether, proceeded to deliver 8,7-fused ring system 310q in 36% yield as a single 
diastereomer (Table 20B). In this example, the formation of the 8-membered ring most likely occurs by 
a similar pathway to that outlined earlier (cf. intermediate 321, Table 19A); however, the formation of 
the 7-membered ring is most easily rationalised via a hydrometallation pathway.211,212 Specifically, it 
was proposed that protonation of the requisite alkyl-Rh(I) intermediate to Rh(III)-hydride 325 is 
followed by hydrometallation of the pendant 1,3-diene to give a Rh-π-allyl intermediate. From here, 
subsequent C–C reductive elimination affords polyheterocycle 310q.  
 
Table 20: Carbonylative C–C bond activation triggered exo-polycyclisations.a [a] The corresponding substrate 
308p-q and catalysis product 310p-q were synthesised by G.-W. Wang.  
On balance, the newly developed Rh(I)-catalysed carbonylative exo-polycyclisation of 
aminocyclopropanes exhibits broad compatibility and versatility with respect to the nucleophilic and 
electrophilic components. Notwithstanding these achievements, attempts by G.-W. Wang to use less 
nucleophilic arenes (e.g. N-benzoyl) for the first ring formation were unsuccessful (cf. Scheme 51). 
Equally, efforts to access 8,6- or 7,6-fused polyheterocycles by inserting an additional methylene linker 
in the alkyne tether were also met with failure, and so too was the replacement of the alkyne unit with 
alternative π-unsaturated units (e.g. an alkene or allene). Despite these drawbacks, a major advantage 
of this protocol is its robust nature, a characteristic reflected by the ease with which polyheterocycles 
310a–q are produced in a single-step from relatively simple precursors.   
4.5 Summary and Conclusion from the studies in Chapter 4 
Alongside G.-W. Wang, it has been shown that rhodacyclopentanones can be successfully employed to 
achieve multifaceted polycyclisation cascades. Our method capitalises on the ambiphilic nature of 
rhodacyclopentanones to construct two new ring systems of a diverse array of polycyclic targets that 
are difficult-to-access by conventional methods. This aspect is exemplified by the development of a 





unique indole dearomatisation protocol and polycyclisations that incorporate challenging medium ring 
formations. For the former, deuterium exchange experiments and DFT experiments (conducted by 
T. Young) are consistent with a mechanistic pathway involving C(sp2)–C(sp2) reductive elimination (i.e. 
296 to 293, Scheme 82) and stereoretentive protodemetallation of alkyl-Rh(I) species 298. By applying 
the knowledge acquired from these studies, it was discovered that related alkyl-Rh(I) intermediates (i.e. 
309/321/323/324) could be repurposed and exploited to engage with pendant π-unsaturated units to 
form a diverse collection of 8,5-, 7,5-, and 8,7-fused polyheterocycles. This proof-of-concept study 
highlights how catalytic C–C bond activation can be harnessed for the design and synthesis of complex 
and unusual molecular scaffolds that ultimately lie in underexplored regions of chemical space.  
 
Scheme 93: Rh(I)-catalysed carbonylative C–C bond activation triggered polycyclisations. 
 





Chapter 5 – The total synthesis of conolidine and the formal synthesis of 
apparicine 
5.1 Introduction 
In Chapter 2, the discovery and development of a general platform to generate heteroarene fused 
8-membered N-heterocycles by Rh(I)-catalysed carbonylation of cyclopropylamides was successfully 
accomplished. Accordingly, it was envisioned that this methodology could be showcased and applied 
in the total synthesis of conolidine. Chapter 5 describes the successful realisation of this concept and its 
implementation as part of a general strategy to access members of the monoterpenoid indole alkaloid 
family.   
5.1.1 The isolation and biological activity of conolidine, apparicine and related indole alkaloids 
Monoterpenoid indole alkaloids constitute the largest class of tryptamine-derived alkaloids found in 
nature.213,214 These compounds are of paramount importance due to their broad range of biological 
activities and diverse structural topologies.215 Accordingly, many of these alkaloids have and continue 
to gain prominence as attractive targets for chemical synthesis.216-218 Among them, is a small subclass 
known as the C5-nor stemmadenine natural products. The first alkaloid of this class to be reported was 
(-)-apparicine, which was isolated from Aspidosperma dasycarpon in 1965 (Figure 3).219 The structural 
elucidation of apparicine revealed an indole fused bicyclic ring system, consisting of an 8-membered 
C-ring and a piperidine D-ring. A nitrogen atom resides at one of the bridgehead positions and an 
E-exocyclic trisubstituted alkene moiety is found at C20.220 Over 20 monoterpenoid indole alkaloids 
structurally related to apparicine have been discovered, and as indicated by the framework in Figure 3, 
they are unified structurally by an indole fused azabicyclo[4.2.2]decane core (highlighted in blue). 
Representative molecules from this intriguing alkaloid family include (+)-conolidine,221 
(+)-ervaticine,222 (-)-apparicine-21-one,223 (Z)-vallesamine,224,225 alstoniascholarine A,226 
16(S) -hydroxyl-16,22-dihydroapparicine,225 schloraisine N,227 and more highly functionalised 
alkaloids such as taberhaine D,228 (+)-alstonamine,229,230 angustilobine C231 and angustilobine A.232  






Figure 3: Structure of conolidine, apparicine and related alkaloids. Biogenetic numbering is shown on (-)-
apparicine.  
The C5-nor stemmadenine family are of great interest to the scientific community due to their 
promising pharmacological value. Investigations have shown that some members exhibit remarkable 
biological activities such as antimicrobial,233,234 antibacterial235 and opioid236,237 properties. More 
specifically, investigations into the medicinal properties of conolidine have revealed that it is an 
effective non-opioid analgesic for persistent pain.237 Additionally, these studies demonstrated that both 
enantiomers of conolidine possess similar in vivo activities with comparable potency to morphine.237 
Furthermore, conolidine has served as a structural platform for the identification of synthetic analogues, 
with recent medicinal chemistry programmes identifying molecules DS39201083 and DS54360155 as 
more potent analgesics in vivo (Figure 4).238,239 However, the exact mode of action of conolidine and 
these compounds remains unclear. Additionally, the low natural abundance of conolidine (conolidine 
was isolated in just 0.00014% from the stem bark of Tabernaemontana divaricata221) and the scarcity 
of chemical approaches to access the azabicyclo[4.2.2]decane skeleton have hindered investigations 
into the potential therapeutic properties of conolidine and related C5-nor stemmadenine natural products.  
 
Figure 4: Medicinally important synthetic analogues of conolidine. 
C5-nor stemmadenine natural products are biogenetically defined by the presence of only one 
carbon (C6) connecting the indole C3-position to the aliphatic nitrogen atom. This unusual structural 





scaffold is a consequence of C5 excision from the original two-carbon tryptamine bridge of the alkaloid 
stemmadenine (Scheme 94). In the biosynthesis of C5-nor stemmadenine compounds, the excision of 
the C5 carbon is proposed to be promoted by N-oxidation of the bridgehead nitrogen atom.221 This 
proposal has been validated chemically through the conversion of stemmadenine to its C5-nor analogue 
(Z)-vallesamine (Scheme 94).240 In this example, excision of the C5 carbon occurs by a sequence of (1) 
N-oxidation of the aliphatic nitrogen atom, (2) fragmentation which results in the loss of the C5 carbon 
as formaldehyde, (3) hydrolysis and (4) cyclisation through intermediate 326 to afford 
(Z)-vallesamine.240-242  
 
Scheme 94: Biomimetic semi-synthesis of (Z)-vallesamine from stemmadenine. Reagents and conditions: i) H2O2; 
ii) (CF3CO)2O, -5 ℃ then dilute aqueous NaOH.  
5.1.2 Previously reported total synthesis of conolidine  
In recent years, conolidine, apparicine and related alkaloids have garnered increased attention from 
synthetic chemists due to their structural complexity coupled with their attractive biological activities. 
Arguably, the greatest synthetic challenge in the synthesis of these alkaloids resides in the formation of 
the strained azabicyclo[4.2.2]decane skeleton (highlighted in blue throughout) and stereochemical 
control of the exocyclic trisubstituted alkene unit. The total synthesis of conolidine and apparicine have 
been accomplished by five research groups and the following section aims to summarise previous 
strategies to these challenging targets.  
5.1.2.1 Micalizio’s total synthesis of (rac)-conolidine and (+)-conolidine and (-)-conolidine 
The first total synthesis of (rac)-conolidine was disclosed by Micalizio and co-workers in 2011 (Scheme 
95). Their synthetic route was inspired by the proposed biosynthetic conversion of stemmadenine to 
(Z)-vallesamine (cf. Scheme 94), and provided (rac)-conolidine in 9 steps in an overall yield of 18%.237 
The synthesis began with N-alkylation of pyridine 327 and subsequent hydride reduction with NaBH4 
to afford 328 in 57% yield. A [2,3]-Still-Wittig rearrangement of allylic alcohol 328 was then utilised 
to establish the desired alkene geometry at C19–C20. This was achieved by the conversion of 328 to its 
corresponding tributylstannylmethyl ether, which was then treated with n-BuLi to give (E)-329 
((E)-329:(Z)-329’ = 12:1). Dess-Martin periodinane mediated oxidation of (E)-329 to the corresponding 
β,γ-unsaturated aldehyde and nucleophilic addition of 2-lithio-benzenesulfonyl-indole 333 provided a 





mixture of stereoisomeric alcohols 330, which was readily converted to keto 331 in an additional three-
step sequence. For the final transformation, Micalizio took advantage of a conformationally-controlled 
intramolecular Mannich cyclisation to incorporate the final C–C bond of the natural product. This was 
accomplished by reacting 331 with formaldehyde in the presence of TFA. The reaction is believed to 
proceed through cyclisation intermediate 332, which structurally resembles that of intermediate 326 in 
the biomimetic synthesis of vallesamine (cf. 332 v.s. 326, see Scheme 94). Intermediate 332 underwent 
spontaneous intramolecular cyclisation to install the strained 1-azabicyclo[4.2.2]decane core, thereby 
completing the total synthesis of (rac)-conolidine. The execution of this reaction not only facilitated the 
total synthesis, but also underscores how chemical innovation can be prompted by inspiration from 
nature. In addition, using this synthetic approach, either enantiomer of conolidine could be assessed via 
enzymatic resolution of alcohol 328 (Scheme 95B). The authors were able to confirm the absolute 
configuration of naturally occurring conolidine (known as (+)-conolidine) and its unnatural enantiomer 
(known as (-)-conolidine) in 10 synthetic steps from commercially available starting material 327.  
 
Scheme 95: Micalizio’s total synthesis of conolidine. A) Reagents and conditions (some details were not provided 
by the authors): i) 4-methoxybenzyl chloride, 1,2-dichloroethane, reflux, 8 h then NaBH4, MeOH, 0 ℃ to r.t., 
57%; ii) KH, Bu3SnCH2I, THF, r.t., 4 h; iii) n-BuLi, THF, -78 ℃ to 0 ℃, 1 h, 76% from 328, Z:E (329:329’) 
= 12:1; iv) Dess-Martin periodinane, CH2Cl2/H2O; v) n-BuLi, indole 333 then keto 329, THF, -78 ℃, 1 h; vi) 
sodium amalgam, r.t., 4 h; vii) MnO2, CH2Cl2, r.t., 3 h; viii) α-chloroethyl chloroformate, 1,2-dichloroethane, 





84 ℃, 4 h, 43% from 330; ix) CF3CO2H, (CH2O)n, CH3CN, reflux, 2 h, 95%, yield reported is for the preparation 
of the ½ H2SO4 salt of (rac)-conolidine. B) Reagents and conditions (some details were not provided by the 
authors): i) vinyl acetate, amano lipase PS, hexane, 4Ǻ MS, 30 ℃, 18 h, 40% (S)-328 and 39% (R)-328; ii) KH, 
Bu3SnCH2I, THF, r.t., 4 h; iii) n-BuLi, THF, -78 ℃ to 0 ℃, 1 h; iv) CH2Cl2, DIPEA, DMSO, SO3-Pyr, -10 ℃ to 
0 ℃, 1 h, 99%; v) n-BuLi, 1-(phenylsulfonyl)indole 333, THF, -78 ℃, 1 h; vi) sodium amalgam, r.t., 4 h; vii) 
MnO2, CH2Cl2, r.t., 3 h; viii) α-chloroethyl chloroformate, 1,2-dichloroethane, 84 ℃, 4 h; viii) CF3CO2H, (CH2O)n, 
CH3CN, reflux, 2 h, 95%, yield reported is for the preparation of the ½ H2SO4 salt of (+)-conolidine. [a] Yield 
reported is for after hydrolysis.  
5.1.2.2 Takayama’s total synthesis of (rac)-conolidine  
In 2016, Takayama reported an alternative 10-step synthesis of (rac)-conolidine with 11% overall yield 
(Scheme 96).243 Initially, 2-pyrrolidinone 334 was elaborated to alcohol 336 in a three-step sequence. 
From here, alcohol 336 was oxidised and transformed into silyl enol ether 337 as a mixture of 
geometrical isomers ((E)-337:(Z)-327 = 1:2.6). Next, after extensive investigation, a Au(I)-catalysed 
6-exo-dig cyclisation assembled the piperidine D-ring and secured the exocyclic (E)-ethylidene 
appendage. The authors commented that employment of electrophilic JohnPhosAu(MeCN)SbF6 
(Echavarren catalyst244) and the judicious inclusion of H2O as a proton source were essential for the 
reaction to proceed. Utilising these conditions, piperidine 338 was obtained in 67% yield, compared to 
19% in the absence of H2O. Nucleophilic addition of 2-lithio-benzenesulfonyl-indole 333 and oxidation 
of the resulting secondary alcohol with Dess-Martin periodinane afforded ketone 339 in 64% yield from 
338. To complete the synthesis, removal of both N-protecting groups provided known intermediate 331, 
and using modified conditions reported by Micalizio, an acid mediated Mannich cyclisation delivered 
(rac)-conolidine in 59% yield.  
 
Scheme 96: Takayama’s total synthesis of (rac)-conolidine. Reagents and conditions: i) n-BuLi, NsCl, 
THF, -78 ℃, 22 h, 85%; ii) NaBH4, THF/H2O (10:1), 0 ℃ to r.t., 12 h; iii) K2CO3, DMF, 50 ℃, 72%; iv) IBX, 





DMSO, 50 ℃, 1.5 h; v) TIPSOTf, Et3N, CH2Cl2, 0 ℃, 5h, 81% from 336, E:Z = 1:2.6; vi) 
JohnPhosAu(MeCN)SbF6, CH2Cl2, H2O, 0 ℃, 12 h, 67%; vii) n-BuLi, 1-(phenylsulfonyl)indole 333, THF -78 ℃ 
then 338, 6 h; viii) DMP, CH2Cl2, 0 ℃ to r.t., 1.5 h, 64% from 338; xi) 1M KOH, MeOH, reflux then PhSH, r.t., 
97%; x) CSA, (CH2O)n, CH3CN, reflux, 59%. 
5.1.2.3 Fujii’s total synthesis of (+)-conolidine  
Simultaneously with the disclosure from Takayama’s group, Fujii and co-workers published a closely 
related synthesis of (+)-conolidine (Scheme 97). Their approach also featured a Au(I)-cyclisation step 
to construct the piperidine D-ring, in addition to the indole unit. Their route delivered (+)-conolidine in 
10 steps in an overall yield of 3% and 84% e.e. (Scheme 97).245 The synthesis commenced with 
alkylation of tosylamine 340 with ethyl 4-bromobutanoate 341 which proceeded in quantitative yield 
to give intermediate 342. Successive treatment of 342 with DIBAL and 1,2-addition of lithium 
(trimethylsilyl)acetylide, followed by desilylation with TBAF delivered terminal alkyne 343 in good 
yield. Sonogashira coupling of alkyne 343 with 2-iodoaniline 344 provided alkynylaniline 345 in 90% 
yield. Oxidation of 345 with MnO2 to keto 346, followed by treatment with TIPSOTf furnished silyl 
enol ether 347 as the substrate for the ensuing key Au(I)-catalysed cyclisation reaction. Inspired by 
conditions developed in the Toste lab,246 treatment of conjugated enyne 347 with (R)-MeO-DTBM-
BIPHEP(AuCl)2/AgSbF6 in toluene afforded cyclised product 348, albeit in a modest 32% yield but 
with 88% e.e. In agreement with Takayama’s report, the fortuitous inclusion of water was critical for 
this transformation.243 Additionally, studies demonstrated that the desired cyclised product 348 could 
only be formed from the sterically less hindered Z-isomer of 347 (the Z and E isomers of 347 could be 
separated by column chromatography). From 348, cleavage of the N-tosyl protecting group with 
sodium/naphthalene, and finally Micalizio’s acid mediated Mannich reaction provided (+)-conolidine 
in 34% yield with 84% enantiopurity. 






Scheme 97: Fujii’s total synthesis of (+)-conolidine. Reagents and conditions: i) NaH, DMF, r.t., 3 h, quantitative; 
ii) DIBAL, CH2Cl2, -78 ℃, 1 h; iii) n-BuLi, trimethylsilylacetylene, -78 ℃, 2h, 90% yield from 342; iv) TBAF, 
THF,  r.t., 1 h, 94%; v) 2-iodoaniline 344, Pd(PPh3)2Cl2, CuI, Et3N, CH3CN, r.t., 1.5 h, 90%; vi) MnO2, CHCl3, 
reflux, 0.5 h, 71%, vii) TIPSOTf, Et3N, CH2Cl2, -78 ℃ to r.t., 2 h, 75%, E:Z = 15:85; viii) (R)-MeO-DTBM-
BIPHEP(AuCl)2, AgSbF6, PhMe, r.t., 10 min then (Z)-347, r.t., 17 h, 32%, 88% e.e.; ix) Na/naphthalene, THF, 
0 ℃, 60%; x) CF3CO2H, (CH2O)n, CH3CN, reflux, 5 h, 34%, 84% e.e.. 
5.1.2.4 Qi’s total synthesis of (rac)-conolidine  
Recently, Qi and co-workers reported a conceptually similar synthesis of (rac)-conolidine (Scheme 98, 
cf. Schemes 96 and 97).247 However, and more significantly, their route involves no non-strategic redox 
manipulations and remains the shortest route to date. Their 6-step synthetic route commenced with 
treatment of N-tosylindole 349 with n-BuLi, followed by addition of N-tosylpyrrolidone 350 provided 
ketone 351 in 48% yield. Next, a one-pot N-alkylation of 351 and selective deprotection of the N-indole-
tosyl group afforded alkynyl ketone 352 in 81% yield. Ketone 352 was then readily converted to silyl 
enol ether 353 (E:Z = 0.08:0.92). Like Takayama and Fujii, Qi also opted for a Au(I)-catalysed 
cyclisation to form the piperidine D-ring and to secure the E-geometry of the exocyclic double bond. 
DFT calculations revealed that an unprotected indole unit was essential for the Au(I)-catalysed 
cyclisation to proceed. Additionally, the group reported that the use of [JohnPhosAu(CH3CN)]SbF6 in 
toluene favoured the formation of the desired 6-exo-dig product 348 (73% yield) over the 7-endo-dig 





product 354 (15% yield). Compared to Fujii’s route (Scheme 97), ketone 348 could be accessed in just 
4 steps. The remainder of the synthesis was accomplished by removal of the N-tosyl group to provide 
piperidine ketone 331, and finally using the conditions identified by Micalizio, an acid promoted 
Mannich reaction of 331 afforded (rac)-conolidine in 82% yield. 
 
Scheme 98: Qi’s total synthesis of (rac)-conolidine. Reagents and conditions: i) n-BuLi, THF, -78 ℃, 5 min then 
N-tosylpyrrolidone 350, -30 ℃ to -15 ℃, 4 h, 48%; ii) K2CO3, 1-bromo-2-butyne, CH3CN, 80 ℃, 16 h then 
TBAF, 35 ℃, 16 h, 81%; iii) TIPSOTf, 2,6-lutidine, 35 ℃, 97%, E:Z = 0.08:0.92; iv) [JohnPhosAu(CH3CN)]SbF6, 
H2O, PhMe, 60 ℃, 2 h, 73% for 348, 15% for 354; v) Na/naphthalene, THF, -78 ℃, 86%; vi) CF3CO2H, (CH2O)n, 
CH3CN, reflux, 2 h, 82%.  
5.1.3 Previously reported total synthesis of apparicine 
As stated previously, conolidine and apparicine share an intriguing azabicyclo[4.2.2]decane 
architecture and are distinguishable by the choice of substituent at C16 (see Figure 3). Apparicine has 
also been the subject of previous synthetic studies; however, due to reactivity and selectivity issues this 
alkaloid remained an elusive target. In the late 1970s, Joule and co-workers developed an approach 
which allowed for the construction of the bicyclic skeleton of apparicine (i.e. azocane 357, Scheme 
99).248 Their approach centred on an acid promoted Mannich reaction between acetal 356 and 
formaldehyde, which after removal of the keto protecting group, afforded bicycle 357 in 35% yield 
(Scheme 99). However, the total synthesis of apparicine was not disclosed/completed at this time. It 
would take a further 40 years until Micalizio successfully utilised an acid mediated Mannich 
transformation to construct the azazbicyclo[4.2.2]decane core of related conolidine with the requisite 
E-exocyclic alkene appendage at C20 (see Scheme 95).  






Scheme 99: Joule’s Approach to the apparicine skeleton. Reagents and conditions (some details were not provided 
by the authors): i) benzyl bromide, EtOAc, reflux, 5 h; ii) NaBH4, MeOH, 10 ℃; iii) H2, Pd/C, MeOH, r.t., 16 h, 
30% from 355; iv) acetic acid, (CH2O)n, r.t., 4.5  h then aqueous HCl, 24 h, 35%.   
5.1.3.1 Bennasar’s total synthesis of (rac)-apparicine 
Following Joule’s initial studies (and before Micalizio’s synthesis of conolidine), Bennasar and co-
workers disclosed the first total synthesis of (rac)-apparicine in 2009 (Scheme 100).249,250 The authors 
developed a two-pronged approach to form the 8-membered C-ring. One approach entailed an acyl 
radical cyclisation followed by ketone-alkene function group interconversion (Scheme 100A). This was 
accomplished via reductive amination of aldehyde 358 with 2-bromo-2-propenylamine 359, followed 
by Boc protection of the resulting secondary amine. From here, ester 360 was advanced to selenoester 
361 in a two-step sequence. Treatment of selenoester 361 with n-Bu3SnH and Et3B initiated a radical 
cyclisation that constructed the 8-membered ring of azocane 362 in 54% yield. Finally, 1,2-addition of 
MeLi and subsequent dehydration under acidic conditions secured amine 363. Alternatively, the 
8-membered C-ring could be formed by ring closing metathesis and base-induced isomerisation of the 
C–C double bond from C14–C15 to C15–C16 (Scheme 100B). This approach was achieved by the 
quick elaboration of indole 333 to 367 via a 3-step sequence. Subsequent treatment of indole 367 with 
Grubbs 2nd generation catalyst forged the 8-membered C-ring and produced amine 368 in 80% yield. 
Exposure of 368 to t-BuOK in refluxing THF simultaneously cleaved the N-indole protecting group and 
promoted alkene isomerisation to deliver amine 363 in 90% yield. Next, N-Boc deprotection and 
N-alkylation with tosylate 364 delivered amine 365 in 30% yield. The authors commented that, 
following Boc deprotection, the resulting secondary amine was highly susceptible to acid mediated 
decomposition. Finally, the synthesis was concluded by a cationic Pd(0)-catalysed Heck cyclisation of 
365 which closed the piperidine ring and furnished (rac)-apparicine in 15% yield. Bennasar noted that 
the Heck-cyclisation was complicated by concomitant unravelling of the exocyclic alkylidene 
substituent which gave rise to unidentified side products, therefore contributing to the low overall yield 
of (rac)-apparicine. 





Scheme 100: Bennasar’s total synthesis of (rac)-apparicine. A) Reagents and conditions: i) 2-bromo-2-
propenylamine 359, NaBH(OAc)3, AcOH, CH2Cl2, r.t., overnight then Boc2O, 1,4-dioxane, r.t., overnight, 76%; 
ii) LiOH, THF/H2O then 1 M aq. HCl then Et3N, Bu3P, PhSeCl, r.t., overnight, 90%; iii) n-Bu3SnH, Et3B, PhH, 
r.t., 2 h, 54%; iv) MeLi, THF, -10 ℃, 2 h then TsOH, CH3CN, r.t., 2 h, 70%; v) 1 M aq. HCl, MeOH, r.t., 4.5 h 
then 364, DIPEA, CH2Cl2/CH3CN, r.t., 2 h, 30%; vi) Pd(OAc)2, Ph3P, Ag2CO3, PhMe, Et3N, 80 ℃, 1.5 h, 15%. 
B) Reagents and conditions: i) n-BuLi, THF, 0 ℃, 2 h then CuCN, -78 ℃ to 0 ℃, 2 h then (E)-4-chloro-2-pentene,  
-78 ℃ to r.t., 12 h, 85%; ii) Cl2CHOMe, TiCl4, CH2Cl2, -78 ℃, 4 h, 76%; iii) allylamine, NaBH(OAc)3, AcOH, 
CH2Cl2, r.t., overnight then Boc2O, Et3N, MeOH, reflux, 5 h, 90%; iv) Grubbs 2nd generation catalyst, CH2Cl2, 
reflux, 4.5 h, 80%; t-BuOK, THF, reflux, 48 h, 90%. Biogenetic numbering is shown on (rac)-apparicine.  
5.1.3.2 Takayama’s total synthesis of (rac)-apparicine 
In conjunction with reporting the synthesis of (rac)-conolidine, Takayama simultaneously 
accomplished the synthesis of (rac)-apparicine.243 To this end, lactam 334 was elaborated in 10 
synthetic steps to afford (rac)-conolidine (Scheme 96). From here, 1,2-addition of MeLi to 
(rac)-conolidine provided the corresponding tertiary alcohol and subsequent dehydration with TFA 
gave (rac)-apparicine in 52% yield (Scheme 101).  






Scheme 101: Takayama’s total synthesis of (rac)-apparicine. Reagents and conditions: i) MeLi, THF, -78 ℃, 1 
h; ii) TFA, CH2Cl2, 0 ℃ to r.t., 5.5 h, 52%.  
5.1.4 Summary of existing methods for the synthesis of conolidine, apparicine and related 
monoterpene indole alkaloids 
Over the past decade, a renaissance of interest in conolidine and apparicine has led to several creative 
and instructive total synthesis being disclosed. Central to Micalizio’s successful synthesis of conolidine, 
was clever inspiration from nature and exploratory studies by Joule to construct the 8-membered C-ring 
via an acid promoted Mannich cyclisation. However, all subsequent synthesis of conolidine have relied 
heavily on this biosynthetically inspired transformation to build the bridged azabicyclo[4.2.2]decane 
core, with yields fluctuating between 34% and 95%. Additionally, existing strategies still suffer from 
unsolved limitations including long step counts, inefficient or unselective transformations or lack of 
control of absolute stereochemistry. However, the most promising of all these synthetic routes was Qi’s 
synthesis of (rac)-conolidine, which proceeded in only 6 steps. In contrast to Micalizio, Bennasar opted 
for a Pd(0)-catalysed Heck cyclisation to close the bridged ring system of apparicine; this 
transformation is highly challenging (the authors reported only a 15% yield) thereby reinforcing the 
notion that further improvements in synthetic efficiency are needed. To date, none of the other alkaloids 
of this class have been synthesised by synthetic chemists and this can perhaps be attributed to the highly 
strained bicyclic core. Therefore, to address the unmet synthetic challenges posed by conolidine and 
related indole alkaloids, investigations towards their synthesis were initiated and will be discussed in 
the following sections.  
5.2 A Rh(I)-catalysed cyclisation approach towards the total synthesis of (rac)-conolidine 
The considerations outlined above prompted attempts to develop a short and selective synthesis of 
C5-nor stemmadine alkaloids. The ideal synthesis would be redox and step economical and allow for a 
modular approach to some of the higher functionalised indole monoterpenoids (see Figure 3). With the 
ultimate goal of rendering the synthesis asymmetric, (rac)-conolidine was selected as the initial target. 
5.2.1 First generation retrosynthetic analysis of (rac)-conolidine 
The first generation retrosynthetic analysis of (rac)-conolidine is outlined in Scheme 102. The planned 
synthesis hinged on two key steps: Rh(I)-catalysed carbonylation to form the 8-membered C-ring and 
a Pd(0)-catalysed α-vinylation of a keto enolate to forge the nitrogen bridgehead. With this strategy in 





mind, it was envisioned that the azabicyclo[4.4.2]decane scaffold would be assembled by late stage 
construction of the C15–C20 bond, which would also secure the E-exocyclic alkene geometry. Thus, 
conolidine would be accessed from vinyl halide 367 through a Pd(0)-catalysed enolate vinylation. Key 
intermediate 367 would derive from lactam 179g via an ambitious chemoselective lactam reduction. In 
a second key retrosynthetic disconnection, it was anticipated that lactam 179g would arise from amide 
178g via the newly developed Rh(I)-catalysed carbonylative ring expansion of cyclopropylamides 
outlined in Chapter 2. Amide 178g would be obtained from acid 368 and amine 369, which, in turn, 
could be formed by a known three-step sequence from trans-crotonaldehyde 370.251  
 
Scheme 102: First generation retrosynthetic analysis of (rac)-conolidine. 
Several aspects of the retrosynthesis detailed in Scheme 102 warrant additional comment. 
Firstly, the carbonylative disconnection to form the 8-membered ring is highly productive because this 
transformation would construct the C-ring of conolidine in just six steps from simple starting materials. 
However, this strategy is not without significant risk, as the necessary survival of the vinyl bromide 
adds an additional layer of complexity. Secondly, whilst formidable advances in Pd(0)-catalysed 
reactions have been made, to the best of our knowledge, there are no reported α-vinylation reactions 
involving (aza)cyclooctane rings to produce bridged ring systems. Nevertheless, we were drawn to the 
prospect of transforming 367 directly to (rac)-conolidine, as it would represent a novel application of 
palladium catalysis for the construction of the azabicyclo[4.2.2]decane core. Literature precedence for 
this α-vinylation strategy will be presented in Section 5.2.4.5. Overall, the value of pursuing this 
particular strategy would be three-fold: (1) it would showcase the power of the Rh(I)-catalysed 





cyclisation methodology to access 8-membered N-heterocycles; (2) it would allow rapid access to the 
8-membered C-ring from relatively simple amide 178g; and more significantly (3), if the Pd(0)-
catalysed α-vinylation transformation could be rendered asymmetric then conolidine would be obtained 
in high enantiomeric purity.  
5.2.1.1 Studies towards the carbonylative ring expansion of a N-vinyl bromide 
aminocyclopropane  
Note: The work in this section was carried out in collaboration with Mr. H. Lan, as part of his CDT 
rotation project at Bristol. 
Initially, amide 178g was prepared in a 5-step sequence as outlined in Scheme 103. Following a known 
procedure, successive treatment of trans-crotonaldehyde with bromine and Et3N, followed by 
subsequent reduction with NaBH4 delivered alcohol 371 in good yield.251 This material was used 
without further purification and all of these steps were easily carried out on multi-gram scale. 
Conversion of alcohol 371 to its corresponding mesylate and subsequent displacement with LiBr, 
delivered dibromide 372.251,252 Next, N-alkylation of cyclopropylamine with 372 and addition of the 
ensuing amine to 1H-indole-3-carbonyl chloride under basic conditions provided amide 178g in 46% 
yield. With substrate 178g in hand, attention turned to the critical Rh(I)-catalysed carbonylative 
cyclisation.   
 
Scheme 103: Synthesis of vinyl bromide 178g. Reagents and conditions i) Br2, CH2Cl2, 0 ℃, 1 h then Et3N, 0 ℃ 
to r.t., 1.5 h, 89%; ii) NaBH4, THF/H2O, 0 ℃, 1 h, 86%; iii) MsCl, THF, -30 ℃ then LiBr, -30 ℃ to r.t., 50%; iv) 
aminocyclopropane, K2CO3, CH3CN, 0 ℃ to r.t., 65%; v) 1H-indole-3-carboxylic acid, oxalyl chloride, cat. DMF, 
CH2Cl2, 0 ℃, 1 h then 372, Et3N, CH2Cl2, 0 ℃ to r.t. 16 h, 46%. Compounds 372 and 178g were synthesised by 
H. Lan. 
Using the previously optimised conditions for parent substrate 178a (see Section 2.5, Table 6), 
exposure of amide 178g to [Rh(cod)OMe]2/P-(4-FC6H4)3/2-NO2C6H4CO2H catalyst system, under an 
atmosphere of CO, was expected to result in the formation of lactam 179g. However, rather than 
obtaining the desired product, analysis of the 1H NMR spectrum of the crude reaction mixture indicated 
trace amounts of protodecyclopropanated 373 and unreacted 178g (Scheme 104A). Side-product 373 
was not isolated but was assigned based on comparison with NMR data of starting material 178g and 
by analogy with observations in related processes (see Chapter 3, Scheme 67). As discussed previously, 
side-products akin to 373 most likely derive from hydrolysis of the corresponding enamide, which in 





turn is generated by rhodacyclobutane decomposition. Subsequently, H. Lan evaluated key reaction 
parameters, such as catalyst ([Rh(cod)OMe]2 vs. [Rh(cod)2]OTf), phosphine ligand (electron-rich vs. 
electron-poor), acid additive (alternative benzoic acids vs. aliphatic acids) and temperature (120 ℃ vs. 
130 ℃ vs. 140 ℃). Unfortunately, the desired product 179g was not formed under any of these 
conditions. From these experiments, it was proposed that the Rh(I)-catalyst was inserting preferentially 
into the C–Br bond of the N-vinyl bromide unit. To test this hypothesis, a competition experiment was 
performed in which equimolar amounts of amides 178a and 178g were subjected to the [Rh(cod)OMe]2 
carbonylative catalysis conditions. Consistent with our hypothesis, only trace amounts of cyclised 
product 179a were observed in the 1H NMR spectrum of the crude material. This result suggests that 
the Rh(I)-catalyst inserts preferentially into the C–Br bond and this unproductive reaction pathway 
outcompetes the desired C–C bond activation (i.e. rhodacyclopentanone formation). This can be 
rationalised by the relative stability of the corresponding 6-membered Rh(III)-chelate I compared to 
rhodacyclopentanone II (Scheme 104). As amide 178g did not exhibit the desired activity, no further 
investigations into this transformation were conducted. 
 
Scheme 104: Experiments conducted by H. Lan. [a] The yield was determined by 1H NMR analysis using 1,4-
dinitrobenzne as an internal standard.   
Given that vinyl bromide 178g was incompatible in the Rh(I)-catalysed carbonylative 
cyclisation, cyclopropylamide 178h bearing a vinyl chloride unit was proposed as a workable 





alternative. It is well established that C−Cl bonds undergo oxidative addition less readily with 
Rh(I)-catalysts compared to C−Br bonds.253 However, vinyl chloride 178h could not be accessed due 
to handling and volatility issues encountered during the conversion of aldehyde 374 to intermediate 375 
(Scheme 105).254  
 
Scheme 105: Attempted synthesis and application of vinyl chloride 178h. Reagents and conditions: i) 
(diacetoxyiodo)benzene, pyridine hydrochloride, CH2Cl2, r.t., 73%.  
5.2.2 Second generation retrosynthetic analysis of (rac)-conolidine 
Due to the unsuitability of vinyl bromide 178g in the critical Rh(I)-catalysed carbonylative cyclisation 
reaction, the retrosynthetic analysis shown in Scheme 102 was re-evaluated. Specifically, carbonylative 
precursor 178g was re-designed to include an alternative pre-installed N-functionalised appendage that 
would be amenable for subsequent construction of the piperidine D-ring. With this strategy in mind, the 
vinyl halide unit of 178g was replaced with an alkyne component and the second generation 
retrosynthetic analysis of (rac)-conolidine is presented in Scheme 106. Taking inspiration from the 
groups of Li255-257, Garg258 and Takayama,243 it was anticipated that the nitrogen bridgehead of 
(rac)-conolidine could be installed by a Au(I) or Ag(I)-catalysed259 cyclisation of silyl enol ether 376. 
The geometry of conolidine’s trisubstituted exocyclic alkene would be defined by the trans alkyne 
activation mode of the Au(I) or Ag(I)-catalyst.260 In turn, silyl enol ether 376 would arise from 
chemoselective lactam reduction and silyl ether formation of key late-stage compound 179i, which 
would be accessed from amide 178i using the Bower group’s Rh(I)-catalysed carbonylation protocol. 
Finally, amide 178i can be traced back to commercially available acid 368 and amine 377, which can 
be readily derived from known compounds. The implementation of this strategy would not only serve 
to construct the 8-membered C-ring of (rac)-conolidine in just three steps, but would also avoid wasteful 
N-functionalisation steps at a later step in the synthesis. 






Scheme 106: Second generation retrosynthetic analysis of (rac)-conolidine.  
When considering the feasibility of substrate 178i in the Rh(I)-catalysed carbonylation reaction, 
a notable concern was whether the catalytically generated Rh(I) intermediate (i.e. 378, Scheme 107) 
would be trapped by the tethered alkyne (for related processes see Chapter 4). However, we remained 
optimistic that the alkyne moiety would remain intact for two reasons. Firstly, polycyclisation via a 
4-exo-dig cyclisation mode would afford highly strained 8,4-fused heterocyclic products; therefore, this 
pathway was considered unfavourable. Secondly, as detailed in Section 4.4, no products arising from a 
5-endo-dig pathway had been detected from structurally similar substrates. 
 
Scheme 107: Rationale for suitability of substrate 178i in Rh(I)-catalysed carbonylative cyclisation.  





5.2.2.1 Studies towards the carbonylative ring expansion of a N-propargyl aminocyclopropane  
Following the retrosynthetic plan outlined in Scheme 106, the synthesis commenced with the scalable 
preparation of catalysis substrate 178i (Scheme 108). N-Alkylation of aminocyclopropane with 
1-bromobut-2-yne provided propargylic amine 377 in 69% yield. Next, addition of amine 377 to 
1H-indole-3-carboxylic acid smoothly furnished amide 178i in 66% yield. Attention then focussed on 
the crucial Rh(I)-catalysed carbonylative cyclisation. Disappointingly, efforts were thwarted, with 
alkyne hydration observed as a severe side reaction (Scheme 108B). Attempts to suppress this 
deleterious pathway by the inclusion of sodium sulfate or 4 Å molecular sieves as a drying agent, were 
also unsuccessful. Li has previously commented that transformations involving propargylic amine 
appendages routinely suffer from undesired hydration pathways.256 However, as the reaction requires a 
balloon of CO, it is difficult to exclude all sources of adventitious water. Additionally, strong 
coordination of the alkyne component of 178i to the Rh(I)-catalyst may prevent directed insertion into 
the cyclopropyl unit of 178i. A brief survey of reaction components in the presence and absence of 
either sodium sulfate or 4 Å molecular sieves was undertaken. These parameters included Rh(I)-source 
([Rh(cod)OMe]2 vs. [Rh(cod)2]OTf), representative phosphine ligands (P(4-FC6H4)3 vs. PPh3 vs. 
P(4-OMeC6H4)3 vs. BINAP) and alternative acid additives (2-NO2C6H4CO2H vs. fumaric acid vs. 
AdCOOH). Unfortunately, these efforts were ineffective with alkyne hydration remaining the 
predominant reaction pathway. Thus, efforts to access the 8-membered C-ring of conolidine with a 
pre-installed amide nitrogen group had again been foiled. Consequently, work on this substrate was 
abandoned and an amide nitrogen protecting group was sought.   
 
Scheme 108: A) Reagents and conditions i) CH3CN, 0 ℃ to r.t., 16 h, 69%; ii) 1H-indole-3-carboxylic acid, 
oxalyl chloride, cat. DMF, CH2Cl2, 0 ℃, 1 h then 377, Et3N, CH2Cl2, 0 ℃ to r.t. 4 h, 66%. [a] The yield was 
determined by 1H NMR analysis using 1,4-dinitrobenzne as an internal standard.   





5.2.3 Third generation retrosynthetic analysis of (rac)-conolidine 
Despite the setbacks discussed above, we returned to the primary task of completing the total synthesis 
of (rac)-conolidine. The greatest synthetic challenge encountered so far was identifying a suitable 
substrate for the Rh(I)-catalysed carbonylative cyclisation that contained a pre-installed 
N-functionalised appendage. In consideration of these challenges, it was decided to construct the 
8-membered C-ring with a benign substituent on the amide nitrogen and then introduce the problematic 
N-vinyl bromide component. It was rationalised that the most expediate and logical approach was to 
revert to parent substrate 178a, which possesses a N-benzyl group. A revised third generation 
retrosynthetic analysis of (rac)-conolidine is presented in Scheme 109.  
 
Scheme 109: Third generation retrosynthetic analysis of (rac)-conolidine.  
Identical to the first generation strategy, it was anticipated that the C15–C20 bond would be 
constructed by Pd(0)-catalysed enolate coupling of vinyl bromide 367. However, key late-state 
compound 367 would be accessed from cyclised lactam 179a through a series of transformations 
including lactam reduction, N-benzyl deprotection and N-alkylation to install the vinyl bromide unit. In 
turn, lactam 179a would arise from amide 178a under the Rh(I)-catalysed carbonylative cyclisation 
protocol developed in Chapter 2. Amide 178a would be derived from 1H-indole-3-carboxylic acid and 
amine 170a, the latter of which would be derived from cyclopropylamine and benzaldehyde. Although 
previous studies have already demonstrated access to cyclised compound 179a (see Section 2.5), the 
opportunity to evaluate a scalable synthetic route to this key intermediate was undertaken. 
5.2.3.1 Further optimisation of Rh(I)-catalysed carbonylative cyclisation of cyclopropylamides 
Cyclisation substrate 178a was available in multigram quantities by a two-step procedure as outlined in 
Scheme 110. Reductive amination of benzaldehyde with cyclopropylamine afforded amine 170a in 
excellent yield.16 EDCI coupling of amine 170a and 1H-indole-3-carboxylic acid delivered amide 178a 





in 79% yield. With a large quantity of 178a in hand, the Rh(I)-catalysed carbonylative cyclisation was 
re-examined. 
 
Scheme 110: Preparation of amide 178a: Reagents and Conditions: i) NaHCO3, MeOH, reflux, 16 h then cool to 
0 ℃, NaBH4, 16 h, 98%; ii) 1H-indole-3-carboxylic acid, EDCI, DMAP, CH2Cl2, r.t., 12 hours, 79%.  
 As discussed in Section 2.5, the carbonylative cyclisation of 178a was readily accomplished 
in 58% yield using 3.75 mol% [Rh(cod)OMe]2 in combination with 22.5 mol% of P(4-FC6H4)3 and 150 
mol% 2-NO2C6H4CO2H in PhCN at 130 ℃. During these original studies, carbonylative reactions were 
performed on 0.15 mmol (0.5 mL) scale using a balloon of CO. Therefore, in order to facilitate studies 
on the remaining transformations, investigations were directed towards increasing the scale of the 
reaction and transferring the protocol to a sealed reactor vessel, for example the ChemSCAN II®, which 
would allow for the rapid screening of reaction conditions in parallel and on a larger scale (limited by 
a reaction volume of 5 mL). A selection of key results are given in Table 21.  
 
Table 21: Evaluation of conditions for carbonylative cyclisation of 178a using a ChemSCAN II® reactor. [a] 
Yields of isolated products unless stated otherwise. [b] A balloon of CO and 22.5 mol% of P(4-FC6H4)3 was used. 





In order to directly compare the effect of the CO delivery method on the yield of 179a, a side-
by-side comparison of a balloon of CO vs. 1 bar of CO in a ChemScan II® reactor was first examined 
(Table 21, Entries 1 and 2). Unfortunately, the yield of 179a decreased dramatically to 10% in the 
ChemScan II® reactor compared to 58% when a balloon of CO was used (Table 21, entries 1 vs. 2). 1H 
NMR analysis of the crude reaction mixture from the ChemScan II® reactor revealed that the majority 
of the mass balance was protodecyclopropanted 178a (for a discussion on degradation of substrates 
related to 178a, see Section 3.1). It was postulated that the lack of any desired product may be due to 
the reversibility of rhodacyclopentanone formation (see mechanistic studies discussed in Section 2.6), 
combined with low concentration of CO in solution.261 Consequently, the effect of CO pressure was 
evaluated. It was found that increasing the pressure of CO to 2 bar and then 3 bar gave an increase in 
yield of 179a to 31% and 45% respectively (Table 21, entries 3 and 5). However, a further increase to 
4 bar was not beneficial (Table 21, entries 7 and 8), presumably due to saturation of the Rh(I)-catalyst 
by CO. Decreasing the temperature of the reaction to 120 ℃  with 2 or 3 bar of CO was detrimental to 
the yield of 179a (Table 21, entries 4 and 6). Further attempts to improve the yield by adjusting the 
concentration of CO at a pressure of 3 bar (0.3 M vs. 0.2 M vs. 0.5 M) provided no further improvement 
(Table 21, entries 5 vs. 9 vs. 10). Of note, minor quantities of unsaturated product 180a were detected 
in all reactions (for discussion on formation of 180a see Section 2.1). Ultimately, the best conditions 
for the ChemScanII® reactor are outlined in Table 21, entry 5, with an optimal CO pressure of 3 bar. 
By comparison to the original balloon conditions, the yield of cyclised product 179a is slightly 
decreased (45% vs. 58%). However, more significantly, the reaction time was dramatically reduced (24 
hours vs. 72 hours) and the loading of P(4-FC6H4)3 was reduced (15.0 mol% vs. 22.5 mol%). Additional 
details regarding reaction setup are provided in Experimental Section 7.5. Whilst this result was 
pleasing, additional studies are still required to elucidate the exact effect of CO pressure on the 
formation of the active catalyst species and conversion of amide 178a to cyclised product 179a. 
Likewise, it may be interesting to investigate the suitability of this transformation to a flow reactor.262  
5.2.4 Studies towards the post-cyclisation transformations  
With a reliable supply chain of key intermediate 179a established, investigations shifted towards 
completing the remaining transformations. As depicted in Scheme 111, it was hypothesised that lactam 
179a could be transformed into (rac)-conolidine through a series of carefully selected post-cyclisation 
manoeuvres. The four post-cyclisation transformations of 179a included: 1) N-benzyl deprotection; 2) 
lactam reduction; 3) N-alkylation to install the N-vinyl halide unit; 4) construction of C15–C20 bond. 
At the outset, it was unclear what the exact order of these post-cyclisation transformations should be. 
Nonetheless, given the ease of substrate synthesis and the fact that a robust carbonylation protocol was 
already in place, we remained optimistic. A full description of these studies is outlined in the following 
sections. 






Scheme 111: Post-cyclisation transformations of lactam 179a. 
5.2.4.1 N-benzyl deprotection of a lactam 
The first post-cyclisation transformation to be attempted was the removal of the N-benzyl protecting 
group from lactam 179a. However, we were cautious about this synthetic manoeuvre as a potential 
drawback of using N-benzylamide protecting groups is that they can be challenging to remove, often 
requiring harsh conditions that are incompatible with other functional groups present in the molecule.263 
Indeed, attempts to remove the N-benzyl group from 179a under hydrogenative conditions failed to 
provide the corresponding lactam 381. Instead, reduction of the ketone carbonyl occurred, resulting in 
the formation of alcohol 382 and lactam 383 (Scheme 112). 
 
Scheme 112: Failed N-benzyl deprotection of 179a. Reagents and conditions: H-cube®, 0.05 M, 20% Pd(OH)2/C, 
EtOH/EtOAc (2:1), 10 bar, 60 ℃, 1 min min-1.  
Following this result, the N-benzyl group of 178a was replaced with a more easily removable 
N-p-methoxybenzyl (PMB).263 Amide 178j was prepared in two steps and 61% yield, beginning with 
reductive amination of p-anisaldehyde with cyclopropylamine, followed by EDCI coupling of with 1H-
indole-3-carboxylic acid (Scheme 113A). Under the established Rh(I)-catalysed carbonylation protocol 
developed in Section 2.4 ([Rh(cod)OMe]2/ P(4-FC6H4)3/2-NO2C6H4CO2H/PhCN/130 ℃), 178j readily 
cyclised, forming 179j in 51% yield and with good selectivity over alkene 180j (Scheme 113B, 
179j:180j = 10:1). With 179j in hand, efforts to remove the N-PMB group under acidic conditions at 
elevated temperatures264 or via oxidative conditions using ceric ammonium nitrate (CAN),265 failed to 
provide the corresponding lactam 381. Reaction monitoring by TLC showed no reactivity and 
consequently, no further investigations into the removal of the N-PMB group were pursued.  






Scheme 113: A) Reagents and Conditions: i) cyclopropylamine, NaHCO3, MeOH, reflux, 16 h then cool to 0 ℃, 
NaBH4, 16 h, 98%; ii) 1H-indole-3-carboxylic acid, EDCI, DMAP, CH2Cl2, r.t., 12 hours, 62%. C) Failed 
conditions i) TFA, CH3Cl, 80 ℃; ii) CAN, CH3CN/H2O (5:1), r.t. to 50 ℃.  
With the N-protecting groups of lactams 178a and 179j proving difficult to remove, it was 
decided to delay the N-deprotection step until later in the synthetic sequence. It was envisaged that 
either an N-benzyl group or an N-PMB group could be more readily removed from a cyclic amine 
compared to a lactam (i.e. re-attempt after the reduction of lactam 179a, see Scheme 111).  
5.2.4.2 Lactam Reduction 
Based on the unsatisfactory results discussed above, investigations turned towards reduction of lactam 
179a. It was hoped that reduction of lactam 179a could occur in the presence of the ketone functional 
group in order to eliminate unnecessary redox fluctuations.266 However, the chemoselective reduction 
or lactams (or amides) in the presence of other reducible groups is highly challenging. Whilst significant 
progress has been made in the field of chemoselective amide reduction,267 only a limited number of 
systems have demonstrated chemoselective reduction of amides over ketones268-271 and a few of these 
have been successfully executed in natural product synthesis.272-275 Among these methodologies, 
protocols that employ Lewis-acidic transition-metal hydrides that can selectively coordinate to the 
Lewis-basic amide carbonyl have emerged as particularly powerful methods. Unfortunately, several 
attempts to effect chemoselective amide reduction using Mo(CO)6/TMDSO269 or Vaska’s catalyst 
(Ir(CO)Cl(PPh3)2 with TMDSO276 did not generate 386 (Scheme 114A). Additionally, treatment of 
179a with triflic anhydride followed by addition of Hantzsch ester268 was also unsuccessful (Scheme 





114B). Alternatively, it was anticipated that stepwise reduction of 179a via thioamide formation (to 
388) and then treatment with Raney-Nickel may offer a potential solution to the problem.273 However, 
it was found that treatment of 179a with Lawesson’s Reagent afforded thioketone 389 exclusively 
(Scheme 114C). Overall, the lack of desired activity exhibited by 179a was believed to be a 
consequence of the conjugated indole unit, which made the activated intermediates (i.e. 385 and 387) 
less electrophilic and the keto carbonyl more nucleophilic compared to the lactam carbonyl. Based on 
these results, it was evident that a stronger reducing agent would be required.  
 
Scheme 114: Attempted chemoselective reduction of lactam 179a. 
Given the difficulty associated with chemoselective reduction of lactam 179a, two solutions 
were proposed: (1) protection of the ketone functional group prior to reduction of the lactam carbonyl; 
or (2) global reduction of 179a followed by re-oxidisation of the ensuing alcohol moiety. Both options 
meant the unavoidable inclusion of additional steps, but given the situation, it was deemed the most 
logical way to proceed. To initiate these studies, the global reduction of 179a using LiAlH4 was first 
investigated and key results are given in Table 22. Initially literature conditions were evaluated,277 
which led to the rapid consumption of 179a and clean conversion to partially reduced intermediate 382 
in 75% yield. However, the lactam carbonyl remained firmly intact. (Table 22, entry 1). Increasing the 
number of equivalents of LiAlH4 and prolonging the reaction time generated the desired product 390 in 
10% and 43% yield respectively (Table 22, entries 2 and 3), with the remaining mass balance consisting 
largely of partially reduced intermediate 382. From these results, it was clear that the reduction of the 





lactam moiety was incredibly sluggish and even more forcing conditions would be required. Ultimately, 
it was found that heating the reaction in a sealed tube at 80 ℃ with 2 equivalents of LiAlH4 afforded 
product 390 in 87% yield (Table 22, entry 4). Finally, increasing the number of equivalents of LiAlH4 
from 2 to 3 gave a further increase in yield from 87% to 93% (Table 22, entry 5) From a safety 
perspective, sufficient material could be prepared by performing multiple reactions in parallel on 0.356 
mmol scale in a sealed tube with a blast shield. 
 
Table 22: Optimisation of the reduction of lactam 179a. [a] Yields of isolated products are given unless stated 
otherwise. [b] The reaction molarity was 0.10 M. [c] Sealed tube was used with a safety shield. 
In parallel studies, BH3·THF was examined as an alternative reducing agent. Treatment of 
amide 179a with 2 equivalents of BH3·THF at reflux successfully reduced the lactam with concomitant 
borylation of the tertiary amine to give amine·BH3 adduct 390’ in 10% yield (Scheme 115). However, 
partially reduced intermediate 382 and the over reduced amine·BH3 adduct 391 were also isolated in 
20% and 29% yield respectively. Although unintentional, the introduction of the amine-boron group 
proved beneficial as it masked the tertiary amine and facilitated purification; however, as the results 
outlined in Table 22 with LiAlH4 proved far superior, no further investigations into borane reduction of 
179a were conducted.  
 
Scheme 115: Reagents and conditions: BH3·THF (2.0 equiv.), THF, 0 ℃ to reflux, 48 h.  
The studies into the reduction of lactam 179a marked the first major crossroad in the synthesis 
of  (rac)-conolidine, from which alternative scenarios could be envisioned. Therefore, before continuing 
with the synthesis, several aspects of the chosen reaction path and the thought process behind it deserve 





additional comment. Firstly, an endocyclic amide directing group was essential for the Rh(I)-catalysed 
carbonylative cyclisation to proceed (see Chapter 2 and Section 2.6) but after this key step, its presence 
was redundant and a hinderance with respect to step count. As the Rh(I)-catalysed carbonylation was 
pivotal in the synthetic route, it was decided that the inclusion of an endo directing group was non-
negotiable. Consistent with this notion, re-design of the carbonylative substrate 178a to include an exo 
directing group (e.g. N-acetate 193a or N-Cbz 193b) was ruled out (Scheme 116). Despite the fact that 
successful formation of 194a or 194b would side-step the need for lactam reduction, there was no 
precedence for either 193a or 193b succeeding in the Rh(I)-catalysed carbonylation step. As 
demonstrated in Section 2.6, exposure of N-acetate 193a to carbonylative conditions led only to 
decomposition pathways (see Scheme 54). Consequently, no studies were initiated into investigating 
the conversion of 193a/b to 194a/b and efforts focused solely on parent indole 178a with the 
prerequisite endo directing group.  
 
Scheme 116: Unsuitable substrates for construction of the eight-membered ring. 
The downside of pursuing studies with amide 178a was that subsequent reduction of lactam 
179a resulted in concomitant reduction of the keto carbonyl group. In contrast to lactams, thiolactams 
can be readily reduced; therefore, a potential solution to eliminating unnecessary redox steps involves 
switching the endocyclic amide directing group of 178a for an endocyclic thioamide directing group. 
In unpublished work in the Bower group, G.-W. Wang has shown that thioureas are competent directing 
groups for the formation of 7-membered rings by carbonylative ring expansion of 
aminocyclopropanes.278 Therefore, provided that thioamide 392 is a suitable candidate in the 
Rh(I)-catalysed carbonylation reaction, reduction of 388 with Raney-nickel279 would avoid oxidation 
and re-oxidation of the keto carbonyl group (Scheme 117). 
 
Scheme 117: Proposed use of thioamide 392. 
Furthermore, as stated previously, the avoidance of chemo-unselective reactions would allow 
for a reduction in the number of unnecessary redox steps and should be re-examined in future studies. 





One strategy to overcome this shortcoming involves transiently protecting the more reactive carbonyl 
group of lactam 179a and regenerating it after reduction of the less reactive lactam group. Common 
protocols that protect ketones in situ include nucleophilic addition of metal amides,280 or phosphines281 
or masking the ketone as an enolate282 prior to the addition of  the reducing agent LiAlH4 or BH3·THF.  
Given the knowledge available at the time of these investigations, the decision was made to persevere 
and persist with the global reduction of 179a. It was therefore accepted that adopting this strategy would 
inevitably lead to a longer route; however, this negative was outweighed by the anticipation that amine 
390 could ultimately be transformed into conolidine.  
5.2.4.3 N-Benzyl deprotection of an amine  
The next hurdle in the synthesis of (rac)-conolidine entailed the removal of the amine N-benzyl 
protecting group. For this transformation, it was not clear if N-debenzylation should be attempted 
directly from amine 390 or if oxidation of 390 to keto 386 should be conducted first (Scheme 118A). 
Nonetheless, we remained cautious about the suitability of substrates 390 and 386 as they both contain 
a potentially labile gramine fragment that could result in unravelling of the 8-membered ring. 
Additionally, we were hesitant to oxidise alcohol 390 prior to N-debenzylation, as studies by Joule 
reported that the product of straight forward N-benzyl removal (i.e. azocane 394) could not be 
obtained.283 Additional investigations by Joule revealed that the N-benzyl group of keto 395 could be 
removed, but only at the expense of replacing it with a phenyl carbamate, which was equally as stubborn 
to remove (Scheme 118B).283  
 
Scheme 118: B) Reagents and Conditions: i) MnO2, CHCl3, r.t., 48 h, 53%; ii) benzenesulfonyl chloride, aq. 
NaOH, benzene, r.t., 1 h, 82%; iii) phenyl chloroformate, KHCO3, CHCl3, reflux, 8 h, 56%. Failed conditions: iv) 
aq. NaOH, reflux; v) NaH, THF, r.t.; vi) CH3Li·LiBr complex in ether, THF 0 ℃ to r.t..  
To gauge if substrate 390 was amenable to N-debenzylation, hydrogenative conditions were 
trialled in flow with 5% Pd/C at 1 bar and 80 ℃.284 Surprisingly, ring contracted pyrrolidine 398 was 





observed as the major product in 57% yield, along with the desired secondary amine 393 in 35% yield 
(Scheme 119), suggesting that this transformation was not as simple as originally thought. This result 
raised two critical issues: (i) which benzylic position of 390 undergoes debenzylation first; and (ii) is 
the desired product 393 only unstable under hydrogenative conditions or is it predisposed to undergo 
fragmentation. Understanding these concepts was of upmost importance if the synthetic route was to 
succeed.  
 
Scheme 119: N-debenzylation of substrate 390 under hydrogenation conditions. Reagents and conditions: 
H-cube®, 0.05 M, 5% Pd/C, EtOH, 1 bar, 80 ℃, 1 min min-1. [a] The yield was determined by 1H NMR analysis 
using 1,4-dinitrobenzne as an internal standard.  
A plausible mechanism for the formation of pyrrolidine side product 398 is outlined in Scheme 
119. In agreement with literature, it is proposed that N-debenzylation occurs first via bond a to give the 
desired product 393.284,285 A second debenzylation via bond b breaks the 8-membered ring, generating 
linear analogue 399. At this stage, the nucleophilic indole core triggers a cascade reaction, eliminating 
a molecule of water to give 400. Nucleophilic attack by the pendant NH2 moiety on the resulting C-sp2 
centre, followed by restoration of the aromatic indole unit affords 398. Cationic cascades involving the 
indole unit of structurally similar analogues have been reported in the literature.286,287 The facile 
fragmentation of 393 under hydrogenation conditions undoubtedly reflects the activation of bond b by 
the strained 8-membered ring, which is enhanced further by the nucleophilic indole core. Indeed, it has 
been observed previously that N-protecting group removal from tertiary amines structurally related to 
390/386 can be challenging as such substrates are prone to fragmentation by C–N bond cleavage (i.e. 
via cleavage of bond b). In some cases, this can be controlled by the introduction of an electron 
withdrawing group (e.g. Boc, benzoyl or tosyl group) on the indole nitrogen atom.288 However, with 
regards to the synthesis of conolidine, the introduction and subsequent removal of a nitrogen indole 
protecting group was undesirable.289 Therefore, in line with these thoughts, efforts focused on 





preventing the unwanted double debenzylation of 390. Subsequent optimisation studies were performed 
in batch with a balloon of H2 and key results are presented in Table 23. 
 
Table 23: N-debenzylation of substrate 390 under hydrogenation condition. [a] Yields of isolated products unless 
stated otherwise. [b] The yield was determined by 1H NMR analysis using 1,4-dinitrobenzne as an internal 
standard.  
The use of 5 mol% Pd/C (10 wt. %) in ethanol with an atmospheric pressure of H2 did not 
promote N-benzylation deprotection at room temperature (Table 23, entry 1). It was found that adjusting 
the molar ratio of 390:Pd/C (1:0.05 to 1:1) resulted in complete consumption of starting material 390, 
affording desired product 393 in 43% and side-product 398 in 49% yield (Table 23, entry 2). Based on 
this insight, the quantities of Pd/C were systematically examined (100−50 mol%, results not provided 
in Table 23) but over reduced side-product 398 was detected in all reactions. Performing the reaction at 
40 ℃ with 5 mol% Pd/C led only to a 7% in situ yield of 393, with the majority of the mass balance 
being starting material 390 (Table 23, entry 3). Attempts to accelerate the process by increasing the 
loading of Pd/C to 50 mol% and heating the reaction at 45 ℃ led solely to side-product 398 in 92% 
yield (Table 23, entry 4). Performing the reaction with 50 mol% of Pd(OH)2 (20 wt. %) (Pearlman’s 
catalyst290) at room temperature gave the desired secondary amine 393 in 65% yield, with only 25% of 
the side-product 398 (Table 23, entry 5). In an effort to minimise the amount of catalyst available to 
effect debenzylation, the loading of Pd(OH)2 was reduced to 20 mol% and this led to a further reduction 
in 398 but importantly maintained good yields of 393 (61% yield, Table 23, entry 6). Despite best efforts 
to curtail the formation of 398 (by careful control of time and reaction monitoring by TLC) its formation 
could not be fully eliminated; however, shortening the reaction time to 13 hours gave the best result in 





terms of isolated yield of 393 and recovered starting material 390 (57% 393, 37% 390, Table 23, entry 
7). Indeed, using these conditions, multiple reactions were set up in parallel, allowing enough material 
to be prepared. Moreover, appreciable amounts of 390 were recovered and re-subjected to 
hydrogenolysis. This result marked a significant milestone towards completing the total synthesis of 
(rac)-conolidine. It should be noted that all experiments were conducted with high dilution (0.05 M) 
and typically on 0.100–0.188 mmol scale. Consequently, future studies will focus on the scalability of 
this process with respect to Pd(OH)2 loading and reaction molarity.   
5.2.4.4 Benzyl oxidation and N-alkylation 
With appreciable amounts of amine 393 in hand, the next objective of the project was to prepare 
cyclisation precursor 367. It was envisaged that 367 could be formed by a straightforward sequence of 
oxidation and N-alkylation. However, the exact order of these two transformations remained unclear, 
with potential pitfalls arising from either option (Scheme 120). 
 
Scheme 120: Alternative synthetic sequences to access cyclisation precursor 367. 
In order to quickly ascertain the feasibility of pathway A, oxidation of alcohol 393 was 
attempted using Dess-martin periodinane (Scheme 121).291 Reaction monitoring by LCMS indicated 
formation of keto 394, but attempts to isolate the desired product were unsuccessful (presumably by 
decomposition on basic HPLC column) and therefore structure 394 was proposed tentatively. It was 
postulated that putatively formed 394 was prone to spontaneous transannular condensation of the 
secondary amine onto the newly formed ketone moiety, which after tautomerization led to cyclic amine 
402. Previously Bennasar has reported that compounds akin to 394 are prone to undesired fragmentation 
pathways.250 The structure of side product 402 was not confirmed but tentatively assigned based on 
comparison with data available in the literature.283 No attempt was made to investigate this reaction 
further or explore alternative oxidising reagents.  






Scheme 121: Attempted oxidation of alcohol 393. 
Since the stability of keto 394 proved problematic, subsequent studies focused on a reversal of 
step order, in which N-alkylation preceded oxidation of the alcohol (Pathway B, Scheme 120). 
Gratifyingly, this decision proved fruitful. Tosylate 403 was chosen as the alkylating reagent and 
following a literature procedure, was readily prepared in three steps from trans-crotonaldehyde 370 
(Scheme 122A).251 With potassium carbonate as the base, N-alkylation of 393 with tosylate 403 (1.0 
equiv.) was readily carried out in DMF at room temperature to provide vinyl bromide 401 in 72% yield 
(Scheme 122B). Following the appendage of the N-vinyl halide segment, attention turned to oxidation 
of alcohol 401. When Dess-Martin periodinane was used as the oxidant, the reaction exhibited poor 
reproducibility, with yields ranging from 10−72%; attempts to identify the cause of this fluctuation 
were unsuccessful (fresh Dess-Martin periodinane reagent, inert conditions, lower temperature). 
Alternatively, when MnO2 was used in acetone, the reaction exhibited a cleaner reaction profile and 
cyclisation precursor 367 could be obtained in 61% yield.292 Using this sequence of events, both the 
N-alkylation and benzyl oxidation could be performed reliably to provide adequate quantities of 367. 
With vinyl bromide 367 in hand, the stage was set to complete the synthesis of (rac)-conolidine. 
 
Scheme 122: Synthesis of vinyl bromide 367. 





5.2.4.5 Palladium catalysed α-vinylation 
The final challenge in the total synthesis of conolidine involved construction of the hallmark 
azabicyclo[4.2.2]decane core. At the outset of the project, it was envisioned that stereospecific 
unification between the geometrically-defined vinyl bromide unit of 367 with its ketone enolate would 
be achieved by Pd(0)-catalysis (see Scheme 109). The direct alkenylation of carbanion nucleophiles 
with vinyl halides is one of the most efficient and economic methods for installing β-γ unsaturated units, 
and palladium is more often than not the catalyst of choice for such processes.293 However, compared 
to related arylation reactions with aryl halides,294-297 α-alkenylation reactions remain in relatively early 
stages of development. A generalised catalytic cycle for Pd(0)-catalysed intramolecular couplings of 
ketone enolates with tethered alkenyl halides is provided in Scheme 123.  
 
Scheme 123: Generalised catalytic cycle for Pd(0)-catalysed intramolecular coupling of ketone enolate and vinyl 
halide.  
As depicted in Scheme 123, oxidative addition of an alkenyl halide with a suitable 
Pd(0)-catalyst forms intermediate II. Base induced ligand exchange of the coordinated halide by the 
ketone enolate nucleophile via III generates Pd(II)-intermediate IV. Reductive elimination from the 





Pd(II)-enolate complex IV provides α-vinyl ketone product and regenerates the Pd(0)-catalyst. The 
exact structure of  the Pd(II)-enolate intermediate IV remains unclear (O-bound or C-bound to 
Pd(II) -centre) and may vary from substrate to substrate.298 While α-alkenylation and α-arylation of 
enolates are considered to be similar reactions, the later presents additional challenges. For example, 
Pd(II) intermediates (i.e. II, III and IV), are prone to side reactions, such as β-hydride elimination or 
protodehalogenation, which can outcompete the productive pathway of ligand exchange and reductive 
elimination. Additionally, under basic conditions, issues arise with respect to the stereoidentity of 
secondary and tertiary α-alkenylated products, due to cis/trans isomerisation or isomerisation to an 
α,β-unsaturated compound.299,300 What is more, alkali metal enolates are typically generated at low 
temperatures, but cross-coupling is usually conducted at elevated temperatures. Therefore, there is a 
fine balance to be struck between stability (to avoid decomposition pathways and undesired β-hydride 
elimination) and reactivity (to promote efficient ligand exchange and reductive elimination).  
Before revealing the final investigations of this target, a brief survey of selected chemical 
literature relating to intramolecular Pd(0)-catalysed α-vinylation reactions will be given. The first 
intramolecular Pd(0)-catalysed α-vinylation was reported by Piers and co-workers in the total synthesis 
of diterpenoid crinipellin B in 1990.301 Since this seminal report, Pd(0)-catalysed intramolecular 
α-vinylation of keto enolates has proven to be an indispensable tool for the construction of bridged 
carbocyclic ring systems in natural product targets. Insightful studies by Cook,302-304 Bonjoch299 and 
Overman305 have pioneered work in this field and four impressive examples from these laboratories are 
summarised in Scheme 124.  
 
Scheme 124: Selected literature examples for Pd(0)-catalysed α-vinylation reactions of substrates structurally 
related to vinyl bromide 367. A) Reagents and conditions: i) Pd(OAc)2 (5 mol%), PPh3 (20 mol%), K2CO3 (4.0 
equiv.), Bu4NBr (1 equiv.), DMF/H2O (9:1), 65 °C, 80%. B) Reagents and conditions: ii) Pd2dba3 (5 mol%), 
DPEPhos (7 mol%), NaOt-Bu (1.5 equiv.), THF, 80 °C, 80% or iii) Pd(PPh3)4 (10 mol%), PhOH (2.0 equiv.), 
KOt-Bu (1.5 equiv.), THF, 75 °C, 83%. C) Reagents and conditions: iv) Pd(PPh3)4 (20 mol%), KOt-Bu (1.5 





equiv.), THF, reflux, 41%. D) Reagents and conditions: v) PdCl2(dppf) (10 mol%), K2CO3 (4.0 equiv.), MeOH, 
70 °C, 74%.  
Of note, the conditions identified by Cook and Overman are highly robust and have been 
utilised in the total synthesis of a wide range of natural product targets.303-319 To the best of our 
knowledge, there are no reported α-vinylation reactions involving (aza)cyclooctane rings to produce 
bridged ring systems.320 Additionally, a small number of enantioselective Pd(0)-catalysed enolate 
alkenylations have been reported through the use of chiral phosphine ligands.321-323  
Following this survey, it was decided that the literature conditions presented in Scheme 124 
would be examined first to install the final C–C bond of (rac)-conolidine. The results of these reactions 
are summarised in Table 24.  
Table 24: Attempts to execute Pd(0)-catalysed intramolecular α-vinylation of 367. 
Disappointingly, all attempts to effect formation of (rac)-conolidine failed, and instead, 
nonspecific decomposition of 367 occured, with none of the desired product observed by 1H NMR 
analysis. Thus, despite the excitement of having overcome a magnitude of synthetic challenges so far, 
it was evident that further modification of the synthetic plan would be required in order to achieve the 
definitive goal of the project. Undeterred by this initial disappointment, it was surmised that perhaps 
the low efficiency may be attributed to the low reactivity of alkenyl bromide 367, given that alkenyl 
iodides are generally required in Pd(0)-mediated cyclisations within the context of total syntheses (for 
selected examples see Scheme 124). Accordingly, tosylate 364 possessing a vinyl iodide appendage 
was prepared following a three-step literature procedure (Scheme 125A).251,324 N-Alkylation of 
secondary amine 393 with tosylate 364, and subsequent MnO2 mediated oxidation provided the requisite 
ketone vinyl iodide substrate 406 in 28% yield for the two steps (Scheme 125B).  






Scheme 125: Synthesis of tosylate 364 and vinyl iodide 406.  
With vinyl iodide 406 in hand, attention turned to the critical Pd(0)-catalysed intramolecular 
α-vinylation (Scheme 126). Exposure of a THF solution of 406 to Pd2dba3 (5 mol%), DPEPhos (7 mol%) 
and NaOt-Bu (1.5 equiv.) resulted in complete consumption of starting material after 18 hours at 80 ℃. 
1H NMR and LCMS analysis of the crude reaction mixture indicated the formation of multiple products 
with the desired mass. Importantly, products of protodeiodination of 406 were not observed. Meticulous 
purification of the crude material by HPLC led to the isolation and characterisation of bicycle 407, 
which contains an unusual azabicyclo[4.2.1]nonane core. The alkene geometry of 407 was confirmed 
to be trans by the diagnostic coupling constant of 13.5 Hz between the alkenyl protons. The relative 
stereochemistry of the C15 and C21 stereocenters was not determined.   
 
Scheme 126: Pd-catalysed intramolecular α-vinylation of 406. Compound 407 was isolated as its HCl salt.  
On the basis of literature reports,325-327 a plausible mechanism for the conversion of 406 to 407 
is outlined in Scheme 127. First, oxidative addition of Pd(0) into the C–I bond of 406 generates species 
I. Subsequent β-hydride elimination generates allene II and a Pd(II)-hydride species. Insertion of allene 
II into Pd(II)-H forms Pd-π-allyl species III, which can be trapped by the keto enolate under basic 
conditions to give IV. Reductive elimination of IV delivers the observed product 407 and regenerates 
the Pd(0)-catalyst. An alternative reaction pathway involving E2 elimination of HI (i.e. generation of 
alkyne 411, see Table 25), followed by alkyne/allene isomerisation and Pd-π-allyl formation cannot be 
ruled out.328  






Scheme 127: Proposed mechanism for the formation of bicycle 407. 
From this preliminary result, it was clear that deleterious β-hydride elimination pathways were 
inhibiting the desired transformation to form (rac)-conolidine. Palladium readily undergoes β-hydride 
elimination but it can be eliminated/suppressed through the inclusion of sterically demanding ligands, 
which either restrict β-hydride elimination and/or promote faster reductive elimination.329 Consequently, 
a brief screen of bulky phosphine ligands (BINAP, Xanthphos, PCy3) was undertaken using Pd2dba3 
and NaOt-Bu in THF at 80 ℃. However, efforts were quickly thwarted as each of these attempts 
resulted in highly complex reaction mixtures, with no formation of (rac)-conolidine detected by 1H 
NMR analysis. With limited options remaining and an ever depleting supply of precursor 406, it was 
hypothesised that alternative transition-metal catalysts may offer a potential solution to this final 
transformation. With this in mind, we turned to nickel, and thus, the fate of the synthesis relied upon 
identifying a suitable nickel-catalysed α-vinylation protocol.   
5.2.4.6 Nickel catalysed α-vinylation and completion of the total synthesis of (rac)-conolidine 
The field of nickel catalysis has expanded rapidly over the last twenty years and this is reflected by the 
highly diverse nickel-catalysed processes reported in the literature.330 There are significant differences 
in reactivity between nickel and palladium, which play an important factor in catalyst selection. Firstly, 
nickel is more electropositive compared to palladium and therefore undergoes oxidative addition more 
readily.331 This facile oxidative addition of nickel means that a broad range of adaptable electrophiles, 
that would be considerably less reactive under palladium catalysis, such as phenols, aromatic nitriles or 
aryl fluorides can be utilised. Conversely, reductive elimination from nickel centres is more difficult.332 
Additionally, β-hydride elimination tends to be slower with nickel, relative to palladium, due to a higher 
energy barrier to Ni–C bond rotation prior to β-elimination.333 Consequently, the inherent reluctance of 
nickel to undergo β-hydride elimination can be advantageous in certain scenarios. Within the context 
of Ni(0)-catalysed Heck reactions, undesired β-hydride elimination can be avoided by tuning the 
coordination environment around nickel by strategically placing nitrogen atoms on the substrate.334 





Empowered by the notion that such an interaction could be exploited between substrate 406 and a 
suitable nickel catalyst, we set out to investigate a nickel-mediated α-vinylation to construct the 
azabicycle[4.2.2]decane scaffold of (rac)-conolidine. Exciting precedent for this transformation will be 
discussed briefly in the following section.  
In 1977 Rathke reported the first alkenylation of an ester enolate using a “ligand free” nickel 
species in stoichiometric quantities.335 Capitalising upon this discovery, Wender applied the procedure 
to the total synthesis of quadrone in 1985, through the synthesis of intermediate 408 (Scheme 128A).336 
However, despite these early advances, there is a scarcity of reported nickel-catalysed α-vinylation 
reactions of keto enolates in the literature.293 In contrast, nickel catalysed arylation of keto enolates 
reactions are marginally more common.296,337,338 In 2015, Helquist reported a nickel catalysed 
intermolecular coupling of an aromatic or aliphatic ketone lithium enolate with a variety of alkenyl 
halides under relatively mild conditions (Scheme 128B).339 Their protocol allowed for retention of β-γ 
unsaturated products, without migration or cis/trans isomerisation. Another advantage of this method 
includes short reaction times at low temperatures and only 1.05 equivalent of base was needed to 
deprotonate the ketone and NHC precursor. By comparison, Pd(0)-catalysed α-vinylations typically 
employ 1.5–4.0 equivalents of base due to the increased acidity of α-hydrogens in the product.340 More 
recently, Newhouse took advantage of a Ni(0)-catalysed α-vinylation reaction to construct the 
bicyclo[3.2.1]octane fragment of Pincipinol D.341 The authors reported that Ni-catalysed vinylation of 
1,1-disubstitued vinyl bromide 409, and subsequent hydrolysis formed bicycle 410 in an impressive 74% 
yield (Scheme 128C).341 Air-stable nickel pre-catalyst Ni(cod)2(PCy3)2 was utilised in this reaction, 
which obviates the need for air sensitive Ni(cod)2, and results in a simpler reaction set-up.  






Scheme 128: Reported literature examples of Ni-catalysed α-vinylation.  
On the basis of these literature examples from Helqvist and Newhouse, Ni-catalysis was 
employed for the final C–C bond forming reaction in the total synthesis of (rac)-conolidine. The results 
of this critical transformation are summarised in Table 25. Toward this end, cyclisation precursor 406 
was exposed to 2.0 equiv. of LiHMDS and 30 mol% Ni(cod)2(PCy3)2 in THF at 0 ℃ and then heated 
at 50 ℃. Formation of (rac)-conolidine was observed through diligent examination of the 1H NMR 
spectrum of the crude reaction mixture, albeit in minute quantities (<5%). The major identifiable side 
product was alkyne 411, which most likely occurs through an E2 elimination pathway.301 More 
significantly, no products arising from either protodeiodination or undesired β-hydride elimination 
pathways (i.e. formation of bicycle 407) were observed by 1H NMR analysis. Chromatographic 
purification of the reaction mixture afforded a 26% isolated yield of 411. Unfortunately, efforts to 
isolate an analytical sample of (rac)-conolidine failed, most likely as a consequence of the low 
conversion coupled with the scale of the reaction (the theoretical maximum yield of (rac)-conolidine 
was 13.5 mg). Strong evidence for the formation of (rac)-conolidine comes from comparison of 1H and 
13C NMR data of the crude reaction mixture with data reported in the literature.221,237,247 These 
assignments are further corroborated by 2D COSY and HSQC data. The assignment and comparison of 
diagnostic 1H and 13C signals are provided in Table 26 and Table 27.  






Table 25: Ni-catalysed α-vinylation of vinyl iodide 406. [a] An in situ yield of (rac)-conolidine was not obtained.  
 
Table 26: Comparison of natural vs. synthetic conolidine by 1H NMR analysis in CDCl3. Diagnostic signals only 
for synthetic (rac)-conolidine. Biogenetic numbering is shown on (rac)-conolidine.221  






Table 27: Comparison of natural vs. synthetic conolidine by 13C NMR analysis in CDCl3. Biogenetic numbering 
is shown on (rac)-conolidine.221 [a] Micalizio reported a chemical shift of 193.4 ppm for C16237 and Qi reported 
a chemical shift of 193.6 ppm for C16.247  
Collectively, 1H and 13C NMR data provide compelling evidence for the formation of 
(rac)-conolidine; however, due to time constraints, no further work was carried out on this reaction. 
Consequently, future reaction development will focus on obtaining a pure sample for characterisation 
purposes. More significantly, these initial experiments provide proof-of-principal for a Ni(0)-catalysed 
α-vinylation to construct the azabicyclo[4.2.2]decane core and an impetus to conduct further studies. 
The major side reaction pathway identified was elimination of HI to form the corresponding propargylic 
amine 411. Therefore, to side-step this obstacle, deprotonation of keto 406 should be performed at lower 
temperature (-40 ℃ ) and with slow addition of base, prior to the addition of the Ni-catalyst. The 
ultimate goal for this process would be to render it asymmetric so as either enantiomer of conolidine 
would be accessible.   





5.3 Formal synthesis of (rac)-apparicine 
In parallel studies, it was anticipated that the Rh(I)-catalysed carbonylation protocol could be 
showcased in the formal synthesis of (rac)-apparicine through the elaboration of cyclisation product 
179a to known intermediate 362. As previously discussed in Section 5.1.3, the total synthesis of 
apparicine was first accomplished by Bennasar and co-workers in 2011 (Scheme 100).249,250 To this end, 
the formal synthesis of (rac)-apparicine was completed in 11 steps from known starting materials 
(Scheme 129). Versatile intermediate 179a was advanced to secondary amine 393 in two steps (see 
Section 5.2.4.2 and Section 5.2.4.3) and the formal synthesis of (rac)-apparicine was concluded by 
N-Boc protection of amine 393 to give N-Boc 412, followed by MnO2 mediated oxidation to afford 362. 
It should be noted the N-debenzylation and Boc protection have the potential to be carried out in one 
pot, thereby eliminating a synthetic step. 
 
Scheme 129: Formal synthesis of (rac)-apparicine. Reagents and conditions: i) EDCI, DMAP, CH2Cl2, r.t., 16 h, 
79%; ii) [Rh(cod)OMe]2 (3.75 mol%), P(4-FC6H4)3 (22.5 mol%), 2-NO2C6H4CO2H (150 mol%), CO (1 atm), 
PhCN (0.3 M), 130 °C, 72 h, 58%; iii) LiAlH4, THF, 0 ℃ to 80 ℃, 24 h, 93%; iv) Pd(OH)2/C, H2, EtOH, r.t., 18 
h, 65%; v) Boc2O, DMF, r.t., 18 h, 43%; vi) MnO2, acetone, r.t., 3 h, 86%.  
5.4 Summary and conclusions from the studies in Chapter 5 
In summary, the total synthesis of (rac)-conolidine has been accomplished by a concise 7-step synthetic 
route (Scheme 130) and the formal synthesis of (rac)-apparicine has been achieved in 11 synthetic steps 
from known amine 362 (Scheme 129). Central to the success of both syntheses was the Rh(I)-catalysed 
carbonylative cyclisation of cyclopropylamide 178a to generate versatile N-heterocycle 179a, which 
thereby validates the carbonylative ring expansion of cyclopropylamides to assemble the 8-membered 
C-ring of C5-nor stemmadenine natural products.  






Scheme 130: Total synthesis of (rac)-conolidine. Reagents and conditions: i) EDCI, DMAP, CH2Cl2, r.t., 16 h, 
79%; ii) [Rh(cod)OMe]2 (3.75 mol%), P(4-FC6H4)3 (15.0 mol%), 2-NO2C6H4CO2H (150 mol%), CO (3 bar, 
ChemSCAN II®), PhCN (0.3 M), 130 °C, 24 h, 45% or [Rh(cod)OMe]2 (3.75 mol%), P(4-FC6H4)3 (22.5 mol%), 
2-NO2C6H4CO2H (150 mol%), CO (1 atm), PhCN (0.3 M), 130 °C, 72 h, 58%; iii) LiAlH4, THF, 0 ℃ to 80 ℃, 
24 h, 93%; iv) Pd(OH)2/C, H2, EtOH, r.t., 18 h, 65%; v) tosylate 364, DMF, K2CO3, r.t., 18 h, 52%; vi) MnO2, 
acetone, r.t., 16 h, 54%; vii) Ni(cod)2(PCy3)2, LiHMDS, THF, 0 ℃ to 50 ℃, 18 h, <5%.  
With regards to the total synthesis of (rac)-conolidine, first and second generation synthetic 
strategies were plagued by competing side reactions of substrates 178g and 178i in the Rh(I)-catalysed 
carbonylative cyclisation (Schemes 104 and 108). These challenges proved insurmountable and 
consequently led to a revised synthesis, in which cyclopropylamide 178a was identified as a viable 
alternative. The existing conditions for the carbonylative cyclisation of 178a were re-examined in order 
to provide sufficient quantities of lactam 179a for subsequent steps. This in turn led to carbonylative 
cyclisation of 178a being performed at 3 bar of CO in a ChemSCAN II© reactor. Extensive 
investigations into the conversion of lactam 179a to penultimate intermediate 406 identified that a 
suitable order of manipulations was; (1) global LiAlH4 reduction of 179a which proceeded in excellent 
yield; (2) hydrogenative removal of the N-benzyl group of 390 with Pd(OH)2; (3) N-alkylation of amine 
393 with tosylate 364 and (4) MnO2 mediated oxidation of alcohol 405. Whilst these transformations 
were reliable, further development is needed to improve the overall efficiency. Specifically, the post-
cyclisation transformations of 179a required several functional group interconversions and redox 
manipulations that ideally would be erased. However, with access to key late-stage compound 406 
established, exploratory investigations into the critical closure of the bridged piperidine ring were 
conducted. Several catalytic methods for this transformation were investigated and without doubt, this 
was the greatest synthetic challenge of the project. Of note, it was discovered that Pd(0)-catalytic 
systems proved unsuitable due to competing β-hydride pathways, which led to the isolation of [4.2.1]-
bicyclic amine 407. Conversely, a Ni(II) pre-catalyst was successfully employed to install the final C–C 
bond of the natural product. Though attempts to isolate an analytic sample of (rac)-conolidine failed, 





NMR data on partially purified material provides convincing evidence for its formation. Going forward, 
future studies must prioritise isolating a clean sample of (rac)-conolidine. Additionally, if the 
Ni(0)-catalysed enolate coupling of vinyl iodide 406 could be rendered asymmetric, then this important 
molecule could be obtained in high enantiomeric purity. Without a doubt, exciting times lie ahead. 
Furthermore, as outlined in Section 5.2.2, it was considered that the azabicyclo[4.2.2]decane core 
of (rac)-conolidine could be assembled by a Au(I) or Ag(I)-catalysed cyclisation of 376 (see Scheme 
106). However, work on this particular route was impeded by failure to evoke Rh(I)-catalysed 
carbonylative cyclisation of amide 178i that possessed a pre-installed N-alkynyl component (see 
Scheme 108). Building upon the post cyclisation transformations discussed in Section 5.2.4, it was 
postulated that the N-benzyl group of 179a could be removed and replaced with an alkyne fragment. 
With this strategy in mind, a fourth generation retrosynthetic analysis of (rac)-conolidine is provided 
in Scheme 131.  
 
Scheme 131: Fourth generation retrosynthetic analysis of (rac)-conolidine and attempted formation of silyl enol 
ether 413 





Brief attempts to form silyl enol ether 413 were met with difficulty due to silyl enol ether hydrolysis, 
competing N-silylation and degradation which precluded investigations into a Au(I) or Ag(I)-catalysed 
cyclisation (Scheme 131B). A literature survey was conducted to help identify suitable conditions, but 
no examples existed at the time that didn’t first involve protecting the nitrogen atom of the indole unit.342 
Indeed, Li has previously commented that indole N-protection was essential for silyl enol ether 
formation256 but for understandable reasons, we were against installing and then removing additional 
protecting groups. During the work reported here, Qi reported similar difficulties, but overcame these 
difficulties by employing 2,6-ludtidine as the base for a related substrate (see Scheme 98).247 
Accordingly, these conditions will be examined in future investigations as the successful realisation of 
this strategy may, in turn, avoid unnecessary redox fluctuations. What is more, this overall strategy has 
the potential to be asymmetric through the use of chiral gold complexes in the final C–C bond forming 
step.246 Without a doubt, exciting times lie ahead. 
 





Chapter 6 – Overall summary and conclusion 
The research presented in this thesis has contributed to a growing body of processes that exploit catalytic 
C–C bond cleavage of small ring systems to access underexplored regions of chemical space. In Chapter 
2, the scope of the Rh(I)-catalysed “capture-collapse” heterocyclisation was extended to include 
electron-rich cyclopropylamides, which enabled flexible access to a range of 8-membered 
N-heterocycles (Scheme 132A). Extensive optimisation of reaction conditions and the employment of 
2-NO2C6H4CO2H or (E)-(CHCOOH)2 were needed to achieve high selectivity for the C7/8 saturated 
heterocycles. Overall, the success of this strategy hinges on the electrophilicity of 
rhodacyclopentanones and a metallacyclic templating effect to overcome the enthalpic and entropic 
barriers associated with challenging medium-sized ring closures. Attempts to expand the methodology 
to systems with electron-neutral/poor aromatic units and to systems that generate ≥8-membered 
N-heterocycles were unsuccessful; however, the development of related protocols remains an area of 
interest within the Bower group.  
In Chapter 3, additional investigations into generality of the “capture-collapse” strategy led to 
the discovery of a second protocol, whereby cyclopropyl guanidine 263 underwent Rh(I)-catalysed 
carbonylative cyclisation to deliver 7-membered cyclic guanidine 264’, albeit in poor yield (Scheme 
132). Taken on balance, the widespread adoption of this strategy has been met with limited success due 
to the challenges associated with rhodacyclopentanone stability. Preliminary investigations into the 
synthesis of γ-lactam adduct 174b by carbonylative ring expansion of secondary aminocyclopropanes 
171b were also described, and these results provide the basis for further studies.   
Alongside G.-W. Wang and T. Young, subsequent studies in Chapter 4 focussed on the design 
of tailored aminocyclopropane substrates to achieve intricate Rh(I)-catalysed polycyclisation cascades. 
This led to the development of a unique indole dearomatisation protocol and polycyclisations that 
incorporate challenging medium-ring formations (Scheme 132B). For the former, deuterium exchange 
experiments and computational studies suggest that the mechanistic pathway involves C(sp2)–C(sp2) 
reductive elimination and stereoretentive protodemetallation of an alkyl-Rh(I) species. In broader terms, 
these results show for the first time that rhodacyclopentanones can be effectively used as a linchpin 
technology for the assembly of various polyheterocyclic targets that are challenging or inaccessible 
using conventional methods.  
The power and synthetic utility of the Rh(I)-catalysed “capture-collapse” heterocyclisation 
developed in Chapter 2 was successfully showcased in a total synthesis of (rac)-conolidine and a formal 
synthesis of apparicine. Significantly, the newly developed route to (rac)-conolidine proceeds in 7-steps 
from known amine 170a and features a number of key transformations, including; (1) Rh(I)-catalysed 
carbonylative cyclisation of cyclopropylamide 178a to construct the 8-membered C-ring; (2) a suite of 





carefully orchestrated post-cyclisation steps of lactam 179a, and (3) a Ni(0)-catalysed enolate coupling 
of vinyl iodide 406 to assemble the natural product’s azabicyclo[4.2.2]decane core (Scheme 132C). It 
is expected that the lessons learned from these studies, including late-stage manipulations and various 
undesired setbacks, should inform and guide future forays towards conolidine and other challenging 
C5-nor stemmadenine natural products.    
Scheme 132:A summary of the Rh(I)-catalysed processes described in this thesis and application to the total 
synthesis of (rac)-conolidine. [a] The yield was determined by 1H NMR spectroscopy using 1,4-dinitrobenzene 
as an internal standard. 





To conclude, this thesis outlines the development of several Rh(I)-catalysed processes that enable 
expeditious access to a wide range of sp3-rich, medium-sized and pharmaceutically relevant 
(poly)heterocycles. These processes are enabled by the regioselective and efficient generation of 
versatile rhodacyclopentanones which are accessed via a step and atom economical reaction design. 
Given the ease with which molecular complexity is generated by the processes developed here, it is 
likely these new methodologies will find utility in synthetic and medicinal chemistry. In this regard, the 
synthesis of (rac)-conolidine validates the use of carbonylative ring expansion of cyclopropylamides in 
natural product synthesis.  





Chapter 7 – Experimental procedures 
7.1 General Experimental Details 
Starting materials sourced from commercial suppliers (Acros, Sigma, Alfa Aesar, Fluorochem, Strem 
and TCI) were used as received unless otherwise stated. All reagents requiring purification were purified 
using standard laboratory techniques according to methods published by Perrin, Armarego, and Perrin 
(Pergamon Press, 1966). Anhydrous solvents, where necessary, were obtained by distillation using 
standard procedures or by passage through drying columns supplied by Anhydrous Engineering Ltd. 
Anhydrous PhCN was purchased as anhydrous grade and stored over activated 4Å molecular sieves 
prior to use. 1,2-DCB was distilled over CaH2 and stored over activated 4Å molecular sieves under 
nitrogen. Petrol refers to the fraction of petroleum ether boiling in the range of 40–60 °C. The removal 
of solvents in vacuo was achieved using both a Büchi rotary evaporator (bath temperatures up to 45 °C) 
at a pressure of either 15 mmHg (diaphragm pump) or 0.1 mmHg (oil pump). Materials were then dried 
on a high-vacuum line prior to analysis. Reactions requiring anhydrous conditions were performed 
under an atmosphere of nitrogen or argon, using Schlenk techniques and flame/oven-dried equipment. 
In particular, catalytic reactions were carried out in oven dried (minimum 2 hours) or flame dried glass 
reaction tubes equipped with a Suba-Seal® and a balloon of inert gas (or carbon monoxide in the case 
of carbonylation reactions); liquid reagents, solutions or solvents were added via syringe through rubber 
septa; solid reagents were added via Schlenk type adapters. Commercially available Merck Kieselgel 
60 F254 aluminium backed plates were used for TLC analysis. Visualisation was achieved by either UV 
fluorescence, basic KMnO4 solution and heat. Flash column chromatography (FCC) was performed 
using silica gel (Aldrich 40-63 μm, 230-400 mesh). The crude material was applied to the column as a 
solution in CH2Cl2 or by pre-adsorption onto silica, as appropriate. Melting points were determined 
using a Reichert melting point table and temperature controller and are uncorrected. Infra-red spectra 
were recorded in the range 4000-600 cm-1 on a Perkin Elmer Spectrum either as neat films or solids 
compressed onto a diamond window. Abbreviations used are: w (weak), m (medium), s (strong) or br. 
(broad). NMR spectra were recorded using either a Varian 400-MR, Varian VNMR S500, Bruker Nano 
400, JEOL ECS 300 or Bruker Advance III HD 500 Cryo. 1H NMR spectra were recorded at 400 MHz 
or 500 MHz as stated. 13C NMR spectra were recorded at 101 MHz or 126 MHz as stated. Chemical 
shifts (δ) are quoted in parts per million (ppm), coupling constants (J) are given in Hz to the nearest 0.5 
Hz. Peaks are described as singlets (s), doublets (d), triplets (t), quartets (q), septets (sept), heptets (hept), 
multiplets (m) and broad (br.). 1H and 13C NMR spectra were referenced to the appropriate residual 
solvent peak. 19F spectra were referenced to CCl3F as an external standard. Assignments of 1H NMR 
and 13C NMR signals were made, where possible, using COSY, HMQC, HMBC, and NOE experiments. 
Where mixtures of isomers (e.g. diastereomers and/or rotamers) have been characterized together, they 
are referred to as A and B. Numbering systems for NMR signal assignments are specified on the structure 





and are not related to those used for the compound names. NMR yields were determined by employing 
1,4-dinitrobenzene as an internal standard. Mass spectra were determined by the University of Bristol 
mass spectrometry service by electron impact (ESI+) using a Bruker Daltonics FT-ICR-MS Apex 4e 
7.0T FT-MS. Chiral SFC was performed using the racemate as a standard on an Agilent 1290 Infinity 
system equipped with a quaternary pump, diode array detector and column thermostat under the 
conditions specified in each case. Optical rotations were measured using an ADP440+ polarimeter at 
the concentration and temperature stated. 
7.2 General Procedures 
General Procedure A: Amine and indole carboxylic acid couplings   
To a suspension of the specified carboxylic acid (100 mol%) in CH2Cl2 (0.3 M) at room temperature 
was added EDCI (110 mol%), DMAP (10 mol%) and the specified amine (105 mol%). The resulting 
solution was stirred at room temperature until the formation of a precipitate was observed. The 
precipitate was collected by vacuum filtration and washed with ice cooled CH2Cl2. The crude product 
was recrystallised, under the conditions noted, to afford the title compound.   
General Procedure B: Amine and carboxylic acid couplings  
To a suspension of the specified carboxylic acid (100 mol%) in CH2Cl2 (0.3 M) at room temperature 
was added EDCI (110 mol%), DMAP (10 mol%) and N-benzylcyclopropanamine (100–105 mol%). 
The resulting solution was stirred at room temperature for 18 hours. 1 M aqueous HCl (5 mL/mmol) 
was added and the solution was extracted with CH2Cl2 (2 × 3 mL/mmol). The organic extracts were 
combined, washed with water (5 mL/mmol), brine (5 mL/mmol), dried over Na2SO4 and concentrated 
in vacuo. The product was purified by flash column chromatography, under the conditions noted to 
afford the title compound.  
General procedure C: Rh(I)-catalysed carbonylative cyclisation of cyclopropylamides   
An oven dried reaction tube, fitted with a magnetic stirrer, was charged with [Rh(cod)OMe]2 (3.75 
mol%), P(4-(F)C6H4)3 (22.5 mol%), 2-nitrobenzoic acid (150 mol%) and the appropriate amide 
substrate (100 mol%). The tube was fitted with a rubber septum and purged with argon for 20 minutes. 
The reagents were dissolved in argon sparged anhydrous PhCN (0.3 M). The reaction vessel was purged 
with CO for approximately 10 minutes and the suspension was subsequently sparged with CO for 
approximately 30 seconds. The reaction was heated at the specified temperature (130–140 °C) under a 
CO atmosphere (1 atm) for the time noted. The mixture was cooled to room temperature and 
concentrated in vacuo. The residue was purified by flash column chromatography, under the conditions 
noted, to yield the target heterocycle.   
  





General Procedure D: Hydrolysis of esters 
To a solution of the appropriate cyclopropyl ester (100 mol%) in MeOH (0.4 M) at room temperature 
was added 4 M aq. NaOH (500 mol%). The mixture was stirred for 18 h before being concentrated in 
vacuo. Water (5 mL/mmol) and Et2O (5 mL/mmol) were added and the layers separated. The aqueous 
portion was adjusted to pH 2 by addition of 2 M aq. HCl and then extracted with Et2O (5 mL/mmol). 
The organic extracts were combined, dried over Na2SO4 and concentrated in vacuo to afford the target 
carboxylic acid. 
General procedure E: Deprotection/reductive amination of Boc-protected cyclopropylamines 
To a solution of the specified Boc-protected cyclopropylamine (100 mol%) in CH2Cl2 (1 M) was added 
trifluoroacetic acid (1000 mol%) and the reaction was stirred at room temperature for 18 h. The reaction 
mixture was concentrated in vacuo, water (5 mL/mmol) was added and the solution was extracted with 
CH2Cl2 (5 mL/mmol). The aqueous portion was adjusted to pH 12 by addition of 2 M aq. NaOH and 
then extracted with CH2Cl2 (3 × 3 mL/mmol). The organic extracts were combined, dried over Na2SO4, 
concentrated in vacuo and the residue was dissolved in MeOH (0.5 M). NaHCO3 (400 mol%) and 
benzaldehyde (95 mol%) were added and the solution was refluxed for 18 h. The reaction mixture was 
cooled to 0 °C and NaBH4 (125 mol%) was added portion-wise over 10 minutes. The reaction was 
warmed to room temperature, stirred for 18 h and then concentrated in vacuo. Sat. aq. NaHCO3 (10 
mL/mmol) and CH2Cl2 (5 mL/mmol) were added, the layers were separated and the aqueous portion 
was further extracted with CH2Cl2 (2 × 5 mL/mmol). The organic extracts were combined, washed with 
brine (5 mL/mmol), dried over Na2SO4 and concentrated in vacuo. The residue was purified by flash 
column chromatography, under the conditions noted, to afford the title compound. 
General Procedure F: Rh(I)-catalysed carbonylative cyclisation of cyclopropylamides   
An oven dried reaction tube, fitted with a magnetic stirrer, was charged with [Rh(cod)OMe]2 (3.75 
mol%), fumaric acid (100–150 mol%) and substrate (100 mol%). Anhydrous benzonitrile (1.0–0.67 M) 
was added by syringe and the tube was fitted with a rubber septum and purged with argon. The reaction 
vessel was purged with CO for 10 minutes and the solution was subsequently sparged with CO for 
approximately 20 seconds. The mixture was then heated at the specified temperature, under a CO 
atmosphere (1 atm), for the specified reaction time. The mixture was cooled to room temperature, 
concentrated in vacuo and the residue was purified by flash column chromatography under the 
conditions noted to afford the desired product. 
General Procedure G: Protection of indole or pyrrole derivatives with carbamoyl chloride 
derivatives  
A flame-dried round-bottomed flask was charged with NaH (60% dispersion in mineral oil, 120 mol%) 
and this was suspended in THF (1.0 M) under nitrogen. The suspension was cooled to 0 °C and a 





solution of indole or pyrrole derivative (100 mol%) in THF (0.5 M) was added dropwise over 10 
minutes. The solution was stirred at 0 °C for 1 h, followed by dropwise addition of carbamoyl chloride 
derivative (110–150 mol%) in THF (0.5 M) over 10 minutes. The solution was then allowed to warm 
to room temperature and stirred for 4 hours. The reaction was quenched by the addition of saturated 
aqueous ammonium chloride solution (3mL/mmol) and extracted with EtOAc (3 × 3mL/mmol). The 
organic extracts were combined, washed with brine (5mL/mmol), dried over Na2SO4, filtered and 
concentrated in vacuo. Purification of the residue by flash column chromatography afforded the pure 
product. 
General Procedure H: Rh(I)-catalysed Carbonylative ring expansion of indole N-carbamoyl 
aminocyclopropanes     
An oven dried reaction tube, fitted with a magnetic stirrer, was charged with [Rh(cod)2]OTf (7.5 mol%), 
4-(dimethylamino)benzoic acid (30 mol%), Na2SO4 (100 mol%) and the appropriate indole substrate 
(100 mol%). The tube was fitted with a rubber septum and purged with argon. Anhydrous 1,2-DCB (0.1 
M) was added by syringe. The reaction vessel was sparged with CO for approximately 10 minutes and 
the solution was subsequently sparged with CO for approximately 20 seconds. The mixture was then 
heated at 130 °C under an atmosphere of CO for 72 h. The mixture was cooled to room temperature, 
concentrated in vacuo and the residue was purified by flash column chromatography, under the 
conditions noted, to yield the target heterocycle.   
7.3 Experimental procedures for the studies in Chapter 2 
7.3.1 Synthesis of substrates and catalysis products 
N-benzylcyclopropanamine (170a) 
 
A solution of benzaldehyde (4.10 mL, 40.0 mmol), cyclopropylamine (3.30 mL, 48.0 mmol) and 
NaHCO3 (5.04 g, 60 mmol) in MeOH (40 mL) were refluxed for 16 hours. The resulting suspension 
was cooled to 0 °C and NaBH4 (1.89 g, 50.0 mmol) was added portion wise over 10 minutes. The 
reaction was warmed to room temperature and stirred for an additional 16 hours. The reaction mixture 
was concentrated in vacuo before the addition of saturated aqueous NaHCO3 (50 mL). The solution was 
extracted with CH2Cl2 (2 × 50 mL). The organic layers were combined, washed with brine (50 mL), 
dried over Na2SO4 and concentrated in vacuo to give the title compound 170a (5.72 g, 98%) as a pale 
yellow oil. The crude material was used without further purification. 1H NMR (400 MHz, CDCl3): δ 
7.40 – 7.20 (5H, m, 2 × C2-H, 2 × C3-H, C1-H), 3.84 (2H, s, C5-H2), 2.15 (1H, tt, J = 6.5, 3.5 Hz, C6-





H), 1.81 (1H, br. s, NH), 0.49 – 0.33 (4H, m, 2 × C7-H2); 13C NMR (100 MHz, CDCl3): δ 140.7 (C4), 
128.5, 128.3, 127.0 (C1, C2, C3), 54.0 (C5), 30.2 (C6), 6.6 (C7). The spectroscopic properties of this 
compound were consistent with the data available in literature.16  
N-Benzyl-N-cyclopropyl-1H-indole-2-carboxamide (151a) 
 
General Procedure A: 1H-Indole-2-carboxylic acid (1.61 g, 10.0 mmol) and 
N-benzylcyclopropylamine 170a (1.54 g, 10.5 mmol) were employed to afford the title compound 151a 
(2.30 g, 79%) as a colourless solid. The crude material was isolated with good purity and was used 
without further purification. m.p.: 207–208 °C (ethanol); νmax/ cm-1: 3271 (s), 3011 (m), 1602 (s), 1521 
(s), 1433 (s), 1401 (s), 1347 (s), 1280 (s); 1H NMR (400 MHz, DMSO-d6): δ 11.55 (1H, s, NH), 7.62 
(1H, d, J = 8.0 Hz, C4-H), 7.46 (1H, d, J = 8.5 Hz, C7-H), 7.39 – 7.11 (7H, m, C2-H, C6-H, 2 × 
C12-H,  2 × C13-H and C14-H), 7.04 (1H, dd, J = 8.5, 8.0 Hz, C5-H), 4.79 (2H, s, C10-H2), 3.05 (1H, 
m, C15-H), 0.93 – 0.60 (4H, m, 2 × 16-H2); 13C NMR (101 MHz, DMSO-d6): δ 164.0 (C9), 138.5 
(C11), 135.9 (C8), 130.6 (C1), 128.5 (C13), 127.1 (C3), 127.1 (C12), 126.9 (C14), 123.5 (C6), 121.7 
(C4), 119.6 (C5), 112.1 (C7), 106.0 (C2), 50.6 (C10), 31.0 (C15), 10.1 (C16); HRMS: (ESI)+ Calculated 
for C19H18N2NaO: 313.1331. Found [M + Na] +: 313.1311.  
2-Benzyl-2,3,4,5-tetrahydro-1H-azocino[3,4-b]indole-1,6(11H)-dione (152a) and (Z)-2-Benzyl-2,5-
dihydro-1H-azocino[3,4-b]indole-1,6(11H)-dione (153a) 
 
General Procedure C: Indole 151a (43.5 mg, 0.15 mmol) was employed and the reaction mixture was 
heated at 140 °C for 72 h. The crude mixture was purified by flash column chromatography (75/15/10 % 
toluene/CH2Cl2/EtOAc) to yield the title compound 152a (36.7 mg, 77%) as a colourless solid. Analysis 
of the crude reaction mixture by 1H NMR revealed a >12:1 (152a:152a) mixture of products. The minor 
product 153a was not isolated. 
Data for major compound 152a: m.p.: 209–211 °C (CH2Cl2); νmax/ cm-1: 3220 (br. m), 2926 (m), 1614 
(br. s), 1577 (m), 1518 (s), 1423 (s), 1321 (s), 1141 (s); 1H NMR (400 MHz, CDCl3): δ 10.48 (1H, br. 
s, NH), 8.49 (1H, m, C4-H), 7.46 – 7.27 (8H, m, C5-H, C6-H, C7-H, 2 × C16-H, 2 × C17-H and C18-





H), 4.91 (2H, s, C14-H2), 3.69 (2H, br. m, C10-H2), 2.86 (2H, br. m, C12-H2), 2.01 (2H, tt, J = 6.5, 6.5 
Hz, C11-H2); 1H NMR (500 MHz, Acetonitrile-d3, 65 °C) δ 10.34 (1H, br. s, NH), 8.50 (1H, d, J = 8.1 
Hz, C4-H), 7.76 – 7.17 (8H, m, C5-H, C6-H, C7-H, 2 × C16-H, 2 × C17-H and C18-H), 4.93 (2H, s, 
C14-H2), 3.73 (2H, t, J = 6.5 Hz, C10-H2), 2.84 (2H, t, J = 7.0 Hz, C12-H2), 2.03 (2H, m, C11-H2); 13C 
NMR (101 MHz, CDCl3): δ 196.2 (C13), 164.5 (C9), 136.5 (C15), 135.3 (C8), 133.9 (C1), 129.0, 128.3, 
128.1 (C16, C17 and C18), 126.2 (C3), 125.4 (C6), 123.7, 123.6 (C4 and C5), 118.2 (C2), 111.9 (C7), 
49.8 (C14), 46.8 (C10), 39.0 (C12), 26.9 (C11); HRMS: (ESI)+ Calculated for C20H18N2NaO2: 341.1260. 
Found [M + Na] +: 341.1270. A 1H NMR spectrum was recorded at 65 °C in Acetonitrile-d3 because 
slow conformational interconversion gave broad signals at room temperature. 
Data for minor compound 153a: Characteristic signals only: 1H NMR (400 MHz, CDCl3): δ 6.11 (1H, 
d, J = 7.5 Hz, C10-H), 5.80 (1H, m, C11-H). 
N-Butylcyclopropanamine (170b) 
 
A solution of cyclopropylamine (4.16 mL, 60.0 mmol), butyraldehyde (4.51 mL, 50.0 mmol) and 
NaHCO3 (6.30 g, 75.0 mmol) in MeOH (50 mL) was heated at reflux for 16 h. The reaction mixture 
was cooled to 0 °C and NaBH4 (2.36 g, 62.5 mmol) was added portion wise over 5 minutes. The solution 
was warmed to r.t. and stirred for 6 h. The reaction mixture was concentrated in vacuo and then saturated 
aqueous NaHCO3 (50 mL) was added. The solution was extracted with CH2Cl2 (3 × 50 mL) and then 
the organic extracts were combined, washed with brine (50 mL), dried over Na2SO4 and concentrated 
in vacuo to yield N-butylcyclopropylamine 170b (3.82 g, 67%) as a yellow oil. N.B. Due to volatility 
issues a cold water bath was used when concentrating in vacuo. 1H NMR (400 MHz, CDCl3): δ 2.67 
(2H, t, J = 7.0 Hz, C4-H2), 2.10 (1H, tt, J = 6.5, 3.5 Hz, C5-H), 1.56 (H, br. s, NH), 1.46 (2H, m, C3-
H2), 1.38 – 1.27 (2H, m, C2-H2), 0.91 (3H, t, J = 7.5 Hz, C1-H3), 0.49 – 0.26 (4H, m, 2 × C6-H2); 13C 
NMR (100 MHz, CDCl3): δ 49.6 (C4), 32.3 (C3), 30.1 (C5), 20.6 (C2), 14.0 (C1), 6.5 (C6). The 









General Procedure A: 1H-indole-2-carboxylic acid (322 mg, 2.00 mmol) and 
N-butylcyclopropanamine 170b (237 mg, 2.10 mmol) were employed. The crude residue was 
recrystallised from ethanol to afford the title compound 151b as an off-white solid (350 mg, 68%); m.p.: 
119–122 °C (ethanol); νmax/ cm-1: 3281 (br. s), 2954 (m), 2870 (m), 1593 (s), 1575 (s), 1402 (s), 1347 
(s); 1H NMR (400 MHz, CDCl3): δ 9.75 (1H, br. s, NH), 7.67 (1H, d, J = 8.0 Hz, C4-H), 7.45 (1H, d, J 
= 8.5 Hz, C7-H), 7.29 (1H, m, C6-H), 7.18 – 7.09 (2H, m, C1-H and C5-H), 3.67 (2H, t, J = 7.5 Hz, 
C10-H2), 3.07 (1H, tt, J = 7.0, 4.0 Hz, C14-H), 1.71 (2H, tt, J = 7.5, 7.5 Hz, C11-H2), 1.44 – 1.34 (2H, 
m, C12-H2), 1.04 – 1.00 (2H, m, 1 × C15-H2), 0.97 (3H, t, J = 7.5 Hz, C13-H3), 0.85 – 0.77 (2H, m, 1 
× C15-H2); 13C NMR (101 MHz, CDCl3): δ 164.4 (C9), 135.6 (C8), 130.6 (C1), 128.0 (C3), 124.4 (C6), 
122.2 (C4), 120.3 (C5), 111.9 (C7), 106.8 (C2), 47.8 (C10), 30.9 (C14), 30.4 (C11), 20.4 (C12), 14.0 
(C13), 11.0 (C15); HRMS: (ESI)+ Calculated for C16H21N2O: 257.1648. Found [M + H] +: 257.1660. 
2-Butyl-2,3,4,5-tetrahydro-1H-azocino[3,4-b]indole-1,6(11H)-dione (152b) and (Z)-2-Butyl-2,5-
dihydro-1H-azocino[3,4-b]indole-1,6(11H)-dione (153b) 
 
General Procedure C: Indole 151b (25.6 mg, 0.10 mmol) was employed and the reaction mixture was 
heated at 140 °C for 72 h. The crude mixture was purified by flash column chromatography (10–35 % 
EtOAc/pentane) to yield the title compound 152b (12.5 mg, 44%) as a colourless oil. Analysis of the 
crude reaction mixture by 1H NMR revealed a 6:1 (152b:153b) mixture of products. The minor product 
153b was not isolated.  
Data for major compound 152b: νmax/ cm-1: 3264 (br. s), 2923 (m), 1642 (s), 1616 (s), 1520 (s), 1424 
(s); 1H NMR (400 MHz, CDCl3): δ 9.84 (1H, s, NH), 8.49 (1H, dd, J = 7.0, 2.0 Hz, C4-H), 7.44 (1H, 
dd, J = 7.0, 2.0 Hz, C7-H), 7.38 – 7.28 (2H, m, C5-H and C6-H), 3.70 (2H, br. m, C10-H2), 3.61 (2H, 
br. m, C14-H2) 2.87 (2H, br. m, C12-H2), 2.13 (2H, tt, J = 6.5, 6.5 Hz, C11-H2), 1.70 (2H, tt, J = 7.5, 
7.5 Hz, C15-H2), 1.42 (tq, J = 7.5, 7.5 Hz, C16-H2), 0.98 (3H, t, J = 7.5 Hz, C17-H3); 13C NMR (101 
MHz CDCl3): δ 196.3 (C13), 163.9 (C9), 134.5 (C8), 129.2 (C1), 126.2 (C3), 125.4 (C6), 123.8, 123.7 
(C4 and C5), 118.2 (C2), 111.7 (C7), 47.4, 47.1 (C10 and C14), 38.9 (C12), 30.2 (C15), 27.5 (C11), 
20.5 (C16), 14.0 (C17); HRMS: (ESI)+ Calculated for C17H21N2O2: 285.1598. Found [M + H] +: 
285.1604. 
Data for minor compound 153b: Characteristic signals only: 1H NMR (400 MHz, CDCl3): δ 5.97 (1H, 
d, J = 7.5 Hz, C10-H), 5.75 (1H, m, C11-H). 
N-Benzyl-N-cyclopropyl-5-methoxy-1H-indole-2-carboxamide (151) 






General Procedure A: 5-Methoxy-1H-indole-2-carboxylic acid (382 mg, 2.00 mmol) and 
N-benzylcyclopropylamine 170a (308 mg, 2.10 mmol) were employed. The crude residue was 
recrystallised from ethanol to afford the title compound 151c (420 mg, 66%) as an off-white solid; m.p.: 
200–202 °C (ethanol); νmax/ cm-1: 3255 (s), 1602 (s), 1520 (s), 1412 (s), 1401 (s), 1277 (s), 1163 (s), 
1027 (s); 1H NMR (400 MHz, CDCl3): δ 9.38 (1H, br. s, NH), 7.36 – 7.23 (6H, m, C7-H, 2 × C12-H, 2 
× C13-H and C14-H), 7.08– 7.06 (2H, m, C2-H and C4-H), 6.96 (1H, dd, J = 9.0, 2.5 Hz, C6-H), 4.88 
(2H, s, C10-H2), 3.84 (3H, s, C17-H3), 2.99 (1H, tt, J = 7.0, 4.0 Hz, C15-H), 1.03 – 0.81 (4H, m, 2 × 
C16-H2); 13C NMR (101 MHz, CDCl3): δ 164.7 (C9), 154.6 (C5), 138.2 (C11), 131.2 (C8), 130.7 (C1), 
128.8, 128.3, 127.6, 127.4 (C3, C12, C13 and C14), 116.2 (C6), 112.8 (C7), 106.8 (C2), 102.6 (C4), 
55.9 (C17), 51.9 (C10), 31.4 (C15), 10.9 (C16); HRMS: (ESI)+ Calculated for C20H21N2O2: 321.1598. 
Found [M + H] +: 321.1613.  
2-Benzyl-8-methoxy-2,3,4,5-tetrahydro-1H-azocino[3,4-b]indole-1,6(11H)-dione (152c) and (Z)-2-
Benzyl-8-methoxy-2,5-dihydro-1H-azocino[3,4-b]indole-1,6(11H)-dione (153c) 
 
General Procedure C: Indole 151c (48.0 mg, 0.15 mmol) was employed and the reaction mixture was 
heated at 140 °C for 72 h. The crude mixture was purified by flash column chromatography (70/15/10%, 
toluene/CH2Cl2/EtOAc) to yield the title compound 152c (35.0 mg, 67%) as a colourless oil. Analysis 
of the crude reaction mixture by 1H NMR revealed a >15:1 (152c: 153c) mixture of products. The minor 
product 153c was not isolated. 
Data for major compound 152c: m.p.: 212–217 °C (CH2Cl2); νmax/ cm-1: 3223 (br. m), 2933 (m), 1614 
(br. s), 1585 (m), 1512 (s), 1492 (m), 1453 (s), 1422 (s), 1268 (s), 1204 (s); 1H NMR (400 MHz, CDCl3): 
δ 10.43 (1H, br. s, NH), 7.95 (1H, d, J = 2.5 Hz, C4-H), 7.44 – 7.27 (6H, m, C7-H, 2 × C16-H, 2 × C17-
H and C18-H), 6.95 (1H, dd, J = 9.0, 2.5 Hz, C6-H), 4.89 (2H, br. m, C14-H2), 3.88 (3H, s, C19-H3), 
3.69 (2H, br. m, C10-H2), 2.84 (2H, br. m, C12-H2), 2.00 (2H, tt, J = 6.5, 6.5 Hz, C11-H2); 13C NMR 
(101 MHz, CDCl3): δ 196.3 (C13), 164.5 (C9), 157.2 (C5), 136.6 (C15), 133.9 (C1), 130.4 (C8), 129.0, 
128.3 (C16 and C17), 128.1 (C18), 127.0 (C3), 118.0 (C2), 116.9 (C6), 112.9 (C7), 103.6 (C4), 55.8 





(C19), 49.8 (C14), 46.8 (C10), 39.0 (C12), 26.9 (C11); HRMS: (ESI)+ Calculated for C21H20N2NaO3: 
371.1366. Found [M + Na] +: 371.1384. 
Data for minor compound 153c: Characteristic signals only: 1H NMR (400 MHz, CDCl3): δ 6.10 (1H, 
d, J = 7.5 Hz, C10-H), 5.80 (1H, m, C11-H). 
N-Benzyl-N-cyclopropyl-5-methyl-1H-indole-2-carboxamide (151d) 
 
General Procedure A: 5-Methyl-1H-indole-2-carboxylic acid (350 mg, 2.00 mmol) and 
N-benzylcyclopropylamine 170a (308 mg, 2.10 mmol) were employed. The crude residue was 
recrystallised from CHCl3 to afford the title compound 151d (415 mg, 68%) as an off-white solid; m.p.: 
191–193 °C (CHCl3); νmax/ cm-1: 3269 (s), 1601 (s), 1525 (m), 1431 (s), 1403 (s), 1277 (s), 1031 (m); 
1H NMR (400 MHz, CDCl3): δ 9.44 (1H, br. s, NH), 7.44 (1H, m, C4-H), 7.37 – 7.23 (6H, m, C7-H, 2 
× C12-H, 2 × C13-H and C14-H ), 7.11 (1H, dd, J = 8.5, 1.5 Hz, C6-H), 7.07 (1H, s, C2-H), 4.89 (2H, 
s, C10-H2), 3.00 (1H, tt, J = 7.0, 4.0 Hz, C15-H), 2.44 (3H, s, C17-H3), 1.07 – 0.78 (4H, m, 2 × C16-
H2); 13C NMR (101 MHz, DMSO-d6): δ 164.1 (C9), 138.5 (C11), 134.3 (C8), 130.5 (C1), 128.5 (C13), 
128.1 (C5), 127.4 (C3), 127.1 (C12), 126.9 (C14), 125.4 (C6), 120.9 (C4), 111.8 (C7), 105.5 (C2), 50.6 
(C10), 31.0 (C15), 21.2 (C17), 10.1 (C16); HRMS: (ESI)+ Calculated for C20H21N2O: 305.1648. Found 
[M + H] +: 305.1651. 
2-Benzyl-8-methyl-2,3,4,5-tetrahydro-1H-azocino[3,4-b]indole-1,6(11H)-dione (152d) and (Z)-2-
Benzyl-8-methyl-2,5-dihydro-1H-azocino[3,4-b]indole-1,6(11H)-dione (153d) 
 
General Procedure C: Indole 151d (45.6 mg, 0.15 mmol) was employed and the reaction mixture was 
heated at 140 °C for 72 h. The crude mixture was purified by flash column chromatography (10–30% 
EtOAc/pentane) to yield the title compound 152d (27.8 mg, 56%) as an off-white solid. Analysis of the 
crude reaction mixture by 1H NMR revealed a 8:1 (152d:153d) mixture of products. The minor product 
153d was not isolated. 





Data for major compound 152d: m.p.: 195–197 °C (CHCl3); νmax/ cm-1: 3226 (br. m), 2924 (m), 1610 
(br. s), 1582 (m), 1516 (s), 1452 (s), 1440 (s), 1420 (s), 1218 (m); 1H NMR (400 MHz, CDCl3): δ 10.20 
(1H, br. s, NH), 8.29 (1H, d, J = 1.5 Hz, C4-H), 7.38 – 7.29 (6H, m, C7-H, 2 × C16-H, 2 × C17-H and 
C18-H), 7.14 (1H, dd, J = 8.5, 1.5 Hz, C6-H), 4.89 (2H, s, C14-H2), 3.67 (2H, br. m, C10-H2), 2.83 
(2H, br. m, C12-H2), 2.47 (3H, s, C19-H3), 1.99 (2H, tt, J = 6.5, 6.5 Hz, C11-H2); 13C NMR (101 MHz, 
CDCl3): δ 196.3 (C13), 164.6 (C9), 136.6 (C15), 133.9 (C1), 133.6 (C5), 133.5 (C8), 129.0, 128.3, 
128.1 (C16, C17 and C18), 127.3 (C6), 126.5 (C3), 123.1 (C4), 117.9 (C2), 111.5 (C7), 49.8 (C14), 
46.7 (C10), 39.0 (C12), 26.9 (C11), 21.8 (C19); HRMS: (ESI)+ Calculated for C21H21N2O2: 333.1598. 
Found [M + H] +: 333.1594. 
Data for minor compound 153d: Characteristic signals only: 1H NMR (400 MHz, CDCl3): δ 6.08 (1H, 
d, J = 7.5 Hz, C10-H), 5.80 (1H, m, C11-H). 
N-Benzyl-N-cyclopropyl-5-phenyl-1H-indole-2-carboxamide (151e) 
 
To an oven dried reaction tube was added N-benzyl-5-bromo-N-cyclopropyl-1H-indole-2-carboxamide 
151g (184 mg, 0.50 mmol), phenylboronic acid (242 mg, 1.00 mmol), Pd(PPh3)4 (28.0 mg, 0.025 mmol) 
and K2CO3 (173 mg, 1.25 mmol). The tube was fitted with a rubber septum and purged with argon. The 
reagents were dissolved in 1,4-dioxane/H2O (3:1, 4.0 mL) The tube was sealed and heated at 105 °C 
for 4 hours and then cooled to room temperature. The reaction mixture was filtered through a pad of 
celite® and concentrated in vacuo. The residue was purified by flash column chromatography (20% 
EtOAc/hexane) to afford the title compound 151e (130 mg, 71%) as a colourless solid; m.p.: 197–
199 °C (ethanol); νmax/ cm-1: 3252 (m), 1604 (s), 1530 (m), 1493 (m), 1431 (m), 1403 (m), 1288 (s); 1H 
NMR (400 MHz, DMSO-d6): δ 11.62 (1H, br. s, NH), 7.89 (1H, s, C4-H), 7.70 – 7.63 (2H, m, 2 × Ar-
CH), 7.56 – 7.51 (2H, m, C6-H and C7-H), 7.47 – 7.43 (2H, m, 2 × Ar-CH ), 7.41 – 7.21 (7H, m, C2-
H and 6 × Ar-CH), 4.80 (2H, s, C10-H2), 3.10 (1H, m, C12-H), 0.94 – 0.67 (4H, m, 2 × C13-H2); 13C 
NMR (101 MHz, DMSO-d6): δ 163.9 (C9), 141.4 (C5), 138.4 (C11), 135.5 (C8), 132.1, 131.3 (Ar-C) 
128.8, 128.5 (4 × Ar-CH), 127.7 (C3), 127.1, 126.9, 126.6, 126.4 (6 × Ar-CH), 123.1 (C6), 119.5 (C4), 
112.6 (C7), 106.4 (C2), 50.6 (C10), 31.0 (C12), 10.1 (C13); HRMS: (ESI)+ Calculated for C25H23N2O: 
367.1732. Found [M + H] +: 367.1820. 
  





2-Benzyl-8-phenyl-2,3,4,5-tetrahydro-1H-azocino[3,4-b]indole-1,6(11H)-dione (152e) and (Z)-2-
Benzyl-8-phenyl-2,5-dihydro-1H-azocino[3,4-b]indole-1,6(11H)-dione (153e) 
 
General Procedure C: Indole 151e (55.4 mg, 0.15 mmol) was employed and the reaction mixture was 
heated at 140 °C for 72 h. The crude mixture was purified by flash column chromatography (10–35% 
EtOAc/pentane) to yield the title compound 152e (41.7 mg, 70%) as an off white solid. Analysis of the 
crude reaction mixture by 1H NMR revealed a 11:1 (152e:153e) mixture of products. The minor product 
153e was not isolated. 
Data for major compound 152e: m.p.: 220–222 °C (CH2Cl2) νmax/ cm-1: 3240 (br. m), 2968 (m), 1615 
(br. s), 1584 (m), 1528 (m), 1452 (m), 1419 (s); 1H NMR (400 MHz, CDCl3): δ 10.54 (1H, br. s, NH), 
8.74 (1H, d, J = 1.5 Hz, C4-H), 7.72 – 7.64 (2H, m, 2 × C20-H), 7.56 (1H, dd, J = 8.5, 1.5 Hz, C6-H), 
7.50 – 7.41 (3H, m, C7-H and 2 × C21-H), 7.40 – 7.28 (6H, m, 2 × C16-H, 2 × C17-H, C18-H and C22-
H), 4.93 (2H, s, C14-H2), 3.71 (2H, br. m, C10-H2), 2.87 (2H, t, J = 7.5 Hz, C12-H2), 2.02 (2H, tt, J = 
7.5, 6.5 Hz, C11-H2); 13C NMR (101 MHz, CDCl3): δ 196.2 (C13), 164.6 (C9), 141.9 (C5), 137.1 (C19), 
136.5 (C15), 134.9 (C8), 134.4 (C1), 129.0 (C17), 128.8 (C21), 128.2 (C16), 128.1 (C18), 127.6 (C20), 
126.9 (C22), 126.7 (C3), 125.3 (C6), 121.9 (C4), 118.5 (C2), 112.1 (C7), 49.9 (C14), 46.8 (C10), 39.0 
(C12), 26.9 (C11); HRMS: (ESI)+ Calculated for C26H23N2O2: 395.1754. Found [M + H] +: 395.1761.  
Data for minor compound 153e: Characteristic signals only: 1H NMR (400 MHz, CDCl3): δ 6.09 (1H, 
d, J = 7.5 Hz, C10-H), 5.81 (1H, m, C11-H).  
N-Benzyl-N-cyclopropyl-6-methoxy-1H-indole-2-carboxamide (151f) 
 
General Procedure A: 6-Methoxy-1H-indole-2-carboxylic acid (382 mg, 2.00 mmol) and 
N-benzylcyclopropylamine 170a (308 mg, 2.10 mmol) were employed. The crude residue was 
recrystallised from CHCl3 to afford the title compound 151f as a yellow solid (400 mg, 63%); m.p.: 
207–208 °C (CHCl3); νmax/ cm-1: 3281 (br. s), 1625 (m), 1593 (s), 1575 (m), 1508 (m), 1417 (m), 1275 
(s), 1230 (m), 1027 (m); 1H NMR (400 MHz, DMSO-d6): δ 11.35 (1H, br. s, NH), 7.49 (1H, d, J = 8.5 





Hz, C4-H), 7.36 – 7.21 (5H, m, 2 × C12-H, 2 × C13-H and C14-H), 7.14 (1H, m, C2-H), 6.92 (1H, d, J 
= 2.5 Hz, C7-H), 6.70 (1H, dd, J = 8.5, 2.5 Hz, C5-H), 4.77 (2H, s, C10-H2), 3.77 (3H, s, C17-H3), 3.04 
(1H, tt, J = 7.0, 4.0 Hz, C15-H), 0.88 – 0.84 (2H, m, 1 × C16-H2), 0.78 – 0.64 (2H, m, 1 × C16-H2); 13C 
NMR (101 MHz, DMSO-d6): δ 163.9 (C9), 157.2 (C6), 138.6 (C11), 136.9 (C8), 129.4 (C1), 128.4, 
127.1 (C12, C13), 126.8 (C14), 122.5 (C4), 121.6 (C3), 111.0 (C5), 106.6 (C2), 93.9 (C7), 55.1 (C17), 
50.5 (C10), 31.0 (C15), 10.2 (C16); HRMS: (ESI)+ Calculated for C20H21N2O2: 321.1598. Found [M + 
H] +: 321.1599. 
2-Benzyl-9-methoxy-2,3,4,5-tetrahydro-1H-azocino[3,4-b]indole-1,6(11H)-dione (152f) and (Z)-2-
Benzyl-9-methoxy-2,5-dihydro-1H-azocino[3,4-b]indole-1,6(11H)-dione (153f) 
  
General Procedure C: Indole 151f (48.0 mg, 0.15 mmol) was employed and the reaction mixture was 
heated at 140 °C for 72 h. The crude mixture was purified by flash column chromatography (10–40% 
EtOAc/pentane) to yield the title compound 152f (23.5 mg, 45%) as a colourless solid. Analysis of the 
crude reaction mixture by 1H NMR revealed an 8:1 (152f:153f) mixture of products. The minor product 
153f was not isolated. 
Data for major compound 152f: m.p.: 192–195 °C (CHCl3); νmax/ cm-1: 3239 (br. m), 2951 (m), 1606 
(br. s), 1576 (m), 1517 (s), 1451 (m), 1410 (s), 1261 (s), 1232 (s), 1109 (s), 1028 (s); 1H NMR (400 
MHz, CDCl3): δ 10.10 (1H, br. s, NH), 8.33 (1H, d, J = 9.0 Hz, C4-H), 7.42 – 7.27 (5H, m, 2 × C16-H, 
2 × C17-H and C18-H), 6.94 (1H, dd, J = 9.0, 2.5 Hz, C5-H), 6.85 (1H, d, J = 2.5 Hz, C7-H), 4.90 (2H, 
s, C14-H2), 3.76 (3H, s, C19-H3), 3.68 (2H, br. m, C10-H2), 2.83 (2H, br. m, C12-H2), 1.99 (2H, tt, J = 
6.5, 6.5 Hz, C11-H2); 13C NMR (101 MHz, CDCl3): δ 196.4 (C13), 164.6 (C9), 158.7 (C6), 136.7, 136.3 
(C8 and C15), 132.7 (C1), 129.0, 128.3, 128.1 (C16, C17 and C18), 124.6 (C4), 120.5 (C3), 118.5 (C2), 
114.4 (C5), 94.0 (C7), 55.6 (C19), 49.9 (C14), 46.9 (C10), 39.0 (C12), 27.1 (C11); HRMS: (ESI)+ 
Calculated for C21H21N2O3: 349.1547. Found [M + H] +: 349.1561. The structure of this compound was 
determined unambiguously by X-ray crystallography.  
 





Data for minor compound 153f: Characteristic signals only: 1H NMR (400 MHz, CDCl3): δ 6.03 (1H, 
d, J = 7.5 Hz, C10-H), 5.70 (1H, td, J = 8.5, 7.5 Hz, C11-H). 
N-Benzyl-5-bromo-N-cyclopropyl-1H-indole-2-carboxamide (151g) 
 
General Procedure A: 5-Bromo-1H-indole-2-carboxylic acid (476 mg, 2.00 mmol) and 
N-benzylcyclopropylamine (308 mg, 2.10 mmol) were employed to afford the title compound 151g 
(420 mg, 67%) as a beige solid (420 mg, 57%). The crude material was isolated with good purity and 
was used without further purification. m.p.: 198–201 °C (ethanol); νmax/ cm-1: 3260 (br. m), 1604 (s), 
1518 (m), 1433 (s), 1340 (s), 1293 (s), 1267 (s); 1H NMR (400 MHz, DMSO-d6): δ 11.87 (1H, br. s, 
NH), 7.81 (1H, d, J = 2.0 Hz, C4-H), 7.41 (1H, d, J = 9.0 Hz, C7-H), 7.38 – 7.24 (6H, m, C6-H, 2 × 
C12-H, 2 × C13-H and C14-H), 7.15 (1H, s, C2-H), 4.78 (2H, s, C10-H2), 3.06 (1H, m, C15-H), 0.90 – 
0.66 (4H, m, 2 × C16-H2); 13C NMR (101 MHz, DMSO-d6): δ 163.7 (C9), 138.3 (C11), 134.5 (C8), 
131.9 (C1), 128.9 (C3), 128.5, 127.1, 126.9 (C12, C13 and C14), 126.0 (C6), 123.7 (C4), 114.2 (C7), 
111.9 (C5), 105.3 (C2), 50.6 (C10), 31.0 (C15), 10.1 (C16); HRMS: (ESI)+ Calculated for 
C19H1879BrN2O: 369.0597. Found [M + H] +: 369.0610. 
2-Benzyl-8-bromo-2,3,4,5-tetrahydro-1H-azocino[3,4-b]indole-1,6(11H)-dione (153g) and (Z)-2-
Benzyl-8-bromo-2,5-dihydro-1H-azocino[3,4-b]indole-1,6(11H)-dione (153g) 
 
General Procedure C: Indole 151g (36.7 mg, 0.10 mmol) was employed and the reaction mixture was 
heated at 140 °C for 72 h. The crude mixture was purified by flash column chromatography (20–35% 
EtOAc/pentane) to yield the title compound 152g (7.2 mg, 18%) as a colourless oil. Analysis of the 
crude reaction mixture by 1H NMR revealed a 12:1 (152g:153g) mixture of products. The minor product 
153g was not isolated. 
Data for major compound 152g: νmax/ cm-1: 3220 (br. m), 2930 (m), 1610 (br. s), 1583 (s), 1520 (s), 
1452 (s), 1420 (s); 1H NMR (500 MHz, CDCl3): δ 9.77 (1H, br. s, NH), 8.67 (1H, m, C4-H), 7.43 (1H, 
dd, J = 8.5, 2.0 Hz, C6-H), 7.38 – 7.34 (5H, m, 2 × C16-H, 2 × C17-H and C18-H), 7.29 (1H, dd, J = 





8.5, 0.5 Hz, C7-H), 4.87 (2H, s, C14-H2), 3.67 (2H, br. m, C10-H2), 2.83 (2H, br. m, C12-H2), 2.00 (2H, 
tt, J = 6.5, 6.5 Hz, C11-H2); 13C NMR (126 MHz, CDCl3): δ 195.9 (C13), 163.9 (C9), 136.4 (C15), 
134.6 (C1), 133.6 (C8), 129.1 128.8, 128.4, 128.3 (C6, C16, C17 and C18), 127.7 (C3), 126.4 (C4), 
117.6, 117.3 (C2 and C5), 113.1 (C7), 49.8 (C14), 46.7 (C10), 38.9 (C12), 26.8 (C11); HRMS: (ESI)+ 
Calculated for C20H1879BrN2O2: 397.0546. Found [M + H] +: 397.0529. 
Data for minor compound 153g: Characteristic signals only: 1H NMR (400 MHz, CDCl3): δ 6.10 (1H, 
d, J = 7.5 Hz, C10-H), 5.79 (1H, m, C11-H). 
N-Benzyl-N-cyclopropyl-5-fluoro-1H-indole-2-carboxamide (151h) 
  
General Procedure A: 5-Fluoro-1H-indole-2-carboxylic acid (358 mg, 2.00 mmol) and 
N-benzylcyclopropylamine 170a (308 mg, 2.10 mmol) were employed. The crude residue was 
recrystallised from ethanol to afford the title compound 151h (470 mg, 76%) as an off-white solid; m.p.: 
216–219 °C (ethanol); νmax/ cm-1: 3258 (m), 1602 (s), 1524 (s), 1435 (s), 1404 (s), 1274 (s), 1162 (s); 
1H NMR (500 MHz, CDCl3): δ 9.59 (1H, br. s, NH), 7.40 – 7.25 (6H, m, C7-H, 2 × C12-H, 2 × C13-H 
and C14-H), 7.20 – 7.11 (1H, br. s, C2-H), 7.06 (1H, dd, J = 9.0, 2.5 Hz, C6-H), 4.91 (2H, s, C10-H2), 
3.03 (1H, tt, J = 7.0, 4.0 Hz, C15-H), 1.03 – 0.84 (4H, m, 2 × C16-H2); 13C NMR (101 MHz, DMSO-
d6): δ 163.8 (C9), 157.03 (d, J = 232.5 Hz, C5), 138.4 (C11), 132.6, 132.3 (C1 and C8), 128.5 (C13), 
127.2 (C3), 127.1 (C12), 126.9 (C14), 113.34 (d, J = 9.6 Hz, C7), 112.2 (d, J = 26.4 Hz, C6), 105.9 
(C2), 105.7 (d, J = 22.9 Hz, C4), 50.6 (C10), 38.9 (C15), 31.0 (C16); 19F NMR (377 MHz, CDCl3): δ 
-123.52 (s); HRMS: (ESI)+ Calculated for C19H18FN2NaO: 331.1217. Found [M + Na] +: 331.1224.  
2-Benzyl-8-fluoro-2,3,4,5-tetrahydro-1H-azocino[3,4-b]indole-1,6(11H)-dione (152h) and (Z)-2-
Benzyl-8-fluoro-2,5-dihydro-1H-azocino[3,4-b]indole-1,6(11H)-dione (153h) 
 
General Procedure C: Indole 151h (46.2 mg, 0.15 mmol) was employed and the reaction mixture was 
heated at 140 °C for 72 h. The crude mixture was purified by flash column chromatography (10–15% 
EtOAc/toluene) to yield the title compound 152h (34.9 mg, 65%) as an orange solid. Analysis of the 





crude reaction mixture by 1H NMR revealed a 10:1 (152h:153h) mixture of products. The minor product 
153h was not isolated. 
Data for major compound 153h: m.p.: 216–220 °C (CH2Cl2/hexane); νmax/ cm-1: 3223 (br. m), 3031 (m), 
1613 (br. s), 1518 (m), 1492 (m), 1451 (s), 1424 (s), 1258 (m), 1156 (m); 1H NMR (400 MHz, CDCl3): 
δ 10.45 (1H, br. s, NH), 8.16 (1H, dd, J = 10.0, 2.5 Hz, C4-H), 7.39 – 7.27 (6H, m, C7-H, 2 × C16-H, 
2 × C17-H and C18-H), 7.05 (1H, dd, J = 9.0, 2.5 Hz, C6-H), 4.90 (2H, s, C14-H2), 3.69 (2H, br. m, 
C10-H2), 2.85 (2H, br. m, C12-H2), 2.01 (2H, tt, J = 6.5, 6.5 Hz, C11-H2); 13C NMR (101 MHz, CDCl3): 
δ 195.8 (C13), 164.4 (C9), 160.19 (d, J = 239.0 Hz, C5), 136.3 (C15), 135.0 (C1), 132.0 (C8), 129.1, 
128.2, (2 signals) (C16, C17 and C18), 126.8 (d, J = 11.5 Hz, C3), 118.3 (d, J = 5.2 Hz, C2), 114.4 (d, 
J = 26.9 Hz, C6), 113.0 (d, J = 9.7 Hz, C7), 108.6 (d, J = 25.3 Hz, C4), 49.9 (C14), 46.9 (C10), 38.8 
(C12), 26.8 (C11); 19F NMR (377 MHz, CDCl3): δ -119.06 (s); HRMS: (ESI)+ Calculated for 
C20H17FN2NaO2: 359.1166. Found [M + H] +: 359.1149.  
Data for minor compound 153h: Characteristic signals only: 1H NMR (400 MHz, CDCl3): δ 6.05 
(1H, d, J = 7.5 Hz, C10-H), 5.75 (1H, m, C11-H).  
N-Benzyl-N-cyclopropyl-4,6-difluoro-1H-indole-2-carboxamide (151i) 
 
General Procedure A: 4,6-Difluoro-1H-indole-2-carboxylic acid (397 mg, 2.00 mmol) and 
N-benzylcyclopropylamine 170a (308 mg, 2.10 mmol) were employed. The crude residue was 
recrystallised from ethanol to afford the title compound 151i as a beige solid (370 mg, 57%); m.p.: 
204–205 °C (ethanol); νmax/ cm-1: 3263 (br. m), 1644 (s), 1602 (s), 1581 (s), 1520 (s), 1435 (s), 1290 
(s), 1151 (s); 1H NMR (500 MHz, CDCl3): δ 10.23 (1H, br. s, NH), 7.40 – 7.27 (5H, m, 2 × C12-H, 2 
× C13-H and C14-H), 7.21 (1H, br. s, C2-H), 6.82 (1H, dd, J = 9.0, 2.0 Hz, C5-H), 6.60 (1H, ddd, J = 
10.0, 2.5, 2.0 Hz, C7-H), 4.91 (2H, s, C10-H2), 3.04 (1H, tt, J = 7.0, 4.0 Hz, C15-H), 1.03 – 0.84 (4H, 
m, 2 × C16-H2); 13C NMR (126 MHz, CDCl3): δ 164.1 (C9), 160.79 (dd, J = 242.5, 11.7 Hz, C6), 156.79 
(dd, J = 251.8, 15.2 Hz, C4), 137.7 (C11), 136.98 (dd, J = 15.2, 12.4 Hz, C8), 130.5 (d, J = 3.5 Hz, C1), 
128.7, 127.4 (2 signals) (C12, C13 and C14), 114.2 (d, J = 21.8 Hz, C3), 103.2 (C2), 95.9 (dd, J = 29.4, 
22.9 Hz, C5), 94.0 (dd, J = 26.2, 4.7 Hz, C7), 51.9 (C10), 31.4 (C15), 10.9 (C16); 19F NMR (283 MHz, 
CDCl3): δ -114.2 (dd, J = 9.0, 5.7 Hz), -117.5 (ddd, J = 10.0, 5.7, 2.5 Hz); HRMS: (ESI)+ Calculated 
for C19H17F2N2O: 327.1303. Found [M + H] +: 327.1318.  
  







General Procedure A: 4-Methoxy-1H-indole-2-carboxylic acid (382 mg, 2.00 mmol) and 
N-benzylcyclopropylamine 170a (308 mg, 2.10 mmol) were employed. The crude residue was 
recrystallised from ethanol to afford the title compound 151j as a yellow solid (384 mg, 60%); m.p.: 
197–198 °C (ethanol); νmax/ cm-1: 3274 (br. m), 1591 (s), 1576 (s), 1513 (s), 1419 (s), 1362 (s), 1249 
(s), 1098 (s); 1H NMR (400 MHz, DMSO-d6): δ 11.57 (1H, br. s, NH), 7.38 – 7.23 (5H, m, 2 × C12-H, 
2 × C13-H and C14-H), 7.15 (1H, s, C2-H), 7.12 (1H, dd, J = 8.0, 7.5 Hz, C6-H), 7.05 (1H, dd, J = 8.0, 
1.0 Hz, C7-H), 6.51 (1H, dd, J = 7.5, 1.0 Hz, C5-H), 4.78 (2H, s, C10-H2), 3.87 (3H, s, C17-H3), 3.11 
(1H, tt, J = 7.0, 4.0 Hz, C15-H), 0.85 – 0.80 (2H, m, 1 × C16-H2), 0.72 – 0.66 (2H, m, 1 × C16-H2); 13C 
NMR (101 MHz, DMSO-d6): δ 163.9 (C9), 153.7 (C4), 138.5 (C11), 137.3 (C8), 129.2 (C1), 128.5, 
127.0 (C12, C13), 126.9 (C14), 124.6 (C6), 118.1 (C3), 105.3 (C7), 103.2 (C2), 99.0 (C5), 55.0 (C17), 
50.6 (C10), 31.0 (C15), 10.2 (C16); HRMS: (ESI)+ Calculated for C20H21N2O2: 321.1598. Found [M + 
H] +: 321.1595.  
N-Cyclopropyl-1H-indole-2-carboxamide (171a) 
 
General Procedure A: 1H-indole-2-carboxylic acid (322 mg, 2.00 mmol) and cyclopropanamine (116 
mg, 2.10 mmol) were employed. The crude residue was recrystallised from ethanol to afford the title 
compound 171a as an off-white solid (220 mg, 55%);  m.p.: 188–189 °C (ethanol); νmax/ cm-1: 3310 (m), 
3283 (m), 2923 (m), 1621 (s), 1538 (s), 1502 (s), 1309 (s), 1263 (s); 1H NMR (400 MHz, CDCl3): δ 
9.40 (1H, br. s, NH), 7.64 (1H, d, J = 8.0 Hz, C4-H), 7.45 (1H, d, J = 8.5 Hz, C7-H), 7.28 (1H, m, C6-
H), 7.14 (1H, dd, J = 8.0, 7.5 Hz, C5-H), 6.78 (1H, s, C2-H), 6.31 (1H, br. s, NH), 2.93 (1H, m, C10-
H), 0.80 (4H, br. m, 2 × C11-H2); 13C NMR (101 MHz, CDCl3): δ 163.2 (C9), 136.5 (C8), 130.7 (C1), 
127.8 (C3), 124.7 (C6), 122.0 (C4), 120.8 (C5), 112.2 (C7), 102.1 (C2), 23.0 (C10), 7.1 (C11); HRMS: 
(ESI)+ Calculated for C12H13N2O: 201.1022. Found [M + H] +: 201.1029. 
  







General Procedure C: In a modification to General procedure C, [Rh(cod)2]OTf (7.5 mol%) was used 
instead of [Rh(cod)OMe]2 (3.75 mol%) and the reagents were dissolved in argon sparged anhydrous 
PhCN (0.10 M). Indole 171a (20.0 mg, 0.10 mmol) was employed and the reaction mixture was heated 
at 140 °C for 72 h. The crude mixture was purified by flash column chromatography (10–35% 
EtOAc/pentane) to yield the title compound 174a (11.4 mg, 50%) as a colourless oil. νmax/ cm-1: 3268 
(br. m), 3064 (m), 2926 (m), 1716 (s), 1679 (s), 1527 (s), 1470 (s), 1348 (s), 1237 (s), 1128 (s); 1H NMR 
(400 MHz, CDCl3): δ 10.8 (1H, br. s, NH), 7.70 (1H, dd, J = 8.0, 1.0 Hz, C4-H), 7.59 (1H, s, C2-H), 
7.44 (1H, m, C7-H), 7.33 (1H, ddd, J = 8.5, 7.0, 1.0 Hz, C6-H), 7.14 (1H, ddd, J = 8.0, 7.0, 1.0 Hz, C5-
H), 4.11 – 4.03 (2H, m, C10-H2), 2.77 (2H, t, J = 8.0 Hz, C12-H2), 2.27 – 2.10 (2H, m, C11-H2); 13C 
NMR (101 MHz, CDCl3): δ 175.5 (C13), 161.3 (C9), 137.2 (C8), 129.3 (C1), 127.2 (C3), 126.1 (C6), 
122.9 (C4), 120.9 (C5), 113.7 (C2), 112.6 (C7), 48.2 (C10), 34.4 (C12), 18.1 (C11); HRMS: (ESI)+ 
Calculated for C13H12N2NaO2: 251.0791. Found [M + Na] +: 251.0796. 
N-Benzyl-N-cyclopropyl-1H-pyrrole-2-carboxamide (151k) 
 
General Procedure B: 1H-Pyrrole-2-carboxylic acid (1.10 g, 10.0 mmol) and 
N-benzylcyclopropylamine 170a (1.54 g, 10.5 mmol) were employed and the reaction was stirred at 
room temperature for 18 hours. The crude residue was purified by flash column chromatography (10% 
EtOAc/CH2Cl2) to give the title compound 151k (1.80 g, 75%) as a colourless solid; m.p.: 141–143 °C 
(ethanol); νmax/ cm-1: 3175 (br. m), 2945 (m), 1576 (s), 1440 (m), 1422 (s), 1139 (m); 1H NMR (400 
MHz, CDCl3):  δ 9.65 (1H, br. s, NH), 7.34 – 7.21 (5H, m, 2 × C8-H, 2 × C9-H and C10-H), 6.94 (1H, 
dd, J = 2.5, 1.5 Hz, C4-H), 6.88 (1H, br. m, C2-H), 6.27 (1H, dd, J = 4.0, 2.5 Hz, C3-H), 4.82 (2H, s, 
C6-H2), 2.90 (1H, tt, J = 7.0, 4.0 Hz, C11-H), 0.95 – 0.80 (4H, m, 2 × C12-H2); 13C NMR (101 MHz, 
CDCl3): 164.1 (C5), 138.5 (C7), 128.6, 127.5 (C8 and C9), 127.1 (C10), 125.6 (C1), 121.5 (C4), 114.1 
(C2), 109.8 (C3), 51.5 (C6), 31.2 (C11), 10.7 (C12); HRMS: (ESI)+ Calculated for C15H17N2O: 
241.1335. Found [M + H] +: 241.1349.  





8-Benzyl-5,6,7,8-tetrahydro-1H-pyrrolo[2,3-c]azocine-4,9-dione (152k) and (Z)-8-Benzyl-5,8-
dihydro-1H-pyrrolo[2,3-c]azocine-4,9-dione (153k) 
 
General Procedure C: In a modification to General procedure C, P(3,4,5-(F)3C6H2)3 (22.5 mol%) was 
used instead of P(4-(F)C6H4) (22.5 mol%). Pyrrole 151k (38.0 mg, 0.15 mmol) was employed and the 
reaction mixture was heated at 140 °C for 72 h. The residue was purified by flash column 
chromatography (70/20/10%, toluene/EtOAc/CH2Cl2) to afford the title compound 152k (27.8 mg, 69%) 
as an off white solid. Analysis of the crude reaction mixture by 1H NMR revealed a 8:1 (152k:153k) 
mixture of products. The minor product 153k was not isolated. 
Data for major compound 152k: m.p.: 145–148°C (CH2Cl2/hexane); νmax/ cm-1: 3217 (br. m), 3029 (m), 
1652 (m), 1601 (s), 1469 (s), 1434 (m), 1137 (m); 1H NMR (400 MHz, CDCl3): δ 10.4 (1H, br. s, NH), 
7.35 – 7.27 (5H, m, 2 × C12-H, 2 × C13-H and C14-H), 6.81 (1H, d, J = 3.0 Hz, C3-H), 6.71 (1H, d, J 
= 3.0 Hz, C4-H), 4.82 (2H, s, C10-H2), 3.60 (2H, t, J = 6.0 Hz, C6-H2), 2.76 (2H, t, J = 6.0 Hz, C8-H2), 
1.94 (2H, tt, J = 6.0, 6.0 Hz, C7-H2); 13C NMR (126 MHz, CDCl3): δ 196.1 (C9), 164.0 (C5), 137.0 
(C11) 129.0, 128.3 (C12 and C13), 128.0 (C14), 127.6, 127.4 (C1 and C2), 121.0 (C4), 110.6 (C3), 49.9 
(C10), 46.8 (C6), 38.6 (C8), 27.1 (C7); HRMS: (ESI)+ Calculated for C16H16N2NaO2: 291.1104. Found 
[M + Na] +: 291.1114.   
Data for minor compound 153k: Characteristic signals only: 1H NMR (400 MHz, CDCl3): δ 6.07 (1H, 
d, J = 7.5 Hz, C6-H), 5.63 (1H, m, C7-H). 
N-Benzyl-N-cyclopropylfuran-2-carboxamide (151l) 
 
General Procedure B: Furan-2-carboxylic acid (488 mg, 4.00 mmol) and N-benzylcyclopropylamine 
170a (618 mg, 4.20 mmol) were employed and the reaction was stirred at room temperature for 18 
hours. The crude residue was purified by flash column chromatography (20% EtOAc/hexane) to give 
the title compound 151l (610 mg, 63 %) as a colourless oil; νmax/ cm-1: 3009 (m), 1626 (s), 1475 (m), 
1401 (s), 1370 (m) 1029 (m); 1H NMR (400 MHz, CDCl3): δ 7.51 (1H, dd, J = 2.0, 1.0 Hz, C4-H), 7.40 





– 7.20 (5H, m, 2 × C8-H, 2 × C9-H and C10-H), 7.06 (1H, dd, J = 3.5, 1.0, C2-H), 6.48 (1H, dd, J = 
3.5, 2.0 Hz, C3-H), 4.77 (2H, s, C6-H2), 2.87 (1H, tt, J = 7.0, 4.0 Hz, C11-H), 0.82 – 0.62 (4H, m, 2 × 
C12-H2); 13C NMR (101 MHz, CDCl3): δ 162.1 (C5), 148.4 (C1), 144.2 (C4), 138.0 (C7), 128.7, 128.0, 
127.4 (C8, C9 and C10), 116.3 (C2), 111.3 (C3), 51.3 (C6), 31.0 (C11), 9.6 (C12); HRMS: (ESI)+ 
Calculated for C15H15NNaO2: 264.0995. Found [M + Na] +: 264.1007.  
8-Benzyl-5,6,7,8-tetrahydrofuro[2,3-c]azocine-4,9-dione (152l) and (Z)-8-Benzyl-5,8-
dihydrofuro[2,3-c]azocine-4,9-dione (153l) 
 
General Procedure C: Furan 151l (38.0 mg, 0.15 mmol) was employed and the reaction mixture was 
heated at 140 °C for 72 h. The residue was purified by flash column chromatography (10–30% 
EtOAc/petroleum ether) to afford the title compound 152l (24.9 mg, 62%) as a yellow oil. Analysis of 
the crude reaction mixture by 1H NMR revealed a 6:1 (152l:153l) mixture of products. The minor 
product 153l was not isolated.  
Data for major compound 152l: νmax/ cm-1: 2923 (m), 2854 (m), 1673 (s), 1642 (s), 1501 (m), 1401 (m), 
1176 (m); 1H NMR (400 MHz, CDCl3): δ 7.52 (1H, d, J = 2.0 Hz, C4-H), 7.39 – 7.29 (5H, m, 2 × C12-
H, 2 × C13-H and C14-H), 6.84 (1H, d, J = 2.0 Hz, C3-H), 4.81 (2H, s, C10-H2), 3.54 (2H, t, J = 6.5 
Hz, C6-H2), 2.84 – 2.66 (2H, m, C8-H2), 1.93 (2H, tt, J = 6.5, 6.5 Hz, C7-H2); 13C NMR (101 MHz, 
CDCl3): δ 194.3 (C9), 161.1 (C5), 148.2 (C1), 144.7 (C4), 136.6 (C11), 129.0, 128.9, 128.7 (C2, C12 
and C13), 128.2 (C14), 109.9 (C3), 49.1 (C10), 46.0 (C6), 38.3 (C8), 26.4 (C7); HRMS: (ESI)+ 
Calculated for C16H16N2O3: 270.1125. Found [M + H] +: 270.1125.  
Data for the minor product 153l: Characteristic signals only: 1H NMR (400 MHz, CDCl3):  δ 6.05 
(1H, dd, J = 7.5, 1.0 Hz, C6-H), 5.57 (1H, m, C7-H).  
N-Benzyl-N-cyclopropylthiophene-2-carboxamide (151m)  
 
General Procedure B: Thiophene-2-carboxylic acid (254 mg, 2.00 mmol) and 
N-benzylcyclopropylamine 170a (309 mg, 2.10 mmol) were employed and the reaction was stirred at 





room temperature for 18 hours to afford the title compound 151m (324 mg, 63 %) as a colourless oil. 
The crude material was used without further purification. νmax/ cm-1: 3005 (m), 1609 (s), 1423 (s), 1395 
(s), 1369 (m); 1H NMR (400 MHz, CDCl3): δ 7.56 (1H, dd, J = 4.0, 1.0 Hz, ArC-H), 7.42 (1H, dd, J = 
5.0, 1.0 Hz, ArC-H), 7.30 – 7.18 (5H, m, 2 × C8-H, 2 × C9-H and C10-H), 6.99 (1H, dd, J = 5.0, 4.0 
Hz, C3-H), 4.73 (2H, s, C6-H2), 2.78 (1H, tt, J = 7.0, 4.0 Hz, C11-H), 0.79 – 0.64 (4H, m, 2 × C12-H2); 
13C NMR (101 MHz, CDCl3): δ 165.5 (C5), 138.9 (C1), 138.0 (C7), 130.8 (Ar-CH), 129.9 (Ar-CH), 
128.7, 127.5, 127.4  (C8, C9 and C10) 126.9 (C3) 51.9 (C6), 31.5 (C11), 11.0 (C12); HRMS: (ESI)+ 
Calculated for C15H15NNaOS: 280.0767. Found [M + Na] +: 280.0758.   
8-Benzyl-5,6,7,8-tetrahydrothieno[2,3-c]azocine-4,9-dione (152m) and (Z)-8-Benzyl-5,8-
dihydrothieno[2,3-c]azocine-4,9-dione (153m)  
 
General Procedure C: Thiophene 151m (38.0 mg, 0.15 mmol) was employed and the reaction mixture 
was heated at 140 °C for 72 h. The residue was purified by flash column chromatography (10–30% 
EtOAc/pentane) to yield the title compound 152m (21.4 mg, 50%) as a yellow oil and minor product 
153m (4.4 mg, 10%) as a colourless oil. Analysis of the crude reaction mixture by 1H NMR revealed a 
5:1 (152m:153m) mixture of products.  
Data for major compound 152m: νmax/ cm-1: 2927 (m), 1667 (s), 1614 (s), 1513 (m), 1440 (s), 1257 (m), 
1221 (m); 1H NMR (400 MHz, CDCl3): δ 7.52 (1H, d, J = 5.5 Hz, ArC-H), 7.40 – 7.28 (6H, m, ArC-
H, 2 × C12-H, 2 × C13-H and C14-H), 4.82 (2H, s, C10-H2), 3.51 (2H, br. m, C6-H2), 2.77 (2H, br. m, 
C8-H2), 1.92 (2H, tt, J = 6.5, 6.5 Hz, C7-H2); 13C NMR (101 MHz, CDCl3): 194.6 (C9), 164.2 (C5), 
143.8 (Ar-C), 141.0 (Ar-C), 136.8 (C11), 129.0, 128.5 (C12 and C13), 128.4, 128.1, 127.9 (C3, C4 and 
C14), 49.5 (C10), 46.2 (C6), 37.5 (C8), 26.6 (C7); HRMS: (ESI)+ Calculated for C16H15NNaO2S: 
308.0716. Found [M + Na] +: 308.0707.  
Data for the minor product 153m: νmax/ cm-1: 2926 (m), 1682 (s), 1616 (s), 1514 (m), 1432 (m), 1339 
(m), 1263 (s); 1H NMR (400 MHz, CDCl3): δ 7.47 (d, J = 5.5 Hz, ArC-H), 7.42 – 7.27 (6H, m, ArC-H, 
2 × C12-H, 2 × C13-H and C14-H), 6.17 (1H, d, J = 7.5 Hz, C6-H), 5.64 (1H, d, J = 8.5 Hz, C7-H), 
5.24 (1H, d, J = 14.5 Hz, 1 × C10-H2), 4.58 (1H, d, J = 14.5 Hz, 1 × C10-H2), 3.36 (1H, m, 1H, 1 × C8-
H2), 3.06 (1H, m, 1H, 1 × C8-H2); 13C NMR (126 MHz, CDCl3): δ 190.7 (C9), 162.5 (C5), 143.9 (Ar-
C), 136.5 (Ar-C), 136.2 (Ar-C), 131.3 (C6), 128.9, 128.7 (C12 and C13), 128.5, 128.2, 127.8 (C3, C4 





and C14), 121.5 (C7), 52.1 (C10), 41.4 (C8); HRMS: (ESI)+ Calculated for C16H13NNaO2S: 306.0559. 
Found [M + Na] +: 306.0553.   
N-Benzyl-N-cyclopropyl-1-methyl-1H-pyrrole-2-carboxamide (151n) 
 
A flame-dried round-bottomed flask was charged with NaH (120 mg, 3.00 mmol, 60% dispersion in 
mineral oil) and suspended in DMF (8.0 mL) under nitrogen. The suspension was cooled to 0 °C and 
151k (600 mg, 2.50 mmol) was added portion wise over 10 minutes. The solution was stirred at 0 °C 
for 1 hour, followed by dropwise addition of iodomethane (0.19 mL, 3.00 mmol). The solution was then 
allowed to warm to room temperature and stirred for 2 hours. The reaction was quenched by the addition 
of saturated aqueous ammonium chloride solution (20 mL) and extracted with EtOAc (3 × 20 mL). The 
organic extracts were combined, washed with brine (30 mL), dried over Na2SO4, filtered and 
concentrated in vacuo. The crude residue was purified by flash column chromatography (20% 
EtOAc/hexane) to afford the title compound 151n (600 mg, 95%) as a colourless oil; νmax/ cm-1: 2935 
(m), 1617 (s), 1529 (s), 1421 (s), 1388 (s), 1368 (s), 1251 (s); 1H NMR (400 MHz, CDCl3): δ 7.38 – 
7.22 (5H, m, 2 × C8-H, 2 × C9-H, C10-H), 6.70 (1H, dd, J = 2.5, 1.5 Hz, C4-H), 6.58 (1H, dd, J = 4.0, 
1.5 Hz, C2-H), 6.08 (1H, dd, J = 4.0, 2.5Hz, C3-H), 4.77 (2H, s, C6-H2), 3.84 (3H, s, C13-H3), 2.72 
(1H, tt, J = 7.0, 4.0 Hz, C11-H), 0.79 – 0.57 (4H, m, 2 × C12-H2); 13C NMR (101 MHz, CDCl3): δ 165.5 
(C5), 138.4 (C7), 128.9, 127.8 (C8, C9), 127.3 (C10), 126.8 (C4), 126.3 (C1), 114.4 (C2), 106.9 (C3), 
51.7 (C6), 36.4 (C13), 31.3 (C11), 10.1 (C12); HRMS: (ESI)+ Calculated for C16H19N2O: 255.1491. 
Found [M + H] +: 255.1504. 
8-Benzyl-1-methyl-5,6,7,8-tetrahydro-1H-pyrrolo[2,3-c]azocine-4,9-dione (152n) and (Z)-8-
Benzyl-1-methyl-5,8-dihydro-1H-pyrrolo[2,3-c]azocine-4,9-dione (153n).  
 
General Procedure C: In a modification to General procedure C, [Rh(cod)2]OTf (7.5 mol%) was used 
instead of [Rh(cod)OMe]2 (3.75 mol%) and the reagents were dissolved in argon sparged anhydrous 
PhCN (0.10 M). Pyrrole 151n (38.6 mg, 0.15 mmol) was employed and the reaction mixture was heated 





at 140 °C for 72 h. The residue was purified by flash column chromatography (20–40% 
EtOAc/petroleum ether) to yield the title compound 152m (20.0 mg, 48%) as a colourless oil and 153n 
(10.0 mg, 24%) as a colourless oil.  
Data for major compound 152n: νmax/ cm-1: 2924 (m), 1645 (s), 1626 (s), 1490 (s), 1470 (s), 1443 (s), 
1216 (s); 1H NMR (400 MHz, CDCl3): δ 7.35 (4H, m, 2 × C12-H and 2 × C13-H), 7.30 (1H, m, C14-
H), 6.69 – 6.65 (2H, m, C3-H and C4-H), 5.31 (1H, br. m, 1 × C10-H2), 4.30 (1H, br. m, 1 × C10-H2), 
3.80 (4H, br. m, 1 × C6-H2 and C15-H3), 3.28 (1H, br. m, 1 × C6-H2), 2.68 (2H, br. m, C8-H2), 1.91 
(2H, br. m, C7-H2); 13C NMR (101 MHz, CDCl3): δ 194.5 (C9), 163.5 (C5), 137.1 (C11), 128.9, 128.6, 
128.2, 128.1 (C1, C2, C12 and C13), 127.9 (C14), 126.5 (C4), 108.6 (C3), 48.2 (C10), 45.9 (C6), 37.5 
(C8), 36.7 (C15), 26.0 (C7); HRMS: (ESI)+ Calculated for C17H19N2O2: 283.1441. Found [M + H] +: 
283.1450. 
Data for minor compound 153n: νmax/ cm-1: 2925 (m), 1667 (s), 1621 (s), 1488 (s), 1442 (s), 1428 (s), 
1243 (s), 1105 (s); 1H NMR (400 MHz, CDCl3): δ 7.41 – 7.28 (5H, m, 2 × C12-H and 2 × C13-H and 
C14-H), 6.67 (1H, d, J = 3.0 Hz, C4-H), 6.60 (2H, d, J = 3.0 Hz, C3-H), 6.10 (1H, dd, J = 7.5, 1.0 Hz, 
C6-H), 5.70 (1H, ddd, J = 10.5, 7.5, 7.0 Hz, C7-H), 5.10 (1H, d, J = 14.0 Hz, 1 × C10-H2), 4.69 (1H, d, 
J = 14.0 Hz, 1 × C10-H2), 3.72 (3H, s, C15-H3), 3.23 (1H, ddd, J = 12.5, 10.5, 1.0 Hz, 1 × C8-H2), 2.94 
(1H, dd, J = 12.5, 7.0 Hz, 1 × C8-H2); 13C NMR (126 MHz, CDCl3) δ 192.4 (C9), 161.6 (C5), 136.4 
(C11), 130.1 (C6), 129.1 (C1), 128.9, 128.7, 128.2 (C12, C13 and C14), 126.5 (C4), 124.0 (C7), 123.1 
(C2), 108.3 (C3), 51.2 (C10), 41.4 (C8), 36.7 (C15); HRMS: (ESI)+ Calculated for C17H17N2O2: 
281.1285. Found [M + H] +: 281.1281. 
N-Benzyl-N-cyclopropylbenzofuran-2-carboxamide (151o)  
 
General Procedure B: Benzofuran-2-carboxylic acid (325 mg, 2.00 mmol) and 
N-benzylcyclopropylamine 170a (309 mg, 2.10 mmol) were employed and the reaction was stirred at 
r.t. for 18 hours. The crude residue was purified by flash column chromatography (15% 
EtOAc/petroleum ether) to give the title compound 151o (500 mg, 86%) as a colourless solid; m.p.: 69–
71 °C (CH2Cl2); νmax/ cm-1: 3029 (m), 1624 (s), 1557 (s), 1434 (m), 1410 (m); 1H NMR (400 MHz, 
CDCl3): δ 7.67 (1H, m, C4-H), 7.52 (1H, m, C7-H), 7.40 (1H, dd, J = 7.0, 1.5 Hz, C6-H), 7.38 – 7.24 
(7H, m, C2-H, C5-H,  2 × C12-H, 2 × C13-H and C14-H ), 4.83 (2H, s, C10-H2), 2.97 (1H, m, C15-H), 
0.83 – 0.65 (4H, m, 2 × C16-H2); 13C NMR (101 MHz, CDCl3): δ 162.7 (C9), 154.8 (C8), 149.5 (C1), 
137.6 (C11), 128.6, 128.0, 127.4 (C12, C13 and C14) 127.1 (C3), 126.4 (C6), 123.4 (C5), 122.3 (C4), 





111.9, 111.8 (C2 and C7), 51.3 (C10), 31.0 (C15), 9.4 (C16); HRMS: (ESI)+ Calculated for C19H18NO2: 
292.1332. Found [M + H] +: 292.1339.   
2-Benzyl-2,3,4,5-tetrahydrobenzofuro[2,3-c]azocine-1,6-dione (152o) and (Z)-2-Benzyl-2,5-
dihydrobenzofuro[2,3-c]azocine-1,6-dione (153o)  
 
General Procedure C: In a modification to general procedure C, [Rh(cod)2]OTf (7.5 mol%) was used 
instead of [Rh(cod)OMe]2 (3.75 mol%) and the reagents were dissolved in argon sparged anhydrous 
PhCN (0.10 M). Benzofuran 151o (29.0 mg, 0.10 mmol) was employed and the reaction mixture was 
heated at 140 °C for 72 h. The conversion to products 152o/153o was determined by 1H NMR 
spectroscopy using 1,4-dinitrobenzene as an internal standard. This revealed 24% 152o and 8% 153o. 
An analytical sample of 152o was also isolated for characterisation by flash column chromatography 
(5–30% EtOAc/pentane). The minor product 153o was not isolated.  
Data for major compound 152o: νmax/ cm-1: 2926 (m), 1638 (s), 1551 (s), 1468 (m), 1439 (m), 1141 (m); 
1H NMR (400 MHz, CDCl3): δ 8.34 (1H, dd, J = 7.5, 1.5 Hz, C4-H), 7.54 – 7.31 (8H, m, C5-H, C6-H, 
C7-H, 2 × C16-H, 2 × C17-H and C18-H), 4.87 (2H, br. s, C14-H2), 3.62 (2H, br. m, C10-H2), 2.84 
(2H, br. m, C12-H2), 1.99 (2H, tt, J = 6.5, 6.5 Hz, C11-H2); 13C NMR (101 MHz, CDCl3): δ 195.5 (C13) 
161.6 (C9), 154.5 (C8), 150.8 (C1), 136.5 (C15), 129.08, 129.0, 128.7, 128.1 (C3, C16, C17 and C18), 
127.5 (C6), 125.4 (C5), 124.5 (C4), 122.2 (C2), 111.9 (C7), 49.1 (C14), 45.9 (C10), 38.8 (C12), 26.3 
(C11); HRMS: (ESI)+ Calculated for C20H17NNaO3: 342.1101. Found [M + Na] +: 342.1108.   
Data for the minor product 153o: Characteristic signals only: 1H NMR (400 MHz, CDCl3): δ 1H NMR 
6.17 (1H, dt, J = 7.5, 1.0 Hz, C10-H), 5.76 (1H, m, C11-H). 
N-Benzyl-N-cyclopropyl-1H-indole-3-carboxamide (178a) 
 
General Procedure A: 1H-Indole-3-carboxylic acid (500 mg, 3.10 mmol) and N-
benzylcyclopropylamine 170a (480 mg, 3.26 mmol) were employed and the reaction was stirred at 





room temperature for 4 hours. The crude residue was recrystallised from EtOH to give the title 
compound 178a (715 mg, 79%) as a white crystalline solid.  
 General Procedure A: (Multi-mmol scale reaction for material throughput). 1H-Indole-3-carboxylic 
acid (6.00g, 37.2 mmol) and N-benzylcyclopropylamine 170a (5.76 g, 39.1 mmol) were employed and 
the reaction was stirred at room temperature for 4 hours. The crude residue was recrystallised from 
MeOH to give the title compound 178a (8.01 g, 75%) as a white crystalline solid.   
Data for compound 178a: m.p.: 143–145 °C (EtOH); νmax/ cm-1: 3271 (br. m), 2982 (m), 1616 (s), 1521 
(m), 1401 (s), 1313 (m), 1280 (s); 1H NMR (400 MHz, CDCl3): δ 9.10 (1H, br. s, NH), 8.01 (1H, dd, J 
= 6.5, 3.0 Hz, C4-H), 7.40 – 7.22 (7H, m, C1-H, C7-H 2 × C12-H, 2 × C13-H and C14-H), 7.20 – 7.14 
(2H, m, C5-H and C6-H), 4.83 (2H, s, C10-H2), 2.69 (1H, tt, J = 6.5, 4.5 Hz, C15-H), 0.71 – 0.63 (4H, 
m, 2 × C16-H2); 13C NMR (101 MHz, CDCl3): δ 169.3 (C9), 138.5 (C11), 135.8 (C3), 128.7, 128.0, 
127.9 (C1, C12 and C13), 127.3 (C14), 126.7 (C8), 122.7 (C5), 121.2 (C4), 121.1 (C6), 111.8 (C2), 
111.2 (C7), 51.7 (C10), 31.0 (C15), 10.3 (C16); HRMS: (ESI)+ Calculated for C19H19N2O: 291.1491. 
Found [M + H] +: 291.1502.  
2-Benzyl-2,3,4,5-tetrahydro-1H-azocino[4,3-b]indole-1,6(7H)-dione (179a) and (Z)-2-Benzyl-2,5-
dihydro-1H-azocino[4,3-b]indole-1,6(7H)-dione (180a) 
 
General Procedure C: Indole 178a (43.5 mg, 0.15 mmol) was employed and the reaction mixture was 
heated at 130 °C for 72 h. The residue was purified by flash column chromatography (5–10% 
acetone/toluene) to yield the title compound 179a (27.7 mg, 58%) as a yellow solid and 180a (2.4 mg, 
5%) as a colourless oil. Analysis of the crude reaction mixture by 1H NMR revealed a 10:1 (179a: 180a) 
mixture of products.  
Data for major compound 179a: m.p. 209–210 °C (EtOAc/petroleum ether); νmax/ cm-1: 3299 (br. m), 
2925 (m), 1656 (s), 1605 (s), 1571 (m), 1518 (s), 1466 (s), 1452 (s), 1417 (s), 1331 (s), 1221 (m), 1147 
(m); 1H NMR (400 MHz, CDCl3): δ 9.22 (1H, br. s, NH), 8.12 (1H, d, J = 8.0 Hz, C4-H), 7.48 – 7.21 
(8H, m, C5-H, C6-H, C7-H, 2 × C16-H, 2 × C17-H and C18-H), 5.31 (1H, m, 1 × C14-H2), 4.53 (1H, 
d, J = 14.5 Hz, 1 × C14-H2), 3.82 (1H, m, 1 × C12-H2), 3.32 (1H, m, 1 × C12-H2), 3.14 (1H, m, 1 × 
C10-H2), 2.63 (1H, d, J = 12.5 Hz, 1 × C10-H2), 2.07 (1H, d, J = 12.0 Hz, 1 × C11-H2), 1.84 (1H, m, 1 
× C11-H2); 13C NMR (101 MHz, CDCl3): δ 192.1 (C9), 166.3 (C13), 137.5 (C15), 136.2 (C8), 133.5 





(C1), 128.9, 128.4, 128.3 (C3, C16 and C17), 127.9 (C6), 127.4 (C18), 123.8 (C4), 122.4 (C5), 115.2 
(C2), 112.1 (C7), 48.6 (C14), 45.8 (C12), 36.9 (C10), 26.5 (C11); HRMS: (ESI)+ Calculated for 
C20H19N2O: 319.1441. Found [M + H] +: 319.1459. The structure of this compound was determined 
unambiguously by X-ray cystrallography. 
 
Data for minor compound 180a: νmax/ cm-1: 3312 (br. m), 2923 (m), 1674 (s), 1612 (s), 1521 (s), 1454 
(s), 1386 (m), 1333 (s), 1265 (s), 1228 (s); 1H NMR (400 MHz, CDCl3):  δ 9.08 (1H, br. s, NH), 8.05 
(1H, d, J = 8.0, Hz, C4-H), 7.51 – 7.23 (8H, m, C5-H, C6-H, C7-H, 2 × C16-H, 2 × C17-H and C18-
H), 6.16 (1H, dd, J = 7.5, 1.0  Hz, C12-H), 5.64 (1H, ddd, J = 10.0, 7.5, 7.0 Hz, C11-H), 5.30 (1H, d, J 
= 14.5 Hz, 1 × C14-H2), 4.77 (1H, d, J = 14.5 Hz, 1 × C14-H2), 3.53 (1H, ddd, J = 12.5, 10.0, 1.0 Hz, 
1 × C10-H2), 3.11 (1H, dd, J = 12.5, 7.0 Hz, 1 × C10-H2); 13C NMR (126 MHz, CDCl3): δ 189.0 (C9), 
163.9 (C13), 136.8 (C15), 135.6 (C8), 131.9 (C12), 130.6 (C1), 128.7, 128.5, 128.4 (C3, C16 and C17), 
127.8 (C18), 126.9 (C6), 123.7 (C4), 122.3 (C5), 120.4 (C11), 114.6 (C2), 111.8 (C7), 51.2 (C14), 40.1 
(C10); HRMS: (ESI)+ Calculated for C20H16N2NaO: 339.1104. Found [M + Na] +: 339.1107.  
N-Benzyl-N-cyclopropylbenzo[b]thiophene-3-carboxamide (178b) 
 
General Procedure B: 1-Benzothiophene-3-carboxylic acid (356 mg, 2.00 mmol) and 
N-benzylcyclopropylamine 170a (308 mg, 2.10 mmol) were employed and the reaction was stirred at 
room temperature for 6 hours. The crude residue was purified by flash column chromatography (5% 
EtOAc/ CH2Cl2) to give the title compound 178b (343 mg, 56%) as a colourless oil; νmax/ cm-1: 2982 
(m), 1616 (s), 1417 (s), 1280 (s); 1H NMR (400 MHz, CDCl3): δ 7.90 – 7.80 (2H, m, 2 × Ar-CH), 7.60 
(1H, s, C2-H), 7.43 – 7.24 (7H, m, 7 × Ar-CH), 4.77 (2H, s, C10-H2), 2.62 (1H, tt, J = 6.5, 4.5 Hz, C15-
H), 0.62 – 0.50 (4H, m, 2 × C16-H2); 13C NMR (101 MHz, CDCl3): δ 168.1 (C9), 139.6 (ArC), 138.0 
(ArC), 137.5 (ArC), 132.7 (ArC), 128.8, 128.2, 127.6, 127.1 (2 signals), 124.9, 123.5, 122.6 (8 × Ar-
CH), 51.3 (C10), 31.1 (C15), 9.4 (C16); HRMS: (ESI)+ Calculated for C19H18NOS: 308.1103. Found 
[M + H] +: 308.1103. 





2-Benzyl-2,3,4,5-tetrahydrobenzo[4,5]thieno[3,2-c]azocine-1,6-dione (179b) and (Z)-2-Benzyl-2,5-
dihydrobenzo[4,5]thieno[3,2-c]azocine-1,6-dione (180b) 
 
General Procedure C: Benzothiophene 178b (46.1 mg, 0.15 mmol) was employed and the reaction 
mixture was heated at 130 °C for 72 h. The conversion to products 179b/180b was determined by 1H 
NMR spectroscopy using 1,4-dinitrobenzene as an internal standard. This revealed 23% 179b and 4% 
180b. The residue was purified by flash column chromatography (5–10% acetone/toluene); however, 
the product 179b could not be readily separated from the ligand, starting material and other side-
products. The structure of product 179b was determined by analysis of the 1H NMR spectrum of 
partially purified material and corroborated by COSY data and HRMS. The minor product 180b was 
not isolated. 
Data for the major product 179b: Characteristic signals only: 1H NMR (400 MHz, CDCl3): δ 5.18 (1H, 
d, J = 14.0 Hz, 1 × C14-H2), 4.73 (1H, d, J = 14.0 Hz, 1 × C14-H2), 3.67 (1H, m, 1 × C12-H2), 3.27 
(1H, m, 1 × C12-H2), 2.65 (1H, m, 1 × C10-H2); HRMS: (ESI)+ Calculated for C20H18NO2S: 336.4210. 
Found [M + H] +: 336.4208. 
Data for the minor product 180b: Characteristic signals only: 1H NMR (400 MHz, CDCl3): δ 6.17 (d, 
J = 7.5 Hz, C12-H), 5.70 (1H, dt, J = 10.0, 7.0 Hz, C11-H). 
N-Benzyl-N-cyclopropylfuran-3-carboxamide (178c) 
 
General Procedure B: Furan-3-carboxylic acid (488 mg, 4.00 mmol) and N-benzylcyclopropylamine 
170a (618 mg, 4.20 mmol) were employed to afford the title compound 178c (690 mg, 72%) as a 
colourless solid. The crude material was used without further purification. m.p.: 53–55 °C (CH2Cl2); 
νmax/ cm-1: 3010 (m), 2940 (m), 1603 (s), 1568 (m), 1414 (s), 1157 (m); 1H NMR (400 MHz, CDCl3): δ 
7.89 (1H, s, C1-H), 7.40 (1H, d, J = 1.5 Hz, C4-H), 7.36 – 7.23 (5H, m, 2 × C8-H, 2 × C9-H, C10-H), 
6.78 (1H, m, C3-H), 4.75 (2H, s, C6-H2), 2.73 (1H, tt, J = 7.0, 4.0 Hz, C11-H), 0.83 – 0.68 (4H, m, 2 × 
C12-H2); 13C NMR (101 MHz, CDCl3): δ 166.1 (C5), 145.1 (C1), 142.4 (C4), 138.2 (C7), 128.7, 127.9, 





127.4 (C8, C9 and C10), 122.5 (C2), 111.1 (C3), 51.2 (C6), 30.9 (C11), 10.5 (C12); HRMS: (ESI)+ 
Calculated for C15H15N2NaO2: 264.0995. Found [M + Na]+: 264.0995.  
5-Benzyl-5,6,7,8-tetrahydrofuro[3,2-c]azocine-4,9-dione (179c) and (Z)-5-Benzyl-5,8-
dihydrofuro[3,2-c]azocine-4,9-dione (180c) 
 
General Procedure C: Furan 178c (36.2 mg, 0.15 mmol) was employed and the reaction mixture was 
heated at 140 °C for 72 h. The residue was purified by flash column chromatography (15–20% 
EtOAc/toluene) to yield the title compound 179c (28.7 mg, 71%) as a colourless oil. Analysis of the 
crude reaction mixture by 1H NMR revealed a 10:1 (179c: 180c) mixture of products. The minor product 
180c was not isolated.  
Data for major compound 179c: νmax/ cm-1: 2923 (m), 2853 (m), 1672 (s), 1630 (s), 1492 (s), 1394 (s), 
1082 (m); 1H NMR (400 MHz, CDCl3, 20 °C): δ 7.62 (1H, d, J = 2.0 Hz, C4-H), 7.41 – 7.25 (5H, m, 2 
× C12-H, 2 × C13-H and C14-H), 6.86 (1H, d, J = 2.0 Hz, C3-H), 4.80 (2H, br. s, C10-H2), 3.48 (2H, 
br. m, C8-H2), 2.69 (2H, br. m, C6-H2), 1.88 (2H, br. m, C7-H2); 1H NMR (500 MHz, DMSO-d6, 
100 °C): δ 7.95 (d, J = 1.5, C4-H), 7.42 – 7.26 (5H, m, 2 × C12-H, 2 × C13-H and C14-H), 6.83 (1H, 
d, J = 1.5 Hz, C3-H), 4.74 (2H, s, C10-H2), 3.46 (2H, t, J = 6.5 Hz, C8-H2), 2.58 (2H, t, J = 6.5 Hz, C6-
H2), 1.85 (2H, tt, J = 6.5, 6.5 Hz, C7-H2); 13C NMR (101 MHz, CDCl3, 20 °C): δ 187.3 (C5), 164.5 
(C9), 149.0 (C1), 146.7 (C4), 136.9 (C11), 129.0, 128.5 (C12, C13), 128.1 (C14), 127.3 (C2), 114.6 
(C3), 49.1 (C10), 46.3 (C8), 36.8 (C6), 26.1 (C7); 13C NMR (126 MHz, DMSO-d6, 100 °C): δ 186.0 
(C5), 163.2 (C9), 148.1 (C1), 146.7 (C4), 137.1 (C11), 128.1, 127.6, 126.7 (C12, C13 and C14), 126.5 
(C2), 113.6 (C3), 47.8 (C10), 45.6 (C8), 36.1 (C6), 25.0 (C7); HRMS: (ESI)+ Calculated for 
C16H15NNaO3: 292.0944. Found [M + Na] +: 292.0948. A 
1H NMR spectrum was recorded at 100 °C in 
DMSO-d6 because at room temperature slow conformational interconversion gave a broad spectrum. 
Data for minor compound 180c: Characteristic signals only: 1H NMR (400 MHz, CDCl3, 20 °C): δ 
6.15 (1H, d, J = 7.5 Hz, C8-H), 5.61 (1H, ddd, J = 10.0, 7.5, 7.0 Hz, C7-H), 5.25 (1H, d, J = 14.0 Hz, 
1 × C10-H2), 4.48 (1H, d, J = 14.0 Hz, 1 × C10-H2), 3.26 (1H, dd, J = 12.5, 10.0 Hz, 1 × C6-H2), 2.98 
(1H, dd, J = 12.5, 7.0 Hz, 1 × C6-H2).  
  







General Procedure B: Thiophene-3-carboxylic acid (256 mg, 2.00 mmol) and 
N-benzylcyclopropylamine 170a (309 mg, 2.10 mmol) were employed and the reaction was stirred at 
room temperature for 18 hours. The crude residue was purified by flash column chromatography (20% 
EtOAc/ hexane) to give the title compound 178d (350 mg, 68%) as a colourless oil; νmax/ cm-1: 3086 
(m), 1618 (s), 1417 (s), 1294 (m), 1259 (m), 1028 (m); 1H NMR (400 MHz, CDCl3): δ 7.72 (1H, m, 
C4-H), 7.43 – 7.24 (7H, m, C1-H, C3-H, 2 × C8-H, 2 × C9-H and C10-H), 4.78 (2H, s, C6-H2), 2.72 
(1H, tt, J = 7.0, 4.0 Hz, C11-H), 0.74 – 0.56 (4H, m, 2 × C12-H2); 13C NMR (101 MHz, CDCl3): δ167.7 
(C5), 138.0, 137.9 (C2 and C7), 128.7, 128.0 127.9, 127.8, 127.4, (C3, C4, C8, C9 and C10), 125.0 
(C1), 51.2 (C6), 31.3 (C11), 9.9 (C12); HRMS: (ESI)+ Calculated for C15H16NOS: 258.0947. Found [M 
+ H] +: 258.0958. 
5-Benzyl-5,6,7,8-tetrahydrothieno[3,2-c]azocine-4,9-dione (179d) and (Z)-5-Benzyl-5,8-
dihydrothieno[3,2-c]azocine-4,9-dione (180d) 
 
General Procedure C: Thiophene 178d (38.6 mg, 0.15 mmol) was employed and the reaction mixture 
was heated at 140 °C for 72 h. The residue was purified by flash column chromatography (15% 
Et2O/toluene) to yield the title compound 179d (24.2 mg, 57%) as a colourless oil and 180d (3.40 mg, 
8%) as a colourless oil. Analysis of the crude reaction mixture by 1H NMR revealed a 7:1 (179d: 180d) 
mixture of products. 
Data for major compound 179d: νmax/ cm-1: 3089 (m), 2915 (m), 1675 (s), 1627 (s), 1524 (m), 1418 (s) 
1253 (m); 1H NMR (400 MHz, CDCl3): δ 7.62 (1H, d, J = 5.0 Hz, C4-H), 7.43 (1H, d, J = 5.0 Hz, C3-
H), 7.40 – 7.27 (5H, m, 2 × C12-H, 2 × C13-H and C14-H), 5.19 (1H, br. m, 1 × C10-H2), 4.46 (1H, br. 
m, 1 × C10-H2), 3.67 – 3.35 (2H, br. m, C8-H2), 3.95 – 2.61 (2H, br. m, C6-H2), 2.19 – 1.69 (2H, br. m, 
C7-H2); 13C NMR (101 MHz, CDCl3): δ 192.5 (C5), 166.0 (C9), 143.7 (C1), 138.8 (C2), 137.0 (C11), 
133.4 (C4), 132.4 (C3), 129.0 (C13), 128.5 (C12), 128.1 (C14), 48.8 (C10), 45.8 (C8), 36.9 (C7), 25.8 
(C6); HRMS: (ESI)+ Calculated for C16H16NO2S: 286.0896. Found [M + H] +: 286.0904.  





Data for minor compound 180d: νmax/ cm-1: 3085 (m), 2926 (m), 1653 (s), 1626 (s), 1517 (m), 1470 (m), 
1439 (s), 1406 (s), 1264 (m), 1227 (m), 1160 (m); 1H NMR (400 MHz, CDCl3): δ 7.56 (1H, d, J = 5.0 
Hz, C4-H), 7.42 – 7.28 (6H, m, C3-H, 2 × C12-H, 2 × C13-H and C14-H), 6.16 (1H, dd, J = 7.5, 1.0 
Hz, C8-H), 5.68 (1H, ddd, J = 10.0, 7.5, 7.0 Hz, C7-H), 5.24 (1H, d, J = 14.0 Hz, 1 × C10-H2), 4.55 
(1H, d, J = 14.0 Hz, 1 × C10-H2), 3.39 (1H, ddd, J = 12.5, 10.0, 1.0 Hz, 1 × C6-H2), 3.04 (1H, dd, J = 
12.5, 7.0 Hz, 1 × C6-H2); 13C NMR (126 MHz, CDCl3): δ 190.2 (C5), 164.6 (C9), 140.2 (C1), 138.5 
(C2), 136.3 (C11), 132.6 (C3), 131.9 (C4), 131.5 (C8), 128.9 (C13), 128.7 (C12), 128.2 (C14), 122.2 
(C7), 51.5 (C10), 40.7 (C6); HRMS: (ESI)+ Calculated for C16H14NO2S: 284.0740. Found [M + H] +: 
284.0749.  
N-Benzyl-N-cyclopropyl-1H-pyrrole-3-carboxamide (179e)  
 
General Procedure B: 1H-Pyrrole-3-carboxylic acid (444 mg, 4.00 mmol) and N-
benzylcyclopropylamine 170a (618 mg, 4.20 mmol) were employed and the reaction was stirred at 
room temperature for 18 hours. The crude residue was purified by flash column chromatography (5% 
EtOAc/ CH2Cl2) to give the title compound 178d (725 mg, 74%) as a colourless solid; m.p.: 82–84 °C 
(ethanol);  νmax/ cm-1: 3189 (br. m), 3032 (m), 1588 (s), 1538 (m), 1496 (m), 1410 (s), 1364 (m), 1200 
(m), 1080 (m); 1H NMR (400 MHz, CDCl3): δ 9.15 (1H, s, NH), 7.36 – 7.20 (6H, m, C1-H, 2 × C8-H, 
2 × C9-H and C10-H), 6.67 (1H, m, C4-H), 6.61 (1H, m, C3-H), 4.79 (2H, s, C6-H2), 2.79 (1H, tt, J = 
7.0, 4.0 Hz, C11-H), 0.81 – 0.64 (4H, m, 2 × C12-H2); 13C NMR (101 MHz, CDCl3): δ 169.0 (C5), 
138.8 (C7), 128.6, 127.7 (C8 and C9), 127.1 (C10), 122.8 (C1), 119.5 (C2), 117.9 (C4), 109.9 (C3), 
51.5 (C6), 31.3 (C11), 10.4 (C12); HRMS: (ESI)+ Calculated for C15H17N2O: 241.1335. Found [M + H] 
+: 241.1343. 
5-Benzyl-5,6,7,8-tetrahydro-1H-pyrrolo[3,2-c]azocine-4,9-dione (179e) and (Z)-5-Benzyl-5,8-
dihydro-1H-pyrrolo[3,2-c]azocine-4,9-dione (180e)  
 
General Procedure C: Pyrrole 178e (36.0 mg, 0.15 mmol) was employed and the reaction mixture was 
heated at 130 °C for 72 h. The residue was purified by flash column chromatography (50% 





EtOAc/hexane) to yield the title compound 179e (28.9 mg, 72%) as a colourless solid. Analysis of the 
crude reaction mixture by 1H NMR revealed a 10:1 (179e:180e) mixture of products. The minor product 
180e was not isolated. 
Data for major compound 179e: m.p.: 176–179 °C (CH2Cl2/hexane); νmax/ cm-1: 3246 (br. m), 2934 (m), 
1638, (s) 1591 (s), 1541 (s), 1495 (s), 1461 (s), 1402 (s), 1117 (s); 1H NMR (400 MHz, CDCl3): δ 9.52 
(1H, br. s, NH), 7.40 – 7.28 (5H, m, 2 × C12-H, 2 × C13-H and C14-H), 7.01 (1H, dd, J = 3.0, 3.0  Hz, 
C4-H), 6.72 (1H, dd, J = 3.0, 3.0 Hz, C3-H), 5.07 (1H, br. m, 1 × C10-H2), 4.50 (1H, br. m, 1 × C10-
H2), 3.80 (1H, br. m, 1 × C8-H2), 3.30 (1H, br. m, 1 × C8-H2), 2.92 (1H, br. m, 1 × C6-H2), 2.50 (1H, 
br. m, 1 × C6-H2), 1.95 (1H, br. m, 1 × C7-H2), 1.79 (1H, br. m, 1 × C7-H2); 1H NMR (500 MHz, 
DMSO-d6, 100 °C): δ 11.72 (1H, br. s, NH), 7.38 – 7.26 (5H, m, 2 × C12-H, 2 × C13-H and C14-H), 
7.05 (1H, d, J = 2.5 Hz, C4-H), 6.46 (1H, d, J = 2.5 Hz, C3-H), 4.73 (2H, s, C10-H2), 3.44 (2H, t, J = 
6.5 Hz, C8-H2), 2.56 (2H, t, J = 6.5 Hz, C6-H2), 1.83 (2H, tt, J = 6.5, 6.5 Hz, C7-H2); 13C NMR (101 
MHz, CDCl3, 20 °C): δ 189.7 (C5), 167.1 (C9), 137.6 (C11), 130.5 (C1), 128.9, 128.4, 127.8 (C12, C13 
and C14), 124.2 (C2), 123.8 (C4), 114.4 (C3), 48.8 (C10), 46.1 (C8), 36.5 (C6), 26.2 (C7). HRMS: 
(ESI)+ Calculated for C16H16N2NaO: 291.1104. Found [M + Na] +: 292.1110. A 
1H NMR spectrum was 
recorded at 100 °C in DMSO-d6 because at room temperature slow conformational interconversion 
gave a broad spectrum. The structure of this compound was determined unambiguously by X-ray 
cystrallography. 
 
Data for minor compound 180e: Characteristic signals only: 1H NMR (400 MHz, CDCl3, 20 °C): δ 
6.12 (1H, d, J = 7.5 Hz, C8-H), 5.62 (1H, dt, J = 10.0, 7.5 Hz, C7-H). 
Benzyl(cyclopropyl)carbamic chloride (299a) 
 
Pyridine (0.97 mL, 12.0 mmol) was added dropwise over 10 minutes to a solution of triphosgene (1.08 g, 
3.60 mmol) in toluene (33 mL) at 0 °C. To the resulting suspension was added a solution of 
N-benzylcyclopropanamine 170a (1.47 g, 10.0 mmol) in toluene (5 mL) and the reaction was warmed 





to room temperature. After 2 hours, the reaction mixture was quenched with saturated aqueous NaHCO3 
(30 mL) and extracted with Et2O (2 × 40 mL). The organic layers were combined and washed with 
0.2 M aqueous HCl (30 mL), H2O (30 mL), brine (30 mL), dried over Na2SO4 and concentrated in 
vacuo to give the title compound 299a (1.98 g, 95%) as a yellow oil. The crude material was used 
without further purification. νmax/ cm-1: 3092 (m), 3063 (m), 1454, (s) 1375 (s), 1232 (s), 1199 (s); 1H 
NMR (400 MHz, CDCl3): δ 7.43 – 7.21 (5H, m, 2 × C4-H, 2 × C5-H and C6-H), 4.60 (2H, s, C2-H2), 
2.74 – 2.57 (1H, m, C7-H), 0.87 (4H, m, 2 × C8-H2); 13C NMR (101 MHz, CDCl3): δ 152.4 (C1), 136.2 
(C3), 128.8, 127.9, 127.7 (C4, C5 and C6), 53.7 (C2), 32.5 (C7), 10.0 (C8). The spectroscopic 
properties of this compound were consistent with the data available in literature.343  
N-Benzyl-N-cyclopropyl-6-isopropyl-1H-indole-3-carboxamide (178f) 
 
To a suspension of 6-isopropyl-1H-indole (212 mg, 1.33 mmol) and AlCl3 (214 mg, 1.61 mmol) in 
CH2Cl2 (15 mL) at 0 °C was added a solution of benzyl(cyclopropyl)carbamic chloride 299a (460 mg, 
1.61 mmol) in CH2Cl2 (10 mL). The resulting solution was stirred at 0 °C for 4 hours and then warmed 
to room temperature. The reaction mixture was quenched by addition of H2O (40 mL) and extracted 
with CH2Cl2 (3 × 30 mL). The organic layers were combined, washed with brine (30 mL), dried over 
Na2SO4, and concentrated in vacuo. The crude material was recrystallised from MeOH to afford the 
title compound 178f (264 mg, 60%) as a white crystalline solid; m.p.: 192–195 °C (MeOH); νmax/ cm-1: 
3192 (br. m), 2957 (m), 1592 (s), 1566 (m), 1529 (m), 1435 (s), 1368 (m); 1H NMR (400 MHz, CDCl3): 
δ 9.13 (1H, br. s, NH), 7.94 (1H, d, J = 8.5 Hz, C4-H), 7.36 (1H, d, J = 3.0 Hz, C1-H), 7.34 – 7.21 (5H, 
m, 2 × C12-H, 2 × C13-H and C14-H), 7.14 – 7.06 (2H, m, C5-H and C7-H), 4.83 (2H, s, C10-H2), 
2.95 (1H, hept, J = 7.0 Hz, C17-H), 2.68 (1H, tt, J = 6.0, 5.0 Hz, C15-H), 1.26 (6H, d, J = 7.0 Hz, 2 × 
C18-H3), 0.71 – 0.60 (4H, m, 2 × C16-H2); 13C NMR (101 MHz, CDCl3): δ 169.1 (C9), 144.1 (C6), 
138.7 (C11), 136.1 (C8), 128.7, 127.9, 127.4, 127.2 (C1, C12, C13 and C14), 125.1 (C3), 121.2 (C4), 
120.7 (C5), 111.7 (C2), 108.7 (C7), 51.7 (C10), 34.3 (C17), 30.8 (C15), 24.5 (C18), 10.2 (C16); HRMS: 
(ESI)+ Calculated for C22H24N2O: 333.1961. Found [M + H] +: 333.1962. 
  





2-Benzyl-9-isopropyl-2,3,4,5-tetrahydro-1H-azocino[4,3-b]indole-1,6(7H)-dione (179f) and (Z)-2-
Benzyl-9-isopropyl-2,5-dihydro-1H-azocino[4,3-b]indole-1,6(7H)-dione (180f) 
 
General Procedure C: Indole 178f (33.2 mg, 0.10 mmol) was employed and the reaction mixture was 
heated at 130 °C for 72 h. The residue was purified by flash column chromatography (5–10% 
acetone/toluene) to yield the title compound 179f (18.3 mg, 51%) as a yellow solid and 180f (1.70 mg, 
5%) as a colourless oil. Analysis of the crude reaction mixture by 1H NMR revealed a 10:1 (179f:180f) 
mixture of products.  
Data for major compound 179f: m.p.: 205–208 °C (EtOAc/petroleum ether); νmax/ cm-1: 3248 (br. s), 
2950 (m), 2925 (m), 1656 (s), 1607 (s), 1524 (s), 1457 (s), 1416 (s), 1212 (m), 1122 (m); 1H NMR (400 
MHz, CDCl3): δ 9.29 (1H, br. s, NH), 8.04 (1H, d, J = 8.5 Hz, C4-H), 7.46 – 7.25 (6H, m, C7-H, 2 × 
C16-H, 2 × C17-H and C18-H), 7.20 (1H, d, J = 8.5 Hz, C5-H), 5.37 (1H, d, J = 14.5 Hz, 1 × C14-H2), 
4.50 (1H, d, J = 14.5 Hz, 1 × C14-H2), 3.82 (1H, m, 1 × C12-H2), 3.30 (1H, m, 1 × C12-H2), 3.17 – 3.01 
(2H, m, 1 × C10-H2 and C19-H), 2.63 (1H, d, J = 12.5 Hz, 1 × C10-H2), 2.08 (1H, m, 1 × C11-H2), 1.86 
(1H, m, 1 × C11-H2), 1.32 (6H, d, J = 7.0 Hz, 2 × C20-H3); 13C NMR (101 MHz, CDCl3): δ 191.9 (C9) 
166.5 (C13), 149.2 (C6), 137.5 (C15), 136.7 (C8), 133.3 (C1), 128.9, 128.3, 127.8 (C16, C17 and C18), 
126.5 (C3), 123.5 (C4), 122.4 (C5), 115.2 (C2), 108.8 (C7), 48.4 (C14), 45.7 (C12), 36.8 (C10), 34.7 
(C19), 26.4 (C11), 24.2 (C20); HRMS: (ESI)+ Calculated for C23H24N2O: 361.1911. Found [M + H] +: 
361.1913.  
Data for minor compound 180f: νmax/ cm-1: 3297 (br. m), 2951 (m), 2926 (m), 1672 (s), 1622 (s), 1523 
(s), 1384 (s), 1265 (s), 1229 (s); 1H NMR (500 MHz, CDCl3): δ 8.99 (1H, br. s, NH), 7.94 (1H, d, J = 
8.5 Hz, C4-H), 7.43 – 7.40 (2H, m, 2 × C16-H), 7.37 – 7.33 (2H, m, 2 × C17-H), 7.31 (1H, m, C18-H), 
7.22 (1H, d, J = 1.5 Hz, C7-H), 7.17 (1H, dd, J = 8.5, 1.5 Hz, C5-H), 6.13 (1H, d, J = 7.5 Hz, C12-H), 
5.62 (1H, ddd, J = 10.0, 7.5, 6.5 Hz, C11-H), 5.25 (1H, d, J = 14.5 Hz, 1 × C14-H2), 4.81 (1H, d, J = 
14.5 Hz, 1 × C14-H2), 3.53 (1H, dd, J = 12.5, 10.0 Hz, 1 × C10-H2), 3.09 (1H, dd, J = 12.5, 6.5 Hz, 1 
× C10-H2), 3.02 (1H, hept, J = 7.0 Hz, C19-H), 1.30 (6H, d, J = 7.0 Hz, 2 × C20-H3); 13C NMR (126 
MHz, CDCl3) 5δ 189.0 (C9), 164.2 (C13), 148.9 (C6), 136.9 (C15), 136.3 (C8), 131.9 (C12), 130.5 
(C1), 128.9 (C16), 128.5 (C17), 127.9 (C18), 126.9 (C3), 123.5 (C4), 122.4 (C5), 120.6 (C11), 114.8 
(C2), 108.7 (C7), 51.3 (C14), 40.2 (C10), 34.5 (C19), 24.25 (C20); HRMS: (ESI)+ Calculated for 
C23H22N2O: 359.1754. Found [M + H] +: 359.1755. 





Methyl-1H-pyrrole-3-carboxylic acid (185) 
 
To a stirred solution of ethyl 2-methyl-pyrrole-3-carboxylate (1.00 g, 6.50 mmol) in 1,4-dioxane (10.0 
mL) and water (5.0 mL) was added lithium hydroxide monohydrate (0.50 g, 12.0 mmol). The reaction 
mixture was heated at reflux for 4 hours and then cooled to room temperature. The mixture was acidified 
to pH 2 with 2 M aqueous HCl and then extracted into EtOAc (2 × 30 mL). The organic extracts were 
combined, washed with H2O (30 mL), brine (20 mL), dried over Na2SO4, filtered and concentrated in 
vacuo to afford the title compound 185 as an off-white solid (800 mg, 98%); 1H NMR (400 MHz, 
DMSO-d6): δ 11.49 (1H, br. s, COOH), 11.07 (1H, br. s, NH), 6.56 (1H, m, C4-H), 6.28 (1H, dd, J = 
2.5, 2.5 Hz, C3-H), 2.39 (3H, s, C5-H3); 13C NMR (101 MHz, CDCl3): δ 166.4 (C6), 134.4 (C4), 115.7 
(C1), 110.4 (C3), 109.7 (C2) 12.5 (C5). The spectroscopic properties of this compound are in agreement 
with the literature.344 
N-Benzyl-N-cyclopropyl-2-methyl-1H-pyrrole-3-carboxamide (186a) 
 
General Procedure B: 2-Methyl-1H-pyrrole-3-carboxylic acid 185 (375 mg, 3.00 mmol) and 
N-benzylcyclopropylamine 170a (485 mg, 3.30 mmol) were employed and the reaction was stirred at 
room temperature for 4 hours. The crude residue was purified by flash column chromatography (30% 
EtOAc/CH2Cl2) to give the title compound 186a (305 mg, 40%) as a colourless oil; νmax/ cm-1: 3240 (br. 
m), 2924 (m), 1598 (s), 1494 (s), 1401 (s), 1368 (s); 1H NMR (400 MHz, CDCl3): δ 9.04 (1H, br. s, 
NH), 7.37 – 7.19 (5H, m, 2 × C8-H, 2 × C9-H and C10-H ), 6.45 (1H, dd, J = 3.5, 3.0 Hz, C4-H), 6.30 
(1H, tt, J = 3.5, 3.0 Hz, C3-H), 4.75 (2H, s, C6-H2), 2.65 (1H, tt, J = 7.0, 3.5 Hz, C11-H), 2.31 (3H, s, 
C13-H3), 0.72 – 0.56 (4H, m, 2 × C12-H2); 13C NMR (101 MHz, CDCl3): δ 170.6 (C5), 138.7 (C7), 
132.4 (C1), 128.6, 127.8, 127.1 (C8, C9 and C10), 115.3, 115.2 (C2 and C4), 109.1 (C3), 51.6 (C6), 
30.8 (C11), 12.7 (C13), 9.7 (C12); HRMS: (ESI)+ Calculated for C16H18N2NaO: 277.1311. Found [M 
+ Na]+: 277.1314. 
  





5-Benzyl-3-methyl-5,6,7,8-tetrahydro-2H-pyrrolo[3,4-c]azocine-4,9-dione (187a) and (Z)-5-
Benzyl-3-methyl-5,8-dihydro-2H-pyrrolo[3,4-c]azocine-4,9-dione (188a) 
 
General Procedure C: In a modification to general procedure C, [Rh(cod)OMe]2 (3.75 mol%), P(4-
(F)C6H4)3 (22.5 mol%) and 2-nitrobenzoic acid (150 mol%) were dissolved in argon sparged anhydrous 
PhCN (0.10 M). Pyrrole 186a (38.1 mg, 0.15 mmol) was employed and the reaction mixture was heated 
at 130 °C for 72 h. The residue was purified by flash column chromatography (20–70% EtOAc/toluene) 
to yield the title compound 187a (10.5 mg, 25%) as an off white solid and the title compound 188b 
(5.04 mg, 12%) as a colourless oil.  
Alternatively, a two-step reaction sequence was more effective for the conversion of pyrrole 186a to 
187a.  
 
An oven dried reaction tube, fitted with a magnetic stirrer, was charged with [Rh(cod)OMe]2 (2.72 mg, 
5.62 µmol), P(4-(F)C6H4)3 (10.6 mg, 33.7 µmol), 1-adamantanecarboxylic acid (40.5 mg, 0.225 mmol) 
and amide substrate 186a (38.1 mg, 0.15 mmol). The tube was fitted with a rubber septum and purged 
with argon. The reagents were dissolved in argon sparged anhydrous PhCN (0.50 mL). The reaction 
vessel was purged with CO for 10 minutes and the solution was subsequently sparged with CO for 
approximately 20 seconds, then heated at 130 °C under a CO atmosphere for 72 h. The mixture was 
cooled to room temperature, filtered through a short plug of silica and concentrated in vacuo. To the 
residue was added xantphos (17.4 mg, 30 μmol) and [Rh(cod)2]BARF (8.9 mg, 7.5 μmol), followed by 
the addition of anhydrous mesitylene (2.0 mL). The resulting suspension was sparged with hydrogen 
for approximately 60 seconds and then heated under a hydrogen atmosphere (1 atm) at 120 °C for 3 h. 
The mixture was cooled to room temperature and concentrated in vacuo. The residue was purified by 
flash column chromatography (90% EtOAc/hexane) to yield the title compound 187a (25.4 mg, 58%) 
as an off white solid.   
Data for compound 187a: m.p.: 177–180 °C (CH2Cl2/hexane); νmax/ cm-1: 3209 (br. m), 2926 (m), 1646 
(m), 1601 (s) 1514 (s), 1445 (s), 1119 (m); 1H NMR (400 MHz, CDCl3): δ 9.68 (1H, br. s, NH), 7.35 – 





7.27 (6H, m, C4-H, 2 × C12-H, 2 × C13-H, C14-H), 5.27 (1H, br. m, 1 × C10-H2), 4.31 (1H, br. m, 1 × 
C10-H2), 3.73 (1H, br. m, 1 × C6-H2), 3.21 (1H, br. m, 1 × C6-H2), 2.85 (1H, br. m, 1 × C8-H2), 2.36 
(4H, br. m, 1 × C8-H2 and C15-H3), 2.04 (2H, br. m, C7-H2); 1H NMR (500 MHz, DMSO-d6, 100 °C): 
δ 11.48 (1H, br. s, NH), 7.34 – 7.14 (6H, m, C4-H, 2 × C12-H, 2 × C13-H and C14-H), 4.70 (2H, s, 
C10-H2), 3.40 (2H, br. m, C6-H2), 2.46 (2H, br. m, C8-H2), 2.29 (3H, s, C15-H3), 1.84 – 1.74 (2H, m, 
C7-H2); 13C NMR (126 MHz, CDCl3, 20 °C): δ 196.5 (C9), 168.0 (C5), 137.6 (C11), 134.7 (C1), 128.8, 
128.1 (C12 and C13), 127.7 (C14), 125.9 (C3), 121.7 (C4), 114.3 (C2), 48.2 (C10), 45.4 (C6), 37.7 
(C8), 25.5 (C7), 12.7 (C15); 13C NMR (126 MHz, DMSO-d6, 100 °C) δ 194.0 (C9), 166.4 (C5), 138.0 
(C11), 133.1 (C1), 127.8, 127.3, 126.5 (C12, C13 and C14), 124.5 (C3), 120.4 (C4), 113.6 (C2), 46.9 
(C10), 44.6 (C6), 36.8 (C8), 24.5 (C7), 11.4 (C15); HRMS: (ESI)+ Calculated for C17H18N2NaO2: 
305.1265. Found [M + Na] +: 305.1260. A 1H NMR spectrum was recorded at 100 °C in DMSO-d6 
because at room temperature slow conformational interconversion gave a broad spectrum.  The signals 
for C6-H2, C7-H2 and C8-H2, coalesced at 100 °C but they were not resolved. 
Data for compound 188a: νmax/ cm-1: 3176 (br. m), 1659 (s), 1624 (s), 1578 (s), 1514 (s), 1448 (s), 1122 
(s); 1H NMR (400 MHz, CDCl3): δ 9.22 (1H, br. s, NH), 7.37 – 7.27 (6H, m, C4-H, 2 × C12-H, 2 × 
C13-H, C14-H), 6.08 (1H, d, J = 7.0 Hz, C6-H), 5.59 (1H, m, C7-H), 5.06 (1H, d, J = 14.5 Hz, 1 × C10-
H2), 4.65 (1H, d, J = 14.5 Hz, 1 × C10-H2), 3.36 (1H, m, 1 × C8-H2), 2.87 (dd, J = 12.0, 6.5 Hz, 1 × 
C8-H2), 2.35 (3H, s, C15-H3); 13C NMR (101 MHz, CDCl3): δ 193.1 (C9), 166.2 (C5), 136.9 (C11), 
133.7 (C1), 131.3 (C6), 128.8, 128.5, 127.8, (C12, C13 and C14), 122.2 (C7), 121.6 (C3), 121.2 (C4), 
115.1 (C2), 51.0 (C10), 41.9 (C8), 12.8 (C15); HRMS: (ESI)+ Calculated for C17H16N2NaO2: 303.1104. 
Found [M + Na] +: 303.1106.  
The use of Pd/C and H2 (1 atm) was also effective for the conversion of enamide 188a to 187a.  
 
To a solution of enamide 188a (28.0 mg, 0.10 mmol) in MeOH (5 mL) was added 20% Pd/C (5.6 mg, 
20 wt.%). The reaction flask was evacuated and backfilled with H2 three times and then stirred at room 
temperature with the hydrogen balloon attached. The reaction mixture was monitored by TLC analysis 
and upon completion (~ 2 hours), the reaction was filtered through Celite® and concentrated in vacuo. 
Purification by flash column chromatography (90%EtOAc/hexane) afforded the title compound 187a 
(25.0 mg, 89%) as an off white solid.  
  







General Procedure B: In a modification to general procedure B, Et3N (1.27 mL, 9.20 mmol) was used 
instead of DMAP. 2-Methyl-1H-pyrrole-3-carboxylic acid 185 (575 mg, 4.60 mmol) and N-
methylcyclopropanamine hydrochloride (596 mg, 5.57 mmol) (prepared according to the literature 
procedure345) were employed and the reaction was stirred at room temperature for 16 hours. The residue 
was purified by flash column chromatography (10–90% EtOAc/hexane) to afford the title compound 
186b (344 mg, 42%) as a colourless oil; νmax/ cm-1: 3223 (br. s), 2929 (m), 1590 (s), 1491 (s), 1384 (s), 
1358 (s); 1H NMR (400 MHz, CDCl3): δ 9.04 (1H, br. s, NH), 6.45 (1H, t, J = 2.5 Hz, ArC-H), 6.27 (t, 
J = 2.5 Hz, ArC-H), 3.03 (3H, s, C7-H3), 2.83 (1H, tt, J = 7.0, 4.0 Hz, C8-H), 2.26 (3H, s, C13-H3), 
0.88 – 0.48 (4H, m, 2 × C9-H2); 13C NMR (101 MHz, CDCl3): δ 170.5 (C5), 132.2 (ArC), 115.3, 115.02, 
109.6 (Ar-CH), 32.4 (C8), 12.6, (2 signals, C7 and C13), 9.0 (C9); HRMS: (ESI)+ Calculated for 




General Procedure C: In a modification to General procedure C 1-adamantanecarboxylic acid (50 
mol%) was used instead of 2-NO2C6H4COOH (150 mol%). Pyrrole 186b (26.5 mg, 0.15 mmol) was 
employed and the reaction mixture was heated at 130 °C for 72 h. The conversion to products 
187b/188b was determined by 1H NMR spectroscopy using 1,4-dinitrobenzene as an internal standard. 
This revealed 28% 187b and 26% 188b. Products 187b/188b were not isolated. The structural 
assignment of 187b/188b was determined by comparison to analogous products.  
Data for product 187b: Characteristic signals only: 1H NMR (400 MHz, CDCl3): 3.87 (1H, m, 1 × C3-
H2), 1.80 (1H, m, 1 × C1-H2). 
Data for product 188b: Characteristic signals only: 1H NMR (400 MHz, CDCl3): δ 6.06 (1H, d, J = 7.5 
Hz, C3-H), 5.56 (1H, dt, J = 10.0, 7.5 Hz, C2-H). 
  







General Procedure B: Benzoic acid (244 mg, 2.00 mmol) and N-benzylcyclopropylamine 170a (309 
mg, 2.10 mmol) were employed and the reaction was stirred at r.t. for 18 hours. The crude residue was 
purified by flash column chromatography (20% EtOAc/hexane) to give the title compound 189 (388 
mg, 78%) as a colourless oil; νmax/ cm-1: 3027 (m), 1632 (s), 1446 (s), 1401 (s), 1371 (s); 1H NMR (400 
MHz, CDCl3): δ 7.58 – 7.46 (2H, m, 2 × C3-H), 7.43 – 7.32 (6H, m, 6 × ArC-H), 7.29 (2H, m, 2 × ACr-
H), 4.75 (2H, s, C6-H2), 2.59 (1H, tt, J = 7.0, 4.0 Hz, C11-H), 0.55 – 0.49 (4H, m, 2 × C12-H2); 13C 
NMR (101 MHz, CDCl3): δ 172.2 (C5), 138.0, 137.5 (C4 and C7), 129.7, 128.7, 128.3 (2 signals), 
127.4, 127.3 (6 × Ar-CH), 51.0 (C6), 31.8 (C11), 10.0 (C12); HRMS: (ESI)+ Calculated for C17H18NO: 
252.1383. Found [M + H] +: 252.1385. 
N-benzyl-N-cyclopropyl-2-naphthamide (190) 
 
General Procedure B: 2-Naphthoic acid (172 mg, 1.00 mmol) and N-benzylcyclopropylamine 170a 
(154 mg, 1.05 mmol) were employed and the reaction was stirred at r.t. for 18 hours. The crude residue 
was purified by flash column chromatography (20% EtOAc/hexane) to give the title compound 190 
(255 mg, 84%) as a white solid; νmax/ cm-1: 3027 (m), 1630 (s), 1446 (s), 1401 (s), 1371 (s); 1H NMR 
(400 MHz, CDCl3): δ 8.01 (1H, s, ArC-H), 7.90 – 7.82 (3H, m, 3 × ArC-H), 7.62 (1H, d, J = 8.0 Hz, 
ArC-H), 7.57 – 7.49 (2H, m, 2 × ArC-H), 7.46 – 7.29 (5H, m, 5 × ArC-H), 4.81 (2H, s, C2-H2), 2.69 
(1H, tt, J = 7.0, 3.0 Hz, C3-H), 0.52 (4H, br. m, 2 × C4-H2); 13C NMR (101 MHz, CDCl3): δ 172.9 (C1), 
134.8 (ArC), 134.8 (ArC), 134.7 (ArC), 132.7 (ArC), 128.8 (2 signals), 128.6, 128.2, 127.9, 127.5, 
127.3, 127.1, 126.6, 124.7 (10 × Ar-CH), 50.9 (C2), 30.9 (C3), 10.3 (C4); HRMS: (ESI)+ Calculated 
for C21H20NO: 303.1534. Found [M + H] +: 303.1535. 
N-benzyl-N-cyclopropyl-1H-imidazole-4-carboxamide (191) 
 





To a suspension of 1H-imidazole-4-carboxylic acid (297 mg, 2.20 mmol) in DMF (7 mL) was added 
HOBt (297 mg, 2.20 mmol) and Et3N (0.86 mL, 6.20 mmol). The reaction mixture was stirred at room 
temperature for 30 minutes and then a solution of N-benzylcyclopropylamine 170a (294mg, 2.00 mmol) 
in DMF (0.5 mL) was added. The resulting solution was stirred at room temperature for 18 hours and 
then CH2Cl2 (15 mL) was added. The solution was washed with water (3 × 50 mL), brine (30 mL), dried 
over Na2SO4 and concentrated in vacuo. The residue was purified by flash column chromatography (50% 
EtOAc/hexane) to afford the title compound 191 (226 mg, 47%) as a white solid; m.p.: 101–103 ℃; 
νmax/ cm-1: 3125 (br. s), 1605 (s), 1437 (s), 1409 (s); 1H NMR (400 MHz, CDCl3): δ 11.8 (1H, br. s. 
NH), 7.66 (1H, s, ArC-H ), 7.49 (1H, s, ArC-H), 7.30 – 7.20 (5H, m, 5 × ArC-H), 4.79 (2H, s, C2-H2), 
2.91 (1H, m, C3-H), 1.08 – 0.68 (4H, m, 2 × C4-H2); 13C NMR (101 MHz, CDCl3): δ 163.7 (C1), 137.9 
(Ar-C) 137.2 (Ar-CH), 131.74 (ArC), 128.6, 127.3, 127.2 (3 × Ar-CH), 51.7 (C2), 31.1 (C3), 10.5 (C4); 
HRMS: (ESI)+ Calculated for C14H17N3O: 241.1215. Found [M + H] +: 241.1211. 
(1S*,2S*)-N-Benzyl-2-methylcyclopropan-1-amine (trans-200a) and (1S*,2R*)-N-Benzyl-2-
methylcyclopropan-1-amine (cis-200a)  
 
General procedure E: N-Boc amine 199a was synthesised by G.-W. Wang. Boc-protected amine 199a 
(2.29 g, 9.27 mmol) was employed and the residue was purified by flash column chromatography (0–30% 
EtOAc/hexane) to afford the title compound trans-200a (1.45 g, 80%) as a colourless oil and the cis-
diastereomer cis-200a (250 mg, 13%) as colourless oils. 
Data for trans-200a: 1H NMR (400 MHz, CDCl3): δ 7.38 – 7.22 (5H, m, 2 × C7-H, 2 × C8-H and C9-
H), 3.85 – 3.78 (2H, m, C5-H2), 1.85 – 1.78 (2H, m, C4-H and NH), 0.98 (3H, d, J = 6.0 Hz, C1-H3), 
0.75 (1H, m, C2-H), 0.55 (1H, m, 1 × C3-H2), 0.21 (1H, ddd, J = 6.5, 5.0, 5.0 Hz, 1 × C3-H2); 13C NMR 
(101 MHz, CDCl3): δ 140.7 (C6), 128.5, 128.4 (C7 and C8), 127.0 (C9), 53.9 (C5), 38.4 (C4), 17.6 
(C1), 14.9 (C3), 14.7 (C2). The spectroscopic properties of this compound were consistent with the data 
available in the literature.16   
Data for cis-200a: 1H NMR (400 MHz, CDCl3): δ 7.37 – 7.22 (5H, m, 2 × C7-H, 2 × C8-H and C9-H), 
3.85 – 3.78 (2H, m, C5-H2), 2.15 (1H, ddd, J = 7.0, 7.0, 4.0 Hz, C4-H), 1.61 (1H, br. s, NH), 1.15 (3H, 
d, J = 6.0 Hz, C1-H3), 0.76 (1H, m, C2-H), 0.63 (1H, ddd, J = 9.0, 7.0, 4.5 Hz, C3-H2), 0.05 (1H, ddd, 
J = 6.0, 4.5, 4.0 Hz, C3-H2); 13C NMR (101 MHz, CDCl3): δ 141.1 (C6), 128.5, 128.4 (C7 and C8), 
126.9 (C9), 54.3 (C5), 34.6 (C2), 13.2 (C3), 12.0 (2 signals, C1 and C2). The spectroscopic properties 
of this compound were consistent with the data available in the literature.16  
N-Benzyl-N-((1S*, 2S*)-2-methylcyclopropyl)-1H-indole-2-carboxamide (trans-201a)  






General Procedure B: 1H-Indole-2-carboxylic acid (1.61 g, 10 mmol) and (1S*,2S*)-N-benzyl-2-
methylcyclopropan-1-amine trans-200a (1.61 g, 10 mmol) were employed and the reaction was stirred 
at room temperature for 18 hours. The crude residue was purified by flash column chromatography 
(5-10% Et2O/toluene) to give the title compound trans-200a (2.44 g, 80%) as a colourless solid; m.p.: 
164–165 °C (ethanol); νmax/ cm-1: 3264 (br. m), 1602 (s), 1520 (s), 1434 (s), 1402 (s), 1348 (s), 1278 
(s); 1H NMR (400 MHz, CDCl3): δ 9.70 (1H, br. s, NH), 7.66 (1H, dd, J = 8.0, 1.0 Hz, C4-H), 7.43 – 
7.23 (7H, m, C6-H, C7-H, 2 × C12-H, 2 × C13-H and C14-H), 7.20 – 7.05 (2H, m, C2-H and C5-H), 
4.95 (1H, d, J = 15.0 Hz, 1 × C10-H2), 4.83 (1H, d, J = 15.0 Hz, 1 × C10-H2), 2.67 (1H, ddd, J = 7.0, 
4.0, 3.5 Hz, C15-H), 1.15 (1H, m, C17-H), 1.05 (3H, d, J = 6.0 Hz, C18-H3), 0.95 (1H, ddd, J = 9.5, 
5.5, 4.0 Hz, 1 × C16-H2), 0.72 (1H, m, 1 × C16-H2); 13C NMR (101 MHz, CDCl3): δ 164.7 (C9), 138.0 
(C11), 135.8 (C8), 130.3 (C1), 128.8 (C13), 127.9 (C3), 127.8, 127.4 (C12 and C14), 124.7 (C6), 122.2 
(C4), 120.4 (C5), 111.9 (C7), 107.2 (C2), 51.6 (C10), 38.8 (C15), 18.6, 18.0 (C16 and C17), 17.5 (C18); 
HRMS: (ESI)+ Calculated for C20H20N2NaO: 327.1467. Found [M + Na] +: 327.1479. 
N-Benzyl-1-methyl-N-((1S*, 2S*)-2-methylcyclopropyl)-1H-indole-2-carboxamide (trans-202a) 
 
To a suspension of NaH (150 mg, 6.25 mmol, 60% dispersion in oil) in DMF (10.0 mL) at 0 °C was 
added indole trans-200a (950 mg, 3.13 mmol). After 15 minutes, iodomethane (0.23 mL, 3.75 mmol) 
was added dropwise over 10 minutes. The solution was then warmed to room temperature and stirred 
for 6 hours. The reaction was quenched by the addition of saturated aqueous ammonium chloride 
solution (50 mL) and extracted with EtOAc (3 × 30 mL). The organic extracts were combined, washed 
with H2O (50 mL), brine (50 mL), dried over Na2SO4, and concentrated in vacuo. The crude residue 
was purified by flash column chromatography (20% EtOAc/hexane) to give the title compound 
trans-202a (900 mg, 90%) as a yellow solid; m.p. 78–80 °C (EtOAc/ hexane); νmax/ cm-1: 2926 (m), 
1632 (s), 1465 (s), 1408 (s), 1261 (s), 736 (s); 1H NMR (400 MHz, CDCl3): δ 7.63 (1H, d, J = 8.0 Hz, 
C4-H), 7.45 – 7.25 (7H, m, C6-H, C7-H, 2 × C12-H, 2 × C13-H and C14-H), 7.14 (1H, m, C5-H), 6.76 
(1H, s, C2-H), 4.96 (1H, d, J = 14.5 Hz, 1 × C10-H2), 4.63 (1H, d, J = 14.5 Hz, 1 × C10-H2), 3.88 (3H, 





s, C19-H3), 2.42 (1H, ddd, J = 7.0, 3.5, 3.5 Hz, C15-H), 0.99 – 0.69 (5H, m, 1 × C16-H2, C17-H, C18-
H3), 0.47 (1H, m, 1 × C16-H2); 13C NMR (101 MHz, CDCl3): δ 166.0 (C9), 138.1 (C8), 137.8 (C11), 
133.1 (C1), 128.8, 128.1, 127.5 (C12, C13 and C14), 126.6 (C3), 123.4 (C6), 121.7 (C4), 120.2 (C5), 
109.9 (C7), 104.7 (C2), 51.1 (C10), 38.8 (C15), 31.4 (C19), 18.1 (C17), 17.0, 16.9 (C18 and C16); 
HRMS: (ESI)+ Calculated for C21H22N2NaO: 341.1624. Found [M + Na] +: 341.1639. 
2-Benzyl-4,11-dimethyl-2,3,4,5-tetrahydro-1H-azocino[3,4-b]indole-1,6(11H)-dione (208a) and 
(Z)-2-Benzyl-4,11-dimethyl-2,5-dihydro-1H-azocino[3,4-b]indole-1,6(11H)-dione (205a) 
 
General Procedure F: Compound trans-202a (31.8 mg, 0.10 mmol), fumaric acid (11.6 mg, 0.10 
mmol) and anhydrous benzonitrile (0.10 mL) were employed and the reaction mixture was heated at 
140 °C for 72 hours. The crude mixture was purified by flash column chromatography (20% 
EtOAc/hexane then 10% toluene/hexane) to yield the title compound 208a and compound 205a (21.2 
mg, 61%) as a colourless solid. 1H NMR analysis revealed a 14:1 ratio of 208a: 205a. The minor product 
205a was not isolated.  
Data for major product 208a: m.p.: 128–130 °C (EtOAc/hexane); νmax/ cm-1: 2959 (m), 1718 (s), 1636 
(s), 1506 (s), 1467 (s), 1389 (s); 1H NMR (500 MHz, CDCl3): δ 8.59 (1H, dd, J = 8.0, 1.0 Hz, C4-H), 
7.42 – 7.30 (8H, m, C5-H, C6-H, C7-H, 2 × C12-H, 2 × C13-H and C14-H), 5.44 (1H, d, J = 14.5 Hz, 
1 × C14-H2), 4.37 (1H, d, J = 14.5 Hz, 1 × C14-H2), 3.90 (3H, s, C20-H3), 3.53 (1H, m, 1 × C10-H2), 
3.23 – 3.14 (2H, m, 1 × C10-H2 and 1 × C12-H2), 2.49 – 2.29 (2H, m, C11-H and 1 × C12-H2), 0.94 
(3H, d, J = 7.0 Hz, C19-H3); 13C NMR (126 MHz, CDCl3): δ 192.9 (C13), 163.6 (C9), 137.7 (C8), 
136.8, 136.7 (C1 and C15), 129.0, 128.2, 128.1 (C16, C17 and C18), 125.4 (C3), 124.9 (C6), 124.1 
(C4), 123.7 (C5), 117.8 (C2), 110.0 (C7), 52.4 (C10), 48.7 (C14), 44.4 (C12), 32.2 (C20), 31.2 (C11), 
16.1 (C19); HRMS: (ESI)+ Calculated for C22H23N2O2: 347.1754. Found [M + H] +: 347.1753. 
Data for minor product 205a: Characteristic signals only: 1H NMR (400 MHz, CDCl3): 5.89 (1H, s, 
C10-H), 5.20 (1H, d, J = 14.0 Hz, 1 × C14-H2), 4.78 (1H, d, J = 14.0 Hz, 1 × C14-H2), 3.67 (1H, d, J = 
12.0 Hz, 1 × C12-H2), 2.86 (1H, d, J = 12.0 Hz, 1 × C12-H2), 1.70 (3H, d, J = 1.5 Hz, 1 × C19-H3)  
  





Ethyl (1S*, 2S*)-2-butylcyclopropane-1-carboxylate (197b) 
 
To a flame-dried screw-top reaction vessel, fitted with a rubber septum under an atmosphere of nitrogen 
was added anhydrous 1,2-dimethoxyethane (100 mL) and triethylphosphonacetate (11.8 mL, 59.0 
mmol). The reaction vessel placed in an ice bath and n-BuLi (24.5 mL, 61.0 mmol, 2.5 M in hexanes) 
was added dropwise over 10 minutes. 2-Butyloxirane (3.61 mL, 30.0 mmol) was then added. The 
reaction vessel was sealed and heated at 130 °C for 16 hours. The reaction mixture was cooled to room 
temperature and saturated aqueous NH4Cl (125 mL) was added. The reaction mixture was transferred 
to a separating funnel with Et2O (75 mL) and the layers were separated. The aqueous layer was further 
extracted with Et2O (3 × 100 mL). The organic layers were combined, washed with H2O (100 mL), 
brine (100 mL), dried over Na2SO4 and concentrated in vacuo. The residue was purified by flash column 
chromatography (5% EtOAc/hexane) to afford the title compound 197b (4.15 g, 80%) as a colourless 
oil; 1H NMR (400 MHz, CDCl3): δ 4.11 (2H, q, J = 7.0 Hz, C9-H2), 1.43 – 1.28 (8H, m, C2-H2, C3-H2, 
C4-H2, C5-H, C7-H), 1.25 (3H, t, J = 7.0 Hz, C10-H3) 1.14 (1H, m, 1 × C6-H2), 0.89 (3H, t, J = 7.0 Hz, 
C1-H3), 0.67 (1H, ddd, J = 8.0, 6.0, 4.0 Hz, 1 × C6-H2); 13C NMR (101 MHz, CDCl3): δ 174.5 (C8), 
60.1 (C9), 32.6 (C4), 31.1 (C3), 22.7 (C5), 22.2 (C2), 20.1 (C7), 15.4 (C6), 14.1 (C10), 13.9 (C1). The 
spectroscopic properties of this compound were consistent with the data available in the literature.2  
(1S*, 2S*)-2-Butylcyclopropane-1-carboxylic acid (198b) 
 
General Procedure D: Ester 197b (4.10 g, 24.1 mmol) was employed to yield the title carboxylic acid 
198b (2.57 g, 75%) as a colourless oil; 1H NMR (400 MHz, CDCl3): δ 1.34 (8H, m, C2-H2, C3-H2, C4-
H2, C5-H and C7-H), 1.22 (1H, m, C6-H2), 0.89 (3H, t, J = 7.0 Hz, C1-H3), 0.77 (1H, ddd, J = 8.0, 6.5, 
4.0 Hz, C6-H2); 13C NMR (101 MHz, CDCl3): δ 181.1 (C8), 32.9 (C4), 31.3 (C3), 24.2 (C5), 22.5 (C2), 
20.2 (C7), 16.6 (C6), 14.2 (C1). The spectroscopic properties of this compound were consistent with 
the data available in the literature.16  
tert-Butyl ((1S*, 2S*)-2-butylcyclopropyl)carbamate (199b) 
 





To a solution of carboxylic acid 198b (2.82 g, 19.8 mmol) and Et3N (3.03 mL, 21.8 mmol) in anhydrous 
t-BuOH (25 mL) was added diphenylphosphoryl azide (4.65 mL, 21.8 mmol) dropwise over 10 minutes. 
The reaction was heated at 80 ℃ for 36 hours, after which time the reaction mixture was cooled to room 
temperature and concentrated in vacuo. Et2O (50 mL) and saturated aqueous NaHCO3 (150 mL) was 
added and the aqueous portion was extracted with Et2O (3 × 75 mL). The organic extracts were 
combined, washed with water (75 mL), brine (75 mL), dried over Na2SO4 and concentrated in vacuo. 
The residue was purified by flash column chromatography (5% EtOAc/toluene) to afford the title 
compound 199b (3.35 g, 79%) as a colourless oil; 1H NMR (400 MHz, CDCl3): δ 4.65 (1H, br. s, NH), 
2.23 (1H, m, C7-H), 1.43 (9H, s, 3 × C10-H3), 1.39 – 1.33 (5H, m, C2-H2, C3-H2 and 1 × C4-H2), 1.12 
(1H, m, 1 × C4-H2), 0.89 (3H, t, J = 7.5 Hz, C1-H3), 0.80 (1H, m, C5-H), 0.59 (1H, m, 1 × C6-H2), 0.47 
(1H, m, 1 × C6-H2); 13C NMR (101 MHz, CDCl3): 156.6 (C8), 79.4 (C9), 32.2 (C4), 31.3 (C3), 29.5 
(C7), 28.6 (C10), 22.6 (C2), 20.8 (C5), 14.2 (C6), 13.9 (C1). The spectroscopic properties of this 
compound were consistent with the data available in the literature.16    
(1S*, 2S*)-N-Benzyl-2-butylcyclopropan-1-amine (trans-200b) 
 
General procedure E: Boc-protected amine 199b (2.29 g, 9.27 mmol) was employed and the residue 
was purified by flash column chromatography (20% EtOAC/toluene) to yield the title compound 
trans-200b (1.52 g, 81%) as a colourless oil; 1H NMR (400 MHz, CDCl3): δ 7.33 – 7.17 (5H, m, 2 × 
C10-H, 2 × C11-H and C12-H), 3.77 (2H, s, C8-H2), 1.82 (1H, ddd, J = 6.5, 3.5, 3.5 Hz, C7-H), 1.68 
(1H, br. s, NH), 1.36 – 1.21 (4H, m, C2-H2 and C3-H2), 1.16 – 1.04  (2H, m, C4-H2), 0.88 (3H, t, J = 
7.0 Hz, C1-H3), 0.71 (1H, m, C5-H), 0.49 (1H, ddd, J = 9.0, 4.5, 3.5 Hz, 1 × C6-H2), 0.20 (1H, ddd, J 
= 6.5, 5.5, 4.5 Hz, 1 × C6-H2); 13C NMR (101 MHz, CDCl3): δ 140.6 (C9), 128.3, 128.2, 126.8 (C10, 
C11 and C12), 53.7 (C8), 37.4 (C7), 32.3 (C4), 31.6 (C3), 22.5 (C2), 20.7 (C5), 14.1 (C1), 13.6 (C6). 
The spectroscopic properties of this compound were consistent with the data available in the 
literature.16  
N-Benzyl-N-((1R*, 2R*)-2-butylcyclopropyl)-1H-indole-2-carboxamide (trans-201b) 
 





General Procedure B: 1H-Indole-2-carboxylic acid (531 mg, 3.30 mmol) and amine trans-200b (704 
mg, 3.47 mmol) were employed and the reaction was stirred at r.t. for 18 hours. The crude residue was 
purified by flash column chromatography (10% EtOAc/toluene) to give the title compound trans-201b  
(808 mg, 66%) as a colourless solid; m.p.: 141-143 °C (ethanol); νmax / cm-1: 3266 (br. s), 2921 (m), 
1605 (s), 1521 (m), 1402 (m), 1278 (s); 1H NMR (400 MHz, CDCl3):  δ 9.76 (1H, br. s, NH), 7.66 (1H, 
d, J = 8.0 Hz, C4-H), 7.42 – 7.22 (7H, m, C6-H, C7-H, 2 × C12-H, 2 × C13-H and C14-H), 7.20 – 7.06 
(2H, m, C2-H and C5-H), 5.09 (1H, d, J = 15.0 Hz, 1 × C10-H2), 4.74 (1H, d, J = 15.0 Hz, 1 × C10-
H2), 2.77 (1H, ddd, J = 7.0, 3.5, 3.5 Hz, C15-H), 1.45 (1H, m, 1 × C18-H2), 1.34 – 1.22 (4H, m, C19-
H2 and C20-H2), 1.21 – 1.04 (2H, m, C17-H and 1 × C18-H2), 0.95 (1H, m, 1 × C16-H2), 0.85 (3H, t, J 
= 7.0 Hz, C21-H3), 0.79 (1H, m, 1 × C16-H2); 13C NMR (101 MHz, CDCl3): δ 164.8 (C9), 138.1 (C11), 
135.8 (C8), 130.3 (C1), 128.8, 128.0, 127.5, 127.3 (C3, C12, C13, C14), 124.7 (C6), 122.2 (C4), 120.4 
(C5), 111.9 (C7), 107.2 (C2), 51.8 (C10), 38.0 (C15), 32.3 (C18), 31.0 (C20), 23.1 (C17), 22.6 (C19), 




To a suspension of NaH (73 mg, 3.02 mmol, 60% dispersion in oil) in DMF (10 mL) at 0 °C was added 
amide trans-201b (525 mg, 1.52 mmol). After 15 minutes, iodomethane (0.11 mL, 1.67 mmol) was 
added in dropwise over 5 minutes. The solution warmed to room temperature and stirred for 4 hours. 
The reaction was quenched by the addition of saturated aqueous ammonium chloride solution (50 mL) 
and extracted with EtOAc (3 × 20 mL). The organic extracts were combined, washed with H2O (50 mL), 
brine (50 mL), dried over Na2SO4 and concentrated in vacuo. The crude residue was purified by flash 
column chromatography (20% EtOAc/hexane) to give the title compound trans-202b (500 mg, 91%) 
as a yellow oil; νmax/ cm-1: 2924 (m), 1630 (s), 1520 (m), 1464 (s), 1407 (s); 1H NMR (400 MHz, CDCl3): 
δ 7.61 (1H, dd, J = 8.0, 1.0 Hz, C4-H), 7.39 – 7.26 (7H, m, C6-H, C7-H, 2 × C12-H, 2 × C13-H, and 
C14-H), 7.12 (1H, ddd, J = 8.0, 7.0, 1.0 Hz, C5-H), 6.74 (1H, s, C2-H), 4.79 (2H, s, C10-H2), 3.86 (3H, 
s, C22-H3), 2.50 (1H, dt, J = 7.1, 3.6 Hz, C15-H), 1.20 – 0.98 (m, 5H, C17-H, C18-H2 and C19-H2), 
0.98 – 0.69 (2H, m, C20-H2), 0.81 – 0.69 (4H, m, 1 × C16-H2 and C21-H3), 0.50 (1H, m, 1 × C16-H2); 
13C NMR (101 MHz, CDCl3): δ 166.2 (C9), 138.1, 137.9 (C8 and C11), 133.2 (C2), 128.8, 127.9, 127.5 
(C12, C13 and C14), 126.6 (C3), 123.4 (C6), 121.7 (C4), 120.2 (C5), 109.9 (C7), 104.6 (C2), 51.5 





(C10), 37.9 (C15), 31.8 (C18), 31.4 (C22), 30.8 (C19), 23.2 (C17), 22.4 (C20), 16.3 (C16), 14.0 (C21); 
HRMS: (ESI)+ Calculated for C24H29N2O: 361.2274. Found [M + H] +: 361.2268.  
(Z)-2-Benzyl-4-butyl-11-methyl-2,5-dihydro-1H-azocino[3,4-b]indole-1,6(11H)-dione (205b) 
 
An oven dried reaction tube, fitted with a magnetic stirrer, was charged with [Rh(cod)2]OTf (3.51 mg, 
7.5 µmol), P(4-(F)C6H4)3 (7.11 mg, 22.5 µmol), 2-NO2C6H4CO2H (25.1 mg, 0.15 mmol) and indole 
trans-202b (36.1 mg, 0.10 mmol). The tube was fitted with a rubber septum and purged with argon. 
The reagents were dissolved in argon sparged anhydrous PhCN (1.0 mL). The reaction vessel was 
purged with CO for 10 minutes and the solution was subsequently sparged with CO for approximately 
20 seconds. The reaction mixture was heated at 140 °C under a CO atmosphere for 72 h. The reaction 
mixture was cooled to room temperature and concentrated in vacuo. The crude residue was purified by 
flash column chromatography (10–20% EtOAc/pentane) to yield the title compound 205b (5.51 mg, 
14%) as a colourless oil; νmax/ cm-1: 2955 (m), 1634 (br. s), 1504 (s), 1465 (s), 1386 (s), 1252 (s); 1H 
NMR (400 MHz, CDCl3): δ 8.41 (1H, dd J = 8.0, 1.0 Hz, C4-H), 7.44 – 7.31 (m, 8H, C5-H, C6-H, C7-
H, 2 × C16-H, 2 × C17-H and C18-H), 5.81 (1H, s, C10-H), 5.19 (1H, d, J = 14.0 Hz, 1 × C14-H2), 4.66 
(d, J = 14.0 Hz, 1 × C14-H2), 3.83 (3H, s, C23-H3), 3.44 (1H, dd, J = 12.5, 1.0 Hz, 1 × C12-H2), 2.85 
(d, J = 12.5 Hz, 1 × C12-H2), 2.01 (2H, td, J = 7.5, 1.0 Hz, C19-H2), 1.36 – 1.23 (2H, m, C20-H2), 1.18 
– 1.05 (2H, m, C21-H2), 0.79 (3H, t, J = 7.5, C22-H3); 13C NMR (101 MHz, CDCl3) δ 193.9 (C13), 
161.9 (C9), 140.4 (C11), 137.6, 137.5 (C1 and C8), 136.1 (C15), 129.0, 128.9, 128.2 (C16, C17 and 
C18), 125.2 (C3), 124.8 (C6), 123.4, 123.3, 123.3 (C4, C5 and C10), 112.3 (C2), 109.8 (C7), 51.4 
(C14), 45.9 (C12), 33.7 (C19), 32.2 (C23), 29.1 (C20), 22.2 (C21), 13.8 (C22); HRMS: (ESI)+ 
Calculated for C25H27N2O2: 387.2067. Found [M + H] +: 387.2076. 
  






and (Z)-2-Benzyl-4-butyl-11-methyl-2,5-dihydro-1H-azocino[3,4-b]indole-1,6(11H)-dione (205b)  
 
General Procedure F: Indole trans-202b (36.1 mg, 0.10 mmol), fumaric acid (11.6 mg, 0.10 mmol) 
and anhydrous benzonitrile (0.10 mL) were employed, the reaction mixture was heated at 140 °C for 
120 hours. The crude mixture was purified by flash column chromatography (10–15 % Et2O/toluene) 
to yield the title compound 205b and the title compound 208b (18.8 mg, 50%). The major product 208b 
was isolated as a colourless oil. The minor product 205b was isolated as a colourless oil. The 
spectroscopic properties of 205b was consistent with the data previously reported in this thesis. 
Data for major compound 205b: νmax/ cm-1: 2924 (m), 1633 (br. s), 1505 (s), 1466 (s), 1389 (s); 1H NMR 
(400 MHz, CDCl3): δ 8.58 (dd, J = 7.5, 1.0 Hz, C4-H), 7.45 – 7.28 (8H, m, C5-H, C6-H, C7-H, 2 × 
C16-H, 2 × C17-H, and C18-H), 5.43 (1H, d, J = 14.5 Hz, 1 × C14-H2), 4.36 (1H, d, J = 14.5 Hz, 1 × 
C14-H2), 3.90 (3H, s, C23-H3), 3.53 (1H, m, 1 × C10-H2), 3.25 (1H, dd, J = 14.5, 5.0 Hz, 1 × C10-H2), 
3.09 (1H, dd, J = 13.0, 4.5 Hz, 1 × C12-H2), 2.56 (1H, dd, J = 13.0, 4.0 Hz, 1 × C12-H2), 2.18 (1H, m, 
C11-H), 1.44 – 1.03 (6H, m, C19-H2, C20-H2 and C21-H2), 0.87 (3H, t, J = 7.0 Hz, C22-H3); 13C NMR 
(101 MHz, CDCl3): δ 193.1 (C13), 163.6 (C9), 137.7 (C8), 136.8, 136.7 (C1 and C15), 129.1, 128.3, 
128.2 (C16, C17 and C18), 125.4 (C3), 125.0 (C6), 124.1 (C4), 123.7 (C5), 117.9 (C2), 110.0 (C7), 
51.4 (C10), 48.7 (C14), 42.3 (C12), 36.5 (C11), 32.3 (C23), 30.5 (C19), 29.4 (C20), 22.7 (C21), 14.1 
(C22); HRMS: (ESI)+ Calculated for C25H28N2O2: 389.2224. Found [M + H] +: 389.2224. 
 N,1-Dibenzyl-N-((1S*,2S*)-2-butylcyclopropyl)-1H-indole-2-carboxamide (trans-203) 
 
To a suspension of NaH (14 mg, 0.35 mmol, 60% dispersion in oil) in DMF (3 mL) at 0 °C was added 
amide trans-201b (100 mg, 0.29 mmol). After 15 minutes, benzyl bromide (55 mg, 0.32 mmol) was 





added in one portion. The solution was then allowed to warm to room temperature and stirred for 1 hour. 
The reaction was quenched by the addition of saturated aqueous ammonium chloride solution (15 mL) 
and extracted with EtOAc (3 × 10 mL). The organic extracts were combined, washed with brine (15mL), 
dried over Na2SO4, filtered and concentrated in vacuo. The crude residue was purified by flash column 
chromatography (20% EtOAc/hexane) to give the title compound trans-203 (75 mg, 60%) as a yellow 
oil; νmax/ cm-1: 2922 (m), 1630 (s), 1526 (s), 1453 (s), 1419 (s); 1H NMR (400 MHz, CDCl3): δ 7.63 
(1H, dd, J = 8.0, 1.0 Hz, C4-H), 7.42 (1H, m, C7-H), 7.35 – 7.06 (12H, m, C5-H, C6-H, 2 × C12-H, 2 
× C13-H, C14-H, 2 × C24-H, 2 × C25-H and C26-H), 6.81 (1H, s, C2-H), 5.65 (2H, s, C22-H2), 4.72 
(1H, d, J = 14.5 Hz, 1 × C10-H2), 4.69 (1H, d, J = 14.5Hz, 1 × C10-H2), 2.41 (m, 1H, C15-H), 1.17 – 
1.00 (m, 5H, C17-H, C18-H2 and C19-H2), 0.78 – 0.71 (4H, m, 1 × C20-H2 and C21-H3), 0.56 (1H, m, 
1 × C20-H2), 0.41 – 0.30 (2H, m, C16-H2); 13C NMR (126 MHz, CDCl3): δ 165.9 (C9), 138.5, 138.0, 
137.9 (C8, C11, C23), 132.4 (C1), 128.7, 128.5, 127.8, 127.5, 127.3, 127.2 (C12, C13, C14, C24, C25 
and C26), 126.6 (C3), 123.8 (C6), 121.8 (C4), 120.4 (C5), 110.4 (C7), 106.1 (C2), 51.2 (C10), 47.5 
(C22), 38.1 (C15), 31.7 (C18), 30.8 (C19), 22.8 (C17), 22.4 (C20), 15.9 (C16), 14.0 (C21); HRMS: 
(ESI)+ Calculated for C30H33N2O: 437.2587. Found [M + H] +: 437.2580. 
(Z)-2,11-Dibenzyl-4-butyl-2,5-dihydro-1H-azocino[3,4-b]indole-1,6(11H)-dione (206) 
 
An oven dried reaction tube, fitted with a magnetic stirrer, was charged with [Rh(cod)2]OTf (2.63 mg, 
5.63 µmol), P(4-(F)C6H4)3 (5.33 mg, 16.8 µmol), 2-NO2C6H4CO2H (18.8 mg, 0.113 mmol) and indole 
trans-203 (33.1 mg, 0.075 mmol). The tube was fitted with a rubber septum and purged with argon. 
The reagents were dissolved in argon sparged anhydrous PhCN (1.0 mL). The reaction vessel was 
purged with CO for 10 minutes and the solution was subsequently sparged with CO for approximately 
20 seconds. The reaction mixture was heated at 140 °C under a CO atmosphere for 72 h. The mixture 
was cooled to room temperature and concentrated in vacuo. The crude residue was purified by flash 
column chromatography (10–20% EtOAc/pentane) to yield the title compound 206 (5.51 mg, 9%) as a 
yellow oil; νmax/ cm-1: 3010 (m), 2956 (m), 1634 (br. s), 1506 (s), 1496 (s), 1453 (s), 1253 (s); 1H NMR 
(400 MHz, CDCl3): δ 8.46 – 8.40 (1H, m, C4-H), 7.40 – 7.16 (13H, m, C5-H, C6-H, C7-H and 10 × 
ArC-H), 5.55 (2H, m, C19-H2), 5.43 (1H, s, C10-H), 5.04 (1H, d, J = 14.0 Hz, 1 × C18-H2), 4.22 (1H, 
d, J = 14.0 Hz, 1 × C18-H2), 3.42 (1H, d, J = 13.0 Hz, 1 × C12-H2), 2.83 (1H, d, J = 13.0 Hz, 1 × C12-
H2), 2.00 – 1.94 (2H, m, C14-H2), 1.31 – 1.21 (2H, m, C15-H2), 1.07 – 1.00 (2H, m, C16-H2), 0.74 (3H, 
t, J = 7.5 Hz, C17-H3); 13C NMR (126 MHz, CDCl3) δ 194.2 (C13), 161.9 (C9), 140.4 (C11), 137.3 





(ArC), 137.2 (ArC), 137.1 (ArC), 135.6 (ArC), 129.2, 128.8, 128.7, 128.6 (4 × Ar-CH), 128.5, 127.9 (2 
× Ar-CH), 126.7, 126.6 (C3 and C6) 123.2, 123.1, 123.0 (C4, C5 and C10), 112.8 (C2), 104.6 (C7), 
51.0 (C18), 48.1 (C19), 46.0 (C12), 33.6 (C14), 28.9 (C15), 21.9 (C16), 13.6 (C17); HRMS: (ESI)+ 
Calculated for C31H31N2O2: 463.2307. Found [M + H] +: 463.2314.  
N,1-Dibenzyl-N-((1S*,2S*)-2-butylcyclopropyl)-1H-indole-2-carboxamide (trans-204) 
 
To a suspension of NaH (14 mg, 0.35 mmol, 60% dispersion in oil) in DMF (3 mL) at 0 °C was added 
indole trans-201b (100 mg, 0.29 mmol). After 15 minutes, p-toluenesulfonyl chloride (60 mg, 0.32 
mmol) was added in one portion. The solution was then allowed to warm to room temperature and 
stirred for 4 hours. The reaction was quenched by the addition of saturated aqueous ammonium chloride 
solution (15 mL) and extracted with EtOAc (3 × 10 mL). The organic extracts were combined, washed 
with brine (5mL/mmol), dried over Na2SO4, filtered and concentrated in vacuo. The crude residue was 
purified by flash column chromatography (5% Et2O/toluene) to give the title compound trans-204 (110 
mg, 77%) as a yellow oil; νmax/ cm-1: 2925 (m), 1644 (s), 1449 (s), 1407 (s), 1371 (s), 1175 (s);  1H NMR 
(500 MHz, CDCl3): δ 8.10 – 7.95 (3H, m, C7-H and 2 × C23-H), 7.49 (1H, dd, J = 8.0, 1.0 Hz, 1H, C4-
H), 7.43 – 7.28 (6H, m, C6-H and 5 × Ar-CH), 7.22 (3H, m, C5-H and 2 × Ar-CH), 6.68 (1H, s, C2-H), 
5.06 – 4.30 (2H, m, C10-H2), 2.48 (1H, m, C15-H), 2.33 (3H, s, C26-H3), 1.34 – 0.80 (8H, m, 1 × C16-
H2, C17-H, C18-H2, C19-H2, C20-H2), 0.63 (3H, t, J = 7.0 Hz, C21-H3), 0.33 (1H, dt, J = 7.0, 6.0 Hz, 1 
× C16-H2); 13C NMR (126 MHz, CDCl3): δ 165.7 (C9), 145.1 (C25), 137.8 (C22), 135.5 (C1), 135.2 
(C8), 134.8 (C11), 129.6 (Ar-CH), 129.3 (C3), 128.5 (Ar-CH), 128.1 (Ar-CH), 127.9 (Ar-CH), 127.2 
(C14), 125.3 (C6), 123.8 (C5), 121.5 (C4), 114.4 (C7), 109.8 (C2), 50.9 (C10), 38.2 (C15), 31.5 (C18), 
30.3 (C19), 22.2 (C20), 21.6 (C26), 14.8 (C16), 14.1 (C17), 13.7 (C21); HRMS: (ESI)+ Calculated for 
C30H33N2O3S: 501.2206. Found [M + H] +: 501.2195. 
2-Benzyloxirane (196c) 
 





To a solution of allylbenzene (10.0 mL, 150 mmol) in CH2Cl2 (150 mL) at 0 °C was added 3-
chlorobenzoic acid (22.2 g, 90 mmol, 70% w/w) portion-wise over 10 minutes. The solution was 
warmed to room temperature and stirred for 16 hours. Saturated aqueous NaHCO3 (150 mL) and CH2Cl2 
(150 mL) were added and the organic layer was separated. The organic extracts were washed with 
saturated aqueous NaHCO3 (2 × 150 mL), water (150 mL), dried over Na2SO4 and concentrated in 
vacuo to afford the title compound 196c (11.7 g, 97 %) as a colourless oil. 1H NMR (400 MHz, CDCl3): 
δ 7.37 – 7.23 (5H, m, C1-H, 2 × C2-H and 2 × C3-H), 3.17 (1H, dddd, J = 5.5, 5.5, 4.0, 2.5 Hz, C6-H), 
2.94 (1H, dd, J = 14.5, 5.5 Hz, 1 × C5-H2), 2.85 (1H, d, J = 14.5, 5.5 Hz, 1 × C5-H2), 2.81 (1H, dd, J = 
5.0, 4.0 Hz, 1 × C7-H2), 2.56 (1H, dd, J = 5.0, 2.5 Hz, 1 × C7-H2); 13C NMR (101 MHz, CDCl3): δ 
137.2 (C4), 129.0, 128.8, 126.7 (C1, C2 and C3), 52.4 (C6), 46.8 (C7), 38.7 (C3). The spectroscopic 
properties of this compound were consistent with the data available in the literature.16  
(1S*,2R*)-Ethyl 2-benzylcyclopropane-1-carboxylate (197c 
 
To a solution of triethylphosphonoacetate (9.92 mL, 50.0 mmol) in anhydrous DME (100 mL) was 
added n-BuLi (20.0 mL, 50.0 mmol, 2.5 M in hexanes) dropwise over 15 minutes. The resulting solution 
was stirred at room temperature for 10 minutes, followed by the addition of 2-benzyloxirane 196c (3.35 
g, 25.0 mmol). The tube was sealed, and the reaction was stirred at 130 °C for 16 hours. The reaction 
was cooled to room temperature and saturated aqueous NH4Cl (125 mL) was added. The solution was 
extracted with Et2O (3 × 100 mL). The organic layers were combined, washed with H2O (100 mL), 
brine (100 mL), dried over Na2SO4 and concentrated in vacuo. The residue was purified by flash column 
chromatography (5% EtOAc/petroleum ether) to afford the title compound 197c (4.15 g, 80%) as a 
colourless oil; 1H NMR (400 MHz, CDCl3): δ 7.33 – 7.20 (5H, m, C1-H, 2 × C2-H and 2 × C3-H), 4.12 
(2H, q, J = 7.0 Hz, C10-H2), 2.77 (1H, dd, J = 15.0, 6.5 Hz, 1 × C5-H2), 2.58 (1H, dd, J = 15.0, 7.0 Hz, 
1 × C5-H2), 1.70 (1H, m, C6-H), 1.52 (1H, m, C8-H), 1.30 – 1.20 (4H, m, 1 × C7-H and C11-H3), 0.83 
(1H, m, 1 × C7-H2); 13C NMR (101 MHz, CDCl3) δ 174.1 (C9), 140.1 (C4), 128.4 (2 signals) (C2 and 
C3), 126.2 (C1), 60.4 (C10), 38.5 (C5), 23.0 (C6), 20.2 (C8), 15.2 (C11), 14.3 (C7). The spectroscopic 
properties of this compound were consistent with the data available in the literature.16  
(1S*,2R*)-2-Benzylcyclopropane-1-carboxylic acid (198c) 
 





General Procedure D: Ester 197c (4.51 g, 20.3 mmol) was employed to yield the title carboxylic acid 
198c (3.38 g, 95%) as a colourless oil; 1H NMR (400 MHz, CDCl3): δ 7.34 – 7.20 (5H, C1-H, 2 × C2-
H and 2 × C3-H), 2.73 (1H, dd, J = 15.0, 6.5 Hz, 1 × C5-H2), 2.64 (1H, dd, J = 15.0, 7.0 Hz, 1 × C5-
H2), 1.76 (1H, m, C6-H), 1.54 (1H, m, C8-H), 1.31 (1H, ddd, J = 9.0, 4.5, 4.5 Hz, 1 × C7-H2), 0.92 (1H, 
ddd, J = 8.0, 6.5, 4.5 Hz, 1 × C7-H2); 13C NMR (101 MHz, CDCl3): δ 180.7 (C9), 140.0 (C4), 128.6, 
128.5, 126.5 (C1, C2 and C3), 38.5 (C5). 24.2 (C6), 20.2 (C8), 16.1 (C7). The spectroscopic properties 
of this compound were consistent with the data available in the literature.16  
(1S*,2S*)-tert-Butyl (2-benzylcyclopropyl)carbamate (199c) 
 
To a solution of (1S*,2R*)-2-benzylcyclopropane-1-carboxylic acid 198c (3.28 g, 18.6 mmol) and Et3N 
(2.85 mL, 20.5 mmol) in t-BuOH (20 mL) was added diphenylphosphoryl azide (4.42 mL, 20.5 mmol) 
dropwise over 10 minutes. The reaction mixture was heated to 80 °C and stirred for 16 hours before 
cooling to room temperature and concentrating in vacuo. Saturated aqueous NaHCO3 (150 mL) was 
added and the solution was extracted with Et2O (3 × 75 mL). The organic extracts were combined, 
washed with water (75 mL) and brine (75 mL), dried over Na2SO4 and concentrated in vacuo. The 
residue was purified by flash column chromatography (3% EtOAc/toluene) to afford the title compound 
199c (2.53 g, 55%) as a white solid. 1H NMR (400 MHz, CDCl3): δ 7.34 – 7.15 (5H, m, C1-H, 2 × C2-
H and 2 × C3-H), 4.68 (1H, br. s, NH), 2.84 (1H, dd, J = 14.5, 6.0 Hz, 1 × C5-H2), 2.44 (2H, m, 1 × 
C5-H2, C8-H), 1.45 (9H, s, 3 × C11-H3), 1.15 (1H, ddddd, J = 9.0, 7.5, 6.0, 6.0, 3.0 Hz, C6-H), 0.84 – 
0.57 (2H, m, C7-H2); 13C NMR (101 MHz, CDCl3): δ 156.6 (C9), 141.0 (C4), 128.5, 128.5 (2 signals), 
126.2 (C1, C2 and C3), 79.5 (C10), 38.1 (C5), 29.6 (C8), 28.5 (C11), 21.5 (C6), 14.03 (C7). The 
spectroscopic properties of this compound were consistent with the data available in the literature.16  
(1S*,2S*)-N,2-Dibenzylcyclopropan-1-amine (trans-200c) 
 
General procedure E: Boc-protected amine 199c (2.29 g, 9.27 mmol) was employed and the residue 
was purified by flash column chromatography (20% EtOAc/hexane) to afford the title compound trans-
200c (1.83 g, 83%) as a colourless oil; 1H NMR (400 MHz, CDCl3): δ 7.37 – 7.12 (10 H, m, C1-H, 2 × 
C2-H, 2 × C3-H, 2 × C11-H, 2 × C12-H and C13-H), 3.72 (2H, s, C9-H2), 2.53 (1H, dd, J = 15.0, 7.0 
Hz, 1 × C5-H2), 2.45 (1H, dd, J = 15.0, 7.5 Hz, 1 × C5-H2), 2.02 (1H, ddd, J = 7.0, 3.5, 3.5 Hz, C8-H), 





1.75 (1H, br. s, NH), 1.06 (1H, m, C6-H), 0.64 (1H, ddd, J = 8.5, 5.0, 3.5 Hz, 1 × C7-H2), 0.41 (1H, 
ddd, J = 7.0, 5.0, 5.0 Hz, 1 × C7-H2); 13C NMR (101 MHz, CDCl3): δ 141.8 (C4), 140.6 (C10), 128.5 
(2 signals), 128.4, 128.3, 127.0, 126.0 (C1, C2, C3, C11, C12 and C13), 53.8 (C9), 38.5 (C5), 37.4 (C8), 
21.7 (C6), 14.0 (C7). The spectroscopic properties of this compound were consistent with the data 
available in the literature.16  
N-Benzyl-N-((1S*, 2S*)-2-benzylcyclopropyl)-1H-indole-2-carboxamide (trans-201c)  
 
General Procedure B: 1H-Indole-2-carboxylic acid (570 mg, 3.53 mmol) and (1S*,2S*)-N,2-
dibenzylcyclopropan-1-amine (trans-200c) (880 mg, 3.71 mmol) were employed and the reaction was 
stirred at room temperature for 18 hours. The crude residue was purified by flash column 
chromatography (10% EtOAc/toluene) to give the title compound trans-201c (950 mg, 67%) as a 
colourless solid; m.p.: 172–173 °C (ethanol); νmax/ cm-1: 3275 (br. m), 1605 (s), 1520 (s), 1436 (s), 1402 
(s), 1312 (m), 1279 (s); 1H NMR (400 MHz, CDCl3): δ 9.55 (1H, br. s, NH), 7.66 (1H, d, J = 8.0 Hz, 
C4-H), 7.41 (1H, dd, J = 8.0, 1.0 Hz, C7-H), 7.33 – 7.19 (7H, m, 7 × ArC-H), 7.17 – 7.05 (6H, m, 7 × 
ArC-H), 4.95 (1H, d, J = 15.0 Hz, 1 × C10-H2), 4.61 (1H, d, J = 15.0 Hz, 1 × C10-H2), 2.89 (1H, ddd, 
J = 7.0, 4.0, 3.5 Hz, C15-H), 2.71 (1H, m, 1 × C18-H2), 2.48 (1H, dd, J = 14.5, 7.5 Hz, 1 × C18-H2), 
1.45 (1H, m, C17-H), 1.03 (1H, ddd, J = 9.5, 6.0, 4.0 Hz, 1 × C16-H2), 0.95 (1H, m, 1 × C16-H2); 13C 
NMR (126 MHz, CDCl3): δ 164.8 (C9), 140.2 (C19), 138.0 (C11), 135.8 (C8), 130.2 (C1), 128.7, 128.6, 
128.6, 127.9, 127.6, 127.3, 126.5 (C3, C12, C13, C14, C20, C21 and C22), 124.7 (C6), 122.2 (C4), 
120.5 (C5), 111.9 (C7), 107.1 (C2), 52.0 (C10), 38.2 (C15), 37.8 (C18), 23.9 (C17), 18.5 (C16); HRMS: 
(ESI)+ Calculated for C26H25N2O: 381.1961. Found [M + H] +: 381.1972.  
N-Benzyl-N-((1S*, 2S*)-2-benzylcyclopropyl)-1-methyl-1H-indole-2-carboxamide (trans-202c) 
 





To a suspension of NaH (74 mg, 3.10 mmol, 60% dispersion in oil) in DMF (5 mL) at 0 °C was added 
N-benzyl-N-((1S*,2S*)-2-benzylcyclopropyl)-1H-indole-2-carboxamide (trans-201c) (590 mg, 1.55 
mmol). After 15 minutes, iodomethane (0.11 mL, 1.71 mmol) was added dropwise over 10 minutes. 
The solution was warmed to room temperature and stirred for 4 hours. The reaction was quenched by 
the addition of saturated aqueous ammonium chloride solution (50 mL) and extracted with EtOAc (3 × 
20 mL). The organic extracts were combined, washed with H2O (50 mL), brine (50 mL), dried over 
Na2SO4 and concentrated in vacuo. The crude residue was purified by flash column chromatography 
(30-50% Et2O/hexane) to give the title compound trans-202c (500 mg, 81%) as a yellow oil; νmax/ cm-
1: 3027 (m), 1631 (s), 1464 (m), 1453 (s), 1403 (s); 1H NMR (400 MHz, CDCl3): δ 7.61 (1H, d, J = 8.0 
Hz, C4-H), 7.40 – 7.24 (5H, m, 5 × Ar-CH), 7.23 – 7.09 (6H, m, 6 × Ar-CH), 6.92 – 6.91 (2H, m, 2 × 
Ar-CH), 6.74 (1H, s, C2-H), 4.70 (2H, s, C10-H2), 3.83 (3H, s, C23-H3), 2.60 (1H, dd, J = 7.5, 3.5 Hz, 
C15-H), 2.49 (1H, m, 1 × C18-H2), 2.13 (1H, m, 1 × C18-H2), 1.18 (1H, m, C17-H), 0.82 – 0.55 (2H, 
m, C16-H2); 13C NMR (101 MHz, CDCl3): δ 166.1 (C9), 140.2 (C19), 138.1 (C8), 137.7 (C11), 133.1 
(C1), 128.7, 128.5, 127.9, 127.5, 126.7, 126.3 (C3, C12, C13, C14, C20, C21 and C22), 123.5 (C6), 
121.7 (C4), 120.3 (C5), 109.9 (C7), 104.4 (C2), 51.3 (C10), 37.7 (C18), 37.5 (C15), 31.3 (C23), 24.2 
(C17), 16.3 (C16); HRMS: (ESI)+ Calculated for C27H27N2O: 395.2118. Found [M + H] +: 395.2119.   
2,4-Dibenzyl-11-methyl-2,3,4,5-tetrahydro-1H-azocino[3,4-b]indole-1,6(11H)-dione (rac-205c) 
and (Z)-2,4-Dibenzyl-11-methyl-2,5-dihydro-1H-azocino[3,4-b]indole-1,6(11H)-dione (208c)  
 
General Procedure F: Compound trans-202c (39.4 mg, 0.10 mmol), fumaric acid (17.6 mg, 0.15 
mmol) and anhydrous benzonitrile (0.15 mL) were employed, the reaction mixture was heated at 140 °C 
for 72 hours. The crude mixture was purified by flash column chromatography (10% toluene/hexane) 
to yield the title compound rac-205b and the title compound 208b (21.2 mg, 50%). 1H NMR analysis 
revealed a 14:1 ratio of rac-205b:208b. The major product rac-205b was isolated as a colourless solid.  
Data for major compound rac-205b: m.p.: 79–81 °C (CH2Cl2); νmax/ cm-1: 2924 (m), 1682 (s), 1630 (s), 
1466 (s), 1417 (s), 1266 (s); 1H NMR (500 MHz, CD3CN, 65 °C): δ 7.88 (1H, d, J = 7.5 Hz, Ar-CH), 
7.56 (1H, m, Ar-CH), 7.49 (1H, m, Ar-CH), 7.43 (1H, m, Ar-CH), 7.38 – 7.32 (2H, m, 2, Ar-CH), 7.31 
– 7.24 (6H, m, 6 × Ar-CH), 7.10 (1H, m, Ar-CH), 6.63 (1H, m, Ar-CH), 4.83 (2H, s, C14-H2), 3.78 (3H, 
s, C21-H3), 3.68 – 3.54 (2H, m, C10-H2), 3.04 (1H, d, J = 15.5 Hz, 1 × C19-H2), 2.76 – 2.66 (3H, br. 





m, C11-H, 1 × C12-H2 and 1 × C19-H2), 2.36 (1H, br. m, 1 × C12-H2); 13C NMR (126 MHz, CD3CN): 
δ 197.9 (C13, A+B), 166.1 (C9, A+B), 144.3, 144.0 (C20, A+B), 138.6, 138.4 (C15 and C8, A+B), 134.6 
(Ar-CH), 133.72 (Ar-C), 133.2 (Ar-C), 130.3, 129.7, 128.4, 128.0, 127.7, 127.5, 127.3 (6 × Ar-CH and 
1 × Ar-C), 124.0 (Ar-CH), 122.3 (Ar-CH), 121.1 (Ar-CH), 111.0 (Ar-CH), 103.1 (Ar-CH), 54.0, 53.5 
(C14, A+B), 49.6, 48.7 (C19, A+B), 43.4, 43.0 (C12, A+B), 34.6, 34.3, 33.8 (C11, C19, A+B), 31.7 
(C21, A+B); HRMS: (ESI)+ Calculated for C28H27N2O2: 423.2067. Found [M + H] +: 423.2065. A 
1H 
NMR spectrum was recorded at 65 °C in CD3CN because at room temperature slow conformational 
interconversion gave a broad spectrum. Due to the presence of rotamers and line broadening, it was 
not possible to confidently assign aromatic signals. 
Data for minor compound 208b: Characteristic signals only: 1H NMR (400 MHz, CDCl3): δ 5.87 (1H, 
s, C10-H). The minor product was tentatively assigned by analogy to that of minor product of 208a. 
N-Benzyl-N-((1S, 2S)-2-benzylcyclopropyl)-1H-indole-2-carboxamide (enantiopure)  
 
Enantioenriched (R)-196c (>99:1 e.r.) was prepared by G.-W. Wang according to a procedure reported 
by Jacobsen and co-workers.165 (R)-196c was then employed in the same cyclopropanation, hydrolysis, 
N-Boc deprotection/benzylation and amide coupling sequence as described above for the racemate to 
access enantiopure (N-Benzyl-N-((1S, 2S)-2-benzylcyclopropyl)-1H-indole-2-carboxamide (98.5:1.5 
e.r.). (1S, 2S)-N,2-dibenzylcyclopropan-1-amine (S,S)-200c was prepared by G.-W. Wang.    
General Procedure B: 1H-Indole-2-carboxylic acid (242 mg, 1.50 mmol) and (1S, 2S)-N,2-
dibenzylcyclopropan-1-amine (356 mg, 1.50 mmol) were employed and the reaction was stirred at r.t. 
for 18 hours. The crude residue was purified by flash column chromatography (10–15% Et2O/toluene) 
to give the title compound (S,S)-200c (541 mg, 95%) as a colourless solid.  
The enantiopurity of this compound was confirmed after the subsequent step.  
[α]D 19 +28.20 (c = 0.69, CHCl3). All other analytical data were identical to those reported earlier. 
N-Benzyl-N-((1S, 2S)-2-benzylcyclopropyl)-1-methyl-1H-indole-2-carboxamide ((S,S)-202c) 






To a suspension of NaH (73 mg, 3.02 mmol, 60% dispersion in oil) in DMF (5 mL) at 0 °C was added 
N-benzyl-N-((1S, 2S)-2-benzylcyclopropyl)-1H-indole-2-carboxamide (enantiopure) (150 mg, 0.39 
mmol). After 15 minutes, iodomethane (0.03 mL, 0.43 mmol) was added in over 5 minutes. The solution 
was then warmed to room temperature and stirred for 4 hours. The reaction was quenched by the 
addition of saturated aqueous NH4Cl (20 mL) and extracted with EtOAc (3 × 20 mL). The organic 
extracts were combined, washed with H2O (20 mL), brine (20 mL), dried over Na2SO4 and concentrated 
in vacuo. The crude residue was purified by flash column chromatography (25% EtOAc/hexane) to give 
the title compound (S,S)-202c (138 mg, 91%) as a yellow oil. 
The enantiopurity of this compound was confirmed after the subsequent step.  
[α]D 19 +19.51 (c = 4.66, CHCl3). All other analytical data were identical to those reported earlier. 
(S)-2,4-Dibenzyl-11-methyl-2,3,4,5-tetrahydro-1H-azocino[3,4-b]indole-1,6(11H)-dione ((S)-205c) 
and (Z)-2,4-Dibenzyl-11-methyl-2,5-dihydro-1H-azocino[3,4-b]indole-1,6(11H)-dione (208b)  
 
General Procedure F: Compound (S,S)-202c (39.4 mg, 0.10 mmol), fumaric acid (17.6 mg, 0.15 mmol) 
and anhydrous benzonitrile (0.15 mL) were employed, the reaction mixture was heated at 140 °C for 
72 h. The crude mixture was purified by flash column chromatography (10 % toluene/hexane) to yield 
the title compound (S)-205c and compound 208c (21.0 mg, 50%). 1H NMR analysis revealed a 14:1 
ratio of (S)-208c:205c.  
[α]D 23 +42.16 (c = 0.90, CHCl3). All other analytical data were identical to those reported earlier.  
The enantiopurity of this compound was determined by chiral SFC (Chiralpak IA, isocratic CO2-MeOH 
65:35, 2.0 mL/min, 25 oC) against a racemic standard; (tR major – 9.14 min and tR (minor) – 9.87 min). 









General Procedure B: 1H-Indole-2-carboxylic acid (244 mg, 2.19 mmol) and (1S*, 2S*)-N-benzyl-2-
methylcyclopropan-1-amine trans-200a (372 mg, 2.31 mmol) were employed and the reaction was 
stirred at room temperature for 18 hours. The crude residue was purified by flash column 
chromatography (60% EtOAc/toluene) to give the title compound (403 mg, 72%) as a yellow oil; νmax/ 
cm-1: 3673 (m), 2956 (m), 1716 (s), 1593 (s), 1416 (s), 1310 (m); 1H NMR (400 MHz, CDCl3): δ 8.67 
(1H, br. s, NH), 7.36 – 7.22 (6H, m, C1-H, 2 × C8-H, 2 × C9-H, and C10-H), 6.72 (1H, dd, J = 2.5, 2.5 
Hz, C4-H), 6.58 (1H, d, J = 2.5 Hz, C3-H), 4.79 (1H, d, J = 15.0 Hz, 1 × C6-H2), 4.72 (1H, d, J = 15.0 
Hz, 1 × C6-H2), 2.42 (1H, ddd, J = 7.0, 3.5, 3.5 Hz, C11-H), 0.98 (1H, m, C13-H), 0.91 (3H, d, J = 6.0 
Hz, C14-H3), 0.79 (1H, m, 1 × C12-H2), 0.48 (1H, m, 1 × C12-H2); 13C NMR (126 MHz, CDCl3): δ 
168.7 (C5), 138.7 (C7), 128.6, 128.0, 127.1 (C8, C9 and C10), 122.1 (C1), 120.2 (C2), 117.6 (C4), 
110.1 (C3), 51.1 (C6), 38.7 (C11), 17.8 (2 signals) (C12 and C13), 17.4 (C14); HRMS: (ESI)+ 
Calculated for C16H19N2O: 255.1492. Found [M + H] +: 255.1494. 
  





N-Benzyl-1-methyl-N-((1R*, 2R*)-2-methylcyclopropyl)-1H-pyrrole-3-carboxamide (trans-202e) 
 
To a suspension of NaH (91.2 mg, 2.28 mmol, 60% dispersion in oil) in DMF (8.0 mL) at 0 °C was 
added N-benzyl-N-((1R*,2R*)-2-methylcyclopropyl)-1H-pyrrole-3-carboxamide (193 mg, 0.76 mmol). 
After 15 minutes, iodomethane (0.095 mL, 1.52 mmol) was added dropwise over 5 minutes. The 
solution warmed to room temperature and stirred for 6 hours. The reaction was quenched by the addition 
of saturated aqueous ammonium chloride solution (15 mL) and extracted with EtOAc (3 × 15 mL). The 
organic extracts were combined, washed with H2O (20 mL), brine (20 mL), dried over Na2SO4 and 
concentrated in vacuo. The crude residue was purified by flash column chromatography (50% EtOAc/ 
hexane) to give the title compound trans-202e (170 mg, 83%) as a colourless solid; m.p.: 95–97 °C 
(EtOAc/ hexane); νmax/ cm-1: 2953 (m), 1605 (s), 1533 (s), 1411 (s), 1258 (s), 751 (m); 1H NMR (400 
MHz, CDCl3): δ 7.37 – 7.21 (5H, m, 2 × C8-H, 2 × C9-H, and C10-H), 7.14 (1H, s, C1-H), 6.70 – 6.31 
(2H, m, C3-H and C4-H), 4.77 (1H, d, J = 15.0 Hz, 1 × C6-H2), 4.71 (1H, d, J = 15.0 Hz, 1 × C6-H2), 
3.65 (3H, s, C15-H3), 2.40 (1H, m, C11-H), 0.99 (1H, m, C13-H), 0.92 (3H, d, J = 6.0 Hz, C14-H3), 
0.80 (1H, m, 1 × C12-H2), 0.48 (1H, m, 1 × C12-H2); 13C NMR (126 MHz, CDCl3, 50 °C): δ 168.3 
(C5), 140.0 (C6), 128.5, 128.0, 127.0 (C8, C9 and C10), 125.9 (C1), 121.4 (C4), 120.3 (C2), 110.5 
(C3), 51.2 (C6), 38.8 (C11), 36.4 (C15), 17.8, 17.7 (C13 and C12), 17.4 (C14); HRMS: (ESI)+ 
Calculated for C17H21N2O: 269.1648. Found [M + H] +: 269.1645. 
N-benzyl-N-((1R*,5S*,6R*)-bicyclo[3.1.0]hexan-6-yl)-1H-indole-2-carboxamide  
 
General Procedure B: Amine trans-218 was synthesised by G.W.-Wang. 1H-Indole-2-carboxylic acid 
(154 mg, 0.96 mmol) and (1S*, 2S*)-N-benzyl-2-methylcyclopropan-1-amine trans-218 (180 mg, 0.96 
mmol) were employed and the reaction was stirred at room temperature for 18 hours. The crude residue 
was purified by flash column chromatography (10% Et2O/toluene) to give the title compound (228 mg, 
72%) as white solid; m.p.: 167–169 °C (EtOAc/ hexane); νmax/ cm-1: 3255 (br. m), 2944 (m), 1606 (s), 
1522 (s), 14101 (s), 1277 (s); 1H NMR (400 MHz, CDCl3): δ 9.41 (1H, br. s, NH), 7.59 (1H, d, J = 8.0 
Hz, C4-H), 7.34 (1H, d, J = 8.5 Hz, C7-H), 7.29 – 7.19 (6H, m, C6-H, 2 × C12-H, 2 × C13-H, and C14-
H), 7.09 – 6.96 (2H, m, C2-H and C5-H), 4.79 (2H, s, C10-H2), 2.57 (1H, d, J = 2.0 Hz, C15-H), 1.81 





(2H, dd, m, 2 × C17-H), 1.68 (2H, m, 2 × C17-H), 1.61 – 1.47 (3H, m, 2 × C16-H and 1 × C18-H), 1.04 
(1H, dtt, J = 13.5, 11.0, 5.5 Hz, 1 × C18-H); 13C NMR (101 MHz, CDCl3): δ 164.6 (C9), 138.0 (C11), 
135.7 (C8), 130.5 (C1), 128.7 (Ar-CH), 128.0 (2 signals, C3 and Ar-CH), 127.4 (Ar-CH), 124.70 (C6), 
122.3 (C4), 120.5 (C7), 111.9 (C5), 106.9 (C2), 51.5 (C10), 38.3 (C15), 29.2 (C16), 27.8 (C17), 21.7 




To a suspension of NaH (26.0 mg, 0.72 mmol, 60% dispersion in oil) in DMF (4.0 mL) at 0 °C was 
added N-benzyl-N-((1R*,2R*)-2-methylcyclopropyl)-1H-pyrrole-3-carboxamide (200 mg, 0.60 mmol). 
After 15 minutes, iodomethane (40.0 μL, 0.72 mmol) was added dropwise over 5 minutes. The solution 
warmed to room temperature and stirred for 6 hours. The reaction was quenched by the addition of 
saturated aqueous ammonium chloride solution (10 mL) and extracted with EtOAc (3 × 15 mL). The 
organic extracts were combined, washed with H2O (20 mL), brine (20 mL), dried over Na2SO4 and 
concentrated in vacuo. The crude residue was purified by flash column chromatography (50% EtOAc/ 
hexane) to give the title compound trans-219 (170 mg, 83%) as a colourless solid; m.p.: 95–97 °C 
(EtOAc/ hexane); νmax/ cm-1: 2926 (m), 1627 (s), 1519 (s), 1402 (s), 1313 (s); 1H NMR (400 MHz, 
CDCl3): 7.63 (1H, dd, J = 8.0, 1.0 Hz, C4-H), 7.42 – 7.28 (7H, m, C6-H, C7-H, 2 × C12-H, 2 × C13-
H, and C14-H,), 7.14 (1H, ddd, J = 8.0, 7.0, 1.0 Hz, C5-H), 6.76 (1H, s, C2-H), 4.79 (2H, s, C10-H2), 
3.90 (3H, s, C19-H3), 2.40 (1H, t, J = 2.0 Hz, C15-H), 1.68 – 1.41 (7H, m, 2 × C16-H2, 2 × C17-H2 and 
1 × C18-H), 0.92 (1H, m, 1 × C18-H);13C NMR (101 MHz, CDCl3): δ 165.8 (C9), 138.1 (C8), 137.7 
(C11), 133.1 (C1), 128.7, 128.2, 127.6 (C12, C13 and C14), 126.6 (C3), 123.4 (C6), 121.7 (C4), 120.1 
(C5), 110.0 (C7), 104.7 (C2), 50.9 (C10), 38.5 (C15), 31.5 (C19), 29.0 (C16), 27.3 (C17), 21.6 (C18); 
HRMS: (ESI)+ Calculated for C23H24N2NaO: 367.1781. Found [M + Na] +: 367.1772. 
  








To a stirred solution of 208a (49.8 mg, 0.14 mmol) in anhydrous CH2Cl2 (1.0 mL) at 0 °C was added 
Et3N (32.0 uL, 0.23 mmol) dropwise under argon. tert-Butyldimethylsilyl trifluoromethanesulfonate 
(46.3 uL, 0.20 mmol) was then added and the mixture was slowly warmed to room temperature and 
stirred for 6 hours. Then the mixture was concentrated in vacuo and the residue was purified by column 
chromatography (10% EtOAc/Hex) to yield (E)-2-benzyl-6-((tert-butyldimethylsilyl)oxy)-4,11-
dimethyl-2,3,4,11-tetrahydro-1H-azocino[3,4-b]indol-1-one (59.0 mg, 89%) as a colourless oil; νmax/ 
cm-1: 2928 (m), 1639 (s), 1472 (m), 1252 (m), 1154 (s), 832 (s); 1H NMR (400 MHz, CDCl3): δ 7.86 
(1H, d, J = 8.0 Hz, C4-H), 7.43 – 7.27 (7H, m, C6-H, C7-H, 2 × C16-H, 2 × C17-H, and C18-H), 7.15 
(1H, m, C5-H), 5.17 (1H, d, J = 6.0 Hz, C12-H), 5.06 (1H, d, J = 14.5 Hz, 1 × C14-H2), 4.61 (1H, d, J 
= 14.5 Hz, 1 × C14-H2), 3.90 – 3.78 (4H, m, 1 × C10-H2 and C20-H3), 2.94 (1H, dd, J = 14.5, 5.0 Hz, 
1 × C10-H2), 2.59 (1H, m, C11-H), 0.90 (3H, d, J = 6.8 Hz, C19-H3), 0.85 (9H, s, 3 × C23-H3), -0.04 
(3H, s, 1 × C21-H3), -0.29 (3H, s, 1 × C21-H3); 13C NMR (101 MHz, CDCl3): δ 164.6 (C9), 143.5 (C13), 
138.1 (C8), 137.6 (C15), 129.1 (C1), 128.8, 128.3, 127.7 (C16, C17 and C18), 126.3 (C3), 123.7 (C6), 
123.3 (C4), 120.2 (C5), 114.4 (C2), 113.8 (C12), 109.7 (C7), 53.7 (C10), 49.3 (C14), 32.0 (C11), 31.2 
(C20), 25.9 (C23), 20.1 (C19), 18.4 (C22), -4.8 (C21), -4.9 (C21); HRMS: (ESI)+ Calculated for 




To a stirred solution of (E)-2-Benzyl-6-((tert-butyldimethylsilyl)oxy)-4,11-dimethyl-2,3,4,11-
tetrahydro-1H-azocino[3,4-b]indol-1-one 226 (31.1 mg, 0.068 mmol) in anhydrous CH2Cl2 (1.00 mL) 





at -78 °C was added 3-chloroperbenzoic acid (m-CPBA) (26.3 mg, 0.11 mmol) in CH2Cl2 (0.75 mL) 
dropwise under an atmosphere of argon. The mixture was slowly warmed to room temperature and 
stirred for 1 hour. The mixture was concentrated in vacuo and the residue was purified by column 
chromatography (3% EtOAc/toluene) to afford the title compound 227 (22.4 mg, 70%) as a colourless 
oil as a single diastereomer. The relative stereochemistry of 227 was corroborated by nOe experiments 
(as indicated on the compound structure 227). nOe correlations were observed between C12-H and 
C19-H, and from C11-H to C15-H. νmax/ cm-1: 2927 (m), 1638 (s), 1504 (s), 1466 (s), 1380 (s), 1054 
(m); 1H NMR (500 MHz, CDCl3): δ 8.68 (1H, dd, J = 8.0, 1.0 Hz, C4-H), 7.45 – 7.31 (8H, m, C5-H, 
C6-H, C7-H, 2 × C16-H, 2 × C17-H, and C18-H), 5.54 (1H, d, J = 14.5 Hz, 1 × C14-H2), 4.87 (1H, d, 
J = 5.0 Hz, C12-H), 4.31 (1H, d, J = 14.5 Hz, 1 × C14-H2), 3.91 (3H, s, C20-H3), 3.55 (1H, dd, J = 15.0, 
13.5 Hz, 1 × C10-H2), 3.23 (1H, dd, J = 15.0, 5.5 Hz, 1 × C10-H2), 2.50 (1H, m, C11-H), 0.93 (9H, s, 
3 × C23-H3), 0.84 (3H, d, J = 7.0 Hz, C19-H3), 0.13 (3H, s, 1 × C21-H3), 0.00 (3H, s, 1 × C21-H3); 13C 
NMR (126 MHz, CDCl3): δ 191.9 (C13), 163.3 (C9), 137.6 (C8), 136.5 (C15), 135.2 (C1), 129.2, 128.3, 
128.2 (C16, C17 and C18), 125.7 (C3), 125.1 (C6), 124.4 (C4), 123.8 (C5), 115.6 (C2), 110.0 (C7), 
75.4 (C12), 51.2 (C10), 48.5 (C14), 38.9 (C11), 32.3 (C20), 26.1 (C23), 18.6 (C22), 11.3 (C19), -4.4 
(C21), -5.2 (C21); HRMS: (ESI)+ Calculated for C28H37N2O3Si: 477.2568. Found [M + H] +: 477.2575. 
N-Benzyl-N-cyclopropyl-3-(1H-indol-3-yl)propenamide (232) 
 
General Procedure B: 3-(1H-indol-3-yl)propanoic acid (278 mg, 2.00 mmol) and N-
benzylcyclopropylamine 170a (308 mg, 2.10 mmol) were employed and the reaction was stirred at r.t. 
for 4 hours. The crude residue was purified by flash column chromatography (50% EtOAc/hexane) to 
give the title compound 232 (350 mg, 55%) as a colourless solid; m.p.: 141–143 °C (ethanol); νmax / cm-
1: 3302 (br. s), 3032 (w), 1627 (s), 1440 (s), 1411 (s), 1223 (s); 1H NMR (400 MHz, CDCl3): δ 8.01 
(1H, br. s, NH), 7.65 (1H, d, J = 8.0 Hz, C4-H), 7.36 (1H, d, J = 8.0 Hz, C7-H), 7.32 – 7.07 (7H, m, 
C5-H, C6-H, 2 × C16-H, 2 × C17-H and C18-H), 7.01 (1H, d, J = 2.5 Hz, C1-H), 4.61 (2H, s, C14-H2), 
3.19 (2H, t, J = 7.5 Hz, C9-H2), 3.05 – 2.94 (2H, m, C10-H2), 2.41 (1H, tt, J = 7.0, 4.0 Hz, C12-H), 0.81 
– 0.64 (4H, m, 2 × C13-H2); 13C NMR (101 MHz, CDCl3): δ 175.8 (C11), 138.5 (C15), 136.4 (C8), 
128.5, 127.8 (C16 and C17), 127.5 (C3), 127.0 (C18), 122.0, 121.9 (C1 and C6), 119.4 (C5), 118.9 
(C4), 115.8 (C2), 111.3 (C7), 49.9 (C14), 35.1 (C10), 30.1 (C12), 21.1 (C9), 9.4 (C13); HRMS: (ESI)+ 
Calculated for C21H22N2NaO: 341.1624. Found [M + Na]+: 341.1637. 
  







To an oven dried reaction tube was added 3-bromo-1-(phenylsulfonyl)-1H-indole (504 mg, 1.50 mmol), 
(2-(methoxycarbonyl)phenyl)boronic acid (403 mg, 2.25 mmol), Pd(PPh3)4 (87.0 mg, 0.075 mmol) and 
K2CO3 (518 mg, 3.75 mmol). The tube was fitted with a rubber septum and purged with argon. The 
reagents were dissolved in 1,4-dioxane/H2O (3:1, 6.5 mL) The tube was sealed and heated at 105 °C 
for 4 hours and then cooled to room temperature. The reaction mixture was filtered through a pad of 
celite® and concentrated in vacuo. The residue was purified by flash column chromatography (30% 
Et2O/hexane) to afford the title compound (352 mg, 60%) as a colourless oil; νmax / cm-1: 2948 (m), 1721 
(s), 1448 (s), 1368 (s); 1H NMR (400 MHz, CDCl3): δ 8.04 (1H, dd, J = 8.5, 1.0 Hz, ArC-H), 7.94 – 
7.88 (3H, m, 3 × ArC-H), 7.62 – 7.51 (3H, m, 3 × ArC-H), 7.49 – 7.41 (4H, m, 4 × ArC-H), 7.35 – 7.27 
(2H, m, 2 × ArC-H), 7.20 (1H, dd, J = 8.0, 7.0, 1.0 Hz, ArC-H), 3.29 (3H, s, C2-H3); 13C NMR (101 
MHz, CDCl3): δ 168.6 (C1), 138.3 (ArC), 134.9 (Ar-CH), 133.9 (ArC), 132.6 (Ar-CH), 131.9 (Ar-CH), 
131.6 (Ar-CH), 131.5 (Ar-CH), 130.7 (ArC), 130.4 (Ar-CH), 129.3 (Ar-CH), 128.1 (Ar-CH), 126.9 
(Ar-CH), 125.0 (ArC), 124.1 (Ar-CH), 123.4 (Ar-CH), 123.7 (Ar-CH), 120.7 (ArC), 120.0 (Ar-CH), 
115.0 (ArC), 113.9 (Ar-CH), 51.9 (C2); HRMS: (ESI)+ Calculated for C22H18NO4S: 391.0878. Found 
[M + H] +: 391.0880. 
N-Benzyl-N-cyclopropyl-2-(1H-indol-3-yl)benzamide (234)  
 
To a solution of methyl 2-(1-(phenylsulfonyl)-1H-indol-3-yl)benzoate (150 mg, 0.38 mmol) in MeOH 
(5 mL) was added lithium hydroxide monohydrate (80 mg, 1.92 mmol). The mixture was heated at 
reflux for 18 h and cooled to room temperature before being concentrated in vacuo. Water (20 mL) and 
EtOAc (20 mL) were added and the layers separated. The aqueous portion was adjusted to pH 2 by 
addition of 2 M aq. HCl and then extracted with EtOAc (2 × 20 mL). The organic extracts were 
combined, dried over Na2SO4 and concentrated in vacuo to afford the crude carboxylic acid intermediate 
as a pale brown solid that was used in the subsequent step without purification. To a stirring solution of 
the crude carboxylic acid in CH2Cl2 (5 mL) was added EDCI (97 mg, 0.63 mmol), DMAP (2.31 mg, 
0.019 mmol) and N-benzylcyclopropanamine 170a (58.6 mg, 0.40 mmol).The resulting solution was 
stirred at room temperature for 18 hours. 1 M aqueous HCl (10 mL) was added and the solution was 





extracted with CH2Cl2 (2 × 10 mL). The organic extracts were combined, washed with water (10 mL), 
brine (10 mL), dried over Na2SO4 and concentrated in vacuo. The residue was purified by flash column 
chromatography (30% EtOAc/hexane) to afford the title compound 234 (50.1 mg, 34%, 3:1 mixture of 
rotamers A:B) as a colourless oil; νmax / cm-1: 3288 (br. s), 3058 (m), 2921 (m), 1621 (s), 1612 (s), 1441 
(s), 1410 (s), 1301 (s), 1H NMR (400 MHz, CDCl3): δ 8.89 (1H, br. s, NH, B), 8.10 (1H, br. s, NH, A), 
7.76 – 7.57 (4H, m, 2 × Ar-CH, A+B), 7.49 – 6.87 (24H, m, 12 × Ar-CH, A+B), 4.96 (1H, d, J = 14.5 
Hz, 1 × C2-H2, A), 4.23 – 4.13 (2H, m, 1 × C2-H2, A and 1 × C2-H2, B), 3.55 (1H, d, J = 14.5 Hz, 1 × 
C2-H2, B), 2.40 (1H, tt, J = 7.5, 4.0 Hz, C3-H, B), 1.77 – 1.65 (1H, m, C3-H, A), 0.57 – 0.07 (8H, m, 
C4-H2 and C5-H2, A+B); 13C NMR (101 MHz, CDCl3): δ 174.7 (C1, A+B), 137.4, 137.3, 136.9, 136.1, 
130.1, 129.8, 129.6, 129.3, 128.8, 128.7, 128.5, 127.7, 127.6, 127.3, 127.1, 126.9, 122.6, 122.4, 120.6, 
120.2, 120.1, 111.8, 111.5, 102.3, 102.1, 102.1, 53.5 (C2, A), 50.5 (C2, A), 32.1 (C3, B), 28.7 (C3, B), 
9.2, 8.3 (C4 and C5, A), 7.7, 7.5 (C4 and C5, B). Due to the presence of rotamers and line broadening, 
it was not possible to confidently assign aromatic signals. HRMS: (ESI)+ Calculated for C25H23N2O: 
367.1805. Found [M + H] +: 367.1809. 
N-Benzyl-N-cyclopropyl-1H-imidazole-1-carboxamide (236) 
 
To a solution of 1,1′-carbonyldiimidazole (851 mg, 5.25 mmol) in THF (12 mL) was added N-
benzylcyclopropanamine 170a (515 mg, 3.50 mmol). The reaction mixture was heated at reflux for 16 
hours and then cooled to room temperature. THF was removed in vacuo and the resulting yellow residue 
was dissolved in CH2Cl2 (30 mL), washed with H2O (2 × 20 mL), brine (20 mL), dried over MgSO4 
and concentrated in vacuo. The crude material was purified through a short pad of silica eluting with 
EtOAc to give the title compound 236 (810 mg, 96%) as a colourless oil; νmax / cm-1: 3119 (m), 2952 
(m), 1689 (s), 1413 (s), 1289 (s), 1254 (s); 1H NMR (400 MHz, CDCl3): δ 8.04 (1H, d, J = 1.0 Hz, C1-
H), 7.43 – 7.28 (6H, m, C3-H, 2 × C7-H, 2 × C8-H and C9-H), 7.07 (1H, m, C2-H), 4.71 (2H, s, C5-
H2), 2.68 (1H, tt, J = 7.0, 4.0 Hz, C10-H), 0.85 – 0.76 (2H, m, C11-H2), 0.66 – 0.60 (2H, m, C11-H2); 
13C NMR (101 MHz, CDCl3): δ 152.1 (C4), 137.3 (C1), 136.5 (C6), 129.4 (C2), 129.0, 128.3 128.1 
(C7, C8 and C9), 118.3 (C3), 53.3 (C5), 31.8 (C10), 10.1 (C11); HRMS: (ESI)+ Calculated for 
C14H16N3O: 242.1288. Found [M + H] +: 242.1292. 
  







The title compound was prepared following a modified literature procedure.172 To a solution of 2-
methylindole (218 mg, 1.60 mmol) and imidazole 236 (350 mg, 1.60 mmol) in toluene (10 mL) at 0 °C 
was added AlMe3 (2.4 mL, 1.80 mmol, 2.0 M in toluene) dropwise over 10 minutes. After addition was 
complete, stirring was maintained for a further 45 minutes, after which time the reaction was heated at 
105 ℃ for 4 hours. The mixture was cooled to 0 °C and quenched with saturated aqueous NaHCO3 (8 
mL). The solution was extracted with EtOAc (2 × 10 mL). The organic layers were combined, washed 
with brine (10 mL), dried over Na2SO4 and concentrated in vacuo. The residue was purified by flash 
column chromatography (50% EtOAc/toluene) to afford the title compound (340 mg, 70%) as an off-
white solid; m.p.: 161–162 °C (MeOH); νmax / cm-1: 3133 (br. s), 2982 (m), 1625 (s), 1444 (s), 1313 (s); 
1H NMR (400 MHz, CDCl3): δ 9.36 (1H, br. s, NH), 7.39 (1H, m, C4-H), 7.34 – 7.25 (5H, m, 2 × C14-
H, 2 × C15-H and C16-H ), 7.14 – 6.94 (3H, m, C5-H, C6-H and C7-H), 4.71 (2H, s, C12-H2), 2.58 
(1H, m, C10-H), 2.20 (3H, s, C17-H3), 0.60 (4H, s, 2 × C11-H2); 13C NMR (101 MHz, CDCl3): δ 170.9 
(C9), 138.2 (Ar-C), 135.0 (2 signals, 2 × Ar-C), 128.7, 128.0, 127.4 (C14, C15 and C16), 126.3 (C3), 
121.5, 120.4 (C5 and C6), 118.8 (C4), 111.1 (C7), 52.7 (C12), 39.1 (C10), 12.4 (C17), 8.7 (C11); HRMS: 
(ESI)+ Calculated for C20H21N2O: 305.1648. Found [M + H] +: 305.1639.  
10-Benzyl-1-methyl-7,8,9,10-tetrahydro-2H-azonino[3,4,5-cd]indole-6,11-dione (238) and N-
benzyl-2-methyl-1H-indole-3-carboxamide (239) 
 
General Procedure C: In a modification to General procedure C, 1-adamantanecarboxylic acid (50 
mol%) was used instead of 2-NO2C6H4COOH (150 mol%). Indole 237 (30.4 mg, 0.10 mmol) was 
employed and the reaction mixture was heated at 140 °C for 72 h. An in situ yield could not be obtained 
by 1H NMR spectroscopy due to broad and overlapping signals at room temperature. The residue was 
purified by flash column chromatography (50% EtOAc/toluene); however, the product 238 could not 
be readily separated from the ligand, starting material and other side products. The structure of product 
238 was determined by analysis of the 1H NMR spectrum of partially purified material and corroborated 





by COSY data and HRMS. Analysis of the 1H NMR spectrum of the mixture indicated formation of 
product 238 due to the presence of characteristic peaks. A 1H NMR spectrum was recorded at 100 °C 
in DMSO-d6 because at room temperature slow conformational interconversion of 238 gave a broad 
spectrum. The signals for C1-H2, C2-H2 and C3-H2, coalesced at 100 °C but they were not resolved.  
Data for 238: Characteristic signals only: 1H NMR (400 MHz, CDCl3): δ 3.46 (2H, br. m, C1-H2), 2.84 
(2H, br. m, C3-H2); 1H NMR (500 MHz, DMSO-d6, 100 °C): δ 3.41 (2H, br. m, C1-H2), 2.63 (2H, br. 
m, C3-H2), 1.85 (2H, br. m, C2-H2); HRMS: (ESI)+ Calculated for C22H8N2NaO2: 355.0478. Found [M 
+ Na] +: 355.0478. 
Data for 239: Characteristic signals only: 1H NMR (400 MHz, CDCl3): δ 4.68 (1H, d, J = 5.5 Hz, C1-
H2); HRMS: (ESI)+ Calculated for C17H16N2O: 265.0914. Found [M + H] +: 265.0913. 
N-Benzyl-N-cyclopropyl-1H-indole-4-carboxamide (242) 
 
General Procedure B: 1H-indole-4-carboxylic acid 1H-Pyrrole-2-carboxylic acid (322 mg, 2.00 mmol) 
and N-benzylcyclopropylamine 170a (309 g, 2.10 mmol) were employed and the reaction was stirred 
at room temperature for 18 hours. The crude residue was purified by flash column chromatography (10% 
EtOAc/CH2Cl2) to give the title compound 242 (335 mg, 58%) as a colourless solid; m.p.: 171–173 °C 
(MeOH); νmax / cm-1: 3257 (br. s), 2918 (m), 1616 (s), 1589 (s), 1429 (s), 1295 (s); 1H NMR (400 MHz, 
CDCl3): δ 8.50 (1H, br. s, NH), 7.57 – 7.28 (6H, m, 6 × ArC-H), 7.24 – 7.14 (3H, m, 3 × ArC-H), 6.47 
(1H, d, J = 2.5 Hz, ArC-H), 4.78 (2H, s, C2-H2), 2.58 (1H, tt, J = 7.0, 4.0 Hz, C3-H), 0.50 (4H, br. m, 
2 × C4-H2); 13C NMR (101 MHz, CDCl3): δ 173.3 (C1), 138.1 (ArC), 136.1 (ArC), 129.2 (ArC), 128.6 
(Ar-CH), 128.2 (Ar-CH), 127.3 (Ar-CH), 125.4 (2 signals, ArC and Ar-CH), 121.2 (Ar-CH), 118.6 (Ar-
CH), 112.4 (Ar-CH), 101.4 (Ar-CH), 51.0 (C2), 31.3 (C3), 8.9 (C4); HRMS: (ESI)+ Calculated for 
C19H18N2NaO: 313.1311. Found [M + Na] +: 313.1322. 
2-Benzyl-2,3,4,5-tetrahydro-1H-azocino[4,3-b]indole-1,6(7H)-dione (181) and N-Benzyl-1H-
indole-3-carboxamide (414) 
 





General Procedure C: In a modification to General procedure C, the reagents were dissolved in argon 
sparged anhydrous 1,2-DCB (0.10 M). Indole 178a (29.0 mg, 0.10 mmol) was employed and the 
reaction mixture was heated at 130 °C for 48h. An in situ yield was obtained by 1H NMR spectroscopy 
using 1,4-dinitrobenzene as an internal standard; a 5% yield of cyclised product 181 was observed. 
Flash column chromatography (20% EtOAc/toluene) afforded the desired product 181 and an NH 
by-product 414 as colourless oils. Due to small quantity of product 181 this compound was not isolated 
as a pure compound. The structure of 181 was determined by analysis of the 1H NMR, COSY, HMBC 
spectra and mass spectrometry. 
Data for 181: Characteristic peaks only: 1H NMR (400 MHz, CDCl3): δ 4.45 (2H, s, C5-H2), 3.26 (2H, 
t, J = 7.0 Hz, C2-H2), 2.45 (2H, t, J = 8.0 Hz, C4-H2), 2.03 – 1.95 (2H, m, C3-H2); 13C NMR (126 MHz, 
CDCl3): δ 174.8 (C1), 46.6, 46.5 (C2, C5), 31.0 (C4) 17.7 (C3); HRMS: (ESI)+ Calculated for 
C19H19N2O: 291.1491. Found [M + H] +: 291.1492.  
Data for 414: Characteristic peaks only: 1H NMR (400 MHz, CDCl3): δ 7.80 (1H, d, J = 3.0 Hz, C1-H), 
6.24 (1H, br. s, NH), 4.72 (2H, d, J = 5.5 Hz, C3-H2); 13C NMR (126 MHz, CDCl3): δ 165.1 (C1), 43.6 
(C3); HRMS: (ESI)+ Calculated for C16H15N2O: 251.1179. Found [M + H] +: 251.1181. The 
spectroscopic properties of this compound were consistent with the data available in the literature.346 
7.3.2 Mechanistic studies from Chapter 2 
Eqn 1: Deuterium exchange experiment of the carbonylative cyclisation of indole 178a with 
2-NO2C6H4CO2D  
 
2-NO2C6H4CO2D was prepared by repeatedly dissolving 2-NO2C6H4CO2H in MeOD-d4 and 
concentrating the resulting solution in vacuo.  
General Procedure C: Indole 178a (43.5 mg, 0.15 mmol) and o-NO2C6H4CO2D (37.8 mg, 0.15 mmol) 
were employed and the reaction mixture was heated at 130 °C for 72 h. The residue was purified by 
flash column chromatography (5–10% acetone/toluene) to afford deuterio-179aa (18.3 mg, 38%). The 
percentage of deuterium incorporation was measured by 1H NMR analysis. Analysis of deuterio-179aa 
revealed 8% and 8% deuterium incorporation at the diastereotopic C12 protons, and 15% and 15% 
deuterium incorporation at the diastereotopic C10 protons. <5% deuterium incorporation was measured 
at NH. The sites of deuterium incorporation were also unambiguously confirmed by 2H NMR analysis. 





Data for product deuterio-179aa: 1H NMR (400 MHz, CDCl3): δ 9.28 (1H, br. s, NH), 8.12 (1H, d, J = 
8.5, C4-H), 7.44 – 7.26 (8H, m, C5-H, C6-H, C7-H,  2 × C16-H, 2 × C17-H and C18-H), 5.32 (1H, d, 
J = 14.5 Hz, 1 × C14-H2), 4.53 (1H, d, J = 14.5 Hz, 1 × C14-H2), 3.82 (0.92H, m, 1 × C12-H2), 3.30 
(0.92H, m, 1 × C12-H2), 3.12 (0.85H, m, 1 × C10-H2), 2.63 (0.85H, m, 1 × C10-H2), 2.08 (1H, m, 1 × 
C11-H2), 1.84 (1H, m, 1 × C11-H2); 2H NMR (77 MHz): δ 2.97 (0.15D, br. m), 2.48 (0.15D, br. m,), 
1.80 (0.16D, br. m). 
Eqn 2: Deuterium exchange experiment of the carbonylative cyclisation of indole 178a with 
2-NO2C6H4CO2D  
 
General Procedure C: Indole 178a (31.8 mg, 0.10 mmol) and 2-NO2C6H4CO2D (25.2 mg, 0.15 mmol) 
were employed and the reaction mixture was heated at 140 °C for 20 h. The residue was purified by 
flash column chromatography (5–20% acetone/toluene) to afford deuterio-179ab (6.20 mg, 13%) and 
deuterio-178aa (35.0 mg, 81%). The percentage of deuterium incorporation was measured by 1H NMR. 
Analysis of deuterio-179ab revealed 5% and 5% deuterium incorporation at the diastereotopic C12 
protons and 5% and 5% deuterium incorporation at the diastereotopic C10 protons. The deuterium 
incorporation was also unambiguously confirmed by 2H NMR. Analysis of deuterio-178aa revealed 4% 
deuterium incorporation at C1 proton and 14% at NH protons. The deuterium incorporation was also 
unambiguously confirmed by 2H NMR.  
Data for product deuterio-179ab: 1H NMR (400 MHz, CDCl3): δ 9.21 (1H, br. s, NH), 8.12 (1H, d, J = 
8.5, C4-H), 7.46 – 7.24 (8H, m, C5-H, C6-H, C7-H,  2 × C16-H, 2 × C17-H and C18-H), 5.31 (1H, d, 
J = 14.5 Hz, 1 × C14-H2), 4.53 (1H, d, J = 14.5 Hz, 1 × C14-H2), 3.82 (0.95H, m, 1 × C12-H2), 3.31 
(0.95H, m, 1 × C12-H2), 3.12 (0.95H, m, 1 × C10-H2), 2.63 (0.95H, m, 1 × C10-H2), 2.08 (1H, m, 1 × 
C11-H2), 1.84 (1H, m, 1 × C11-H2); 2H NMR (77 MHz): δ 3.21 (0.10D, br. m), 2.60 (0.05D, br. m,), 
2.01 (0.05D, br. m). 
Data for recovered starting material deuterio-178aa: 1H NMR (400 MHz, Acetonitrile-d3) δ 9.73 (0.86H, 
s, NH), 8.02 (1H, dd, J = 8.0, 1.0 Hz, C4-H), 7.80 (0.96D, d, J = 3.0 Hz, C1-H), 7.46 (1H, dd, J = 8.0, 
1.0 Hz, C7-H), 7.37 – 7.30 (4H, m 2 × C11-H and 2 × C12-H), 7.26 (1H, m, C13-H), 7.20 (1H, ddd, J 
= 8.0, 7.0, 1.0 Hz, C6-H), 7.14 (1H, ddd, J = 8.0, 7.0, 1.0 Hz, C5-H), 4.79 (2H, s, C9-H2), 2.86 (1H, tt, 
J = 7.0, 4.0 Hz, C14-H), 0.75 – 0.61 (4H, m, 2 × C15-H2); 2H NMR (77 MHz, ) δ 9.71 (0.02D, s), 7.83 
(0.04D, s, C1-H). 





Eqn 3: Deuterium exchange experiment of indole 179a with 2-NO2C6H4CO2D under standard 
reaction conditions  
 
General Procedure C: Indole 179a (31.8 mg, 0.10 mmol) and 2-NO2C6H4CO2D (25.2 mg, 0.15 mmol) 
were employed and the reaction mixture was heated at 130 °C for 72 h. The residue was purified by 
flash column chromatography (10–20% acetone/toluene) to afford deuterio-179ac (25.6 mg, 81%). The 
percentage of deuterium incorporation was measured by 1H NMR. Analysis of deuterio-179ac revealed 
14% and 14% deuterium incorporation at the diastereotopic C10 protons. <5% deuterium incorporation 
was measured at NH proton. The deuterium incorporation was also unambiguously confirmed by 2H 
NMR analysis. 
Data for product deuterio-179ac: 1H NMR (400 MHz, CDCl3): δ 9.39 (1H, br. s, NH), 8.12 (1H, dd, J 
= 8.5, 1.0 Hz, C4-H), 7.44 – 7.26 (8H, m, C5-H, C6-H, C7-H,  2 × C16-H, 2 × C17-H and C18-H), 5.32 
(1H, d, J = 14.5 Hz, 1 × C14-H2), 4.53 (1H, d, J = 14.5 Hz, 1 × C14-H2), 3.82 (1H, m, 1 × C12-H2), 
3.37 (1H, m, 1 × C12-H2), 3.13 (0.86H, m, 1 × C10-H2), 2.63 (0.86H, m, 1 × C10-H2), 2.08 (1H, m, 1 
× C11-H2), 1.85 (1H, m, 1 × C11-H2); H NMR (CHCl3, 77 MHz): δ 2.95 – 2.48 (0.28D, br. m, C10-
H2).  
These results support the hypothesis that deuterium incorporation at C10 occurs via enolization of the 
product.   
N-Benzyl-N-ethyl-1H-indole-3-carboxamide (192) 
 
General Procedure B: 1H-Indole-3-carboxylic acid (500 mg, 3.11 mmol) and N-benzylethanamine 
(417 mg, 3.11 mmol) were employed and the reaction was stirred at room temperature for 18 hours. 
The crude residue recrystallised from MeOH to give the title compound 192 (412g, 48%) as a colourless 
solid; m.p.: 155–157 °C (MeOH); νmax/ cm-1: 3206 (br. s), 2961 (s), 1591 (s), 1568 (s), 1432 (s), 1200 
(s); 1H NMR (500 MHz, DMSO-d6) δ 11.49 (1H, s, NH), 7.78 (1H, d, J = 8.0 Hz, C4-H), 7.57 (1H, m, 
C1-H), 7.43 (1H, d, J = 8.0 Hz, C7-H), 7.39 – 7.25 (5H, m, 2 × C12-H, 2 × C13-H and C14-H), 7.19 – 





7.07 (2H, m, C5-H and C6-H), 4.75 (2H, s, C10-H2), 3.44 (2H, q, J = 7.0 Hz, C15-H2), 1.13 (3H, t, J = 
7.0 Hz, C16-H3); 13C NMR (126 MHz, DMSO-d6) δ 166.3 (C9), 138.5 (C11), 135.6 (C8), 128.6 (C13), 
127.1, 127.0, 126.6, 126.2 (C1, C3, C12 and C14), 121.9 (C6), 120.4, 120.1 (C4 and C5), 111.8 (C7), 
109.9 (C2), 49.0 (C10), 41.4 (C15), 13.4 (C16); HRMS: (ESI)+ Calculated for C18H18N2NaO: 301.1311. 
Found [M + Na] +: 301.1325. 
Eqn 4: Deuterium exchange experiment of indole 192 with 2-NO2C6H4CO2D under standard 
reaction conditions  
 
General Procedure C: Indole 192 (41.7 mg, 0.15 mmol) and 2-NO2C6H4CO2D (37.8 mg, 0.15 mmol) 
were employed and the reaction mixture was heated at 130 °C for 20 h. The residue was purified by 
flash column chromatography (10–20% acetone/toluene) to afford recovered 192 (27.9 mg, 67%). The 
percentage of deuterium incorporation was measured by 1H NMR analysis, which revealed no 
deuterium incorporation.   
Intramolecular kinetic isotope effect experiment 
N-Benzyl-N-cyclopropyl-1H-indole-3-carboxamide-2-d (deuterio-178ab) 
 
To a suspension of 1H-indole-2-d (354 mg, 3.00 mmol) (prepared according to the literature 
procedure347) and AlCl3 (480 mg, 3.60 mmol) in CH2Cl2 (15.0 mL) at 0 °C was added a solution of 
benzyl(cyclopropyl)carbamic chloride 299a (1.03 g, 3.60 mmol) in CH2Cl2 (10.0 mL). The resulting 
solution was stirred at 0 °C for 4 hours and then allowed the warm to room temperature. The reaction 
mixture was quenched by addition of H2O (35 mL) and extracted with CH2Cl2 (3 × 30 mL). The organic 
layers were combined, washed with brine (30 mL), dried over Na2SO4, filtered and concentrated in 
vacuo. The residue was purified by flash column chromatography (10–20% EtOAc/CH2Cl2) to afford 
deuterio-178ab (264 mg, 30%) as an off-white solid. The percentage of deuterium incorporation was 
measured by 1H NMR analysis, which revealed 75% deuterium incorporation at the C1 proton. 1H NMR 
(400 MHz, Acetonitrile-d3): δ 9.65 (1H, s, NH), 7.99 (1H, dd, J = 8.0, 1.0 Hz, C4-H), 7.80 (0.25H, m, 





C1-H), 7.45 (1H, d, J = 8.0 Hz, C7-H), 7.34 – 7.30 (4H, m, 2 × C11-H and 2 × C12-H), 7.24 (1H, m, 
C13-H), 7.19 – 7.09 (2H, m, C5-H and C6-H), 4.76 (2H, s, C9-H2), 2.84 (1H, s, C14-H), 0.73 – 0.58 
(4H, m, 2 × C15-H2); 2H NMR (77 MHz, ) δ 7.83 (0.75D, s, C1-H); HRMS: (ESI)+ Calculated for 
C19H17DN2O: 292.1555. Found [M + H]+: 292.1549. 
Eqn 5: Kinetic isotope effect determination for the Rh(I)-catalysed carbonylative cyclisation of 
178 and deuterio-178ab.  
 
Five identical, oven dried reaction tubes were fitted with a magnetic stirrer and charged with 178a (29.0 
mg, 100 mol%), [Rh(cod)OMe]2 (1.84 mg, 3.75 mol%), P-(4-(F)C6H4)3 (7.11 mg, 22.5 mol%) and 2-
NO2C6H4CO2H (25.5 mg, 150 mol%). Each tube was fitted with a rubber septum and purged with argon 
for 20 minutes. The reagents were dissolved in argon sparged anhydrous PhCN (0.30 M). The reaction 
vessel was purged with CO for approximately 10 minutes and the suspension was subsequently sparged 
with CO for approximately 30 seconds. Each reaction tube was heated at 140 °C under a CO atmosphere 
(1 atm) for the time noted. The reactions were stopped at 7 h, 9 h, 11 h, 13 h and 15 h respectively. The 
conversion to product 179a was determined by 1H NMR spectroscopy using 1,4-dinitrobenzene as an 
internal standard. Five analogous reaction tubes were set up using deuterio-178ab (29.1 mg, 100 mol%) 
and were stopped after 7 h, 9 h, 11 h, 13 h and 15 h respectively. The conversion to product deuterio-
179ad was determined by 1H NMR spectroscopy using 1,4-dinitrobenzene as an internal standard.  






Entry time (hours) Yield 178aa  
1 7 6% 
2 9 10% 
3 11 20% 
4 13 23% 
5 15 32% 
[a] The yield was determined by 1H NMR spectroscopy using 1,4-dinitrobenzene as an internal standard. 
 
Entry time (hours) Yield deuterio-179ada  
1 7 4% 
2 9 7% 
3 11 19% 
4 13 22% 
5 15 25% 
[a] The yield was determined by 1H NMR spectroscopy using 1,4-dinitrobenzene as an internal standard. 






kH/kD = 3.25/2.85=1.14  
Figure 5: Formation of product 179a and deuterio-179ad as a function of time  
N-((1H-indol-3-yl)methyl)-N-cyclopropylacetamide (193a) 
 
A solution of 1H-indole-3-carbaldehyde (290 mg, 2.00 mmol) and cyclopropylamine (0.15 mL, 2.20 
mmol) in MeOH (10.0 mL) was heated at reflux for 2 hours. The resulting suspension was cooled to 
0 °C and NaBH4 (91.0 mg, 2.40 mmol) was added portion wise over 10 minutes. The reaction was 
warmed to room temperature and stirred for an additional 16 hours. The reaction mixture was 
concentrated in vacuo before the addition of saturated aqueous NaHCO3 (20 mL). The solution was 
extracted with CH2Cl2 (2 × 20 mL). The organic layers were combined, washed with brine (50 mL), 
dried over Na2SO4 and concentrated in vacuo to give the crude amine intermediate which was used 
without further purification. The crude material was re dissolved in CH2Cl2 (10.0 mL) and the solution 
was cooled to 0 °C. Et3N (0.42 mL, 3.00 mmol) was added, followed by dropwise addition of acetyl 
chloride (0.14 mL, 2.00 mmol) over 5 minutes. The reaction mixture was warmed to room temperature 
and stirred for a further 3 hours. The reaction mixture was diluted with CH2Cl2 (30 mL) and washed 
with water (40 mL), brine (40 mL), dried over Na2SO4, filtered and concentrated in vacuo. The crude 
y = 3.25x - 17.55




























Intramolecular kinetic isotope effect experiment
179a deuterio-179ad
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residue was purified by flash column chromatography (60–70% EtOAc/hexane) to give the title 
compound 193a (395 mg, 87%) as an off-white solid; m.p.: 155–157 °C (MeOH); νmax/ cm-1: 3288 (br. 
s), 2058 (m), 1621 (s), 1442 (s), 1410 (s), 1310 (s); 1H NMR (400 MHz, CDCl3): δ 8.45 (1H, br. s, NH), 
7.74 (1H, dd, J = 8.0, 1.0 Hz, C4-H), 7.36 (dd, J = 8.0, 1.0 Hz, C7-H), 7.22 – 7.17 (2H, m, C1-H and 
C6-H), 7.13 (1H, ddd, J = 8.0, 7.0, 1.0 Hz, C5-H), 4.75 (2H, s, C9-H2), 2.47 (1H, tt, J = 6.5, 4.0 Hz, 
C10-H), 2.21 (3H, s, C13-H2), 0.88 – 0.80 (4H, m, 2 × C11-H2); 13C NMR (101 MHz, CDCl3): δ 173.6 
(C12), 136.2 (C8), 127.1 (C3), 124.3 (C1), 122.1 (C6), 119.7 (C5), 119.4 (C4), 113.0 (C2), 111.3 (C7), 
40.7 (C9), 30.3 (C10), 22.9 (C13), 9.6 (C11); HRMS: (ESI)+ Calculated for C14H16N2NaO: 251.1155. 
Found [M + Na] +: 251.1147. 
Attempted Rh(I)-catalysed carbonylation of indole 193a 
 
General Procedure C: Compound 193a (34.2 mg, 0.15 mmol) was employed and the reaction mixture 
was heated at 140 °C for 48 h. Analysis of the crude reaction mixture by 1H NMR spectroscopy revealed 
decomposition and none of the desired product 194a. 
7.4 Experimental procedures for the studies in Chapter 3 
7.4.1 Synthesis of substrates and catalysis products  
N-Benzyl-2-oxooxazolidine-3-sulfonamide (256) 
 
The title compound 255 was prepared following a literature procedure.182 Chlorosulfonylisocyanate 
(2.18 mL, 25.0 mmol) was dissolved in dry CH2Cl2 (30 mL) and cooled to 0 °C. 2-Chloroethanol (1.67 
mL, 25.0 mmol) was dissolved in dry CH2Cl2 (8 mL) and added dropwise over 30 minutes. A mixture 
of benzylamine (3.00 mL, 27.5 mmol) and triethylamine (7.67 mL, 55.0 mmol) in CH2Cl2 (15 mL) was 
added over 10 minutes. The mixture was warmed to room temperature and stirred for 1 hour. 0.2 M 
aqueous HCl (25 mL) was added and the pH was adjusted to 2 by the addition of conc. HCl. The organic 
layer was washed with 0.05 M aqueous HCl (25 mL), H2O (25 mL), brine (25 mL), dried over Na2SO4 
and concentrated in vacuo. The residue was purified by flash column chromatography (50% 
EtOAc/hexane) to afford the title compound 256 (4.16 g, 65%) as an off-white solid; 1H NMR (400 





MHz, CD3CN): δ 7.46 – 7.27 (5H, m, C1-H, 2 × C2-H, 2 × C3-H ), 6.35 (1H, t, J = 6.0 Hz, NH), 4.31 
(2H, t, J = 7.0, C7-H2), 4.25 (2H, d, J = 6.0 Hz, C5-H2), 3.74 (2H, t, J = 7.0, C8-H2); 13C NMR (101 
MHz, CD3CN): δ 153.0 (C6), 137.8 (C4), 129.5, 129.1 (C2, C3), 128.7 (C1), 66.6 (C7), 48.4 (C8), 43.1 




To a solution of N-benzylcyclopropanamine 170a (3.01 g, 22.5 mmol) and triethylamine (5.64 mL, 40.5 
mmol) in MeCN (60 mL) was added N-benzyl-2-oxooxazolidine-3-sulfonamide 256 (3.50 g, 14.0 
mmol). The reaction mixture was heated to reflux for 16 hours and then cooled to room temperature. 
The volatiles were removed in vacuo and the crude residue was purified by flash column 
chromatography (20% EtOAc/hexane) to afford the title compound 257a (3.72 g, 84%) as an off-white 
solid; m.p.: 66–67 °C (EtOAc); νmax/ cm-1: 3296 (br. m), 2987 (m), 1454 (s), 1328 (s), 1150 (s), 1066 
(s), 1027 (s); 1H NMR (400 MHz, CDCl3): δ 7.45 – 7.39 (2H, m, ArC-H), 7.38 – 7.28 (6H, m, ArC-H), 
7.23 (2H, dd, J = 7.8, 1.7 Hz, ArC-H), 4.42 (2H, s, C1-H2), 4.37 (1H, t, J = 6.0 Hz, NH), 4.09 (2H, d, J 
= 6.0 Hz, C2-H2), 2.39 (1H, tt, J = 6.5, 4.0 Hz, C3-H), 0.81 – 0.64 (4H, m, 2 × C4-H2); 13C NMR (101 
MHz, CDCl3): δ 137.0 (ArC), 136.8 (ArC), 129.1, 128.9, 128.6, 128.4 (2 signals), 127.9 (6 × Ar-CH), 
55.2 (C2), 47.6 (C1), 30.4 (C3), 7.8 (C4); HRMS: (ESI+) Calculated for C17H21N2O2S: 317.1318. Found 
[M + H]+: 317.1338.  
tert-Butyl (N-benzyl-N-cyclopropylsulfamoyl)carbamate (257b) 
 
To a solution of chlorosulfonylisocyanate (0.39 mL, 4.50 mmol) in CH2Cl2 (10 mL) at 0 °C was added 
t-BuOH (0.43 mL, 4.50 mmol). The solution was stirred at 0 °C for 10 minutes and then allowed to 
warm to room temperature. A solution of N-benzylcyclopropanamine 170a (695 mg, 4.73 mmol) and 
triethylamine (1.25 mL, 9.00 mmol) in CH2Cl2 (5 mL) was added dropwise to the reaction mixture over 
10 minutes and the resulting yellow suspension was stirred for an additional 1 hour. The reaction 
mixture was diluted with CH2Cl2 (20 mL) and washed with 1 M aqueous HCl (2 × 25 mL). The organic 
layers were combined and washed with H2O (20 mL), dried over Na2SO4, filtered and concentrated in 
vacuo. The residue was purified by flash column chromatography (20% EtOAc/hexane) to afford the 





title compound 257b (1.21 g, 83%) as an off-white solid; m.p.: 139–141 °C (EtOAc); νmax/ cm-1: 3300 
(br. m), 3273 (m), 1715 (s), 1398 (s), 1148 (s); 1H NMR (400 MHz, CDCl3): δ 7.55 – 7.27 (5H, m, C1-
H, 2 × C2-H, 2 × C3-H), 7.07 (1H, s, NH), 4.60 (2H, s, C5-H2), 2.57 (1H, m, C6-H), 1.49 (9H, s, 3 × 
C10-H3), 0.85 – 0.65 (4H, m, 2 × C7-H2); 13C NMR (101 MHz, CDCl3) δ 149.8 (C8), 137.2 (C4), 128.7, 
128.3 (C2, C3) 127.8 (C1), 83.7 (C9), 56.0 (C5), 31.0 (C6), 28.2 (C10), 7.3 (C7); HRMS: (ESI+) 
Calculated for C15H22N2NaO4S: 349.1192. Found [M + Na]+: 349.1190.  
N-Benzyl-N-cyclopropylsulfamide (257c)  
 
To a solution of sulfamide 257b (250 mg, 0.77 mmol) in CH2Cl2 (2 mL) at 0 °C was added trifluoracetic 
acid (0.27 mL, 2.31 mmol). After 2 hours, the ice bath was removed and the reaction mixture was stirred 
at room temperature for 18 hours. The reaction mixture was diluted with CH2Cl2 (15 mL) and washed 
with saturated aqueous NaHCO3 (2 × 10 mL). The aqueous layer was extracted with CH2Cl2 (2 × 20 
mL). The organic extracts were combined, washed with H2O (20 ml), brine (20 mL), dried over Na2SO4, 
filtered and concentrated in vacuo to afford the title compound 257c (167 mg, 96%) as a white solid 
which was used without further purification; m.p.: 124–126 °C (CH2Cl2); νmax/ cm-1: 3745 (br. m), 3156 
(m), 2939 (m), 1554 (s), 1398 (s), 1300 (s), 1163 (s); 1H NMR (400 MHz, CDCl3): δ 7.48 – 7.32 (5H, 
m, C1-H, 2 × C2-H, 2 × C3-H), 4.43 (2H, s, C5-H2), 4.15 (2H, br. s, NH2), 2.36 (1H, tt, J = 7.0, 3.5 Hz, 
C6-H), 0.94 – 0.70 (4H, m, 2 × C7-H2); 13C NMR (101 MHz, CDCl3): δ 135.9 (C4), 129.1, 128.8 (C2, 
C3), 128.3 (C1), 55.2 (C5) 30.2 (C6), 7.9 (C7); HRMS: (ESI+) Calculated for C10H14N2NaO2S: 
249.0668. Found [M + Na]+: 249.0666. 
N-(N-Benzyl-N-cyclopropylsulfamoyl)acetamide (257d) 
 
To a solution of sulfamide 257c (200 mg, 0.88 mmol) in pyridine (6 mL) was added acetyl chloride (70 
µL, 0.97 mmol). The reaction mixture was stirred at room temperature for 6 hours and then concentrated 
in vacuo. The residue was dissolved in CH2Cl2 and washed with saturated aqueous NH4Cl (20 mL), 
H2O (20 mL), brine (20 mL), dried over Na2SO4, filtered and concentrated in vacuo. The crude residue 
was purified by flash column chromatography (50% EtOAc/hexane) to afford the title compound 257d 
(161 mg, 68%) as a colourless solid; m.p.: 112–114 °C (EtOAc); νmax/ cm-1: 3130 (m), 2986 (m), 1688 
(s), 1469 (s), 1427 (s), 1361 (s), 1240 (s), 1162 (s); 1H NMR (400 MHz, CDCl3): δ 8.39 (1H, s, NH), 





7.44 – 7.25 (5H, m, C1-H, 2 × C2-H, 2 × C3-H), 4.61 (2H, s, C5-H2), 2.59 (1H, m, C6-H), 2.06 (3H, s, 
C9-H3), 0.84 – 0.66 (4H, m, 2 × C7-H2); 13C NMR (101 MHz, CDCl3) δ 168.5 (C8), 136.9 (C4), 128.6, 
128.2 (C3, C2), 127.7 (C1), 55.6 (C5), 31.1 (C6), 23.4 (C9), 7.2 (C7); HRMS: (ESI+) Calculated for 
C12H16N2NaO3S: 291.0774. Found [M + Na]+: 291.0779. 
N-Ethoxycarbonyl-N’-benzyl-thiourea (262) 
 
Ethoxycarbonyl isothiocyanate (787 mg, 6.00 mmol) was dissolved in dry CH2Cl2 (30 mL) and cooled 
to 0 °C. A solution of benzylamine (0.643 g, 6.00 mmol) in CH2Cl2 (5 mL) was added over 10 minutes 
and the reaction mixture was warmed to room temperature and stirred for 1 hour. The solution was 
diluted with CH2Cl2 (20 mL) and washed with 1 M aqueous HCl (25 mL). The aqueous layer was 
extracted twice with CH2Cl2 (2 × 20 mL). The organic extracts were combined, washed with H2O (25 
mL), brine (25 mL), dried over Na2SO4, filtered and concentrated in vacuo to afford the title compound 
262 (1.40 g, 98%) as an off-white solid. The product was used in the following step without any further 
purification. νmax/ cm-1: 3171 (m), 1715 (s), 1707 (s), 1549 (s), 1434 (s), 1240 (s), 1188 (s), 1046 (s); 1H 
NMR (400 MHz, CDCl3): δ 9.88 (1H, s, NH), 8.18 (1H, s, NH), 7.34 – 7.16 (5H, m, 2 × C7-H, 2 × C8-
H, C9-H), 4.78 (2H, s, C5-H2), 4.12 (2H, q, J = 7.0 Hz, C2-H2), 1.21 (3H, t, J = 7.0 Hz, C1-H3); 13C 
NMR (101 MHz, CDCl3): δ 179.5 (C4), 152.8 (C3), 136.4 (C6), 129.0, 128.1, 128.0, (C7, C8, C9), 62.9 
(C2), 49.7 (C5), 14.3 (C1); HRMS: (ESI+): Calculated for C15H16N2NaO2S: 261.0668. Found [M + Na]+: 
261.0664. The spectroscopic properties of this compound were consistent with the data available in the 
literature.184  
N-Ethoxycarbonyl-N’, N’’-dibenzyl-N’’-cyclopropylguanidine (263)  
 
Carbamoyl thiourea 262 (1.00 g, 4.20 mmol), N-benzylcyclopropanamine 170a (0.741 g, 5.04 mmol) 
and triethylamine (0.59 mL, 4.20 mmol) were dissolved in CH2Cl2 (20 mL). EDCI (0.966 g, 5.04 mmol) 
was then added in one portion and the reaction mixture was stirred at room temperature for 22 hours. 
The reaction mixture was diluted with CH2Cl2 (20 mL) and washed sequentially with 1 M aqueous HCl 
(20 mL), water (20 mL) and brine (15 mL). The organic extracts were combined, dried over Na2SO4, 
filtered and concentrated in vacuo. The residue was purified by flash column chromatography (30%  
EtOAc/toluene, modified with 1% Et3N) to yield the title compound 263 (1.19 g, 81%) as a colourless 





solid; m.p.: 110–111 °C (EtOAc); νmax/ cm-1: 3241 (m), 2985 (m), 1644 (s), 1558 (s), 1520 (s), 1297 (s),  
1151 (s), 1095 (s); 1H NMR (400 MHz, CDCl3): δ 7.32 – 7.13 (8H, m, 8 × ArC-H), 7.11 – 7.05 (2H, m, 
ArC-H), 4.56 (2H, s, C1-H2), 4.44 (2H, d, J = 5.0 Hz, C3-H2), 4.05 (2H, q, J = 7.0 Hz, C5-H2), 2.28 
(1H, tt, J = 6.5, 4.0 Hz, C7-H), 1.21 (3H, t, J = 7.0 Hz, C6-H3), 0.79 – 0.62 (4H, m, 2 × C8-H2); 13C 
NMR (101 MHz, CDCl3): δ 162.7 (C2), 161.4 (C4), 137.9 (ArC), 137.4 (ArC), 128.9, 128.5, 128.1, 
127.9, 127.7, 127.3 (6 × Ar-CH), 60.8 (C5), 53.3 (C3), 48.2 (C1), 29.7 (C7), 14.8 (C6), 9.5 (C8); HRMS: 
(ESI)+ Calculated for C21H26N3O2: 352.2020. Found [M + H]+: 352.2013.  
Ethyl (Z)-(1,3-dibenzyl-4-oxo-1,3,4,5-tetrahydro-2H-1,3-diazepin-2-ylidene)carbamate (264’) and 
N-Ethoxycarbonyl-N’, N’’-dibenzyl guanidine (265).  
 
An oven dried reaction tube, fitted with a magnetic stirrer, was charged with [Rh(cod)OH]2 (2.28 mg, 
5.0 μmol, 5 mol%), PPh3 (3.24 mg, 0.015 mmol, 15 mol%), benzoic acid (3.66 mg, 0.030 mmol, 30 
mol%) and guanidine substrate 263 (35.2 mg, 0.10 mmol, 100 mol%). The tube was fitted with a rubber 
septum and purged with argon. The reagents were dissolved in argon sparged 1,2-DCB (0.5 mL). The 
reaction mixture was sparged with CO for approximately 10 seconds, then heated at 100 °C under a CO 
atmosphere for 24 h. The mixture was cooled to room temperature and concentrated in vacuo. An in 
situ yield was obtained by 1H NMR spectroscopy against 1,4-dinitrobenzene as an internal standard; a 
7% yield of cyclised product 264’ was observed. Flash column chromatography (40% EtOAc/hexane) 
afforded the desired product 264’ and side-product 265 as colourless oils. Due to small quantity of 
product 264’ this compound was not isolated as a pure compound. The structure of 264’ was determined 
by analysis of the 1H, 13C, COSY, HSQC and HMBC NMR spectra, mass spectrometry and by 
comparison to analogous products.  
Data for 264’: Characteristic peaks only: 1H NMR (400 MHz, CDCl3): 5.97 (1H, d, J = 7.0 Hz, C2-H), 
5.66 (dt, 1H, J = 7.0, 7.0 Hz, C3-H), 4.58 (2H, s, C1-H2), 3.82 (2H, s, C7-H2), 2.99 (2H, d, J = 7.0 Hz, 
C4-H2); 13C NMR (101 MHz, CDCl3): δ 170.2 (C5), 153.9 (C6), 130.0 (C2), 117.4 (C3), 50.2, 50.0 (C1, 
C7), 34.8 (C4); HRMS: (ESI)+ Calculated for C22H24N3O3: 378.1812. Found [M + H]+: 378.1812. 
Data for 265: Characteristic peaks only: 1H NMR (400 MHz, CDCl3): 4.80 (4H, d, J = 8.5 Hz, C1-H2, 
C7-H2), 4.49 (2H, br. s, 2 × NH); 13C NMR (101 MHz, CDCl3): 153.5 (C2), 54.8 (C1, C3); HRMS: 
(ESI)+ Calculated for C18H22N3O2: 312.1707. Found [M + H]+: 312.1718. The spectroscopic properties 
of this compound were consistent with the data available in the literature.184  
  







To an oven dried reaction tube was added 2-bromo-6-methoxypyridine (486 mg, 2.60 mmol), N-
benzylcyclopropanamine 170a (458 mg, 3.12 mmol), Pd(OAc)2 (29.1 mg, 0.13 mmol), dppp (107 mg, 
0.26 mmol) and NaOt-Bu (500 mg, 5.20 mmol). The tube was fitted with a rubber septum and purged 
with argon. The reagents were dissolved in dry toluene (13 mL). The tube was sealed and heated at 
80 °C for 14 hours and then cooled to room temperature. The reaction mixture was filtered through a 
pad of celite® and concentrated in vacuo. The crude residue was purified by flash column 
chromatography (30% toluene/hexane) to afford the title compound 268 (328 mg, 50%) as a colourless 
oil; υmax/cm-1: 2944 (m), 1589 (s), 1587 (s), 1368 (s), 1257 (s), 1149 (s); 1H NMR (400 MHz, CDCl3): 
δ 7.41 (1H, dd, J = 8.0, 8.0 Hz, C3-H), 7.30 – 7.17 (5H, m, 2 × C8-H, 2 × C9-H, C10-H), 6.50 (1H, dd, 
J = 8.0, 1.0 Hz, C2-H), 6.09 (1H, dd, J = 8.0, 1.0 Hz, C4-H), 4.90 (2H, s, C6-H2), 3.76 (3H, s, C13-H3), 
2.46 (1H, tt, J = 6.5, 3.5 Hz, C11-H), 0.85 – 0.79 (2H, m, 1 × C12-H2), 0.74 – 0.67 (2H, m, 1 × C12-
H2); 13C NMR (101 MHz, CDCl3): δ 162.9 (C1), 158.4 (C5), 140.2 (C7), 139.7 (C3), 128.2, 127.4 (C8, 
C9) 126.5 (C10), 99.3 (C2), 97.9 (C4), 52.9 (C13), 51.8 (C6), 30.3 (C11), 8.8 (C12); HRMS: (ESI+) 
Calculated for C16H19N2O: 255.1419. Found [M + H]+: 255.1502. 
6-(Benzyl(cyclopropyl)amino)pyridin-2(1H)-one (269)  
 
To a solution of pyridine 268 (600 mg, 2.37 mmol) in anhydrous MeCN (12 mL) was added NaI (710 
mg, 4.74 mmol) and trimethylsilyl chloride (0.60 mL, 4.74 mmol). The solution was heated at 80 °C 
for 2 hours and then cooled to room temperature. MeOH (1 mL) was added and the reaction mixture 
was stirred for an additional 2 hours at room temperature. The volatiles were removed in vacuo and the 
residue was dissolved in EtOAc (25 mL) and washed with 10% aqueous NaS2O3 solution (2 × 25 mL), 
water (25 mL) and brine (25 mL). The organic layers were combined, dried over Na2SO4, filtered and 
concentrated in vacuo. The crude material was purified by flash chromatography (90% EtOAc/hexane) 
to afford the title compound 269 (434 mg, 76%) as an off-white solid; m.p.: 98–99 °C (EtOAc); υmax/cm-
1: 3006 (m), 2919 (m), 1654 (s), 1572 (s), 1444 (s), 1367 (s); 1H NMR (400 MHz, CDCl3): δ 10.96 (1H, 
br. s, NH), 7.34 – 7.08 (6H, m, C3-H, 2 × C8-H, 2 × C9-H, C10-H), 5.84 (1H, d, J = 8.5 Hz, C2-H), 
5.54 (1H, d, J = 8.0 Hz, C4-H), 4.67 (2H, s, C6-H2), 2.62 (1H, tt, J = 7.0, 3.5 Hz, C11-H), 0.91 – 0.86 





(2H, m, 1 × C12-H2), 0.76 – 0.67 (2H, m, 1 × C12-H2); 13C NMR (101 MHz, CDCl3): δ 163.3 (C1), 
151.9 (C5), 142.9 (C3), 136. (C7), 128.8, 127.4, 126.3 (C8, C9, C10), 104.9 (C2), 88.9 (C4), 54.3 (C6), 
30.4 (C11), 8.9 (C12); HRMS: (ESI+) Calculated for C15H18N2O: 241.1335. Found [M + H]+: 241.1337. 
N-Benzyl-6-methoxy-N-(prop-1-en-1-yl)pyridin-2-amine (270) and N-Benzyl-6-methoxypyridin-
2-amine (415) 
 
An oven dried reaction tube, fitted with a magnetic stirrer, was charged with substrate 268 (50.0 mg, 
0.208 mmol), [Rh(cod)2]BF4 (4.22 mg, 10.4 µmol, 5 mol%), and PPh3 (8.17 mg, 31.2 µmol, 15 mol%). 
The tube was fitted with a rubber septum and purged with argon. The reagents were dissolved in 
anhydrous toluene (2.1 mL). The tube was sealed and the reaction mixture was heated at 140 °C for 4 
hours. After this time, the reaction mixture was cooled to room temperature and concentrated in vacuo. 
An in situ yield was obtained by 1H NMR spectroscopy using 1,4-dinitrobenzene as an internal standard; 
a 13% yield of alkene product 270 and a 65% yield of remaining starting material 268 was observed. 
The product 270 could not be isolated by column chromatography due to its instability. Flash column 
chromatography (FCC) (40% toluene/EtOAc) afforded the NH side-product 415 (5.2 mg, 10%) as a 
colourless oil. The structure of alkene 270 was determined by analysis of the 1H NMR spectrum of the 
reaction mixture and corroborated by COSY and HSQC data.  
Data for alkene 270: Characteristic peaks only: 1H NMR (400 MHz, CDCl3): δ 7.56 (1H, dd, J = 7.5, 
1.5 Hz, C2-H), 5.00 (2H, s, C1-H2), 4.87 (1H, dt, J = 7.5, 6.5 Hz, C3-H), 1.74 (3H, dd, J = 6.5, 1.5 Hz, 
C4-H3). 
Data for amine 415: υmax/cm-1: 3646 (br. m), 2901 (m), 1601 (s), 1469 (s), 1382 (s), 1242 (s), 1147 (s); 
1H NMR (400 MHz, CDCl3): δ 7.40 – 7.30 (5H, m, 2 × C8-H, 2 × C9-H, C10-H), 7.26 (1H, m, C3-H), 
6.04 (1H, d, J = 8.0 Hz, C2-H), 5.94 (1H, d, J = 8.0 Hz, C4-H), 4.74 (1H, br. s, NH), 4.49 (2H, d, J = 
5.5 Hz, C6-H2), 3.84 (3H, s, C11-H3); 13C NMR (126 MHz, CDCl3): δ 163.6 (C1), 157.5 (C5), 140.3 
(C3), 139.4 (C7), 128.9, 127.5 (C8, C9), 127.2 (C10), 97.84 (C4), 97.6 (C2), 53.2 (C11), 46.4 (C6); 
HRMS: (ESI+) Calculated for C13H15N2O: 215.1179. Found [M + H]+: 215.1185.  
  







An oven dried reaction tube, fitted with a magnetic stirrer, was charged with pyridone substrate 269 
(30.0 mg, 0.125 mmol), [Rh(cod)2] OTf (2.93 mg, 6.25 µmol, 5 mol%), and PPh3 (4.91 mg, 18.6 µmol, 
15 mol%). The tube was fitted with a rubber septum and purged with argon. The reagents were dissolved 
in argon sparged 1,2-DCB (0.63 mL). The reaction mixture was sparged with CO for approximately 10 
seconds, then heated at 150 °C under a CO atmosphere for 24 h. After this time, the mixture was cooled 
to room temperature and concentrated in vacuo. The crude material was purified by flash column 
chromatography (5% MeOH/CH2Cl2) to afford the product 272 (3.0 mg, 12%) as a colourless oil; 
υmax/cm-1: 3264 (br. m), 3061 (m), 2992 (m), 1618 (m), 1452 (m), 1353 (m), 1277 (m); 1H NMR (400 
MHz, CDCl3): δ 7.39 – 7.24 (5H, m, 2 × C8-H, 2 × C9-H, C10-H), 7.20 (1H, m, C3-H), 6.14 (1H, br. 
s, NH), 5.60 (1H, d, J = 8.5 Hz, C2-H), 5.31 (1H, d, J = 8.0 Hz, C4-H), 4.30 (2H, d, J = 5.0 Hz, C6-H2); 
13C NMR (126 MHz, CDCl3): δ 164.7 (C1), 151.5 (C5), 144.1 (C3), 137.5 (C7), 128.4, 127.5, 127.0 
(C8, C9, C10), 103.2 (C2), 87.1 (C4), 46.4 (C6); HRMS: (ESI+) Calculated for C12H13N2O: 201.1022. 
Found [M + H]+: 201.1025.   
2-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)benzoic acid 
 
To a solution of 2-boronobenzoic acid (650 mg, 3.93 mmol) in anhydrous THF (10 mL) was added 
pinacol (464 mg, 3.93 mmol) and MgSO4 (943 mg, 7.86 mmol). The reaction mixture was stirred at 
room temperature for 20 hours, then filtered and concentrated in vacuo to afford the title compound 416 
(927 mg, 95%) as a white solid. The product was used in the following step without any further 
purification. νmax/ cm-1: 2972 (w), 1671 (s), 1340 (s), 1307 (s), 1140 (s); 1H NMR (400 MHz, DMSO-
d6): δ 7.85 (1H, dt, J = 7.5, 1.0 Hz, C2-H), 7.55 (1H, td, J = 7.5 1.5 Hz, ArC-H), 7.51 – 7.40 (2H, m, 2 
× ArC-H), 1.30 (12H, s, 4 × C9-H3); 13C NMR (101 MHz, DMSO-D6): δ 169.2 (C7), 134.2 (C4), 131.5, 
131.5, 128.8, 128.0 (4 × Ar-CH), 83.1 (C8), 24.6 (C9). The carbon bearing the boron substituent is not 
observed due to broadening. The spectroscopic properties of this compound were consistent with the 
data available in the literature.349  







To a solution of carboxylic acid 416 (250 mg, 1.01 mmol) in anhydrous CH2Cl2 (10 mL) was added 
diisopropylethylamine (0.26 mL, 1.51 mmol) and HBTU (574 mg, 1.51 mmol). The reaction mixture 
was stirred at room temperature for 45 minutes. A solution of amine 170a (148 mg, 1.01 mmol) in 5 
mL of CH2Cl2 was sparged with argon and added to the reaction mixture. The reaction mixture was 
stirred for an additional 16 hours and then concentrated in vacuo. The crude material was purified by 
flash column chromatography (20–40% EtOAc/hexane) to afford the title compound 275 (220 mg, 58%, 
4:1 mixture of rotamers A:B) as a colourless oil; 1H NMR (400 MHz, CDCl3): δ 7.79 (2H, d, J = 6.5 Hz, 
C2-H, A+B), 7.47 – 7.26 (16H, m, 8 × ArC-H, A+B), 4.80 (2H, s, C8-H2, A), 4.30 (2H, s, C8-H2, B), 
2.62 (2H, tt, J = 7.5, 4.0 Hz, C9-H, A+B), 1.32 (24H, s, 4 × C12-H3, A+B), 0.90 – 0.83 (4H, m, 2 × C10-
H2, B), 0.67 – 0.27 (4H, m, 2 × C10-H2, A); 13C NMR (126 MHz, CDCl3): δ 174.2 (C7, A), 174.0 (C7, 
B) 143.1 (ArC, B), 142.5 (ArC, A), 138.5 (ArC, B), 137.4 (C2, B), 135.6 (C2, A), 130.9, 129.6, 128.7, 
128.5, 128.1, 127.4, 127.1, 126.1 (12 × Ar-CH, A+B), 83.9 (C11, B), 83.3 (C11, A), 53.4 (C8, B), 51.5 
(C8, A), 32.2 (C9, A), 28.3 (C9, B), 24.9 (C12, A+B), 9.2 (C10, A), 7.4 (C10, B). The carbon bearing 
the boron substituent is not observed due to broadening. 11B NMR (128 MHz, CDCl3): δ 28.9. HRMS: 
(ESI)+ Calculated for C23H29BNO3: 378.2239. Found [M + H +]: 378.2237.  
N-(2-Bromobenzyl)cyclopropanamine  
 
A solution of cyclopropylamine (0.42 mL, 6.00 mmol), 2-bromobenzaldehyde (0.58 mL, 5.00 mmol) 
and NaHCO3 (640 mg, 7.50 mmol) in MeOH (20 mL) was heated to reflux for 24 h. The reaction 
mixture was cooled to 0 °C and NaBH4 (231 mg, 6.25 mmol) was added portionwise over 10 minutes. 
The solution was warmed to room temperature and stirred for 5 hours. The reaction mixture was 
concentrated in vacuo and  sat. aq. NaHCO3 (25 mL) was added. The solution was extracted with 
CH2Cl2 (3 × 25 mL), the organic extracts were combined, washed with brine (20 mL), dried over 
Na2SO4 and concentrated in vacuo. The crude material was purified by flash column chromatography 
(20–100% Et2O/hexane) to afford the title compound (500 mg, 45%) as a colourless oil; νmax/ cm-1: 3071 
(m), 2921 (w), 1468 (m), 1437 (m), 1342 (m), 1066 (s), 655 (s); 1H NMR (400 MHz, CDCl3): δ 7.53 





(1H, dd, J = 7.5, 1.5 Hz, C2-H), 7.35 (1H, dd, J = 7.5, 2.0 Hz, ArC-H), 7.27 (1H, dd, J = 7.5, 1.5 Hz, 
ArC-H), 7.11 (1H, ddd, J = 7.5, 2.0, 1.5 Hz, ArC-H), 3.91 (2H, s, C7-H2), 2.17 – 2.03 (2H, m, C8-H 
and NH), 0.48 – 0.37 (4H, m, 2 × C9-H2); 13C NMR (101 MHz, CDCl3): δ 139.4 (C4), 133.0 (C2), 
130.8, 128.8, 127.5 (2 × Ar-CH), 124.2 (C3), 53.7 (C7), 29.8 (C8), 6.6 (C9). The spectrscophic 
properties of this compound are in agreement with the literature.350 
Benzyl (2-bromobenzyl)(cyclopropyl)carbamate (277) 
 
A solution of N-(2-bromobenzyl)cyclopropanamine (2.00 g, 7.84 mmol), K2CO3 (2.16 g, 15.7 mmol) 
and benzyl chloroformate (1.37 mL, 9.41 mmol) in toluene (30 mL) was heated at 80 °C for 24 hours. 
The reaction mixture was cooled to room temperature and water (30 mL) was added. The solution was 
extracted with EtOAc (3 × 50 mL), the organic extracts were combined, washed with brine (50 mL), 
dried over Na2SO4, filtered and concentrated in vacuo. The crude material was purified by flash column 
choromagraphy (20% Et2O/hexane) to afford the title compound 277 (2.13 g, 76%) as a colourless oil; 
νmax/ cm-1: 2972 (w), 1598 (s), 1440 (m), 1402 (s), 1291 (m), 1139 (m), 1026 (m), 745 (s), 696 (s); 1H 
NMR (400 MHz, CDCl3): δ 7.52 (1H, dd, J = 8.0, 1.5 Hz, C2-H), 7.47 – 7.16 (6H, m, 6 × ArC-H), 7.12 
– 7.07 (2H, m, 2 × ArC-H), 5.17 (2H, s, C9-H2), 4.58 (2H, s, C7-H2), 2.64 (1H, m, s, C14-H), 0.79 – 
0.61 (4H, m, 2 × C15-H2); 13C NMR (126 MHz, CDCl3): δ  154.1 (C8), 137.3, 136.7 (2 × ArC), 132.8 
(C2), 128.5, 128.4, 127.9, 127.8, 127.8, 127.5 (6 × Ar-CH), 122.7 (ArC), 67.3 (C9), 52.0 (C7), 29.6 
(C14), 8.01 (C15); HRMS: (ESI)+ Calculated for C18H1979BrNO2: 360.0593. Found [M + H] +: 360.0599.  
Benzyl cyclopropyl(2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzyl)carbamate (278) and 
benzyl 1,5-dihydro-2H-benzo[c]azepine-2-carboxylate (279) 
 
To a two-necked round-bottom flask containing Pd(dppf)Cl2·CH2Cl2 (240 mg, 0.295 mmol, 5 mol%) 
was added bis(pinacolato)diboron (1.79 g, 7.09 mmol) and potassium acetate (1.16 g, 11.8 mmol) under 
nitrogen. The reagents were dissolved in anhydrous 1,4-dioxane (50 mL). A solution of aryl bromide 
277 (2.12 g, 5.91 mmol) in anhydrous 1,4-dioxane (5 mL) was sparged with argon and added to the 
reaction mixture. The reaction mixture was heated at 70 °C for 16 hours, then cooled to room 





temperature and water (50 mL) was added. The solution was extracted with EtOAc (3 × 50 mL) and the 
organic extracts were combined, washed with brine (50 mL), dried over Na2SO4, filtered and 
concentrated in vacuo. The crude material was purified by flash column choromagraphy (10–15% 
Et2O/hexane) to afford the title compound 278 (1.61 g, 67%) as white solid and the title compound 279 
(426 mg, 26%, 3:1 mixture of rotamers A:B) as an off-white solid.  
Data for compound 277: m.p.: 118–120 ℃ (CH2Cl2); νmax/ cm-1: 2977 (w), 1699 (s), 1343 (s), 1142 (s), 
1056 (s); 1H NMR (400 MHz, CDCl3): δ 7.74 (1H, dd, J = 7.5, 1.5 Hz, C2-H), 7.39 – 7.03 (8H, m, C1-
H, C5-H, C6-H, 2 × C11-H, 2 × C12-H and C13-H), 5.09 (2H, s, C9-H2), 4.80 (2H, s, C7-H2), 2.54 (1H, 
br. m, C14-H), 1.26 (12H, s, 4 × C17-H3), 0.66 – 0.53 (4H, m, 2 × C15-H2); 13C NMR (101 MHz, 
CDCl3): δ 157.9 (C8), 145.3 (C4), 137.0 (C10), 136.4 (C2), 131.3, 128.5, 128.4, 127.8, 127.8, 125.6 (6 
× Ar-CH), 83.7 (C16), 67.1 (C9), 50.7 (C7), 29.8 (C14), 25.0 (C17), 7.84 (C15). The carbon bearing 
the boron substituent is not observed due to line broadening. 11B NMR (128 MHz, CDCl3): δ 31.7. 
HRMS: (ESI)+ Calculated for C24H30BNNaO4: 430.2164. Found [M + Na] +: 430.2164.  
Data for compound 279: m.p.: 73–75 ℃ (CH2Cl2); νmax/ cm-1: 2939 (w), 1702 (s), 1660 (w), 1412 (m), 
1348 (m), 1232 (s), 1115 (m); 1H NMR (400 MHz, CDCl3): δ 7.46 – 7.01 (18H, m, 9 × ArC-H, A+B), 
6.67 (1H, d, J = 10.0 Hz, C4-H, B) 6.58 (1H, d, J = 10.0 Hz, C4-H, A), 5.13 (2H, s, C8-H2, B), 5.06 (2H, 
s, C8-H2, A), 4.93 – 4.84 (5H, m, C3-H, B and C5-H2, A+B), 4.76 (1H, dt, J = 10.5, 5.5 Hz, C3-H, A), 
3.50 (4H, d, J = 5.5, C2-H2,  A+B); 13C NMR (101 MHz, CDCl3): δ 153.7 (C7, A+B), 140.9 (2 signals, 
C6, A+B) 136.4, 136.2, 136.1 136.0 (C1 and C9, A+B), 129.1, 128.7, 128.6, 128.5, 128.4, 128.3, 128.3, 
128.2, 128.2, 128.0, 127.9, 127.5, 127.4, 127.1, 127.0, 126.1 (C2, A+B and 14 × Ar-CH, A+B), 107.2 
(C3, B), 106.3 (C3, A), 68.0 (C8, A), 67.9 (C8, B), 49.0 (C5, B), 48.8 (C5, A), 32.3 (C2, A), 32.2 (C2, 
B); HRMS: (ESI)+ Calculated for C18H18NO2: 280.1332. Found [M + H] +: 280.1319. 
Benzyl benzylcarbamate (281) 
 
An oven dried reaction tube, fitted with a magnetic stirrer, was charged with [Rh(cod)OH]2 (1.71 mg, 
3.75  µmol, 3.75 mol%), P-(4FC6H4)3 (4.74 mg, 15.0 μmol, 15 mol%) and substrate 278 (28.1 mg, 0.10 
mmol, 100 mol%). The tube was fitted with a rubber septum and purged with argon. The reagents were 
dissolved in argon sparged 1,2-DCB (1.0 mL). The reaction mixture was sparged with CO for 
approximately 10 seconds, then heated at 120 °C under a CO atmosphere for 72 h. The mixture was 
cooled to room temperature and concentrated in vacuo. The residue was purified by flash column 
chromatography (10–50% EtOAc/hexane) to afford the title compound 281 (10.6 mg, 44%) as a 
colourless solid. 1H NMR (400 MHz, CDCl3): δ 7.46 – 7.25 (10H, m, 10 × ArC-H), 5.13 (2H, s, C3-





H2), 5.05 (1H, br. s, NH), 4.38 (2H, d, J = 6.0 Hz, C1-H2); 13C NMR (126 MHz, CDCl3): δ 156.4 (C2), 
138.3 (ArC), 136.5 (ArC), 128.7, 128.5 (2 signals), 128.2, 127.5 (Ar-CH), 66.8 (C3), 45.2 (C1); LRMS: 
(ESI)+ Calculated for C15H16NO2: 241.11. Found [M + H] +: 242.12. The spectroscopic properties of 
this compound were consistent with the data available in the literature.351 
(2-((((Benzyloxy)carbonyl)(cyclopropyl)amino)methyl)phenyl)boronic acid (282) 
 
To a solution of substrate 278 (407 mg, 1.00 mmol) in THF:H2O (12 mL, 5:1) was added NaIO4 (639 
mg, 3.00 mmol). The reaction mixture was stirred at room temperature for 3 hours. After this time, 3 M 
aq. HCl (0.6 mL) was added and the reaction was stirred for an additional hour and then concentrated 
in vacuo. The residue was dissolved in EtOAc (20 mL) and washed with water (20 mL). The aqueous 
portion was further extracted with EtOAc (2 × 20 mL) and the organic extracts were combined, washed 
with brine (30 mL), dried over Na2SO4, filtered and concentrated in vacuo. The crude material was 
purified by flash column choromagraphy (20–100% EtOAc/hexane) to afford the title compound 282 
(103 mg, 32%, 2:1 mixture of rotamers A:B) as white solid; m.p.: 115–118 ℃ (MeOH); νmax/ cm-1: 3356 
(br. s), 3015 (w), 1573 (s), 1412 (s), 1341 (s), 1272 (s), 1139 (m); 1H NMR (400 MHz, Methanol-d4): δ 
7.38 – 7.07 (18H, m, 9 × Ar-CH, A+B), 5.10 (4H, s, C6-H2, A+B), 4.65 (2H, s, C4-H2, B), 4.50 (2H, s, 
C4-H2, A), 2.54– 2.43 (2H, C8-H, A+B), 0.69 – 0.60 (8H, m, 2 × C9-H2, A+B); 13C NMR (101 MHz, 
methanol-D4): δ 158.2 (C5, B), 158.0 (C5, A), 141.9 (C3, B), 140.7 (C3, A), 136.7 (2 signals, C7, A+B), 
133.2 (C1, B), 131.5 (C1, A), 129.1, 128.7, 128.2, 128.1, 127.8, 127.7, 127.6, 127.5, 127.1, 126.5, 126.2, 
125.9 (12 × Ar-CH, A+B), 67.1 (C6, A+B), 51.2 (C4, A), 50.1 (C4, B), 29.4 29.0 (C8, A+B), 7.5 (C15, 
A+B). The carbon bearing the boron substituent is not observed due to line broadening. 11B NMR (128 




Substrate 171a was synthesised by M. Shaw. An oven dried reaction tube, fitted with a magnetic stirrer, 
was charged with [Rh(cod)2]OTf (7.02 mg, 15.0 µmol, 7.5 mol%), P(4-(F)C6H4)3 (9.48 mg, 0.03 mmol, 
22.5 mol%), 2-nitrobenzoic acid (50.1 mg, 0.3 mmol, 150 mol%) and substrate 171b (32.2 mg, 0.20 
mmol, 100 mol%). The tube was fitted with a rubber septum and purged with argon. The reagents were 





dissolved in argon sparged PhCN (2 mL). The reaction mixture was sparged with CO for approximately 
10 seconds, then heated at 130 °C under a CO atmosphere for 48 h. The mixture was cooled to room 
temperature and concentrated in vacuo. The residue was purified by flash column chromatography 
(10–35 % EtOAc/pentane) to yield the title compound 174b (11.3 mg, 30%) as a colourless oil. 1H NMR 
(400 MHz, CDCl3): δ 7.61 – 7.57 (4H, m, 2 × C2-H and 2 × C3-H), 7.53 – 7.44 (1H, m, C1-H), 3.96 
(2H, t, J = 7.0 Hz, C6-H2), 2.59 (2H, t, J = 8.0 Hz, C8-H2), 2.15 (2H, tt, J = 8.0, 7.0 Hz, C7-H2); 13C 
NMR (101 MHz, CDCl3): δ 175.4 (C9), 170.1 (C5), 134.1 (C4), 129.8, 128.4, 127.1 (C1, C2 and C3), 
47.7 (C6), 33.7 (C8), 17.4 (C7). The spectroscopic properties of this compound are in agreement with 
the literature.352  
7.5 Experimental procedures for the studies in Chapter 4 
7.5.2 Synthesis of substrates and catalysis products 
N-Benzyl-N-cyclopropyl-1H-indole-1-carboxamide (292a) 
 
General Procedure G: Indole (400 mg, 3.40 mmol) and carbamoyl chloride 299a (781 mg, 3.74 mmol) 
were employed. The crude mixture was purified by flash column chromatography (40% toluene/hexane 
then 100% EtOAc) to afford the title compound 292a (897 mg, 91%) as colourless solid; m.p. 50–52 °C 
(CH2Cl2); νmax/ cm-1: 1673 (s), 1453 (s), 1405 (m), 1319 (s); 1H NMR (400 MHz, CDCl3): δ 7.67 (1H, 
m, C7-H), 7.49 (1H, dd, J = 7.5, 1.0 Hz, C4-H), 7.34 (1H, d, J = 3.5 Hz, C1-H), 7.30 – 7.16 (6H, m, 
C6-H , 2 × C12-H, 2 × C13-H and C14-H), 7.11 (1H, dd, J = 7.5, 1.0 Hz, C5-H), 6.49 (1H, d, J = 3.5 
Hz, C2-H), 4.61 (2H, s, C10-H2), 2.54 (1H, tt, J = 7.0, 4.0 Hz, C15-H), 0.63 – 0.45 (4H, m, 2 × C16-
H2); 13C NMR (101 MHz, CDCl3): δ 155.2 (C9), 137.0 (C11), 135.7 (C8), 129.5 (C3), 128.7, 128.3 
(C12 and C13), 127.7 (C14), 125.9 (C1), 123.6 (C6), 122.0 (C5), 120.8 (C4), 113.8 (C7), 105.8 (C2), 










General Procedure H: Indole 292a (43.5 mg, 0.15 mmol), [Rh(cod)2]OTf (5.28 mg, 7.5 mol%) and 
anhydrous 1,2-DCB (1.50 mL) were employed was employed and the reaction mixture was heated at 
130 °C for 72 h. The crude mixture was purified by flash column chromatography (20% EtOAc/hexane) 
to yield the title compound 295a (39.1 mg, 82%) as a colourless solid; m.p.: 126–127 °C (CDCl3); νmax/ 
cm-1: 2919 (m), 1748 (s), 1710 (s), 1480 (s), 1409 (s), 1290 (s), 1158 (s); 1H NMR (400 MHz CDCl3): 
δ 7.50 (1H, d, J = 8.0 Hz, C7-H), 7.40 – 7.26 (5H, m, 2 × C12-H, 2 × C13-H and C14-H), 7.24 – 7.17 
(2H, m, C4-H and C6-H), 7.06 (1H, dd, J = 7.5, 1.0 Hz, C5-H), 4.67 (1H, d, J = 15.0 Hz, 1 × C10-H2), 
4.36 (1H, d, J = 15.0 Hz, 1 × C10-H2), 4.09 (1H, d, J = 5.5 Hz, C15-H), 3.35 (1H, d, J = 16.0 Hz, 1 × 
C2-H2), 3.08 (1H, d, J = 16.0 Hz, 1 × C2-H2), 2.62 (1H, ddd, J = 17.5, 13.5, 9.0 Hz, 1 × C17-H2), 2.36. 
– 2.20 (2H, m, 1 × C17-H2, 1 × C16-H2), 1.86 (1H, dddd, J = 13.5, 7.5, 5.5, 2.0 Hz, 1 × C16-H2); 13C 
NMR (101 MHz, CDCl3): δ 212.3 (C18), 159.2 (C9), 142.4 (C8), 136.2 (C11), 130.1 (C3), 128.9, 128.2, 
128.1, 128.0 (C4, C12, C13, C14), 124.7 (C6), 124.3 (C5), 116.0 (C7), 70.1 (C1), 63.8 (C15), 45.9 
(C10), 35.7 (C2), 33.2 (C17), 23.3 (C16); HRMS: (ESI)+ Calculated for C20H19N2O2: 319.3760. Found 
[M + H]+: 319.1456.  
N-Butyl-N-cyclopropyl-1H-indole-1-carboxamide (292b) 
 
Pyridine (1.91 mL, 24.0 mmol) was added dropwise to a solution of triphosgene (2.24 g, 7.66 mmol) in 
CH2Cl2 (50 mL) at 0 °C. To the resulting suspension was added a solution of N-butylcyclopropanamine 
170b (2.26 g, 21.0 mmol) in CH2Cl2 (3 mL) and the resulting solution was warmed to room temperature. 
After 2 hours, the reaction mixture was quenched with saturated aqueous NaHCO3 (30 mL) and 
extracted with Et2O (2 × 40 mL). The organic layers were combined and washed with 0.2 M aqueous 
HCl (30 mL), brine (30 mL), dried over Na2SO4 and concentrated in vacuo to give 
butyl(cyclopropyl)carbamic chloride (1.98 g, 67%) as a yellow oil which was used without further 
purification. A flame-dried round-bottomed flask was charged with NaH (240 mg, 6.00 mmol) and this 
was suspended in anhydrous THF (10 mL) under nitrogen. The suspension was cooled to 0 °C and 
indole (351 mg, 3.00 mmol) was added portion wise over 5 minutes. The solution was warmed to room 
temperature and stirred for 1 hour, followed by dropwise addition of butyl(cyclopropyl)carbamic 





chloride (578 mg, 3.30 mmol) in THF (7.00 mL) over 10 minutes. The solution was then stirred for 4 
hours at room temperature. The reaction was quenched by the addition of saturated aqueous NH4Cl (10 
mL) and extracted with EtOAc (3 × 10 mL). The organic extracts were combined, washed with brine 
(20 mL), dried over Na2SO4, filtered and concentrated in vacuo. The crude mixture was purified by 
flash column chromatography (10% toluene/hexane then 100% EtOAc) to afford the title compound 
292b (699 mg, 91%) as a colourless oil; νmax/ cm-1: 2958 (m), 1671 (s), 1524 (m), 1452 (s), 1407 (s), 
1210 (s); 1H NMR (400 MHz, CDCl3): δ 7.72 (1H, dd, J = 8.0, 1.0 Hz, C7-H), 7.59 (1H, ddd, J = 8.0, 
1.0, 1.0 Hz, C4-H), 7.41 (1H, d, J = 3.5 Hz, C1-H), 7.28 (1H, m, C6-H), 7.19 (1H, ddd, J = 8.0, 8.0, 1.0 
Hz, C5-H), 6.57 (1H, dd, J = 3.5, 1.0 Hz, C2-H), 3.52 (2H, t, J = 7.0 Hz, C10-H2), 2.84 (1H, tt, J = 7.0, 
4.0 Hz, C14-H), 1.79 – 1.66 (2H, m, C11-H2), 1.39 (2H, tt, J = 7.5, 7.5 Hz, C12-H2), 0.94 (3H, t, J = 
7.5 Hz, C13-H3), 0.77 – 0.67 (2H, m, 1 × C15-H2), 0.60 – 0.50 (2H, m, 1 × C15-H2); 13C NMR (101 
MHz, CDCl3): δ 155.5 (C9), 135.9 (C8), 129.9 (C3), 126.2 (C1), 123.6 (C6), 121.9 (C5), 120.9 (C4), 
113.9 (C7), 105.6 (C2), 49.4 (C10), 31.0 (C14), 30.2 (C11), 20.2 (C12), 13.9 (C13), 9.1 (C15); m/z 




General Procedure H: Indole 292b (38.4 mg, 0.15 mmol), [Rh(cod)2]OTf (5.28 mg, 7.5 mol%) and 
anhydrous 1,2-DCB (1.50 mL) were employed was employed and the reaction mixture was heated at 
130 ℃ for 72 h. The crude mixture was purified by flash column chromatography (15% EtOAc/toluene) 
to yield the title compound 295b (22.6 mg, 54%) as a yellow oil; νmax/ cm-1: 2958 (m), 1750 (s), 1708 
(s), 1480 (s), 1409 (s), 1292 (s), 1160 (s); 1H NMR (400 MHz, CDCl3): δ 7.45 (1H, dd, J = 8.0, 1.0 Hz, 
C7-H), 7.24 – 7.16 (2H, m, C5-H and C6-H), 7.04 (1H, dd, J = 7.5, 1.0 Hz, C4-H), 4.24 (1H, d, J = 5.5 
Hz, C10-H), 3.48 – 3.37 (2H, m, 1 × C2-H2 and 1 × C14-H2), 3.22 – 3.10 (2H, m, 1 × C2-H2 and 1 × 
C14-H2), 2.67 (1H, ddd, J = 17.5, 13.5, 9.0 Hz, 1 × C12-H2), 2.42 – 2.27 (2H, m, 1 × C11-H2 and 1 × 
C12-H2), 1.99 (1H, ddd, J = 14.0, 7.5, 5.5 Hz, 1 × C11-H2), 1.61 – 1.45 (2H, m, C15-H2), 1.39 – 1.23 
(2H, m, C16-H2), 0.93 (3H, t, J = 7.3 Hz, C17-H3); 13C NMR (101 MHz, CDCl3) δ 212.4 (C13), 159.2 
(C9), 142.7 (C3), 130.1 (C8), 128.1 (C4), 124.8 (C5), 124.3 (C6), 116.0 (C7), 70.2 (C1), 64.1 (C10), 
41.7 (C14), 35.9 (C2), 33.3 (C12), 29.6 (C15), 23.8 (C11), 20.3 (C16), 13.9 (C17); HRMS: (ESI+) 
Calculated for C17H21N2O2: 285.1598. Found [M + H]+: 285.1601. 
  







General Procedure G: 4-Methylindole (131 mg, 1.00 mmol) and carbamoyl chloride 299a (220 mg, 
2.40 mmol) were employed. The crude mixture was purified by flash column chromatography (20% 
EtOAc/hexane) to afford the title compound 292d as a colourless oil (258 mg, 85%); νmax/ cm-1: 3027 
(m), 1672 (s), 1485 (s), 1406 (s), 1273 (s), 1158 (s); 1H NMR (400 MHz, CDCl3): δ 7.62 (1H, dd, J = 
8.5, 1.0 Hz, C7-H), 7.45 (1H, d, J = 3.5 Hz, C1-H), 7.42 – 7.30 (5H, m, 2 × C12-H, 2 × C13-H and 
C14-H), 7.21 (1H, dd, J = 8.5, 7.5 Hz, C6-H), 7.03 (1H, dd, J = 7.5, 1.0 Hz, C5-H), 6.64 (1H, d, J = 3.5 
Hz, C2-H), 4.72 (2H, s, C10-H2), 2.65 (1H, tt, J = 7.0, 4.0 Hz, C15-H), 2.57 (3H, s, C17-H3), 0.73 – 
0.58 (4H, m, 2 × C16-H2); 13C NMR (101 MHz, CDCl3): δ 155.4 (C9), 137.1 (C11), 135.5 (C8), 130.3 
(C4), 129.3 (C3), 128.9, 128.4 (C12, C13), 127.8 (C14), 125.5 (C1), 123.8 (C6), 122.4 (C5), 111.5 (C7), 
104.3 (C2), 53.5 (C10), 31.4 (C15), 18.7 (C17), 9.2 (C16); HRMS: (ESI+) Calculated for C20H21N2O: 




General Procedure H: Indole 292d (45.6 mg, 0.15 mmol) ), [Rh(cod)2]OTf (5.28 mg, 7.5 mol%) and 
anhydrous 1,2-DCB (1.50 mL) were employed and the reaction mixture was heated at 140 °C for 72 h. 
The crude mixture was purified by flash column chromatography (15% EtOAc/toluene) to yield the title 
compound 295d (32.8 mg, 66%) as a yellow oil; νmax/ cm-1: 2914 (m), 1750 (s), 1704 (s), 1409 (s), 1288 
(s), 1158 (s); 1H NMR (400 MHz, CDCl3): δ 7.39 – 7.24 (6H, m, C7-H, 2 × C12-H, 2 × C13-H and 
C14-H), 7.16 (1H, dd, J = 7.5, 7.5 Hz, C6-H), 6.88 (1H, d, J = 7.5 Hz, C5-H), 4.68 (1H, d, J = 15.0 Hz, 
1 × C10-H2), 4.36 (1H, d, J = 15.0 Hz, 1 × C10-H2), 4.10 (1H, d, J = 5.0 Hz, C15-H), 3.26 (1H, d, J = 
16.0 Hz, 1 × C2-H2), 2.97 (1H, d, J = 16.0 Hz, 1 × C2-H2), 2.61 (1H, ddd, J = 17.5, 13.5, 9.0 Hz, 1 × 
C17-H2), 2.37 – 2.24 (2H, m, 1 × C16-H2, 1 × C17-H2), 2.22 (3H, s, C19-H3), 1.87 (1H, ddd, J = 14.0, 
7.5, 5.5 Hz, 1 × C16-H2); 13C NMR (101 MHz, CDCl3): δ 212.7 (C18), 159.4 (C9), 142.1 (C8), 136.3 





(C11), 134.4 (C4), 129.0 (C3), 129.0, 128.4 (C12, C13), 128.3 (C6), 128.0 (C14), 125.4 (C5), 113.4 
(C7), 70.2 (C1), 64.2 (C15), 46.0 (C10), 34.9 (C2), 33.3 (C17), 23.3 (C16), 19.0 (C19); HRMS: (ESI+) 
Calculated for C21H21N2O2: 333.1598 Found [M + H]+: 333.1603.  
N-Benzyl-N-cyclopropyl-5-fluoro-1H-indole-1-carboxamide (292i) 
 
General Procedure G: 5-Fluoro-1H-indole (142 mg, 1.05 mmol) and carbamoyl chloride 299a (209 
mg, 1.10 mmol) were employed. The crude mixture was purified by flash column chromatography (40% 
toluene/hexane then 100% EtOAc) to afford the title compound 292i as a yellow oil (280 mg, 91%); 
νmax/ cm-1: 2932 (m), 1675 (s), 1468 (s), 1405 (s), 1268 (s), 1199 (s); 1H NMR (400 MHz, CDCl3): δ 
7.73 (1H, m, C4-H), 7.48 (1H, d, J = 3.5 Hz, C1-H), 7.43 – 7.24 (5H, m, 2 × C12-H, 2 × C13-H and 
C14-H), 7.23 (1H, dd, J = 9.0, 2.5 Hz, C7-H), 7.02 (1H, dd, J = 9.0, 2.5 Hz, C6-H), 6.54 (1H, dd, J = 
3.5, 1.0 Hz, C2-H), 4.70 (2H, s, C10-H2), 2.63 (1H, tt, J = 7.0, 4.0 Hz, C15-H), 0.78 – 0.49 (4H, m, 2 × 
C16-H2); 13C NMR (101 MHz, CDCl3): δ 159.0 (d, J = 237.9 Hz, C5), 155.0 (C9), 137.0 (C11), 132.3 
(d, J = 0.6 Hz, C8), 130.2 (d, J = 10.2 Hz, C3), 128.1, 128.4, 127.9 (C12, C13 and C14), 127.5 (C1), 
114.9 (d, J = 9.4 Hz, C7), 111.83 (d, J = 25.6 Hz, C6), 106.11 (d, J = 24.0 Hz, C4), 105.7 (d, J = 3.9 
Hz, C2), 53.4 (C10), 31.6 (C15), 9.4 (C16); 19F NMR (377 MHz, CDCl3): δ -121.94 (ddd, J = 9.0, 9.0, 




General Procedure H: Indole 292i (46.2 mg, 0.15 mmol) ), [Rh(cod)2]OTf (5.28 mg, 7.5 mol%) and 
anhydrous 1,2-DCB (1.50 mL) were employed and the reaction mixture was heated at 130 °C for 72 h. 
The crude mixture was purified by flash column chromatography (10% EtOAc/toluene) to yield the title 
compound 295i (27.0 mg, 54%) as a colourless oil; νmax/ cm-1: 2922 (m), 1751 (s), 1710 (s), 1485 (s), 
1408 (s), 1308 (s), 1261 (s), 1160 (s); 1H NMR (400 MHz, CDCl3): δ 7.42 (1H, dd, J = 8.5, 4.5 Hz, C7-
H), 7.40 – 7.27 (5H, m, 2 × C12-H, 2 × C13-H and C14-H), 6.96 – 6.88 (2H, m, C4-H and C6-H), 4.68 
(1H, d, J = 15.0 Hz, 1 × C10-H2), 4.36 (1H, d, J = 15.0 Hz, 1 × C10-H2), 4.09 (1H, d, J = 5.5 Hz, 1 × 





C15-H), 3.34 (1H, d, J = 16.5 Hz, 1 × C2-H2), 3.07 (1H, dd, J = 16.5, 1.0 Hz, 1 × C2-H2), 2.64 (1H, 
ddd, J = 17.5, 13.5, 9.0 Hz, 1 × C17-H2), 2.35 – 2.19 (2H, m, 1 × C16-H2, 1 × C17-H2), 1.87 (1H, m, 1 
× C16-H2); 13C NMR (101 MHz, CDCl3): δ 211.8 (C18), 160.4 (d, J = 241.8 Hz, C5), 159.2 (C9), 138.3 
(d, J = 1.9 Hz, C3), 136.2 (C11), 132.10 (d, J = 8.7 Hz, C8), 129.0, 128.4 (C12, C13), 128.1 (C14), 
116.8 (d, J = 8.8 Hz, C7), 114.7 (d, J = 23.6 Hz, C6), 112.1 (d, J = 24.2 Hz, C4), 70.6 (C1), 63.5 (C15), 
46.1 (C10), 35.7 (d, J = 2.0 Hz, C2), 33.2 (C17), 23.5 (C16); 19F NMR (377 MHz, CDCl3): δ -119.1 




General Procedure G: 5-Methoxy-1H-indole (147 mg, 1.00 mmol) and carbamoyl chloride 299a (220 
mg, 1.10 mmol) were employed. The crude mixture was purified by flash column chromatography (90% 
toluene/hexane then 100% EtOAc) to afford the title compound 292j (280 mg, 91%) as a light brown 
oil; νmax/ cm-1: 2940 9m), 1673 (s), 1473 (s), 1406 (s), 1266 (s), 1149 (s); 1H NMR (400 MHz, CDCl3): 
δ 7.68 (1H, d, J = 9.0 Hz , C7-H), 7.42 (1H, d, J = 3.5 Hz, C1-H), 7.40 – 7.28 (5H, m, 2 × C12-H, 2 × 
C13-H and C14-H), 7.05 (1H, d, J = 2.5 Hz, C4-H), 6.92 (1H, dd, J = 9.0, 2.5 Hz, C6-H), 6.50 (1H, d, 
J = 3.5 Hz, C2-H), 4.69 (2H, s, C10-H2), 3.85 (3H, s, C17-H3), 2.62 (1H, tt, J = 7.0, 4.0 Hz, C15-H), 
0.72 – 0.55 (4H, m, 2 × C16-H2); 13C NMR (101 MHz, CDCl3): δ 155.5, 155.3 (C5 and C9), 137.0 
(C11), 130.6, 130.2 (C3, C8), 128.8, 128.3 (C12, C13), 127.7 (C14), 126.5 (C1), 114.7 (C7), 113.0 (C6), 
105.6 (C2), 103.0 (C4), 55.7 (C17), 53.3 (C10), 31.4 (C15), 9.2 (C16); HRMS: (ESI)+ Calculated for 




General Procedure H: Indole 292j (48.0 mg, 0.15 mmol), [Rh(cod)2]OTf (5.28 mg, 7.5 mol%) and 
anhydrous 1,2-DCB (1.50 mL) were employed and the reaction mixture was heated at 130 °C for 72 h. 
The crude mixture was purified by flash column chromatography (15% EtOAc/toluene) to yield the title 





compound 295j (34.3 mg, 66%) as a colourless oil; νmax/ cm-1: 2921 (m), 1750 (s), 1709 (s), 1496 (s), 
1406 (s), 1155 (s), 1027 (s); 1H NMR (400 MHz, CDCl3): δ 7.40 (1H, d, J = 8.5 Hz, C7-H), 7.38 – 7.12 
(5H, m, 2 × C12-H, 2 × C13-H and C14-H), 6.81 – 6.74 (2H, m, C4-H and C6-H), 4.69 (1H, d, J = 15.0 
Hz, 1 × C10-H2), 4.35 (1H, d, J = 15.0 Hz, 1 × C10-H2), 4.08 (1H, d, J = 5.5 Hz, C15-H), 3.77 (3H, s, 
C19-H3), 3.32 (1H, d, J = 16.0 Hz, 1 × C2-H2), 3.06 (1H, d, J = 16.0 Hz, 1 × C2-H2), 2.66 (1H, ddd, J 
= 17.5, 13.5, 9.5 Hz, 1 × C17-H2), 2.31 (1H, m, 1 × C17-H2), 2.21 (1H, m, 1 × C16-H2), 1.86 (1H, m, 
1 × C16-H2); 13C NMR (101 MHz, CDCl3): δ 212.0 (C18), 159.7 (C9), 157.4 (C5), 136.3 (C11), 135.8 
(C3), 131.7 (C8), 129.0, 128.2 (C12, C13), 128.0 (C14), 116.7 (C7), 113.1 (C6), 111.0 (C4), 70.6 (C1), 
63.5 (C15), 55.9 (C19), 46.0 (C10), 35.9 (C2), 33.3 (C17), 23.6 (C16); HRMS: (ESI+) Calculated for 
C21H21N2O3: 349.1547. Found [M + H]+: 349.1551.  
N-Benzyl-N-cyclopropyl-6-isopropyl-1H-indole-1-carboxamide (292k) 
 
General Procedure G: 6-Isopropyl-1H-indole (318 mg, 2.00 mmol) and carbamoyl chloride 299a (502 
mg, 2.40 mmol) were employed. The crude mixture was purified by flash column chromatography (90% 
toluene/hexane) to afford the title compound 292k as a brown oil (610 mg, 92%); νmax/ cm-1: 2958 (m), 
1671 (s), 1437 (s), 1404 (s), 1318 (s), 1210 (s); 1H NMR (400 MHz, CDCl3): δ 7.64 (1H, dd, J = 1.5, 
1.0 Hz, C7-H), 7.49 (1H, dd, J = 8.0, 1.0 Hz, C4-H), 7.40 – 7.29 (6H, m, C1-H, 2 × C12-H, 2 × C13-H 
and C14-H), 7.10 (1H, dd, J = 8.0, 1.5 Hz, C5-H), 6.53 (1H, d, J = 3.5 Hz, C2-H), 4.71 (2H, s, C10-
H2), 3.01 (1H, hept, J = 7.0 Hz, C17-H), 2.62 (1H, tt, J = 6.5, 4.0 Hz, C15-H), 1.28 (6H, d, J = 7.0 Hz, 
2 × C18-H3), 0.74 – 0.53 (4H, m, 2 × C16-H2); 13C NMR (101 MHz, CDCl3): 155.4 (C9), 145.1 (C6), 
137.2 (C11), 136.2 (C8), 128.9, 128.5, 127.9 (C12, C13, and C14), 127.8 (C3), 125.6 (C1), 121.4 (C5), 
120.6 (C4), 111.5 (C7), 105.8 (C2), 53.4 (C10), 34.6 (C17), 31.6 (C15), 24.6 (C18), 9.4 (C16); HRMS: 









General Procedure H: Indole 292k (50.0 mg, 0.15 mmol), [Rh(cod)2]OTf (5.28 mg, 7.5 mol%) and 
anhydrous 1,2-DCB (1.50 mL) were employed and the reaction mixture was heated at 130 °C for 72 h. 
The crude mixture was purified by flash column chromatography (15% EtOAc/toluene) to yield the title 
compound 295k (45.0 mg, 83%) as a colourless solid; m.p.: 186–189 °C (EtOAc/petroleum ether); νmax/ 
cm-1: 2956 (m), 1751 (s), 1698 (s), 1493 (s), 1410 (s), 1286 (s), 1153 (s); 1H NMR (400 MHz, CDCl3): 
δ 7.40 (1H, d, J = 1.5 Hz, C7-H), 7.38 – 7.26 (5H, m, 2 × C12-H, 2 × C13-H and C14-H), 7.11 (1H, dd, 
J = 7.5, 1.0 Hz, C4-H), 6.94 (1H, dd, J = 7.5, 1.5 Hz, C5-H), 4.63 (1H, d, J = 15.0 Hz, 1 × C10-H2), 
4.40 (1H, d, J = 15.0 Hz, 1 × C10-H2), 4.09 (1H, d, J = 5.0 Hz, C15-H), 3.30 (1H, d, J = 16.0, 1 × C2-
H2), 3.05 (1H, d, J = 16.0 Hz, 1 × C2-H2), 2.93 (1H, hept, J = 7.0 Hz, C19-H), 2.59 (1H, ddd, J = 17.5, 
13.5, 9.0 Hz, 1 × C17-H2), 2.38 – 2.16 (2H, m, 1 × C17-H2 and 1 × C16-H2), 1.85 (1H, ddd, J = 14.5, 
7.5, 5.5 Hz, 1 × C16-H2), 1.26 (6H, d, J = 7.0 Hz, 2 × C20-H3); 13C NMR (101 MHz, CDCl3): δ 212.7 
(C18), 159.3 (C9), 149.5 (C6), 142.5 (C8), 136.4 (C11), 129.0, 128.3 (C12, C13), 128.0 (C14), 127.5 
(C3), 124.5 (C4), 122.5 (C5), 114.2 (C7), 70.6 (C1), 64.1 (C15), 46.1 (C10), 35.6 (C2), 34.3 (C19), 
33.3 (C17), 24.4 (C20), 24.0 (C20), 23.4 (C16); m/z (ESI+) HRMS: Calculated for C23H25N2O2: 
361.1911. Found [M + H]+: 361.1921. The structure of this compound was determined unambiguously 




General Procedure G: 6-Methoxy-1H-indole (147 mg, 1.00 mmol) and carbamoyl chloride 299a (220 
mg, 1.05 mmol) were employed. The crude mixture was purified by flash column chromatography (90% 
toluene/hexane then 100% EtOAc) to afford the title compound 292l (231 mg, 73%) as a light brown 
oil; νmax/ cm-1: 2925 (m), 1676 (s), 1612 (s), 1486 (s), 1407 (s), 1227 (s), 1227 (s); 1H NMR (400 MHz, 
CDCl3): δ 7.44 (1H, d, J = 8.5 Hz, C4-H), 7.37 – 7.36 (4H, m, 2 × C12-H and 2 × C13-H), 7.34 – 7.30 
(3H, m, C1-H, C7-H and C14-H), 6.85 (1H, dd, J = 8.5, 2.5 Hz, C5-H), 6.50 (1H, d, J = 3.5, Hz, C2-





H), 4.71 (2H, s, C10-H2), 3.81 (3H, s, C17-H3), 2.63 (1H, tt, J = 7.0, 4.0 Hz, C15-H), 0.72 – 0.56 (4H, 
m, 2 × C16-H2): 13C NMR (101 MHz, CDCl3): δ 157.4 (C6), 155.3 (C9), 137.0 (C11), 136.7 (C8), 128.8, 
128.4 (C12, C13), 127.8 (C14), 124.6 (C1), 123.3 (C3), 121.2 (C4), 112.0 (C5), 105.7 (C2), 97.6 (C7), 
55.6 (C17), 53.2 (C10), 31.4 (C15) 9.2 (C16); HRMS: (ESI)+ Calculated for C20H20N2NaO2: 343.1417. 




General Procedure H: Indole 292l (48.0 mg, 0.15 mmol) ), [Rh(cod)2]OTf (5.28 mg, 7.5 mol%) and 
anhydrous 1,2-DCB (1.50 mL) were employed and the reaction mixture was heated at 130 °C for 72 h. 
The crude mixture was purified by flash column chromatography (15% EtOAc/toluene) to afford the 
title compound 295l (15.6 mg, 29%) as a colourless oil; νmax/ cm-1: 2921 9m), 1749 (s), 1708 (s), 1617 
(s), 1485 (s), 1406 (s), 1309 (s), 1287 (s), 1155 (s); 1H NMR (500 MHz, CDCl3): δ 7.39 – 7.27 (5H, m, 
2 × C12-H, 2 × C13-H and C14-H), 7.11 (1H, d, J = 2.5 Hz, C7-H), 7.05 (1H, d, J = 8.5 Hz, C4-H), 
6.62 (1H, dd, J = 8.5, 2.5 Hz, C5-H), 4.67 (1H, d, J = 15.5 Hz, 1 × C10-H2), 4.37 (1H, d, J = 15.5 Hz, 
1 × C10-H2), 4.09 (1H, d, J = 5.5 Hz, 1 × C15-H), 3.82 (3H, s, C19-H3), 3.26 (1H, d, J = 15.5 Hz, 1 × 
C2-H2), 3.02 (1H, d, J = 15.5 Hz, 1 × C2-H2), 2.59 (1H, ddd, J = 18.0, 13.5, 9.0 Hz, 1 × C17-H2), 2.36 
– 2.20 (2H, m, 1 × C17-H2, 1 × C16-H2), 1.87 (1H, dddd, J = 13.5, 8.0, 5.0, 2.5 Hz, 1 × C16-H2); 13C 
NMR (126 MHz, CDCl3): δ 212.5 (C18), 160.1 (C6), 159.1 (C9), 143.5 (C8), 136.2 (C11), 128.9, 128.2 
(C12, C13), 127.9 (C14), 124.9 (C4), 121.6 (C3), 110.8 (C5), 101.6 (C7), 70.9 (C1), 63.9 (C15), 55.6 
(C19), 45.9 (C10), 35.1 (C2), 33.2 (C17), 23.2 (C16); HRMS: (ESI+) Calculated for C21H20N2NaO3: 
371.1366. Found [M + Na]+: 371.1370.  
N-Benzyl-N-cyclopropyl-6-nitro-1H-indole-1-carboxamide (292m) 
 
General Procedure G: 6-Nitro-1H-indole (330 mg, 2.00 mmol) and carbamoyl chloride 299a (502 mg, 
2.40 mmol) were employed. The crude mixture was purified by flash column chromatography (15% 
EtOAc/hexane) to afford the title compound 292m as a yellow solid (599 mg, 89%); m.p; 134–134 °C 





(CHCl3); νmax/ cm-1: 3132 (m), 1669 (s), 1519 (s), 1499 (s), 1413 (s), 1333 (s), 1313 (s), 1255 (s); 1H 
NMR (400 MHz, CDCl3): δ 8.72 (1H, d, J = 2.0 Hz, C7-H), 8.11 (1H, dd, J = 8.5, 2.0 Hz, C5-H), 7.71 
(1H, d, J = 3.5, C1-H), 7.66 (1H, dd, J = 8.5, 1.0 Hz, C4-H), 7.45 – 7.31 (5H, m, 2 × C12-H, 2 × C13-
H and C14-H), 6.69 (1H, dd, J = 3.5, 1.0 Hz, C2-H), 4.75 (2H, s, C10-H2), 2.67 (1H, tt, J = 6.5, 3.5 Hz, 
C15-H), 0.76 – 0.50 (4H, m, 2 × C16-H2); 13C NMR (101 MHz, CDCl3): δ 153.9 (C9), 144.7 (C6), 
136.6 (C11), 134.6 (C8), 134.2 (C3), 131.1 (C1), 129.1, 128.5 (C12, C13), 128.2 (C14), 121.0 (C4), 
117.5 (C5), 110.7 (C7), 105.8 (C2), 53.4 (C10), 31.8 (C15), 9.5 (C16); HRMS: (ESI)+ Calculated for 




General Procedure H: Indole 292m (50.3 mg, 0.15 mmol) ), [Rh(cod)2]OTf (5.28 mg, 7.5 mol%) and 
anhydrous 1,2-DCB (1.50 mL) were employed and the reaction mixture was heated at 130 °C for 72 h. 
The crude mixture was purified by flash column chromatography (10% EtOAc/toluene) to afford the 
title compound 295m (9.8 mg, 18%) as a yellow oil; νmax/ cm-1: 2921 (m), 1754 (s), 1714 (s), 1523 (s), 
1410 (s), 1344 (s), 1215 (s); 1H NMR (400 MHz, CDCl3): δ 8.30 (1H, d, J = 2.0 Hz, C7-H), 7.97 (1H, 
dd, J = 8.5, 2.0 Hz, C5-H), 7.37 – 7.27 (6H, m, C4-H, 2 × C12-H, 2 × C13-H and C14-H), 4.72 (1H, d, 
J = 15.0 Hz, 1 × C10-H2), 4.36 (1H, d, J = 15.0 Hz, 1 × C10-H2), 4.14 (1H, d, J = 5.5 Hz, C15-H), 3.44 
(1H, d, J = 17.0 Hz, 1 × C2-H2), 3.15 (1H, dd, J = 17.0, 1.0 Hz, 1 × C2-H2), 2.65 (1H, ddd, J = 18.0, 
13.5, 9.0 Hz, 1 × C17-H2), 2.42 – 2.25 (2H, m, 1 × C16-H2, 1 × C17-H2), 1.91 (1H, ddd, J = 14.0, 7.5, 
5.5 Hz, 1 × C16-H); 13C NMR (101 MHz, CDCl3): δ 211.9 (C18), 158.3 (C9), 148.7 (C6), 143.5 (C8), 
137.9 (C3), 135.8 (C11), 129.2 (C13), 128.3 (C12), 128.3 (C14), 125.0 (C4), 120.2 (C5), 111.2 (C7), 
70.6 (C1), 63.6 (C15), 46.2 (C10), 35.6 (C2), 33.1 (C17), 23.4 (C16) HRMS: (ESI+) Calculated for 









Substrate 308d was synthesised by G.-W. Wang. An oven dried reaction tube, fitted with a magnetic 
stirrer, was charged with [Rh(cod)2]OTf (3.51 mg, 7.5 × 10-3 mmol, 7.5 mol%), 4-
(dimethylamino)benzoic acid (2.47 mg, 15.0 μmol, 15 mol%l), tris(3,5-dimethylphenyl)phosphine 
(5.19 mg, 15.0 μmol, 15 mol%) Na2SO4 (14.2 mg, 0.1 mmol, 100 mol%) and substrate 308a (27.8 mg, 
0.10 mmol). The tube was fitted with a rubber septum and purged with argon. Anhydrous 1,2-DCB (1.0 
mL) was added by syringe. The reaction vessel was purged with CO for 10 minutes and the solution 
was subsequently sparged with CO for approximately 20 seconds. The reaction mixture was heated at 
130 °C for 72 hours. The mixture was cooled to room temperature, concentrated in vacuo and the crude 
residue was purified by flash column chromatography (10% EtOAc/Hex) to yield the title compound 
310d (25.9 mg, 82%) as a colourless oil; νmax / cm-1: 2923 (m), 1681 (s), 1654 (s), 1434 (s), 1398 (s), 
1068 (m); 1H NMR (400 MHz, CDCl3): δ 7.44 (1H, dd, J = 3.0, 2.0 Hz, 1 × ArC-H), 7.29 – 7.27 (2H, 
m, C1-H and 1 × ArC-H), 7.19 – 7.15 (4H, m, 4 × ArC-H), 6.27 – 6.23 (2H, m, C11-H and 1 × ArC-
H), 4.52 (1H, dd, J = 13.0, 4.5 Hz, C6-H), 4.23 (1H, ddd, J = 12.5, 8.5, 6.0 Hz, 1 × C8-H2), 3.67 (1H, 
m, 1 × C8-H2), 2.94 – 2.85 (3H, m, 1 × C4-H2, C9-H2), 2.56 (1H, ddd, J = 12.5, 4.0, 3.0 Hz, 1 × C4-
H2), 2.10 (1H, m, 1 × C5-H2), 1.93 (1H, m, 1 × C5-H2); 13C NMR (101 MHz, CDCl3): δ 188.8 (C3), 
150.6 (C7), 139.8 (C10), 136.2 (ArC), 134.4 (C2) 130.1 (ArC), 128.5 (ArC-H), 128.3 (ArC-H), 127.3 
(ArC-H), 123.3 (C11), 121.0 (C1), 110.7 (ArC-H), 61.8 (C6), 46.1 (C8), 37.1 (C4), 33.9 (C5), 26.7 
(C9); HRMS: (ESI+) Calculated for C19H19N2O2: 307.1441. Found [M+H]+: 307.1441. 
N-Benzyl-N-cyclopropyl-3-methyl-1H-indole-1-carboxamide (292x) 
 
General Procedure G: 3-Methyl-1H-indole (551 mg, 4.20 mmol) and carbamoyl chloride 299a (836 
mg, 4.00 mmol) were employed. The crude mixture was purified by flash column chromatography (10% 
toluene/petroleum ether) to afford the title compound 292x as a yellow oil (1.15mg, 95% yield); νmax/ 
cm-1: 3028 (m), 1671 (s), 1454 (s), 1405 (s), 1335 (s), 1223 (s); 1H NMR (400 MHz, CDCl3): δ 7.75 
(1H, d, J = 8.0 Hz, C7-H), 7.52 (1H, m, C4-H), 7.41 – 7.10 (8H, m, C1-H, C5-H, C6-H, 2 × C12-H, 2 
× C13-H and C14-H ), 4.67 (2H, s, C10-H2), 2.61 (2H, tt, J = 6.5, 3.5 Hz, C15-H), 2.29 (3H, s, C17-
H3), 0.74 – 0.53 (4H, m, 2 × C16-H2); 13C NMR (101 MHz, CDCl3): δ 155.5 (C9), 137.3 (C11), 136.2 
(C8), 130.6 (C3), 128.9, 128.5 (C12, C13), 127.8 (C14), 123.8 (C6), 123.2 (C1), 121.8 (C5), 119.0 (C4), 
115.2 (C2), 114.1 (C7), 53.6 (C10), 31.3 (C15), 9.9 (C17), 9.3 (C16); HRMS: (ESI)+ Calculated for 
C20H21N2NaO: 327.1468. Found [M + Na]+: 327.1475. 





2-Benzyl-7-methyl-2,3,4,5-tetrahydro-[1,3]diazocino[1,8-a]indole-1,6-dione (312a) and (Z)-2-
Benzyl-7-methyl-2,5-dihydro-[1,3]diazocino[1,8-a]indole-1,6-dione (313a) 
 
An oven dried reaction tube, fitted with a magnetic stirrer, was charged with [Rh(cod)2]OTf (3.51 mg, 
7.5  µmol, 7.5 mol%), COD (4 µL, 30 µmol, 30 mol%), and indole substrate 292x (30.4 mg, 0.10 mmol, 
100 mol%). The tube was fitted with a rubber septum and purged with argon. The reagents were 
dissolved in argon sparged 1,2-DCB (1.0 mL). The reaction mixture was sparged with CO for 
approximately 10 seconds, then heated at 130 °C under a CO atmosphere for 72 h. The mixture was 
cooled to room temperature and concentrated in vacuo. The residue was purified by flash column 
chromatography (5–20% EtOAc/pentane) to afford the title compound 312a (9.0 mg, 27%) as a 
colourless solid. Analysis of the crude reaction mixture by 1H NMR revealed a 3:1 (312a:313a) mixture 
of products. The minor product 313a was not isolated. 
Data for major compound 312a: νmax/ cm-1: 3044 (m), 2982 (m), 1687 (s), 1653 (s), 1519 (s), 1429 (s), 
1280 (s); 1H NMR (500 MHz, DMSO-d6, 100 °C): δ 7.76 (1H, d, J = 8.0 Hz, C7-H), 7.61 (1H, d, J = 
8.5 Hz, C4-H), 7.49 – 7.32 (6H, m, C6-H, 2 × C16-H, 2 × C17-H and C18-H), 7.25 (1H, dd, J = 8.5, 
7.5 Hz, C5-H), 4.80 (2H, s, C14-H2), 3.36 (2H, t, J = 6.0 Hz, C10-H2), 2.73 (2H, t, J = 6.5 Hz, C12-H2), 
2.60 (3H, s, C19-H3), 2.00 (2H, tt, J = 6.5, 6.0 Hz, C11-H2); 13C NMR (126 MHz, CDCl3): δ 192.7 
(C13), 154.3 (C9), 138.3 (C8), 136.2 (C15), 133.5 (C1), 129.1, 128.4, 128.2 (2 signals), 128.1 (C3, C6, 
C16, C17 and C18), 127.2 (C2), 122.2 (C5), 121.0 (C4), 114.7 (C7), 50.0 (C14), 44.1 (C10), 37.8 (C12), 
24.4 (C11), 12.1 (C19); 13C NMR (126 MHz, DMSO-d6, 100 °C): δ 192.0 (C13), 152.9 (C9), 136.8 
(C8), 136.3 (C15), 132.4 (C1), 128.1, 127.4, 127.4, 127.0, 126.7 (C3, C6, C16, C17 and C18), 123.6 
(C2), 121.2 (C5), 120.1 (C4), 113.5 (C7), 49.2 (C14), 44.0 (C10), 37.1 (C12), 23.3 (C11), 10.5 (C19); 
HRMS: (ESI)+ Calculated for C21H21N2O2: 333.1598. Found [M + H] +: 333.1602. A 
1H NMR spectrum 
was recorded at 100 °C in DMSO-d6 because at room temperature slow conformational interconversion 
gave a broad spectrum.  
Data for minor compound 313a: Characteristic signals only: 1H NMR (400 MHz, CDCl3): δ 6.07 (1H, 
dt, J = 7.0, 1.0 Hz, C10-H), 5.69 (1H, td, J = 8.0, 7.0 Hz, C11-H). 
  







General Procedure G: 1H-Pyrrole (0.69 mL, 10.0 mmol) and carbamoyl chloride 299a (313 mg. 15.0 
mmol) were employed. The crude mixture was purified by flash column chromatography (10% 
EtOAc/hexane) to afford the title compound 314 (2.08 g, 87%) as a yellow oil; νmax/ cm-1: 2971 (m), 
2900 (m), 1671 (s), 1412 (s), 1386 (s), 1291 (s), 1073 (s); 1H NMR (400 MHz, CDCl3): δ 7.41 – 7.27 
(5H, m, 2 × C6-H, 2 × C7-H, C8-H), 7.20 (2H, d, J = 2.0 Hz, 2 × C1-H), 6.23 (2H, d, J = 2.0 Hz, 2 × 
C2-H), 4.69 (2H, s, C4-H2), 2.64 (1H, tt, J = 7.0, 4.0 Hz, C9-H), 0.78 – 0.55 (4H, m, 2 × C10-H2); 13C 
NMR (101 MHz, CDCl3): δ 154.7 (C3), 137.03 (C5), 128.7, 128.2 (C6, C7), 127.6 (C8), 120.6 (C1), 
110.5 (C2), 53.2 (C4), 31.7 (C9), 9.6 (C10); HRMS: (ESI+) Calculated for C15H17N2O: 241.1335. Found 
[M + H]+: 241.1344.  
2-Benzyl-2,3,4,5-tetrahydropyrrolo[1,2-c][1,3]diazocine-1,6-dione (312b) and (Z)-2-Benzyl-2,5-
dihydropyrrolo[1,2-c][1,3]diazocine-1,6-dione (313b) 
 
An oven dried reaction tube, fitted with a magnetic stirrer, was charged with [Rh(cod)2]OTf (3.5 mg, 
7.5  µmol, 7.5 mol%), COD (4 µL, 30 µmol, 30 mol%), and pyrrole substrate 314 (24.0 mg, 0.10 mmol, 
100 mol%). The tube was fitted with a rubber septum and purged with argon. The reagents were 
dissolved in argon sparged 1,2-DCB (1.0 mL). The reaction mixture was sparged with CO for 
approximately 10 seconds, then heated at 130 °C under a CO atmosphere for 72 h. The mixture was 
cooled to room temperature and concentrated in vacuo. The residue was purified by flash column 
chromatography (10–30% EtOAc/pentane) to afford the title compounds 312b (13.1 mg, 49%) as a 
colourless solid and 313b (4.3 mg, 16%) as a colourless solid.  
Data for major product 312b: m.p.: 97–98 °C (pentane/EtOAc); νmax/ cm-1: 2928 (m), 1684 (s), 1654 
(s), 1434 (s), 1418 (s), 1283 (s), 1139 (s); 1H NMR (500 MHz, DMSO-d6, 100 °C): δ 7.47 – 7.33 (6H, 
m, C9-H, 2 × C12-H, 2 × C13-H, C14-H), 7.08 (1H, dd, J = 3.5, 2.0 Hz, ArC-H), 6.38 – 6.32 (1H, m, 
ArC-H, 4.75 (2H, s, C10-H2), 3.38 (2H, t, J = 6.5 Hz, C4-H2), 2.60 (2H, t, J = 6.5 Hz, C2-H2), 1.92 (2H, 
tt, J = 6.5, 6.5 Hz, C3-H2); 1H NMR (301 MHz, CDCl3, ˗ 50 °C): δ 7.49 (1H, dd, J = 3.0, 2.0 Hz, ArC-





H), 7.40  – 7.34 (5H, m, ArC-H), 7.24 (1H, m, ArC-H), 6.35 (1H, dd, J = 5.0, 3.0 Hz, ArC-H), 5.32 
(1H, d, J = 14.5 Hz, 1 × C10-H2), 4.19 (1H, d, J = 14.5 Hz, 1 × C10-H2), 3.61 (1H, ddd, J = 15.0, 3.0, 
3.0 Hz, 1 × C4-H2), 3.25 (1H, ddd, J = 15.0, 5.0, 5.0 Hz, 1 × C2-H2), 2.91 (1H, ddd, J = 13.0, 5.0, 5.0 
Hz, 1 × C4-H2), 2.59 (1H, ddd, J = 12.0, 3.0, 3.0 Hz, 1 × C2-H2), 2.15 (1H, m, 1 × C3-H2), 1.86 (1H, 
m, 1 × C3-H2); 13C NMR (101 MHz, CDCl3): δ 188.6 (C1), 153.7 (C5), 135.8 (ArC), 135.2 (ArC), 130.3 
(Ar-CH), 128.9, 128.3, 128.3 (C12, C13 and C14), 120.9 (Ar-CH), 111.0 (Ar-CH), 50.7 (C10), 44.6 
(C4), 36.3 (C2), 24.5 (C3); HRMS: (ESI)+ Calculated for C16H16N2NaO2: 291.1104. Found [M + Na] +: 
291.1113. A 1H NMR spectrum was recorded at 100 °C in DMSO-d6 and at ˗ 50 °C in CDCl3 because 
at room temperature slow conformational interconversion gave a broad spectrum. The structure of this 
compound was determined unambiguoulsy by X-ray cystrallography. 
 
Data for minor product 313b: m.p.: 115–117 °C (pentane/EtOAc); νmax/ cm-1: 2987 (m), 1685 (s), 1667 
(s), 1483 (s), 1406 (s), 1257 (s), 1075 (s), 1066 (s), 1056 (s); 1H NMR (500 MHz, DMSO-d6, 100 °C): 
δ 7.44 – 7.33 (6H, m, C9-H, 2 × C12-H, 2 × C13-H, C14-H), 6.93 (1H, dd, J = 4.0, 2.0 Hz, ArC-H), 
6.32 (1H, dd, J = 4.0, 1.5 Hz, ArC-H), 6.24 (1H, d, J = 7.0 Hz, C4-H), 5.82 (1H, m, C3-H), 4.84 (2H, 
s, C10-H2), 3.14 (1H, d, J = 8.0 Hz, C2-H2); 1H NMR (301 MHz, CDCl3, ˗ 50 °C): δ 7.44 – 7.34 (5H, 
m, 5 × ArC-H), 7.30 (1H, m, ArC-H), 7.10 (1H, dd, J = 3.0, 1.5 Hz, ArC-H), 6.33 (dd, J = 4.0, 3.0 Hz, 
ArC-H), 6.12 (1H, dd, J = 7.0, 1.0 Hz, C4-H), 5.84 (1H, ddd, J = 10.0, 7.0, 6.5 Hz, C3-H), 5.16 (1H, d, 
J = 14.0 Hz, 1 × C10-H2), 4.49 (1H, d, J = 14.0 Hz, 1 × C10-H2), 3.22 (1H, dd, J = 13.5, 10.0 Hz, 1 × 
C2-H2), 2.93 (1H, dd, J = 13.5, 6.5 Hz,1 × C2-H2); 13C NMR (101 MHz, CDCl3): δ 185.3 (C1), 152.6 
(C5), 135.0 (C11), 132.4 (C6), 130.0 (Ar-CH), 129.2 (C4), 128.9 (2 signals) (C12, C13), 128.5 (C14), 
124.9 (C3), 120.2 (Ar-CH), 110.9 (Ar-CH), 53.6 (C10), 40.3 (C2); HRMS: (ESI)+ Calculated for 
C16H14N2NaO2: 289.0947. Found [M + Na] +: 289.0951. A 
1H NMR spectrum was recorded at 100 °C 
in DMSO-d6 and at ̠  50 °C in CDCl3 because at room temperature slow conformational interconversion 
gave a broad spectrum. 
4-phenylbut-3-yn-1-ol 
 





The title compound was prepared following a modified literature procedure.210 To an oven dried 
reaction tube was added CuI (19.0 mg, 0.010 mmol), PdCl2(PPh)3 (70.2 mg, 0.010 mmol) and Et3N (8 
mL). The tube was fitted with a rubber septum and purged with argon. The resulting solution was stirred 
at room temperature for 15 minutes then iodobenzene (1.23 mL, 11.0 mmol) and but-3-yn-1-ol (0.76 
mL, 10.0 mmol) and another 2 mL of Et3N were added. The mixture was heated at 65 ℃ for 12 hours. 
The reaction mixture was concentrated in vacuo and the residue was purified by flash column 
chromatography (30% EtOAc/hexane) to afford the title compound 319 (1.34 g, 85%) as a colourless 
solid; νmax / cm-1: 3360 (br. s), 30332 (m), 2932 (m), 1675 (s), 1590 (s), 1440 (s), 1042 (s); 1H NMR 
(400 MHz, CDCl3): δ 7.44 – 7.32 (5H, m, 5 × ArC-H), 3.80 (1H, t, J = 6.5 Hz, CH2), 2.70 (t, J = 6.5 
Hz, CH2). The spectroscopic properties of this compound were consistent with the data available in 




Substrate 308f was synthesised by G.-W. Wang. An oven dried reaction tube, fitted with a magnetic 
stirrer, was charged with [Rh(cod)2]OTf (3.51 mg, 7.5 × 10-3 mmol, 7.5 mol%), P(4-(F)C6H4)3 (4.74 mg, 
0.015 mmol, 15 mol%), 2-nitrobenzoic acid (25.0 mg, 0.10 mmol), and substrate 308a (32.8 mg, 0.10 
mmol). The tube was fitted with a rubber septum and purged with argon. Anhydrous PhCN (0.1 mL) 
was added by syringe. The reaction vessel was purged with CO for 10 minutes and the solution was 
subsequently sparged with CO for approximately 20 seconds. The reaction mixture was heated at 140 °C 
for 72 hours. The mixture was cooled to room temperature, concentrated in vacuo and the crude residue 
was purified by flash column chromatography (5–10% acetone/toluene) to yield the title compound 
310f (22.1 mg, 62%) as a yellow solid; m.p. 253–255 °C (CDCl3); νmax / cm-1: 3288 (m), 1657 (s), 1605 
(s), 1519 (s), 1456 (s), 1333 (s); 1H NMR (400 MHz, CDCl3): δ 9.41 (1H, br. s, NH), 8.05 (1H, d, J = 
8.0 Hz, 1 × ArC-H), 7.38 – 7.24 (4H, m, 4 × ArC-H), 7.18 – 7.14 (4H, m, 4 × ArC-H), 6.22 (1H, d, J = 
2.5 Hz, C9-H), 4.60 (1H, dd, J = 13.0, 5.0 Hz, C5-H), 4.40 (1H, ddd, J = 12.5, 9.0, 5.5 Hz, 1 × C2-H2), 
3.68 (1H, ddd, J = 12.5, 9.0, 6.5 Hz, 1 × C2-H2), 3.20 (1H, ddd, J = 13.0, 13.0, 5.5 Hz, 1 × C7-H2), 3.01 
– 2.86 (2H, m, C3-H2), 3.60 (1H, m, 1 × C7-H2), 2.22 – 2.01 (2H, m, 2 × C6-H2); 13C NMR (101 MHz, 
CDCl3): δ 192.4 (C8), 163.9 (C1), 141.0 (C4), 136.6 (ArC), 136.0 (ArC), 133.3 (ArC), 128.4 (Ar-CH), 
128.2 (Ar-CH), 127.7 (Ar-CH), 127.2 (Ar-CH), 127.1 (ArC), 123.8 (Ar-CH), 122.8 (C9), 122.3 (Ar-





CH), 116.2 (ArC), 111.9 (Ar-CH), 62.7 (C5), 44.2 (C2), 37.7 (C7), 35.9 (C6), 27.3 (C3); HRMS: (ESI+) 
Calculated for C23H21N2O2: 357.1598. Found [M + H]+: 357.1593. 
7.5.2 Mechanistic studies from Chapter 4 
Eqn 7: Deuterium exchange experiment of the carbonylative cyclisation of indole 292a with 
4-N(Me)2C6H4CO2D  
 
p-NMe2C6H4CO2H was initially prepared by repeatedly dissolving p-NMe2C6H4CO2H in MeOD-d4 and 
concentrating the resulting solution in vacuo.  
An oven dried reaction tube, fitted with a magnetic stirrer, was charged with [Rh(cod)2]OTf (5.28 mg, 
11.2 × 10-3 mmol), p-NMe2C6H4CO2D (7.47 mg, 45.0 × 10-3 mmol), and substrate 292a (43.5 mg, 0.15 
mmol). The tube was fitted with a rubber septum and purged with argon. Anhydrous 1,2-DCB (1.5 mL) 
was added by syringe. The reaction vessel was purged with CO for 10 minutes and the solution was 
subsequently sparged with CO for approximately 20 seconds. The reaction mixture was heated at 130 °C 
for 24 hours. The mixture was cooled to room temperature and concentrated in vacuo. The residue was 
purified by flash column chromatography (10% EtOAc/Hexane then 5% EtOAc/toluene) to afford 
deuterio-295ad (25.8 mg, 54%) and deuterio-292ad (11.7 mg, 27%). The percentage of deuterium 
incorporation was measured by 1H NMR. Analysis of deuterio-295ad revealed 7% and 5% deuterium 
incorporation at the diastereotopic C2 protons. Analysis of deuterio-292ad revealed 8% and 10% 
deuterium incorporation at the C1 and C2 protons.   
Data for deuterio-295ad: 1H NMR (400 MHz, CDCl3):δ 7.51 (1H, dd, J = 8.0, 1.0 Hz, C7-H), 7.41 – 
7.26 (5H, m, 2 × C16-H, 2 × C17-H and C18-H), 7.24 – 7.17 (2H, m, C4-H and C6-H), 7.06 (1H, dd, J 
= 7.5, 1.0 Hz, C5-H), 4.67 (1H, d, J = 15.0 Hz, 1 × C10-H2), 4.37 (1H, d, J = 15.0 Hz, 1 × C10-H2), 
4.09 (1H, d, J = 5.5 Hz, C15-H), 3.35 (0.93H, d, J = 16.0 Hz, 1 × C2-H2), 3.09 (0.95H, d, J = 16.0 Hz, 
1 × C2-H2), 2.62 (1H, ddd, J = 17.5, 13.5, 9.0 Hz, 1 × C12-H2), 2.38 – 2.19 (2H, m, 1 × C12-H2, 1 × 
C11-H2), 1.87 (1H, dddd, J = 13.5, 7.5, 5.5, 2.0 Hz, 1 × C11-H2). 
Data for deuterio-292ad: 1H NMR (400 MHz, CDCl3): δ 7.67 (1H, m, C7-H), 7.49 (1H, dd, J = 7.5, 1.0 
Hz, C4-H), 7.34 (0.92H, d, J = 3.5 Hz, C1-H), 7.31 – 7.15 (6H, m, C6-H , 2 × C12-H, 2 × C13-H and 





C14-H), 7.11 (1H, dd, J = 7.5, 1.0 Hz, C5-H), 6.49 (0.90H, d, J = 3.5 Hz, C2-H), 4.61 (2H, s, C10-H2), 
2.54 (1H, tt, J = 7.0, 4.0 Hz, C15-H), 0.62 – 0.45 (4H, m, 2 × C16-H2).  
Eqn 11: Deuterium exchange experiment of the carbonylative cyclisation of pyrrole 308d with 
4-N(Me)2C6H4CO2D  
 
An oven dried reaction tube, fitted with a magnetic stirrer, was charged with [Rh(cod)2]OTf (3.52 mg, 
7.0 μmol, 7.5 mol%), 4-NMe2C6H4CO2D (2.30 mg, 14.0 μmol, 15 mol%), tris(3,5-
dimethylphenyl)phosphine (4.83 mg, 14.0 μmol, 15 mol%) and N-cyclopropyl-N-(4-phenylbut-3-yn-1-
yl)-1H-pyrrole-1-carboxamide 308d (25.8 mg, 0.093 mmol). The tube was fitted with a rubber septum 
and purged with argon. Anhydrous 1,2-DCB (0.93 mL) was added by syringe. The reaction vessel was 
purged with CO for 10 minutes and the solution was subsequently sparged with CO for approximately 
20 seconds. The reaction mixture was heated at 130 ℃ for 72 hours. The mixture was cooled to room 
temperature and concentrated in vacuo. The crude mixture was purified by column chromatography (5% 
EtOAc/toluene) to yield the title compound deuterio-310db (19.7 mg, 70%) as a colourless oil. The 
percentage of deuterium incorporation was measured by 1H NMR. Analysis of deuterio-310d revealed 
3% deuterium incorporation at the C11 proton. 
Data for product deuterio-310db: 1H NMR (400 MHz, DMSO-d6): δ 7.49 (1H, dd, J = 3.0, 2.0 Hz, 
ArC-H), 7.39 – 7.21 (5H, m, 5 × ArC-H), 7.10 (1H, dd, J = 4.0, 2.0 Hz, ArC-H), 6.49 (0.97H, d, J = 2.5 
Hz, C11-H), 6.36 (1H, dd, J = 4.0, 3.0 Hz, ArC-H), 4.49 (1H, dd, J = 11.5, 6.0 Hz), 4.12 (1H, ddd, J = 
12.0, 9.5, 5.0 Hz), 3.75 (1H, ddd, J = 12.0, 9.4, 6.5 Hz), 3.05 (1H, m,), 2.93 – 2.84 (2H, m), 2.10 – 1.94 
(2H, m). 
Eqn 12: Deuterium exchange experiment of the carbonylative cyclisation of pyrrole 308d with 
D2O  
 
An oven dried reaction tube, fitted with a magnetic stirrer, was charged with [Rh(cod)2]OTf (2.48 mg, 
5.2 μmol, 7.5 mol%), 4-(dimethylamino)benzoic acid (1.77 mg, 10.5 μmol, 15 mol%), tris(3,5-
dimethylphenyl)phosphine (3.68 mg, 10.5 μmol, 15 mol%) and 310d (21.6 mg, 0.071 mmol). The tube 





was fitted with a rubber septum and purged with argon. Anhydrous 1,2-DCB (0.71 mL) was added by 
syringe. The reaction vessel was purged with CO for 10 minutes and the solution was subsequently 
sparged with CO for approximately 20 seconds. Then the CO balloon was removed and D2O (2.5 uL, 
0.14 mmol) was added. The tube was sealed and the reaction was heated at 130 °C for 72 hours. The 
mixture was cooled to room temperature and concentrated in vacuo. The crude mixture was purified by 
column chromatography (5% EtOAc/toluene) to yield the title compound deuterio-310dc (17.9 mg, 
82%) as a colourless oil. The percentage of deuterium incorporation was measured by 1H NMR. 
Analysis of deuterio-310dc revealed no exchange at the vinylic position of the product was observed.  
Data for product deuterio-310db: 1H NMR (400 MHz, DMSO-d6): δ 7.50 (0.83H, dd, J = 3.0, 2.0 Hz, 
ArC-H), 7.41 – 7.20 (5H, m, 5 × ArC-H), 7.10 (1H, m, ArC-H), 6.49 (1H, d, J = 2.5 Hz, C11-H), 6.37 
(1H, dd, J = 4.0, 3.0 Hz, ArC-H), 4.49 (1H, dd, J = 11.5, 6.0 Hz), 4.13 (1H, ddd, J = 12.0, 9.5, 5.0 Hz), 
3.75 (1H, ddd, J = 12.0, 9.5, 6.5 Hz), 3.07 (1H, m), 2.93 – 2.84 (0.86H, m), 2.10 – 1.94 (2H, m). 
7.5 Experimental procedures for the studies in Chapter 5 
 (Z)-2-Bromobut-2-enal  
 
To a solution of trans-crotonaldehyde (2.95 mL, 35.7 mmol) in CH2Cl2 (50 mL) at 0 °C was added 
bromine (1.85 mL, 36.1 mmol) in CH2Cl2 (5 mL) dropwise over 10 minutes via a dropping funnel. The 
reaction mixture was stirred at 0 °C for 1 hour. Triethylamine (6.00 mL, 43.2 mmol) was added, the 
reaction mixture was warmed to room temperature and stirred for an additional 1.5 hours. The reaction 
was quenched with saturated aqueous Na2S2O3 (10 mL). The organic layer was washed with 1 M aq. 
HCl (10 mL), brine (20 mL), dried over Na2SO4, filtered and concentrated in vacuo to afford the title 
compound (4.68 g, 89%, >95:5 Z:E) as a pale yellow oil. The product was used in the following step 
without any further purification. 1H NMR (400 MHz, CDCl3): δ 9.21 (1H, d, J = 1.0 Hz, C1-H), 7.27 
(1H, q, J = 6.5 Hz, C3-H), 2.14 (3H, dd, J = 6.5, 1.0 Hz, C4-H3); 13C NMR (101 MHz, CDCl3): δ 186.2 
(C1), 151.3 (C3), 130.2 (C2), 18.1 (C4). The spectroscopic properties of this compound were consistent 
with the data available in literature.251  
(Z)-2-Bromobut-2-en-1-ol (371) 
 
To a solution of (Z)-2-Bromobut-2-enal (4.72 g, 31.7 mmol) in THF/H2O (9:1, 80 mL) at 0 °C was 
added NaBH4 (740 mg, 19.0 mmol) portion wise over 10 minutes. The reaction mixture was stirred for 





1 hour and then quenched with 1 M aq. HCl (10 mL) and warmed to room temperature. The reaction 
mixture was diluted with EtOAc/hexane (1:4, 80 mL) and H2O (100 mL). The aqueous layer was 
separated and extracted with EtOAc/hexane (1:4, 80 mL). The organic layers were combined, washed 
with brine (100 mL), dried over Na2SO4, filtered and concentrated in vacuo to give the title compound 
371 (4.08 g, 86%) as a pale yellow oil. The product was used in the following step without any further 
purification. 1H NMR (400 MHz, CDCl3): δ 6.08 (1H, qt, J = 6.5, 1.0 Hz, C3-H), 4.25 (2H, qd, J = 1.0, 
1.0 Hz, C1-H2), 1.78 (3H, dt, J = 6.5, 1.0 Hz, C4-H3); 13C NMR (101 MHz, CDCl3): δ 128.0 (C3), 125.4 
(C2), 68.7 (C1), 16.5 (C4).The spectroscopic properties of this compound were consistent with the data 
available in literature.251  
(Z)-2-Chlorobut-2-enal (374) 
 
The title compound 374 was prepared following a literature procedure.254 To a solution of trans-
crotonaldehyde (1.05 g, 15.0 mmol) in CH2Cl2 (50 mL) was added (diacetoxyiodo)benzene (5.79 g, 
18.6 mmol) and pyridine hydrochloride (5.18 g, 45.0 mmol). The reaction mixture was stirred at room 
temperature for 18 hours. The reaction mixture was transferred to a separating funnel and washed with 
1 M aq. HCl (20 mL). The layers were separated and the aqueous layer was further extracted with 
CH2Cl2 (2 × 10 mL). The organic layers were combined, washed with brine (20 mL), dried over Na2SO4, 
filtered and concentrated in vacuo. The crude residue was purified by flash column chromatography 
(20% Et2O/petrol) to give the title compound 374 (1.14 g, 73%) as a yellow oil; 1H NMR (400 MHz, 
CDCl3): δ 9.37 (1H, s, C1-H), 6.97 (1H, q, J = 7.0 Hz, C3-H), 2.13 (3H, d, J = 7.0 Hz, C4-H3); 13C 
NMR (101 MHz, CDCl3): δ 185.7 (C1), 147.1 (C3), 136.9 (C2), 15.4 (C4). The spectroscopic properties 
of this compound were consistent with the data available in literature.354  
N-(But-2-yn-1-yl)cyclopropanamine (377) 
 
To a solution of 1-bromobut-2-yne (0.86 mL, 10.0 mmol) in MeCN (30 mL) was added a solution of 
cyclopropylamine (4.46 mL, 50.0 mmol) in MeCN (5mL) over 10 minutes at room temperature. After 
addition was complete, the reaction mixture was stirred for a further 3 hours at room temperature, 
diluted with CH2Cl2 (10 mL) and washed with H2O (2 × 20 mL). The organic layer was separated and 
washed with brine (30 mL), dried over Na2SO4, filtered and concentrated in vacuo. The crude residue 
was purified by flash column chromatography (30% EtOAc/hexane) to afford the title compound 377 





(750 mg, 69%) as a colourless oil; νma x/ cm-1: 3749 (br. m), 2926 (m), 1441 (s), 1321 (s); 1H NMR (400 
MHz, CDCl3): δ 3.38 (2H, q, J = 2.5 Hz, C3-H2), 2.30 (1H, m, C2-H), 1.81 (3H, t, J = 2.5 Hz, C6-H3), 
1.75 (1H, br. s, NH), 0.48 – 0.33 (4H, m, 2 × C1-H2);13C NMR (101 MHz, CDCl3): δ 78.7, 77.7 (C4 
and C5), 38.5 (C3), 29.7 (C2), 6.3 (C1), 3.6 (C6); LRMS: (ESI)+ Calculated for C7H12N: 109.09. Found 
[M + H] +: 109.09.  
N-(But-2-yn-1-yl)-N-cyclopropyl-1H-indole-3-carboxamide (178i) 
 
To a solution of 1H-indole-3-carboxylic acid (500 mg, 3.10 mmol) in CH2Cl2 (10 mL) was added oxalyl 
chloride (0.26 mL, 3.10 mmol) dropwise over five minutes and DMF (2 drops) at 0 ℃. After addition 
was complete, the mixture was warmed to room temperature and stirred for a further 2 hours. The 
reaction mixture was concentrated in vacuo and then suspended in CH2Cl2 (15 mL). A solution of N-
(but-2-yn-1-yl)cyclopropanamine 377 (338 mg, 3.10 mol) in 5 mL of CH2Cl2 was added and 
triethylamine (0.65 mL, 4.65 mmol). The reaction mixture was stirred at room temperature for 16 hours, 
diluted with CH2Cl2 (25 mL) and washed with H2O (3 × 20 mL). The organic layer was separated and 
washed with brine (25 mL), dried over Na2SO4, filtered and concentrated in vacuo. The crude residue 
was recrystallised from MeOH to give the title compound 178i (513 mg, 66%) as a white crystalline 
solid; m.p.: 159–160 °C (MeOH); νma x/ cm-1: 3158 (m), 2916 (m), 1586 (s), 1522 (s), 1439 (s), 1312 
(s), 1219 (s); 1H NMR (400 MHz, CDCl3): δ 9.67 (1H, br. s, NH), 8.03 (1H, dd, J = 6.5, 3.0 Hz, C4-H), 
7.33 (1H, d, J = 3.0 Hz, C1-H), 7.25 (1H, m, C7-H), 7.19 – 7.12 (2H, m, C5-H and C6-H), 4.30 (2H, q, 
J = 2.5 Hz, C10-H2), 2.89 (1H, m, C14-H), 1.81 (3H, t, J = 2.5 Hz, C13-H3), 0.71 (4H, m, 2 × C15-H2); 
13C NMR (101 MHz, CDCl3): δ 168.8 (C9), 135.7 (C8), 128.4 (C1), 127.0 (C3), 122.6 (C6), 121.3, 
121.1 (C4 and C5), 111.7 (C7), 110.9 (C2), 79.0, 75.7 (C11 and C12), 38.5 (C10), 31.1 (C14), 9.7 (C15), 
3.8 (C13); HRMS: (ESI)+ Calculated for C16H16N2O: 253.1335. Found [M + H] +: 253.1336.  
N-Cyclopropyl-N-(2-oxobutyl)-1H-indole-3-carboxamide (379) and N-Cyclopropyl-N-(3-
oxobutyl)-1H-indole-3-carboxamide (380) 
 
General Procedure C: Indole 178i (37.8 mg, 0.15 mmol) was employed and the reaction mixture was 
heated at 140 °C for 72 h. The reaction was cooled to room temperature and concentrated in vacuo. An 





in situ yield was obtained by 1H NMR spectroscopy using 1,4-dinitrobenzene as an internal standard; 
a 25% yield of 379 and 9% yield of 380 were observed. The products could not be readily separated 
from the ligand, starting material and the other side products, the structure of the products 379 and 
380 were determined by analysis of the 1H NMR spectrum of the reaction mixture and corroborated by 
COSY data.  
Data for 379: Characteristic signals only: 1H NMR (400 MHz, CDCl3): δ 4.40 (2H, s, C1-H2), 3.13 –
2.55 (2H, q, J = 7.5 Hz, C3-H2), 1.12 (3H, t, J = 7.5 Hz, C4-H3). 
Data for 380: Characteristic signals only: 1H NMR (400 MHz, CDCl3): δ 4.46 (2H, t, J = 6.0 Hz, C1-
H2), 2.99 (2H, t, J = 6.0 Hz, C2-H2), 2.12 (3H, s, C4-H3). 
Data for both 379 and 380: HRMS: (ESI)+ Calculated for C16H19N2O2: 271.1434. Found [M + H] +: 
271.1441.  
2-Benzyl-2,3,4,5-tetrahydro-1H-azocino[4,3-b]indole-1,6(7H)-dione (179a) and (Z)-2-Benzyl-2,5-
dihydro-1H-azocino[4,3-b]indole-1,6(7H)-dione (180a) 
 
Procedure for the Rh(I)-catalysed carbonylative cyclisation of indole 178a in a ChemSCAN II® reactor. 
To a stainless stain ChemSCAN II® reactor vessel was added indole 178a (290 mg, 1.00 mmol), 2-
nitrobenzoic acid (250 mg, 1.50 mmol), P(4-(F)C6H4)3 (47.4 mg, 0.150 mmol) and [Rh(cod)OMe]2 
(18.0 mg, 0.038 mmol). The reagents were dissolved in anhydrous PhCN (3.0 mL). The reaction vessel 
was attached to a ChemSCANII® reactor and purged with nitrogen (× 4 cycles) and then purged with 
CO (×4 cycles). The vessel was heated at 130 ℃ at 3 bar of CO for 24 hours. After this time, the reaction 
vessel was cooled to room temperature, vented and purged with nitrogen. The reaction mixture was 
transferred to a round-bottom flask, washing with MeOH (~2 mL) and concentrated in vacuo. The crude 
material was purified by flash column chromatography (80 g silica column, 20–70% EtOAc/hexane, 16 
column volumes) to give the title compound 179a (146 mg, 45%) as an off-white solid and the title 
compound 180a (19.9 mg, 6%) as an off-white solid. The spectroscopic properties of 179a and 180a 
were consistent with the data previously reported in this thesis. 
Data for major compound 179a: 1H NMR (400 MHz, CDCl3): δ 9.22 (1H, br. s, NH), 8.12 (1H, d, J = 
8.0 Hz, C4-H), 7.48 – 7.21 (8H, m, C5-H, C6-H, C7-H, 2 × C16-H, 2 × C17-H and C18-H), 5.31 (1H, 
m, 1 × C14-H2), 4.53 (1H, d, J = 14.5 Hz, 1 × C14-H2), 3.82 (1H, m, 1 × C12-H2), 3.32 (1H, m, 1 × 





C12-H2), 3.14 (1H, m, 1 × C10-H2), 2.63 (1H, d, J = 12.5 Hz, 1 × C10-H2), 2.07 (1H, d, J = 12.0 Hz, 1 
× C11-H2), 1.84 (1H, m, 1 × C11-H2); 13C NMR (101 MHz, CDCl3): δ 192.1 (C9), 166.3 (C13), 137.5 
(C15), 136.2 (C8), 133.5 (C1), 128.9, 128.4, 128.3 (C3, C16 and C17), 127.9 (C6), 127.4 (C18), 123.8 
(C4), 122.4 (C5), 115.2 (C2), 112.1 (C7), 48.6 (C14), 45.8 (C12), 36.9 (C10), 26.5 (C11).  
Data for minor compound 180a: m.p.: 198–200 °C; 1H NMR (400 MHz, CDCl3):  δ 9.08 (1H, br. s, 
NH), 8.05 (1H, d, J = 8.0, Hz, C4-H), 7.51 – 7.23 (8H, m, C5-H, C6-H, C7-H, 2 × C16-H, 2 × C17-H 
and C18-H), 6.16 (1H, dd, J = 7.5, 1.0  Hz, C12-H), 5.64 (1H, ddd, J = 10.0, 7.5, 7.0 Hz, C11-H), 5.30 
(1H, d, J = 14.5 Hz, 1 × C14-H2), 4.77 (1H, d, J = 14.5 Hz, 1 × C14-H2), 3.53 (1H, ddd, J = 12.5, 10.0, 
1.0 Hz, 1 × C10-H2), 3.11 (1H, dd, J = 12.5, 7.0 Hz, 1 × C10-H2); 13C NMR (126 MHz, CDCl3): δ 189.0 
(C9), 163.9 (C13), 136.8 (C15), 135.6 (C8), 131.9 (C12), 130.6 (C1), 128.7, 128.5, 128.4 (C3, C16 and 
C17), 127.8 (C18), 126.9 (C6), 123.7 (C4), 122.3 (C5), 120.4 (C11), 114.6 (C2), 111.8 (C7), 51.2 (C14), 
40.1 (C10).  
 
Figure 6:355 A) Image of a ChemScan II® reactor vessel and stirrer motor. B) Image of the ChemSCAN II®. A 
ChemSCAN II® consists of 8 reactor vessels that are independently controlled and monitored.  
2-Benzyl-6-hydroxy-2,3,4,5,6,7-hexahydro-1H-azocino[4,3-b]indol-1-one (382) and 2-Benzyl-
2,3,4,5,6,7-hexahydro-1H-azocino[4,3-b]indol-1-one (383) 
 
Indole 179a (48.0 mg, 0.151 mmol) was dissolved in ethanol (2 mL) ethyl acetate (1 mL). The reaction 
mixture was hydrogenated using the H-cube (settings: 60 °C, 10 bar, 1mL/min flow rate) and 20% 
Pd(OH)2/C CatCart 30 as the catalyst. The crude material was concentrated in vacuo, dissolved in 
DMSO (1.2 mL) and purified by preparative high-performance liquid chromatography using an XSelect 
CSH C18 column (100 mm x 30 mm, 5 µm). The preprative HPLC was conducted using a 40 mL/min 
flow rate using a gradient elution (30–100%, A:B, with the eluents as A) 10 mM ammonium bicarbonate 





in water adjusted to pH 10 with ammonia solution and B) acetonitrile) over 27.0 minutes. The fractions 
containing the products were concentrated under reduced pressure to give the title compounds 382 (10.5 
mg, 21%) as an off-white solid and 383 (9.1 mg, 20%) as an off-white solid.  
Data for compound 382: m.p: 180–182 ℃ (MeOH); νmax/ cm-1: 3264 (br. s), 3158 (br. s), 2974 (m), 
2862 (m), 1590 (s), 1484 (s), 1454 (s), 1267 (s), 1189 (s), 1065 (s); 1H NMR (400 MHz, DMSO-d6): δ 
11.27 (1H, br. s, NH), 7.66 (1H, dd, J = 8.0, 1.5 Hz, C4-H), 7.40 – 7.30 (5H, m, C7-H, 2 × C16-H, 2 × 
C17-H), 7.26 (1H, m, C18-H), 7.09 (1H, ddd, J = 8.0, 7.0, 1.5 Hz, C6-H), 7.02 (1H, ddd, J = 8.0, 7.0, 
1.0 Hz, C5-H), 5.61 (1H, d, J = 6.0 Hz, OH), 4.86 (1H, br. m, C9-H), 4.69 (2H, br. m, C14-H2), 3.36 – 
3.16 (2H, br. m, C12-H2), 2.03 – 1.76  (3H, m, 1 × C10-H2 and C11-H2), 1.67 (1H, m, 1 × C10-H2); 13C 
NMR (126 MHz, DMSO-d6): δ 166.9 (C13), 141.9 (C1), 138.6 (C15), 135.4 (C8), 128.6 (C17), 128.0 
(C16), 127.8 (C3), 127.2 (C18), 121.9 (C6), 120.5 (C4), 119.7 (C5), 111.3 (C7), 105.3 (C2), 66.1 (C9), 
47.5 (C14), 45.8 (C12), 29.7 (C10), 22.9 (C11); HRMS: (ESI)+ Calculated for C20H20N2NaO2: 343.1417. 
Found [M + Na] +: 343.1418.  
Data for compound 383: m.p.: 159–162 ℃ (CH2Cl2); νmax/ cm-1: 3323 (br. s), 1556 (s), 1482 (m), 1365 
(m), 1200 (s), 1046 (s); 1H NMR (400 MHz, CDCl3): δ 8.23 (1H, s, NH), 8.00 – 7.92 (1H, m, C4-H), 
7.45 – 7.08 (8H, m, C5-H, C6-H, C7-H, 2 × C16-H, 2 × C17-H and C18-H), 4.83 (2H, s, C14-H2), 3.47 
(2H, br. m, C9-H2), 2.90 (2H, br. m, C12-H2), 1.91 (2H, br. m, C11-H2), 1.71 (2H, br. m, C10-H2); 13C 
NMR (101 MHz, CDCl3): δ 167.9 (C13), 139.1 (C1), 138.1 (C15), 135.4 (C8), 128.9 (C3), 128.7, 128.3, 
127.4 (C16, C17 and C18), 122.5 (C6), 121.1, 120.8 (C4 and C5), 110.1 (C7), 107.8 (C2), 48.3 (C14), 
46.0 (C12), 28.1 (C9), 27.6 (C11), 20.8 (C10); LRMS: (ESI)+ Calculated for C20H20NO: 305.10. Found 
[M + H] +: 305.10. 
N-(4-Methoxybenzyl)cyclopropanamine (170c) 
 
A solution of p-anisaldehyde (4.87 mL, 40.0 mmol), cyclopropylamine (3.33 mL, 48.0 mmol) and 
NaHCO3 (5.04 g, 60 mmol) in MeOH (70 mL) were refluxed for 16 hours. The resulting suspension 
was cooled to 0 °C and NaBH4 (1.89 g, 50.0 mmol) was added portion wise over 10 minutes. The 
reaction was warmed to room temperature and stirred for an additional 3 hours. The reaction mixture 
was concentrated in vacuo before the addition of saturated aqueous NaHCO3 (100 mL). The solution 
was extracted with CH2Cl2 (2 × 100 mL). The organic layers were combined, washed with brine (100 
mL), dried over Na2SO4 and concentrated in vacuo to give the title compound 170c (6.93 g, 98%) as a 
pale yellow oil. The crude material was used without further purification. νmax/ cm-1: 3320 (m), 2995 
(m), 1611 (m), 1510 (s), 1242 (s), 1173 (s), 1034 (s); 1H NMR (400 MHz, CDCl3): δ 7.25 – 7.21 (2H, 





m, 2 × C3-H), 6.89 – 6.81 (2H, m, 2 × C2-H), 3.80 (3H, s, C8-H3), 3.78 (2H, s, C5-H2), 2.14 (1H, m, 
C6-H), 1.71 (1H, br. s, NH), 0.47 – 0.30 (4H, m, 2 × C7-H2); 13C NMR (101 MHz, CDCl3): δ 158.7 
(C1), 132.9 (C4), 129.5 (C3), 113.9 (C2), 55.4 (C8), 53.2 (C5), 30.1 (C6), 6.5 (C7). The spectroscopic 
properties of this compound were consistent with the data available in literature.118 
-cyclopropyl-N-(4-methoxybenzyl)-1H-indole-3-carboxamide (178j) 
 
General Procedure A: 1H-Indole-3-carboxylic acid (2.01 g, 12.5 mmol) and N-(4-
methoxybenzyl)cyclopropanamine 170c (2.32 g, 13.1 mmol) were employed and the reaction was 
stirred at r.t. for 12 hours. The crude residue was recrystallised from MeOH to give the title compound 
178j (2.46 mg, 62%) as white crystalline solid; m.p.: 149–151 °C (MeOH); νmax/ cm-1: 3300 (m), 3007 
(m), 1509 (s), 1439 (s), 1244 (s), 1231 (m); 1H NMR (400 MHz, CDCl3): δ 9.69 (1H, s, NH), 7.97 (1H, 
m, C4-H), 7.27 – 7.22 (2H, m, 2 × C12-H), 7.19 – 7.08 (4H, m, C1-H, C5-H, C6-H and C7-H), 6.89 – 
6.82 (2H, m, 2 × C13-H), 4.75 (2H, s, C10-H2), 3.78 (3H, s, C17-H3), 2.59 (1H, m, C15-H), 0.63 – 0.59 
(4H, m, 2 × C16-H2); 13C NMR (101 MHz, CDCl3): δ 169.2 (C9), 158.9 (C14), 135.8 (ArC), 130.6 
(C11), 129.2 (C12), 128.0 (C1), 126.9 (ArC), 122.6, 121.2, 121.1 (C4, C5 and C6), 114.1 (C13), 111.8 
(C7), 111.4 (C2), 55.4 (C17), 51.1 (C10), 30.7 (C15), 10.2 (C16); HRMS: (ESI)+ Calculated for 
C20H21N2O2: 321.1597. Found [M + H] +: 321.1591.  
2-(4-Methoxybenzyl)-2,3,4,5-tetrahydro-1H-azocino[4,3-b]indole-1,6(7H)-dione (179j) and (Z)-2-
(4-Methoxybenzyl)-2,5-dihydro-1H-azocino[4,3-b]indole-1,6(7H)-dione (180j) 
 
General Procedure C: Indole 178j (49.8 mg, 0.150 mmol) was employed and the reaction mixture was 
heated at 130 °C for 72 h. The residue was purified by flash column chromatography (50% 
EtOAc/hexane) to yield the title compound 179j (27.6 mg, 51%) as a yellow solid. Analysis of the crude 
reaction mixture by 1H NMR revealed a 10:1 (179j:180j) mixture of products. The minor product 180j 
was not isolated.  





Data for major compound 179j: m.p.: 151–153 °C (MeOH); νmax/ cm-1: 3132 (br. s), 2925 (m), 1653 (s), 
1600 (s), 1513 (s), 1240 (s); 1H NMR (500 MHz, CDCl3): δ 9.23 (1H, s, NH), 8.14 (1H, dd, J = 8.5, 1.0 
Hz, C4-H), 7.47 – 7.40 (2H, m, C6-H and C7-H), 7.42 – 7.35 (2H, m, 2 × C16-H), 7.28 (1H, m, C5-H), 
6.97 – 6.81 (2H, m, 2 × C17-H), 5.20 (1H, d, J = 14.5 Hz, 1 × C14-H2), 4.55 (d, J = 14.5 Hz, 1 × C14-
H2), 3.92 – 3.71 (4H, m, 1 × C12-H2 and C19-H3), 3.33 (1H, d, J = 14.5 Hz, 1 × C12-H2), 3.12 (1H, m, 
1 × C10-H2), 2.64 (1H, m, 1 × C10-H2), 2.03 (1H, m, 1 × C11-H2), 1.85 (1H, m, 1 × C11-H2); 13C NMR 
(126 MHz, CDCl3): δ 192.0 (C9), 166.0 (C13), 159.2 (C18), 136.0 (C8), 133.4 (C1), 129.7 (C15), 129.6 
(C16), 128.1 (C3), 127.2 (C6), 123.8 (C4), 122.3 (C5), 115.2 (C2), 114.2 (C17), 111.9 (C7), 55.3 (C19), 
48.0 (C14), 45.6 (C12), 36.8 (C10), 26.4 (C11); HRMS: (ESI)+ Calculated for C21H21N2O3: 349.1547. 
Found [M + H] +: 349.1522.  
Data for minor compound 180j: Characteristic signals only: 1H NMR (400 MHz, CDCl3): δ 6.14 (1H, 
d, J = 7.5 Hz, C12-H), 5.62 (1H, ddd, J = 10.0, 7.5, 7.0 Hz, C11-H). 
2-Benzyl-6-thioxo-2,3,4,5,6,7-hexahydro-1H-azocino[4,3-b]indol-1-one (389) 
 
To a solution of substrate 179a (40.0 mg, 0.126 mmol) in THF (1.3 mL) was added Lawessons’s reagent 
(50.8 mg, 0.126 mmol). The reaction mixture was heated at reflux for 6 hours and then cooled to room 
temperature. The reaction mixture was diluted with EtOAc (5 mL) and washed with saturated aqueous 
NaHCO3 (5 mL), H2O (5 mL), brine (5 mL), dried over Na2SO4, filtered and concentrated in vacuo. The 
crude residue was purified by flash column chromatography (5% acetone/toluene) to afford the title 
compound 389 (27.8 mg, 66%) as a yellow oil. νmax/ cm-1: 3224 (br. s), 3061 (m), 2922 (m), 1607 (s), 
1505 (s), 1496 (s), 1333 (s), 1210 (s), 1130 (s); 1H NMR (400 MHz, CDCl3): δ 9.4 (1H, br. s, NH), 8.08 
(d, J = 8.5 Hz, C4-H), 7.46 – 7.25 (7H, m, C6-H, C7-H, 2 × C16-H, 2 × C17-H and C18-H), 7.22 (1H, 
m, C5-H), 5.38 (1H, d, J = 14.5 Hz, 1 × C14-H2), 4.43 (1H, d, J = 14.5 Hz, 1 × C14-H2), 3.74 (1H, ddd, 
J = 15.0, 4.0, 4.0 Hz, 1 × C12-H2), 3.61 (1H, ddd, J = 13.0, 4.0, 4.0 Hz, 1 × C10-H2), 3.37 (1H, dd, J = 
13.0, 4.0 Hz, 1 × C10-H2), 3.24 (1H, dd, J = 15.0, 5.0 Hz, 1 × C12-H2), 2.12 (1H, m, 1 × C11-H2), 1.87 
(1H, m, 1 × C11-H2); 13C NMR (101 MHz, CDCl3): δ 224.8 (C9), 166.5 (C13), 140.2 (C1), 138.8 (C8), 
137.5 (C15), 129.4 (C3), 128.9 (C16), 128.4, 128.3 (C6 and C17), (C18), 127.9 (C18), 124.8 (C4), 
122.8 (C5), 112.4 (C2), 111.9 (C7), 48.5 (C14), 45.9 (C10), 45.4 (C12), 30.3 (C11); HRMS: (ESI)+ 
Calculated for C20H18N2NaOS: 357.1032. Found [M + Na] +: 357.1048.  
  







To a solution of indole 179a (31.9 mg, 0.10 mmol) in THF (1.0 mL) at 0 °C was added LiAlH4 (0.10 
mL, 0.10 mmol, 1.0 M in THF) dropwise over 10 minutes. After addition was complete, stirring was 
maintained for a further 30 minutes, after which time the reaction was heated at reflux for 16 hours. The 
mixture was cooled to 0 °C and H2O (0.5 mL) was added, followed by 15% aqueous NaOH solution 
(0.5 mL) and a further portion of H2O (1 mL). The resulting suspension was stirred for 30 minutes and 
warmed to room temperature. EtOAc (5 mL) and Na2SO4 were added and the suspension was filtered 
through celite®, washing with EtOAc (10 mL). The solution was concentrated in vacuo to afford the 
title compound 382 (24.0 mg, 75 %) as a colourless solid. The product was obtained with good purity 
and not purified further. The spectroscopic properties of this compound were consistent with the data 
previously reported in this thesis. 1H NMR (400 MHz, DMSO-d6): δ 11.27 (1H, br. s, NH), 7.66 (1H, 
dd, J = 8.0, 1.5 Hz, C4-H), 7.40 – 7.30 (5H, m, C7-H, 2 × C16-H, 2 × C17-H), 7.26 (1H, m, C18-H), 
7.09 (1H, ddd, J = 8.0, 7.0, 1.5 Hz, C6-H), 7.02 (1H, ddd, J = 8.0, 7.0, 1.0 Hz, C5-H), 5.61 (1H, d, J = 
6.0 Hz, OH), 4.86 (1H, br. m, C9-H), 4.69 (2H, br. m, C14-H2), 3.36 – 3.16 (2H, br. m, C12-H2), 2.03 
– 1.76  (3H, m, 1 × C10-H2 and C11-H2), 1.67 (1H, m, 1 × C10-H2); 13C NMR (126 MHz, DMSO-d6): 
δ 166.9 (C13), 141.9 (C1), 138.6 (C15), 135.4 (C8), 128.6 (C17), 128.0 (C16), 127.8 (C3), 127.2 (C18), 
121.9 (C6), 120.5 (C4), 119.7 (C5), 111.3 (C7), 105.3 (C2), 66.1 (C9), 47.5 (C14), 45.8 (C12), 29.7 
(C10), 22.9 (C11). 
2-Benzyl-2,3,4,5,6,7-hexahydro-1H-azocino[4,3-b]indol-6-ol (390) 
 
This procedure was carried out in 3 identical reaction tubes in parallel. To a flame-dried screw-top 
tube, fitted with a rubber septum under an atmosphere of nitrogen was added indole 179a (111 mg, 
0.356 mmol) and THF (4.0 mL). The reaction tube was placed in an ice bath before the dropwise 
addition of  LiAlH4 (1.05 mL, 1.05 mmol, 1.0 M in THF) dropwise over 10 minutes. After addition was 
complete, stirring was maintained for a further 30 minutes, after which time the reaction tube was sealed 





and heated at 80 ℃ for 16 hours. Caution: Use a blast shield. The reaction mixture was cooled to 0 °C, 
diluted with Et2O (5 mL) and quenched by careful addition of H2O (0.2 mL), followed by 15% aqueous 
NaOH solution (0.2 mL). An additional 1 mL of H2O was added and the resulting suspension was stirred 
for 20 minutes and then warmed to room temperature. At this point, the 3 identical reaction tubes were 
combined and filtered through celite®, washing with EtOAc (20 mL). The filtrate was transferred to a 
separating funnel with H2O (10 mL). The layers were separated and the aqueous layer was further 
extracted with EtOAc (2 × 10 mL). The organic layers were combined, washed with brine (10 mL), 
dried over Na2SO4, filtered and concentrated in vacuo. The crude residue was purified by flash column 
chromatography (0–5% MeOH/CH2Cl2) to give the title compound 390 (305 mg, 93%) as a colourless 
solid; m.p.: 164–167 °C (MeOH); νmax/ cm-1: 3191 (br. s), 2920 (m), 1453 (s), 1338 (s), 1234 (s), 1205 
(s), 1062 (s), 1010 (s); 1H NMR (400 MHz, CDCl3): δ 8.45 (1H, br. s, NH), 7.38 – 7.23 (7H, m, C4-H, 
C7-H, 2 × C16-H, 2 × C17-H and C18-H), 7.12 (1H, ddd, J = 8.0, 7.0, 1.5 Hz, C6-H), 7.06 (1H, ddd, J 
= 8.0, 7.0, 1.0 Hz, C5-H), 4.89 (1H, dd, J = 4.5, 3.0 Hz, C9-H), 4.15 (1H, d, J = 16.0 Hz, 1 × C13-H2), 
3.90 (1H, d, J = 13.0 Hz, 1 × C14-H2), 3.78 (1H, d, J = 13.0 Hz, 1 × C14-H2), 3.69 (1H, d, J = 16.0 Hz, 
1 × C13-H2), 2.91 (1H, ddd, J = 12.0, 4.0, 1.0 Hz, 1 × C12-H2), 2.58 (1H, ddd, J = 12.0, 5.0, 3.5 Hz, 1 
× C12-H2), 1.99 (1H, dddd, J = 14.5, 10.0, 4.5, 3.0 Hz, 1 × C10-H2), 1.86 (1H, m, 1 × C10-H2), 1.80 – 
1.62 (2H, m, C11-H2); 13C NMR (101 MHz, CDCl3): δ 137.3 (C15), 136.6 (C1), 134.4 (C8), 129.4 
(C16), 128.8 (C17), 127.8 (C18), 127.5 (C3), 121.7 (C6), 119.4 (C5), 118.1 (C4), 111.1, 111.0 (C2 and 
C7), 67.5 (C9), 64.0 (C14), 56.9 (C12), 51.2 (C13), 35.6 (C10), 24.0 (C11); HRMS: (ESI)+ Calculated 
for C20H23N2O: 307.1805. Found [M + H] +: 307.1805.  
2-Benzyl-6-hydroxy-2,3,4,5,6,7-hexahydro-1H-azocino[4,3-b]indol-1-one (382) and 2-Benzyl-
2,3,4,5,6,7-hexahydro-1H-azocino[4,3-b]indol-6-ol (390’) and 2-Benzyl-2,3,4,5,6,7-hexahydro-1H-
azocino[4,3-b]indole (391) 
 
BH3·THF (6.2 mL, 2.00 mmol) was added to a stirring solution of indole 179a (318 mg, 1.00 mmol) 
in THF (5 mL) at 0 ℃ over 10 minutes. The resulting solution was warmed to room temperature and 
then heated at reflux for 48 hours. The reaction mixture was cooled to 0 ℃ and quenched by the addition 
of MeOH (~ 2 mL) until no more effervescence was observed and stirred for 15 minutes. The quenched 
reaction was concentrated in vacuo and the crude residue was purified by flash column chromatography 
(20–40% EtOAc/hexane) to give the title compound 390’ (50.5 mg, 10%) as colourless oil, the title 
compound 391 (89.9 mg, 29%) as a colourless oil and the title compound 382 (20.5 mg, 20%) as a white 





solid. The spectroscopic properties of 382 were consistent with the data previously reported in this 
thesis. 
Data for product 390’: νmax/ cm-1: 3390 (s), 2928 (w), 2330 (br. s), 2279 (m), 1454 (s), 1163 (s), 1070 
(s); 1H NMR (400 MHz, CDCl3): δ 8.91 (1H, br. s, NH)), 7.61 (1H, dd, J = 8.0, 1.0 Hz, C4-H), 7.44 
(1H, ddd, J = 8.0, 1.0, 1.0 Hz, C7-H), 7.38 – 7.13 (7H, m, C5-H, C6-H, 2 × C16-H, 2 × C17-H  and 
C18-H), 5.11 (1H, dd, J = 10.5, 3.5 Hz, C9-H), 4.32 (2H, s, C13-H2), 4.18 (1H, d, J = 11.5 Hz, 1 × C14-
H2), 3.82 (1H, d, J = 11.5 Hz, 1 × C14-H2), 2.74 (1H, ddd, J = 12.5, 9.5, 1.5 Hz, 1 × C12-H2), 2.49 – 
2.17 (3H, m, 1 × C10-H2, 1 × C11-H2 and 1 × C12-H2), 1.94 – 1.76 (2H, m, 1 × C10-H2 and 1 × C11-
H2); 13C NMR (101 MHz, CDCl3): δ 141.6 (C1), 134.7 (C8), 133.4 (C16), 132.1 (C15), 129.5 (C3), 
128.6 (C18), 127.6 (C17), 122.2 (C6), 120.9 (C4), 118.4 (C5), 111.6 (C7), 100.7 (C2), 68.4 (C9), 66.8 
(C14), 55.2 (C12), 54.6 (C13), 37.5 (C10), 19.2 (C11); HRMS: (ESI+) Mass peak of the borane adduct 
390’; Calculated for C20H25BN2NaO: 343.1956. Found [M + Na] +: 343.1921; Mass peak of the tertiary 
amine; Calculated for C20H23N2O: 307.1805. Found [M + H] +: 307.1796. 
Data for product 391: νmax/ cm-1: 3350 (s), 2928 (w), 2334 (br. s), 2277 (m), 1453 (s), 1163 (s), 1017 
(s); 1H NMR (400 MHz, CDCl3): δ 8.26 (1H, br. s, NH), 7.62 (1H, m, d, J = 8.5 Hz, C4-H), 7.42 – 7.35 
(3H, m, C7-H and 2 × C16-H), 7.31 – 7.24 (3H, m, 2 × C17-H  and C18-H), 7.22 – 7.14 (2H, m, C5-H 
and C6-H), 4.54 (1H, d, J = 15.0 Hz, 1 × C13-H2), 4.28 (1H, d, J = 15.0 Hz, 1 × C13-H2), 4.18 (d, J = 
12.0 Hz, 1 × C14-H2), 3.80 (d, J = 12.0 Hz, 1 × C14-H2),  3.02 (1H, ddd, J = 16.0, 10.0, 3.0 Hz, 1 × C9-
H2), 2.89 (1H, ddd, J = 16.0, 8.0, 3.0 Hz, 1 × C9-H2), 2.77 (1H, m, 1 × C12-H2), 2.53 (1H, m, 1 × C12-
H2), 2.32 (1H, br. m, 1 × C11-H2), 2.10 (1H, br. m, 1 × C10-H2), 1.86 – 1.67 (2H, m, 1 × C10-H2 and 1 
× C11-H2); 13C NMR (101 MHz, CDCl3): δ 140.3 (C1), 134.8 (C8), 133.3 (C16), 132.3 (C15), 129.7 
(C3), 128.5 (C18), 127.5 (C17), 121.8 (C6), 120.6 (C5), 118.0 (C4), 110.9 (C7), 102.9 (C2), 66.5 (C14), 
55.1 (C13), 54.8 (C12), 27.3 (C9), 26.7 (C10), 23.5 (C11); HRMS: (ESI+) Mass peak of the borane 
adduct 391; Calculated for C20H25BN2Na: 322.2595. Found [M + Na] +: 322.2552; Mass peak of the 
tertiary amine; Calculated for C20H23N2: 291.1856. Found [M + H] +: 291.1862. 
4-Amino-1-(3-methyl-1H-indol-2-yl)butan-1-ol (398) 
 
A flame-dried reaction tube, fitted with a magnetic stirrer, was charged with indole 390 (57.5 mg, 0.188 
mmol) and ethanol (3.7 mL). The tube was fitted with a rubber septum and purged with argon. Under 
an atmosphere of argon, 10 wt.% Pd/C (28.8 mg, 0.271 mmol, 50 mol%) was added and the reaction 





tube was fitted with a balloon of hydrogen The reaction mixture was sparged with hydrogen gas for 30 
seconds, heated to 45 °C under an atmosphere of hydrogen and stirred vigorously for 23 hours. The 
reaction mixture was cooled to room temperature, degassed with argon and filtered through a pad of 
celite®, washing with EtOAc (5 mL). The filtrate was concentrated in vacuo to afford the title compound 
398 (34.6 mg, 92%) as a colourless oil. The product was obtained with good purity and was not purified 
further. νmax/ cm-1: 3351 (br. s), 2925 (w), 2925 (w), 1460 (m) 1119 (s); 1H NMR (400 MHz, Methanol-
d4): δ 7.43 (1H, d, J = 8.0 Hz, C4-H), 7.30 (1H, d, J = 8.0 Hz, C7-H), 7.09 – 6.93 (2H, m, C5-H and 
C6-H), 4.99 (1H, t, J = 7.0 Hz, C9-H), 2.87 – 2.73 (2H, m, C12-H2), 2.29 (3H, s, C13-H3), 2.04 – 1.84 
(2H, m, C10-H2), 1.77 – 1.46 (2H, m, C11-H2); 13C NMR (101 MHz, Methanol-d4): δ 137.2 (2 signals, 
C1 and C8) 130.2 (C3), 122.3 (C6), 119.4 (C5), 119.1 (C4), 111.8 (C7), 107.6 (C2), 67.0 (C9), 41.3 
(C12), 35.2 (C10), 26.8 (C11), 8.6 (C13); HRMS: (ESI)+ Calculated for C13H17N2: 201.1403. Found [M 
+ H] +: 201.1406.  
2,3,4,5,6,7-Hexahydro-1H-azocino[4,3-b]indol-6-ol (393) 
 
This procedure was carried out in 4 identical reaction tubes in parallel. A flame-dried reaction tube, 
fitted with a magnetic stirrer, was charged with 20 wt.% Pd(OH)2 (11.5 mg, 0.0821 mmol, 20 mol%). 
The tube was fitted with a rubber septum and purged with argon. Indole 390 (57.5 mg, 0.188 mmol) 
was added as a solution in ethanol (3.75 mL). The reaction mixture was sparged with hydrogen gas for 
30 seconds and then stirred vigorously under an atmosphere of hydrogen at room temperature for 13 
hours. The reaction mixture was degassed with argon and at this point, the 4 identical reaction tubes 
were combined and filtered through a pad of celite®, washing with EtOAc (25 mL). The filtrate was 
concentrated in vacuo and the crude residue was purified by flash column chromatography (10–15% 
MeOH/CH2Cl2 modified with 1% Et3N) to afford the title compound 393 (92.6 mg, 57%) as a colourless 
oil and recovered starting material 390 (85.1 mg, 37%) as a colourless solid. The spectroscopic 
properties of recovered starting material 390 were consistent with the data previously reported in this 
thesis.  
Data for major product 393: νmax/ cm-1: 3252 (br. s), 2926 (m), 1456 (s), 1341 (m), 1021 (s); 1H NMR 
(400 MHz, Methanol-d4): δ 7.54 (1H, d, J = 8.0 Hz, C4-H), 7.37 (1H, d, J = 8.0 Hz, C7-H), 7.15 – 7.02 
(2H, m, C5-H and C6-H), 5.12 (1H, dd, J = 6.5, 3.5 Hz, C9-H), 4.67 (1H, d, J = 14.5 Hz, 1 × C13-H2), 
4.32 (1H, d, J = 14.5 Hz, 1 × C13-H2), 2.91 (2H, dt, J = 5.5, 3.0 Hz, C12-H2), 2.16 – 1.80 (4H, m, C10-
H2 and C11-H2); 13C NMR (126 MHz, Methanol-d4): δ 140.9 (C1), 135.4 (C8), 127.3 (C3), 121.6 (C6), 





119.5 (C5), 117.1 (C4), 111.1 (C7), 99.9 (C2), 66.3 (C9), 43.2 (C12), 38.2 (C13), 35.4 (C10), 19.5 
(C11); HRMS: (ESI)+ Calculated for C13H17N2O: 217.1335. Found [M + H] +: 217.1337.  
(Z)-2-Bromobut-2-en-1-yl 4-methylbenzenesulfonate (403  
 
To a solution of alcohol 371 (146 g, 9.80 mmol), Et3N (1.59 mL, 10.8 mmol) and DMAP (127 mg, 10 
mol%) in CH2Cl2 (30 mL) was added tosyl chloride (1.86 g, 9.80 mmol) and the reaction mixture was 
stirred at room temperature for 18 hours. H2O (50 mL) was added and the solution was extracted with 
CH2Cl2 (2 × 30 mL). The organic layers were combined, washed with brine (50 mL), dried over Na2SO4, 
filtered and concentrated in vacuo. The residue was purified by flash column chromatography (10 % 
EtOAc/hexane) to afford the title compound 403 (659 mg, 44%) as a colourless oil; νmax/ cm-1: 2945 
(w), 1659 (w), 1598 (w), 1359 (s), 1189 (s), 1176 (s), 940 (s), 813 (s) 667 (s); 1H NMR (400 MHz, 
CDCl3): δ 7.88 – 7.75 (2H, m, 2 × C4-H), 7.41 – 7.29 (2H, m, 2 × C3-H), 6.13 (1H, qt, J = 6.5, 1.0 Hz, 
C8-H), 4.68 (2H, qd, J = 1.0, 1.0 Hz, C6-H2), 2.45 (3H, s, C1-H3), 1.71 (3H, dt, J = 6.5, 1.0 Hz, C9-H3); 
13C NMR (101 MHz, CDCl3): δ 145.1 (C2), 133.4 (C5), 131.4 (C8), 129.9 (C3), 128.2 (C4), 119.2 (C7), 
74.5 (C6), 21.8 (C1), 16.8 (C9); HRMS: (ESI)+ Calculated for C11H1379BrN2O3S: 326.9661. Found [M 
+ H] +: 326.9656.  
(Z)-2-(2-Bromobut-2-en-1-yl)-2,3,4,5,6,7-hexahydro-1H-azocino[4,3-b]indol-6-ol (401) 
 
To a suspension of amine 393 (76.0 mg, 0.351 mmol), K2CO3 (49.7 mg, 0.369 mmol) in DMF (2 mL) 
was added tosylate 403 (112 mg, 0.369 mmol). The reaction mixture was stirred at room temperature 
for 18 hours and then CH2Cl2 (15 mL) was added. The solution was washed with water (2 × 30 mL), 
brine (20 mL), dried over Na2SO4 and concentrated in vacuo. The residue was purified by flash column 
chromatography (50–70% EtOAc/hexane) to afford the title compound 401 (87.9 mg, 72%)  as a white 
solid; m.p.: 71 –72 °C (MeOH); νmax / cm-1: 3397 (w), 3222 (w), 2919 (w), 1457 (m), 1340 (m), 1233 
(m), 908 (s), 734 (s), 1H NMR (400 MHz, CDCl3): δ 8.11 (1H, br. s, NH), 7.38 (1H, dd J = 8.0, 1.0 Hz, 
C4-H), 7.27 (dd, J = 8.0, 1.0 Hz, C7-H), 7.17 – 7.05 (2H, m, C5-H and C6-H), 6.04 (1H, q, J = 6.5 Hz, 
C16-H), 4.96 (1H, br. m, C9-H), 4.10 (d, J = 15.5, Hz, 1 × C13-H2), 3.66 (d, J = 15.5, Hz, 1 × C13-H2), 





3.59 – 3.47 (2H, m, C14-H2), 2.84 (1H, m, 1 × C12-H2), 2.55 (1H, m, 1 × C12-H2), 2.05 (1H, m, 1 × 
C10-H2), 1.88 (1H, m, 1 × C10-H2), 1.80 – 1.69 (5H, m, C11-H2 and C17-H3); 13C NMR (101 MHz, 
CDCl3): δ 136.6 (C1), 134.4 (C8), 128.3 (C16), 127.6 (C3), 125.0 (C15), 121.7 (C6), 119.4 (C5), 118.0 
(C4), 111.1 (C7), 110.6 (C2), 68.5 (C14), 67.5 (C9), 56.7 (C12), 50.9 (C13), 35.7 (C10), 24.1 (C11), 
17.0 (C17); HRMS: (ESI)+ Calculated for C17H2279BrN2O: 349.0910. Found [M + H] +: 349.0904.   
(Z)-2-(2-Bromobut-2-en-1-yl)-1,2,3,4,5,7-hexahydro-6H-azocino[4,3-b]indol-6-one (367) 
 
Compound 367 was prepared via two alternative methods: Method A or Method B 
Method A: To a solution of alcohol 401 (10.0 mg, 0.290 mmol) in CH2Cl2 (1 mL) was added Dess-
Martin periodinane (15.3 mg, 0.0319 mmol). The resulting solution was stirred for 4 hours at room 
temperature. The reaction mixture was diluted with CH2Cl2 (5 mL), quenched by the addition of 5% 
aqueous Na2S2O3 solution (2 mL) and saturated aqueous NaHCO3 (2mL) and stirred until all the solids 
dissolved. The organic layer was separated and washed with H2O (5 mL), brine (5 mL), dried over 
Na2SO4, filtered and concentrated in vacuo. The crude residue was purified by flash column 
chromatography (20–30% EtOAc/hexane) to afford the title compound 367 (7.22 mg, 72%) as a 
colourless solid.  
Method B: To a solution of alcohol 401 (50.0 mg, 0.143 mmol) in acetone (2 mL) was added activated 
MnO2 (370 mg, 5.03 mmol, 30.0 equiv.) and the resulting black suspension was stirred at room 
temperature for 16 hours. The reaction mixture was filtered through Celite®, washing with EtOAc (10 
mL) and concentrated in vacuo. The residue was purified by flash column chromatography (0–20% 
Et2O/toluene) to yield the title compound 367 (30.3 mg, 61%) as a colourless solid. 
Data for compound 367: m.p.: 112–114 °C (MeOH); νmax / cm-1: 3315 (br. m), 2920 (w), 1637 (s), 1525 
(m), 1443 (m), 1335 (s), 744 (s); 1H NMR (400 MHz, CDCl3): δ 9.09 (1H, s, NH), 7.67 (1H, d, J = 8.0 
Hz, C4-H), 7.46 – 7.31 (2H, m, C6-H and C7-H), 7.17 (1H, ddd, J = 8.0, 6.5, 1.0 Hz, C5-H), 5.92 (1H, 
q, J = 6.5 Hz, C16-H), 4.41 (2H, s, C13-H2), 3.29 (2H, s, C14-H2), 3.07 (2H, t, J = 7.0 Hz, C10-H2), 
2.69 – 2.61 (2H, m, C12-H2), 2.05 (2H, tt, J = 7.0, 7.0 Hz, C11-H2), 1.78 (3H, d, J = 6.5 Hz, C17-H3); 
13C NMR (126 MHz, CDCl3): δ 193.7 (C9), 136.0 (C8), 134.5 (C1), 128.4 (C3), 126.5 (2 signals, C6 
and C16), 121.0 (C4), 120.7 (C5), 116.2 (C2), 112.0 (C7), 110.1 (C15), 65.0 (C14), 50.0 (C12), 47.1 





(C13), 40.2 (C10), 23.6 (C11), 16.7 (C17); HRMS: (ESI)+ Calculated for C17H2079BrN2O: 347.0754. 
Found [M + H] +: 347.0751.   
(Z)-2-iodobut-2-enal  
 
To a solution of trans-crotonaldehyde (4.14 mL, 50.0 mmol) in 1:1 THF/H20 (300 mL) at 0 °C was 
added K2CO3 (8.28 g, 60.0 mmol), iodine (19.0 g, 75.0 mmol) and DMAP (1.22 g, 10.0 mmol). The 
reaction mixture was stirred at 0 °C for 1 hour and then warmed to room temperature and stirred for an 
additional 1.5 hours. The reaction was quenched with saturated aqueous Na2S2O3 (40 mL). The aqueous 
layer was extracted with Et2O (2 × 75 mL). The organic layers were combined, washed with 0.1 M aq. 
HCl (30 mL), brine (50 mL), dried over MgSO4, filtered and concentrated in vacuo to afford the title 
compound (Z)-2-iodobut-2-enal (7.81 g, 80%, >95:5 Z:E) as an orange oil. The product was used in the 
following step without any further purification. 1H NMR (400 MHz, CDCl3): δ 8.65 (1H, d, J = 1.0 Hz, 
C1-H), 7.26 (1H, qd, J = 6.5, 1.0 Hz, C3-H), 2.17 (3H, d, J = 6.5 Hz, C4-H3); 13C NMR (101 MHz, 
CDCl3): δ 186.2 (C1), 151.3 (C3), 113.2 (C2), 18.1 (C4). The spectroscopic properties of this compound 
were consistent with the data available in literature.251  
 (Z)-2-Iodobut-2-en-1-ol (404) 
 
To a solution of (Z)-2-iodobut-2-enal (7.81 g, 40.1 mmol) in MeOH (130 mL) at 0 °C was added NaBH4 
(2.27 g, 60.1 mmol) portion wise over 10 minutes. The reaction was warmed to room temperature, 
stirred for 2 hours and then concentrated in vacuo. Saturated aqueous NaHCO3 (100 mL) and CH2Cl2 
(50 mL) were added, the layers were separated and the aqueous portion was further extracted with 
CH2Cl2 (2 × 50 mL). The organic extracts were combined, washed with brine (100 mL), dried over 
Na2SO4, filtered and concentrated in vacuo. The crude material was purified by flash column 
chromatography (20–50% EtOAc/hexane) to give the title compound (1.69 g, 21%) as a pale yellow oil. 
1H NMR (400 MHz CDCl3): δ 5.95 (1H, qt, J = 6.5, 1.5 Hz, C3-H), 4.28 – 4.16 (2H, d, J = 6.5 Hz, C1-
H2), 2.22 (1H, m, OH), 1.77 (3H, dt, J = 6.5, 1.5 Hz, C4-H3); 13C NMR (101 MHz, CDCl3): δ 131.5 
(C3), 109.8 (C2), 71.7 (C1), 21.5 (C4). The spectroscopic properties of this compound were consistent 
with the data available in literature.251  
(Z)-2-Iodobut-2-en-1-yl 4-methylbenzenesulfonate (364)  






To a solution of alcohol 404 (500 mg, 2.62 mmol), Et3N (0.40 mL, 2.88 mmol) and DMAP (32.0 mg, 
10 mol%) in CH2Cl2 (6 mL) was added tosyl chloride (497 mg, 2.62 mmol) and the reaction mixture 
was stirred at room temperature for 18 hours. H2O (15 mL) was added and the solution was extracted 
with CH2Cl2 (2 × 15 mL). The organic layers were combined, washed with brine (15 mL), dried over 
Na2SO4, filtered and concentrated in vacuo. The residue was purified by flash column chromatography 
(0–20% Et2O/hexane) to afford the title compound 364 (400 mg, 43%) as a pale yellow oil; νmax / cm-1: 
2922 (w), 1597 (w), 1355 (s), 1172 (s), 929 (s); 1H NMR (400 MHz, CDCl3): δ 7.89 – 7.72 (2H, m, 2 × 
C4-H), 7.46 – 7.30 (2H, m, 2 × C3-H), 6.02 (1H, qt, J = 6.5, 1.0 Hz, C8-H), 4.71 (2H, dt, J = 1.0, 1.0 
Hz, C6-H2), 2.44 (3H, s, C1-H3), 1.71 (3H, dt, J = 6.5, 1.0 Hz, C9-H3); 13C NMR (101 MHz, CDCl3): δ 
145.1 (C2), 137.5 (C8), 133.3 (C5), 129.9 (C3), 128.2 (C4), 98.0 (C7), 77.5 (C5), 21.8, 21.71 (C1 and 
C9); LRMS: (ESI)+ Calculated for C11H13NaIO3S: 374.96. Found [M + Na] +: 375.00. The spectroscopic 
properties of this compound were consistent with the data available in the literature.324   
(Z)-2-(2-Iodobut-2-en-1-yl)-2,3,4,5,6,7-hexahydro-1H-azocino[4,3-b]indol-6-ol (405) 
 
To a solution of amine 393 (81.3 mg, 0.376 mmol), K2CO3 (53.5 mg, 0.387 mmol) in DMF (2 mL) was 
added tosylate 364 (132 mg, 0.376 mmol). The reaction mixture was stirred at room temperature for 18 
hours and then CH2Cl2 (15 mL) was added. The solution was washed with H2O (2 × 20 mL), brine (20 
mL), dried over Na2SO4 and concentrated in vacuo. The residue was purified by flash column 
chromatography (50–70% EtOAc/hexane) to afford the title compound 405 (76.2 mg, 52%) as a white 
solid; m.p.: 74–76 °C (MeOH); νmax / cm-1: 3389 (s), 3287 (br. s), 2926 (w), 1457 (s), 1442 (s), 1047 (s), 
907 (s); 1H NMR (400 MHz, CDCl3): δ 8.46 (1H, s, NH), 7.37 (1H, m, C4-H), 7.24 (1H, m, C7-H), 
7.13 – 7.04 (2H, m, C5-H and C6-H), 5.92 (1H, m, C16-H), 5.06 (1H, t, J = 4.5 Hz, C9-H), 4.06 (1H, 
d, J = 15.5 Hz, 1 × C13-H2), 3.65 (1H, d, J = 15.5 Hz, 1 × C13-H2), 3.62 – 3.48 (2H, m, C14-H2), 2.78 
(1H, m, 1 × C12-H2), 2.54 (1H, dt, J = 12.0, 5.0 Hz, 1 × C12-H2), 2.03 – 1.82 (2H, m, C10-H2), 1.78 – 
1.65 (5H, m, C11-H2 and C17-H3); 13C NMR (101 MHz, CDCl3): δ 136.7 (C1), 134.5, 134.4 (C8 and 
C16), 127.5 (C3), 121.5 (C6), 119.2 (C5), 117.9 (C4), 111.2 (C7), 110.2 (C2), 105.9 (C15), 71.9 (C14), 





67.4 (C9), 56.7 (C12), 50.9 (C13), 35.7 (C10), 24.0 (C11), 22.1 (C17); HRMS: (ESI)+ Calculated for 
C17H22IN2O: 397.0771. Found [M + H] +: 397.0763.   
 (Z)-2-(2-Iodobut-2-en-1-yl)-1,2,3,4,5,7-hexahydro-6H-azocino[4,3-b]indol-6-one (406) 
 
To a solution of alcohol 405 (72.0 mg, 0.189 mmol) in acetone (1.9 mL) was added activated MnO2 
(406 mg, 4.73 mmol, 25.0 equiv.) and the resulting black suspension was stirred at room temperature 
for 16 hours. The reaction mixture was filtered through celite® and concentrated in vacuo. The residue 
was purified by flash column chromatography (0–10% Et2O/CH2Cl2) to yield the title compound 406 
(40.3 mg, 54%) as a colourless solid; m.p.: 121–122°C (MeOH); νmax / cm-1: 3313 (br. s), 2921 (w), 
1634 (s), 1524 (s), 1442 (s), 1334 (s); 1H NMR (400 MHz, CDCl3): δ 9.23 (1H, s, NH), 7.65 (1H, dd, J 
= 8.0, 1.0 Hz, C4-H), 7.44 – 7.30 (2H, m, C6-H and C7-H), 7.15 (1H, ddd, J = 8.0, 7.0, 1.0 Hz, C5-H), 
5.80 (1H, m, C16-H), 4.37 (2H, s, C13-H2), 3.25 (2H, br. m, C14-H2), 3.07 (2H, t, J = 7.0 Hz, C10-H2), 
2.63 (2H, dd, J = 7.5, 4.0 Hz, C12-H2), 2.07 – 2.00 (2H, m, C11-H2), 1.79 (3H, dd, J = 6.5, 1.5 Hz, C17-
H3); 13C NMR (101 MHz, CDCl3): δ 193.9 (C9), 136.12 (C8), 134.6 (C1), 132.3 (C16), 128.5 (C3), 
126.6 (C6), 121.1 (C4), 120.7 (C5), 116.7 (C2), 112.2 (C7), 110.0 (C15), 67.8 (C14), 50.0 (C12), 47.1 
(C13), 40.3 (C10), 23.7 (C11), 21.9 (C17); HRMS: (ESI)+ Calculated for C17H20IN2O: 395.0615. Found 
[M + H] +: 395.0616.   
(E)-12-(prop-1-en-1-yl)-1,4,5,7-tetrahydro-2,5-methanoazocino[4,3-b]indol-6(3H)-one (407) 
 
An oven-dried reaction tube, fitted with a magnetic stirrer, was charged with indole 406 (15.0 mg, 0.038 
mmol), Pd2dba3 (1.7 mg, 1.9 μmol, 5 mol%), DPEPhos (1.4 mg, 2.6 μmol, 7 mol%) and NaOt-Bu (5.5 
mg, 0.057 mmol). The tube was fitted with a rubber septum and evacuated and back-filled with N2 three 
times. Anhydrous THF (1.0 mL) was added by syringe and the reaction mixture was heated at 80 ℃ for 
18 hours. After this time, the reaction mixture was cooled to room temperature and filtered through 
celite® and concentrated in vacuo. The crude residue was dissolved in 0.5 mL of DMSO and purified 
by preparative high-performance liquid chromatography using an XSelect CSH C18 OBD Prep column 
(19 mm x 150 mm, 5 µm). The preprative HPLC was conducted using a 20 mL/min flow rate using a 





gradient elution (5–50%, MeCN/H2O, modified with 0.1% HCl) over 30.0 minutes. The fractions 
containing the product were concentrated under reduced pressure to give the title compound 407 (1.0 
mg, 10%) as an off-white solid. The product 407 was obtained as its HCl salt. The relative 
stereochemistry of 407 was not determined. νmax / cm-1: 3245 (br. m), 2926 (m), 2490 (br. m), 1666 (s), 
1456 (m), 1333 (m), 1198 (s); 1H NMR (500 MHz, CDCl3): δ 13.87 (1H, br. s), 9.13 (1H, br. s, NH), 
7.61 (1H, d, J = 8.0 Hz, ArC-H), 7.54 – 7.46 (2H, m, 2 × ArC-H), 7.30 (1H, m, ArC-H), 6.37 (1H, dd, 
J = 13.5, 6.5 Hz, C16-H), 5.55 (1H, d, J = 15.5 Hz, C15-H), 4.85 – 4.72 (3H, m, C13-H2 and C14-H), 
4.19 (1H, br. m, 1 × C12-H2), 3.56 (1H, br. m, C10-H), 3.45 (1H, br. m, 1 × C12-H2), 2.69 (1H, m, 1 × 
C11-H2), 2.34 (1H, m, 1 × C11-H2), 1.74 (3H, d, J = 5.5 Hz, C17-H3); 13C NMR (126 MHz, CDCl3): δ 
189.8 (C9), 142.2 (C16), 136.9 (ArC), 130.4 (ArC), 128.3 (C6), 126.1 (ArC), 122.4 (C5), 120.7 (C4), 
117.7 (C15), 112.6 (C7), 112.2 (C2), 66.7 (C14), 53.5 (C10), 51.5 (C12), 48.2 (C13), 29.9 (C11), 18.4 
(C17); HRMS: (ESI)+ Calculated for C17H19N2O: 267.1492. Found [M + H] +: 267.1504. Due to the 
small quantity of indole 407, no further data could be obtained. 
2-(But-2-yn-1-yl)-1,2,3,4,5,7-hexahydro-6H-azocino[4,3-b]indol-6-one (411) and preliminary data 
for (rac)-conolidine.  
 
An oven-dried reaction tube, fitted with a magnetic stirrer, was charged with indole 406 (20.0 mg, 0.051 
mmol). The tube was fitted with a rubber septum and evacuated and back-filled with N2 three times. 
Anhydrous THF (2.0 mL) was added by syringe and the reaction mixture was cooled to 0 ℃. LiHMDS 
(0.10 mL, 0.102 mmol, 1.0 M in THF) was added and the resulting solution was stirred for 1 hour. 
NiCl2(PCy3)2 (10.6 mg, 0.015 mmol) was added and the reaction mixture was stirred for a further 10 
minutes at 0 ℃. After this time, the reaction tube was sealed and heated at 50 ℃ for 18 hours. After 
this time, the reaction mixture was cooled to room temperature and saturated aqueous NH4Cl (0.5 mL) 
was added. The organic phase was separated and the aqueous phase was extracted with EtOAc (2 × 2 
mL). The organic layers were combined, washed with brine (1 mL), dried over Na2SO4, filtered and 
concentrated in vacuo. 1H NMR and 13C NMR analysis of the crude product indicated formation of 
(rac)-conolidine. Due to the small quantity of (rac)-conolidine, this compound was not isolated and the 
structure was deduced by analysis and comparison of the 1H NMR and 13C NMR spectra of the crude 
reaction mixture with the data reported in the literature.221,237,247 These assignments are further 
corroborated by 2D COSY and HSQC data. The assignment and comparison of diagnostic 1H and 13C 
signals are provided in Table 25 and Table 26. The crude material was purified by flash column 





chromatography (10–25% solvent A in hexane (solvent A was EtOAc/MeOH (3:1))) to afford the title 
compound 411 (3.51 mg, 26%) as a colourless solid.   
(rac)-conolidine: Diagnostic signals only: 1H NMR (500 MHz, CDCl3): δ 7.56 (1H, d, J = 8.0 Hz, C9-
H), 5.47 (1H, d, J = 7.0 Hz, C19-H), 4.78 (1H, d, J = 18.5 Hz, 1 × C6-H2), 4.27 (1H, d, J = 18.5 Hz, 1 
× C6-H2), 3.97 (1H, d, J = 7.0 Hz, C15-H), 3.86 (1H, d, J = 16.0 Hz, 1 × C21-H2), 3.41 (1H, m, 1 × C3-
H2), 3.32 (1H, d, J = 16.0 Hz, 1 × C21-H2), 1.50 (3H, dd, J = 7.0, 2.0 Hz, C18-H3); 13C NMR (126 MHz, 
CDCl3): δ 193.9 (C16), 136.3 (C13), 133.5 (C2), 130.3 (C20), 127.9 (C8), 126.6 (C11), 120.9 (C9), 
120.6 (C10), 120.3 (C7), 111.9 (C12), 55.1 (C21), 53.3 (C6), 48.1 (C15), 44.2 (C3), 22.9 (C14), 12.8 
(C18). 
Data for compound 411: m.p.: 160–162 °C (MeOH); 1H NMR (500 MHz, CDCl3): δ 9.10 (1H, s, NH), 
7.84 (1H, dd, J = 8.0, 1.0 Hz, C4-H), 7.46 – 7.33 (2H, m, C6-H and C7-H), 7.19 (1H, ddd, J = 8.0, 6.5, 
1.0 Hz, C5-H), 4.58 (2H, s, C13-H2), 3.16 – 3.13 (2H, br. m, C14-H2), 3.08 (2H, t, J = 7.5 Hz, C10-H2), 
2.65 (2H, t, J = 6.0 Hz, C12-H2), 2.13 (2H, tt, J = 7.5, 6.0 Hz, C11-H2), 1.85 (3H, t, J = 2.5 Hz, C17-
H3); 13C NMR (126 MHz, CDCl3): δ 193.1 (C9), 136.0 (C8), 134.9 (C1), 128.9 (C3), 126.6 (C6), 121.2 
(C4), 120.9 (C5), 115.2 (C2), 111.9 (C7), 80.5, 75.3 (C15 and C16), 50.0 (C12), 46.0, 45.8 (C13 and 
C14), 40.0 (C10), 23.9 (C11), 3.6 (C17); HRMS: (ESI)+ Calculated for C17H19N: 267.1492. Found [M 
+ H] +: 267.1490. The spectroscopic properties of this compound were consistent with the data available 
in the literature.356  
tert-Butyl 6-hydroxy-1,3,4,5,6,7-hexahydro-2H-azocino[4,3-b]indole-2-carboxylate (412) 
 
To a solution of amine 393 (20.0 mg, 0.0925 mmol), K2CO3 (12.7 mg, 0.0925 mmol) in DMF (1 mL) 
was added di-tert-butyl dicarbonate (20.0 mg, 0.0925 mmol). The reaction mixture was stirred at room 
temperature for 18 hours and then EtOAc (5 mL) was added. The solution was washed with water (2 × 
15 mL), brine (15 mL), dried over Na2SO4 and concentrated in vacuo. The residue was purified by flash 
column chromatography (20–70% EtOAc/hexane) to afford the title compound 412 (12.3 mg, 43%) as 
a white solid; m.p.: 133–134 °C (MeOH); νmax / cm-1: 3360 (br. s), 2930 (w), 1552 (s), 1417 (s), 1355 
(s), 1152 (s); 1H NMR (400 MHz, CDCl3): δ 8.59 (1H, s, NH), 7.44 (1H, d, J = 8.0 Hz, C4-H), 7.32 
(1H, d, J = 8.0 Hz, C7-H), 7.19 – 7.03 (2H, m, C5-H and C6-H), 5.26 (1H, m, C9-H), 5.05 (1H, br. m, 
1 × C13-H2), 4.25 (1H, d, J = 16.5 Hz, 1 × C13-H2), 3.90 (1H, br. m, 1 × C12-H2), 2.97 (1H, d, J = 14.0 
Hz, 1 × C12-H2), 2.66 (1H, s, OH), 2.09 (1H, m, 1 × C10-H2), 1.71 (3H, br. m, 1 × C10-H2 and C11-





H2), 1.44 (9H, s, 3 × C16-H3); 13C NMR (126 MHz, CDCl3): δ 155.7 (C14), 135.5 (C1), 134.5 (C8), 
127.5 (C3), 121.4 (C6), 119.3 (C5), 118.0 (C4), 110.9 (C7), 107.4 (C2), 79.9 (C15), 67.2 (C9), 46.6 
(C12), 43.0 (C13), 36.9 (C10), 28.6 (C16), 24.4 (C11); HRMS: (ESI)+ Calculated for C18H24N2NaO3: 
339.1679. Found [M + Na] +: 339.1672.  
tert-Butyl 6-oxo-1,3,4,5,6,7-hexahydro-2H-azocino[4,3-b]indole-2-carboxylate (362) 
 
To a solution of alcohol 412 (5.0 mg, 0.0158 mmol) in acetone (0.3 mL), was added activated MnO2 
(41.3 mg, 0.475 mmol, 30.0 equiv.) and the resulting black suspension was stirred at room temperature 
for 3 hours. The reaction mixture was filtered through celite®, washing with EtOAc (2 mL) and 
concentrated in vacuo. The residue was purified by flash column chromatography (30% EtOAc/hexane) 
to yield the title compound 362 (4.3 mg, 86%, 1:1 mixture of rotamers A:B) as a colourless solid; νmax / 
cm-1: 3320 (br. s), 2973 (w), 1677 (s), 1638 (s), 1453 (m), 1408 (s), 1152 (s), 1550 (s); 1H NMR (500 
MHz, CDCl3): δ 9.39 – 9.10 (2H, br. m, NH, A+B), 7.89 – 7.68 (2H, m, C4-H, A+B), 7.44 – 7.35 (4H, 
m, C6-H and C7-H, A+B), 7.23 – 7.15 (2H, m, C5-H, A+B), 5.03 (2H, s, C13-H2, A), 4.90 (2H, s, C13-
H2, B), 3.72 – 3.59 (2H, br. m, C12-H2, A), 3.57 – 3.43 (2H, br. m, C12-H2, B), 3.04 – 2.92 (4H, m, 
C10-H2, A+B), 2.12 – 1.92 (4H, m, C11-H2, A+B), 1.52 (9H, s, 3 × C16-H3, A), 1.33 (9H, s, 3 × C16-
H3, B); 13C NMR (126 MHz, CDCl3) δ 193.4, 192.7 (C9, A+B), 155.4, 155.3 (C14, A+B), 135.9, 135.7 
(C8, A+B), 133.9, 132.7 (C1, A+B), 128.1, 127.7 (C3, A+B), 126.9, 126.7 (C6, A+B), 121.1 (2 signals, 
C4, A+B), 120.9, 120.5 (C5, A+B), 119.5, 117.5 (C2, A+B), 112.0 (C7, A+B), 80.2, 80.1 (C15, A+B), 
46.4 (C12, A), 43.3 (C12, B), 42.7, 42.6 (C13, A+B), 39.5, 38.7 (C10, A+B), 28.5, 28.4 (C16, A+B), 
25.1, 24.0 (C11, A+B); HRMS: (ESI)+ Calculated for C18H22N2NaO3: 337.1523. Found [M + Na] +: 
337.1532. The spectroscopic properties of this compound were consistent with the data available in the 
literature.250
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